
<html lang="en"     class="pb-page"  data-request-id="090cc7e3-4787-4e16-9613-993bd9cb0d44"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2018.61.issue-4;requestedJournal:journal:jmcmar;article:article:10.1021/acs.jmedchem.7b01261;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia" /></meta><meta name="dc.Creator" content="Yue  Wang" /></meta><meta name="dc.Creator" content="Yanle  Zhi" /></meta><meta name="dc.Creator" content="Qiaomei  Jin" /></meta><meta name="dc.Creator" content="Shuai  Lu" /></meta><meta name="dc.Creator" content="Guowu  Lin" /></meta><meta name="dc.Creator" content="Haoliang  Yuan" /></meta><meta name="dc.Creator" content="Taotao  Yang" /></meta><meta name="dc.Creator" content="Zhanwei  Wang" /></meta><meta name="dc.Creator" content="Chao  Yao" /></meta><meta name="dc.Creator" content="Jun  Ling" /></meta><meta name="dc.Creator" content="Hao  Guo" /></meta><meta name="dc.Creator" content="Tonghui  Li" /></meta><meta name="dc.Creator" content="Jianlin  Jin" /></meta><meta name="dc.Creator" content="Baoquan  Li" /></meta><meta name="dc.Creator" content="Li  Zhang" /></meta><meta name="dc.Creator" content="Yadong  Chen" /></meta><meta name="dc.Creator" content="Tao  Lu" /></meta><meta name="dc.Description" content="A series of 1-H-pyrazole-3-carboxamide derivatives have been designed and synthesized that exhibit excellent FLT3 and CDK inhibition and antiproliferative activities. A structure–activity-relations..." /></meta><meta name="Description" content="A series of 1-H-pyrazole-3-carboxamide derivatives have been designed and synthesized that exhibit excellent FLT3 and CDK inhibition and antiproliferative activities. A structure–activity-relations..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 12, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01261" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01261" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01261" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01261" /></link>
        
    
    

<title>Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01261" /></meta><meta property="og:title" content="Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0016.jpeg" /></meta><meta property="og:description" content="A series of 1-H-pyrazole-3-carboxamide derivatives have been designed and synthesized that exhibit excellent FLT3 and CDK inhibition and antiproliferative activities. A structure–activity-relationship study illustrates that the incorporation of a pyrimidine-fused heterocycle at position 4 of the pyrazole is critical for FLT3 and CDK inhibition. Compound 50 (FN-1501), which possesses potent inhibitory activities against FLT3, CDK2, CDK4, and CDK6 with IC50 values in the nanomolar range, shows antiproliferative activities against MV4-11 cells (IC50: 0.008 μM), which correlates with the suppression of retinoblastoma phosphorylation, FLT3, ERK, AKT, and STAT5 and the onset of apoptosis. Acute-toxicity studies in mice show that compound 50 (LD50: 186 mg/kg) is safer than AT7519 (32 mg/kg). In MV4-11 xenografts in a nude-mouse model, compound 50 can induce tumor regression at the dose of 15 mg/kg, which is more efficient than cytarabine (50 mg/kg). Taken together, these results demonstrate the potential of this unique compound for further development into a drug applied in acute-myeloid-leukemia (AML) therapeutics." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="A series of 1-H-pyrazole-3-carboxamide derivatives have been designed and synthesized that exhibit excellent FLT3 and CDK inhibition and antiproliferative activities. A structure–activity-relationship study illustrates that the incorporation of a pyrimidine-fused heterocycle at position 4 of the pyrazole is critical for FLT3 and CDK inhibition. Compound 50 (FN-1501), which possesses potent inhibitory activities against FLT3, CDK2, CDK4, and CDK6 with IC50 values in the nanomolar range, shows antiproliferative activities against MV4-11 cells (IC50: 0.008 μM), which correlates with the suppression of retinoblastoma phosphorylation, FLT3, ERK, AKT, and STAT5 and the onset of apoptosis. Acute-toxicity studies in mice show that compound 50 (LD50: 186 mg/kg) is safer than AT7519 (32 mg/kg). In MV4-11 xenografts in a nude-mouse model, compound 50 can induce tumor regression at the dose of 15 mg/kg, which is more efficient than cytarabine (50 mg/kg). Taken together, these results demonstrate the potential of this unique compound for further development into a drug applied in acute-myeloid-leukemia (AML) therapeutics." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0016.jpeg" /></meta><meta name="twitter:title" content="Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01261"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01261">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01261&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01261&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01261&amp;href=/doi/10.1021/acs.jmedchem.7b01261" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1499-1518</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b01176" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b01407" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 4-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yue++Wang">Yue Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-3471-682X" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yanle++Zhi">Yanle Zhi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-6066-2231" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qiaomei++Jin">Qiaomei Jin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shuai++Lu">Shuai Lu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Guowu++Lin">Guowu Lin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Haoliang++Yuan">Haoliang Yuan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0003-0248-4347" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Taotao++Yang">Taotao Yang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhanwei++Wang">Zhanwei Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chao++Yao">Chao Yao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jun++Ling">Jun Ling</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hao++Guo">Hao Guo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tonghui++Li">Tonghui Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jianlin++Jin">Jianlin Jin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Baoquan++Li">Baoquan Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Li++Zhang">Li Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yadong++Chen">Yadong Chen</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tao++Lu">Tao Lu</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="AFF-d231e204-autogenerated"><span class="aff-text"><sup>†</sup>School of Sciences and <sup>‡</sup>State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China</span></div><div class="corresp-info"><strong>*</strong>Tel.: +86-25-86185153, Fax: +86-25-86185170, E-mail: <a href="/cdn-cgi/l/email-protection#037a67606b666d436073762d6667762d606d"><span class="__cf_email__" data-cfemail="f089949398959eb0938085de959485de939e">[email protected]</span></a> (Y.C.).</div><div class="corresp-info"><strong>*</strong>Tel.: +86-25-86185180, Fax: +86-25-86185179, E-mail: <a href="/cdn-cgi/l/email-protection#ea869f9edbdcd9aadbdcd9c4898587"><span class="__cf_email__" data-cfemail="f39f8687c2c5c0b3c2c5c0dd909c9e">[email protected]</span></a> (T.L.).</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01261&amp;href=/doi/10.1021%2Facs.jmedchem.7b01261" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1499–1518</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 22, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>24 August 2017</li><li><span class="item_label"><b>Published</b> online</span>12 February 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 February 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01261" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01261</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1499%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYue%2BWang%252C%2BYanle%2BZhi%252C%2BQiaomei%2BJin%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D4%26contentID%3Dacs.jmedchem.7b01261%26title%3DDiscovery%2Bof%2B4-%2528%25287H-Pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%2529-N-%25284-%2528%25284-methylpiperazin-1-yl%2529methyl%2529phenyl%2529-1H-pyrazole-3-carboxamide%2B%2528FN-1501%2529%252C%2Ban%2BFLT3-%2Band%2BCDK-Kinase%2BInhibitor%2Bwith%2BPotentially%2BHigh%2BEfficiency%2Bagainst%2BAcute%2BMyelocytic%2BLeukemia%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1518%26publicationDate%3DFebruary%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01261"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3284</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">33</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01261" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yue&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Yanle&quot;,&quot;last_name&quot;:&quot;Zhi&quot;},{&quot;first_name&quot;:&quot;Qiaomei&quot;,&quot;last_name&quot;:&quot;Jin&quot;},{&quot;first_name&quot;:&quot;Shuai&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Guowu&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Haoliang&quot;,&quot;last_name&quot;:&quot;Yuan&quot;},{&quot;first_name&quot;:&quot;Taotao&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Zhanwei&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Chao&quot;,&quot;last_name&quot;:&quot;Yao&quot;},{&quot;first_name&quot;:&quot;Jun&quot;,&quot;last_name&quot;:&quot;Ling&quot;},{&quot;first_name&quot;:&quot;Hao&quot;,&quot;last_name&quot;:&quot;Guo&quot;},{&quot;first_name&quot;:&quot;Tonghui&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Jianlin&quot;,&quot;last_name&quot;:&quot;Jin&quot;},{&quot;first_name&quot;:&quot;Baoquan&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Yadong&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Tao&quot;,&quot;last_name&quot;:&quot;Lu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;12&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;1499-1518&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01261&quot;},&quot;abstract&quot;:&quot;A series of 1-H-pyrazole-3-carboxamide derivatives have been designed and synthesized that exhibit excellent FLT3 and CDK inhibition and antiproliferative activities. A structure–activity-relationship study illustrates that the incorporation of a pyrimidine-fused heterocycle at position 4 of the pyrazole is critical for FLT3 and CDK inhibition. Compound 50 (FN-1501), which possesses potent inhibitory activities against FLT3, CDK2, CDK4, and CDK6 with IC50 values in the nanomolar range, shows antiproliferative activities against MV4-11 cells (IC50: 0.008 μM), which correlates with the suppression of retinoblastoma phosphorylation, FLT3, ERK, AKT, and STAT5 and the onset of apoptosis. Acute-toxicity studies in mice show that compound 50 (LD50: 186 mg/kg) is safer than AT7519 (32 mg/kg). In MV4-11 xenografts in a nude-mouse model, compound 50 can induce tumor regression at the dose of 15 mg/kg, which is more efficient than cytarabine (50 mg/kg). Taken together, these results demonstrate the potential of this uni&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01261&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01261" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01261&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01261" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01261&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01261" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01261&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01261&amp;href=/doi/10.1021/acs.jmedchem.7b01261" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01261" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01261" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01261%26sid%3Dliteratum%253Aachs%26pmid%3D29357250%26genre%3Darticle%26aulast%3DWang%26date%3D2018%26atitle%3DDiscovery%2Bof%2B4-%2528%25287H-Pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%2529amino%2529-N-%25284-%2528%25284-methylpiperazin-1-yl%2529methyl%2529phenyl%2529-1H-pyrazole-3-carboxamide%2B%2528FN-1501%2529%252C%2Ban%2BFLT3-%2Band%2BCDK-Kinase%2BInhibitor%2Bwith%2BPotentially%2BHigh%2BEfficiency%2Bagainst%2BAcute%2BMyelocytic%2BLeukemia%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D4%26spage%3D1499%26epage%3D1518%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (6)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291074" title="Purification">Purification</a>,</li><li><a href="/action/doSearch?ConceptID=291011" title="High-performance liquid chromatography">High-performance liquid chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=291235" title="Column chromatography">Column chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/4" title="Go to Volume 61, Issue 4"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/jmcmar.2018.61.issue-4/20180222/jmcmar.2018.61.issue-4.largecover.jpg" alt="Go to Volume 61, Issue 4"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01261&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A series of 1-<i>H</i>-pyrazole-3-carboxamide derivatives have been designed and synthesized that exhibit excellent FLT3 and CDK inhibition and antiproliferative activities. A structure–activity-relationship study illustrates that the incorporation of a pyrimidine-fused heterocycle at position 4 of the pyrazole is critical for FLT3 and CDK inhibition. Compound <b>50</b> (FN-1501), which possesses potent inhibitory activities against FLT3, CDK2, CDK4, and CDK6 with IC<sub>50</sub> values in the nanomolar range, shows antiproliferative activities against MV4-11 cells (IC<sub>50</sub>: 0.008 μM), which correlates with the suppression of retinoblastoma phosphorylation, FLT3, ERK, AKT, and STAT5 and the onset of apoptosis. Acute-toxicity studies in mice show that compound <b>50</b> (LD<sub>50</sub>: 186 mg/kg) is safer than AT7519 (32 mg/kg). In MV4-11 xenografts in a nude-mouse model, compound <b>50</b> can induce tumor regression at the dose of 15 mg/kg, which is more efficient than cytarabine (50 mg/kg). Taken together, these results demonstrate the potential of this unique compound for further development into a drug applied in acute-myeloid-leukemia (AML) therapeutics.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11325" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11325" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Acute myeloid leukemia (AML) is a heterogeneous disease of hematopoietic progenitor cells and is characterized by a block in differentiation and uncontrolled proliferation.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> More than a quarter of a million adults throughout the world are diagnosed with AML annually. Induction chemotherapy with cytarabine (ara-C) and an anthracycline (most often daunorubicin) is usually performed as the first-line treatment of AML.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Although some improvement has been apparent among younger patients during the last four decades, only approximately 35% of patients entered in clinical trials are cured of the disease, and older people, who are not able to withstand intensive chemotherapy, only survive 5–10 months.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Thus, there is an unmet need for effective therapeutics.</div><div class="NLM_p">Fms-like receptor tyrosine kinase 3 (FLT3) is a class III receptor tyrosine kinase (RTK) that acts as an important regulatory molecule in hematopoiesis and is overexpressed in most cases of acute leukemia.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The FLT3 pathway plays an important role in the growth and differentiation of hematopoietic progenitor cells (HPCs).<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> Many studies have shown that AML and other hematologic cancers are closely related to abnormal FLT3 pathways.<a onclick="showRef(event, 'ref6 ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9 ref10">(6-10)</a> Like other RTKs, the FLT3 receptor dimerizes when binding to the FLT3 ligand, resulting in autophosphorylation and activation of downstream signaling pathways, such as RAS/MEK, PI3K/AKT/mTOR, and JAK/STAT. These pathways play important roles in regulating the cell cycle, cell apoptosis, and cell differentiation. However, mutations of FLT3 lead to the hyperactivation of FLT3 in the absence of ligand binding and the activation of downstream signaling pathways.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> About 30% of AML patients harbor some form of FLT3 mutation, and the constitutively activating internal-tandem-duplication (ITD) mutations (of 1–100 amino acids) in the juxtamembrane domain (in approximately 25% of AML patients) invariably present the greatest clinical challenge. FLT3 has always been an important target for the treatment of AML, with a lot of small-molecule FLT3 inhibitors (quizartinib, sorafenib, midostaurin, lestaurtinib, crenolanib) being marketed or under investigation.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Although some of these compounds have shown initial therapeutic benefits, responses have been transient and relapses occur within a few weeks, partially because of insufficient target coverage, activation of parallel pathways, and acquisition of resistance mutations.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Midostaurin (PKC412, <i>N</i>-benzoylstaurosporin) is a multitargeted tyrosine-kinase inhibitor (TKI) used against FLT3, VEGFR2, KIT, PDGFR, and PKC-a. Midostaurin was approved and first launched in 2017 in the United States for the treatment of adult patients with newly diagnosed acute myeloid leukemia in combination with chemotherapy. The success of midostaurin indicates that the inhibition of FLT3 and other antitumor targets can improve antitumor efficiency.</div><div class="NLM_p">Cyclin-dependent kinases (CDKs) are a family of 20 serine and threonine protein kinases that are generally classified as regulators of the cell cycle (CDK1, -2, -4, and -6) or transcription (CDK7, -8, -9, -11, and -20).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The uncontrolled regulation of CDK activity has been identified as a hallmark of cancer.<a onclick="showRef(event, 'ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17">(15-17)</a> Indeed, oncogenic alterations of CDKs, cyclins, and other components of the Rb pathway have been reported in more than 90% of human cancers.<a onclick="showRef(event, 'ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20">(18-20)</a> For example, overexpression of cyclin E or cyclin A results in CDK2 hyperactivation in several human malignancies, including AML, lung-cell carcinoma, melanoma, osteosarcoma, ovarian carcinoma, and pancreatic neoplasia and sarcoma.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Cyclin D2 and cyclin D3 belong to D-type cyclins, which bind and activate CDK4 and CDK6 and play important roles in hematologic malignancies. Mutations or overexpression of CDK4 and cyclin D as well as reduced levels of p27Kip1 have also been found in various tumors, indicating that deregulation at checkpoints throughout the cell cycle contributes to the process of tumorigenesis.<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22-24)</a> These studies suggest that the CDK family has been considered as one of the most important targets for therapeutic interventions in cancers, including hematologic malignancies. CDK inhibitors (AT-7519, flavopiridol, AMG-925, and palbociclib)<a onclick="showRef(event, 'ref18 ref25 ref26 ref27 ref28 ref29 ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref18 ref25 ref26 ref27 ref28 ref29 ref30 ref31 ref32">(18, 25-32)</a> are currently in clinical development in various solid tumors and hematopoietic malignances.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> However, most CDK inhibitors were discontinued during phase II trials because of severe toxicities<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> or limited clinical activities as monotherapies.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><div class="NLM_p">In fact, the activation of the FLT3 downstream signal-transduction pathway is an extremely important process in promoting cell proliferation and requires the cooperation of CDKs. Therefore, inhibitors of FLT3 and CDKs can arrest antimitotic signaling pathways and the cell cycle simultaneously, which may exert synergistic effects to increase antileukemic efficiencies.<a onclick="showRef(event, 'ref18 ref28 ref36'); return false;" href="javascript:void(0);" class="ref ref18 ref28 ref36">(18, 28, 36)</a> We have reported a series of compounds with moderate CDK2 activities.<a onclick="showRef(event, 'ref37 ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39 ref40">(37-40)</a> Among these compounds, <b>26</b> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) has a certain inhibitory activity against CDK2 (IC<sub>50</sub>: 318.21 nM) and FLT3 (IC<sub>50</sub>: 42.60 nM) and shows moderate activity in MV4-11 (IC<sub>50</sub>: 0.45 μM). Starting from <b>26</b>, our group has explored the biological properties of variously substituted 1-<i>H</i>-pyrazole-3-carboxamide derivatives with the aim to find new active compounds and pharmacophores that are potent FLT3 and CDK inhibitors. Among these compounds, compound <b>50</b> was found to be the most active in vitro and in vivo, and it also possesses good pharmacokinetic properties and low toxicity. This report presents the discovery of <b>50</b> as a highly efficient multitarget FLT3 and CDK kinase inhibitor suitable for further evaluation.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Molecular docking analysis of compound <b>26</b> to CDK2 kinase and FLT3 kinase. (A) Chemical structure of <b>26</b>. (B) Compound <b>26</b> docked into CDK2 kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VU3">2VU3</a>). (C) Compound <b>26</b> docked into a homology model of FLT3.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01261&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51246" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51246" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of compounds <b>27</b>–<b>62</b> was depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. In total, 35 pyrazole-carboxamide derivatives were prepared (<a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Compounds <b>27</b>–<b>62</b> were prepared in a similar fashion. 4-Nitrobenzyl bromide was used as the starting material, and compounds <b>2</b>–<b>7</b> were prepared through a nucleophilic substitution reaction. The reduction of compounds <b>2</b>–<b>7</b> with 80% hydrazine hydrate gave compounds <b>8</b>–<b>13</b>, and after the coupling of 4-nitropyrazole-3-carboxylic acid with EDC·HCl and HOBt,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> compounds <b>14</b>–<b>19</b> were obtained. Compounds <b>20</b>–<b>25</b> were obtained via the reduction of the nitro-groups in compounds <b>14</b>–<b>19</b>. All target compounds (<b>27</b>–<b>62</b>) were prepared by ammonolysis of the appropriate chlorides with <b>20</b>–<b>25</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Routes of Compounds <b>27</b>–<b>62</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01261&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) relative amine, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>; (b) FeO(OH)/C, 80% NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O, 95% EtOH; (c) 4-nitropyrazole-3-carboxylic acid, EDC·HCl, HOBt, DMF, room temperature; (d) FeO(OH)/C, 80% NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O, 95% EtOH; (e) <b>R<sup>2</sup></b>–Cl, AcOH/H<sub>2</sub>O, 50 °C.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structures and Biological Evaluations of the Target Compounds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0010.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0011.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0012.gif" alt="" id="GRAPHIC-d231e625-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0013.gif" alt="" id="GRAPHIC-d231e626-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">In the presence of 10 μM ATP and 0.123 μM concentrations of the target compounds. The values are the means ± SD from three independent experiments.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">nd: not determined.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last"><i>n</i> = 3.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Optimization of the Hydrophilic Group in the Solvent-Accessible Area</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0014.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0015.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">In the presence of 10 μM ATP and 0.123 μM concentrations of the target compounds. The values are the means ± SD from three independent experiments.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last"><i>n</i> = 3.</p></div></div><div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28863" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28863" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In our previous studies,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> a series of pyrazole-3-carboxamide compounds were synthesized. Recently, it has been identified that compound <b>26</b> inhibits FLT3 and CDK2 with IC<sub>50</sub>’s of 42.6 nM and 318 nM, respectively. With the help of computer-aided drug design (CADD), we found that the hydrophobic cavity of CDK2 formed by ASP145, VAL18, PHE80, and LYS33 (corresponding to ASP757, PHE691, PHE627, and LYS650 in FLT3) was wide enough to accommodate a larger hydrophobic group. Guided by our previous studies, we kept the 1-<i>H</i>-pyrazole-3-carboxamide skeleton and the hydrophobic phenyl ring linked to 3-carboxamide (the binding modes were shown in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). In position 4 of the pyrazole, the benzoyl group was cyclized to give a pyrimidobenzene ring structure, and then various binary aromatic heterocycles were incorporated to study the effects of the hydrophobic group on kinase-inhibitory activities. In the solvent-accessible region, different hydrophilic fragments were introduced, leading to a series of 1-<i>H</i>-pyrazole-3-carboxamide derivatives. All derivatives were tested for their inhibitory potencies toward recombinant human CDK2/cyclin A1 and FLT3 and their antiproliferative effects on MV4-11 cells (human-acute-monocytic-leukemia-cell line).</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Structure–Activity-Relationship (SAR) Studies</h3><div class="NLM_p">The results of the kinase-inhibition assays are listed in <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> with AT-7519 and sorafenib as the positive controls. Minimizing the diversity of the substituents in the phenyl ring enabled us to investigate how varying the substituents at the C4-position of the pyrazole affected the activity against CDK2 and FLT3. As is shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, both CDK2 and FLT3 affinities increased slightly compared with that of the parent compound when the benzoyl in <b>26</b> was replaced by quinolone (compounds <b>27</b> and <b>42</b>) or isoquinoline (compounds <b>28</b> and <b>44</b>) . This might be the benefit of the edge-to-face aromatic–aromatic interactions between the pyridine and PHE80 in CDK2 and PHE691 in FLT3 and the hydrophobic interactions formed by the phenyl ring with the ASP145 in CDK2 and ASP698 in FLT3, respectively (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding-mode analysis of compound <b>42</b> to CDK2 kinase and FLT3 kinase. (A) Compound <b>42</b> docked into CDK2 kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VU3">2VU3</a>). (B) Compound <b>42</b> docked into the homology model of FLT3.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01261&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">CDK2- and FLT3-inhibitory activities were lost when the hydrogen at position 2 of quinoline was replaced by trifluoromethyl (<b>33</b>), probably because trifluoromethyl prevented the edge-to-face interaction between the aromatic ring and PHE80. Further introduction of different substituents to isoquinoline or quinoline yield analogues <b>29</b>–<b>30</b> and <b>44</b>–<b>46</b>. Electron-withdrawing groups, such as bromine, in <b>29</b> and <b>46</b> can improve the affinity to FLT3. However, compounds <b>30</b>, <b>44</b>, and <b>46</b>, substituted with electron-donating groups such as methoxyl, were slightly less active against both CDK2 and FLT3 when compared with <b>27</b> and <b>42</b>.</div><div class="NLM_p">The introduction of a nitrogen into the pyridine ring of <b>27</b> yielded analogue <b>31</b>, which interestingly showed a significant increase in its inhibitory activities against CDK2 and FLT3 (IC<sub>50</sub>’s of 5.30 nM and 0.588 nM, respectively). Replacement of the morpholine (<b>31</b>) with <i>N</i>-methylpiperazine (<b>47</b>) also retained excellent activity against CDK2 (IC<sub>50</sub>: 3.17 nM) and FLT3 (IC<sub>50</sub>: 8.27 nM). The inhibitory activities were approximately 10 times more potent than those of AT7519 and sorafenib. The addition of a chlorine atom into the 2 position of pyrimidine (<b>32</b>) resulted in a decrease in the affinity to CDK2 when compared with that of <b>31</b>, supporting the hypothesis that a substituent in C2 position of pyrimidine or pyridine might prevent edge-to-face interactions between the aromatic ring and PHE80 (CDK2). However, the introduction of a chlorine atom has no impact on the inhibitory activity of <b>32</b> against FLT3. We speculate that the distance between the pyrimidine ring and the gatekeeper residue PHE675 of FLT3 is far enough to accommodate the chlorine atom.</div><div class="NLM_p">The pyrimidine in the fused heterocycle seems to be optimal for forming an aromatic–aromatic interaction with the gatekeeper PHE80 in CDK2. To further investigate the hydrophobic interactions of aromatic rings with the hydrophobic cavity, the phenyl ring of the fused heterocycle was then replaced with five-membered aromatic heterocycles. Modifications to the phenyl ring resulted in analogues <b>35</b>–<b>39</b> and <b>48</b>–<b>56</b>, among which the thienopyrimidine analogues (<b>35</b> and <b>48</b>) retained the same affinities to CDK2 and FLT3 when compared with those of <b>31</b> and <b>47</b>. Even when the position 7 or 8 hydrogen of thieno[2,3-<i>d</i>]pyrimidine was substituted with methyl (<b>39</b>, <b>53</b>, and <b>54</b>), ethyl (<b>37</b> and <b>56</b>), or isopropyl (<b>38</b> and <b>55</b>), the strong inhibitory activities against CDK2 and FLT3 were maintained. Moreover, changing the position of the sulfur atom (<b>51</b>) did not affect the kinase-inhibitory activities. In order to obtain additional SAR information, we replaced the thiazole ring with furan (<b>49</b>) and pyrrole (<b>36</b> and <b>50</b>) on the basis of the bioisosterism. The pyrrolopyrimidine analogue, <b>50</b>, exhibited a similar kinase-inhibitory potency to that of <b>48</b> for both CDK2 and FLT3. But the furan-substituted compound, <b>49</b>, showed a decreased inhibitory efficiency against CDK2. Overall, the introduction of pyrrolopyrimidine or thienopyrimidine is important for kinase-inhibitory activities, especially against FLT3.</div><div class="NLM_p">Although having the 1-methylpiperazine or morpholine stretched to hydrophilic region conferred good potency for either CDK2- or FLT3-inhibitory activities, there was no evidence to clarify which hydrophilic group would be optimal in consideration of potency and physical properties. Thus, a series of piperazine replacements was investigated using both the thieno[2,3-<i>d</i>]pyrimidine and the 7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine as the hydrophobic segments. All these compounds are listed in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>.</div><div class="NLM_p last">It is noteworthy that modifications in the hydrophilic region could maintain the inhibitory activities of the compounds against CDK2 and FLT3. However, the 7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine derivatives (<b>61</b>–<b>62</b>, <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) led to decreases in cell-based activities compared with those of the thieno[2,3-<i>d</i>]pyrimidine derivatives (<b>57</b>–<b>58</b>, <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). These decreases may be caused by decreases in the lipophilicity of the compounds, which influences the permeability of compounds. Further studies have shown that introducing thieno[2,3-<i>d</i>]pyrimidine led to higher clearance rates in liver microsomes. The introduction of a diethylamine group (<b>62</b>, <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) maintained cell potency with acceptable lipophilicity but showed poor CDK2 activity. Taken together, optimizing the hydrophilic region did not significantly improve the efficiencies of the compounds. Hence, the introduction of a fused heterocycle that contains a pyrimidine or pyridine structure to pyrazole is suggested to be the most critical factor in determining the potency of pyrazole-carboxamide derivatives toward FLT3 and CDKs.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Kinase-Inhibition Profile of Compound <b>48</b></h3><div class="NLM_p">Among the series of compounds mentioned above, one promising compound, <b>48</b>, was tested against a panel of 339 kinases by Reaction Biology Corporation at a single concentration of 10 μM (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A). On the basis of kinase-activity results, 28 kinases were selected for further assays (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B and <a class="ref internalNav" href="#notes-2" aria-label="Table S1">Table S1</a>). Compound <b>48</b> displayed the highest inhibitory activities against CDK2/cyclinA1 (IC<sub>50</sub>: 9.47 nM) and FLT3 (IC<sub>50</sub>: 0.438 nM). It should be noted that <b>48</b> also has inhibitory activities against CDK4/cyclinD1 (IC<sub>50</sub>: 5.57 nM) and CDK6/cyclinD1 (IC<sub>50</sub>: 4.5 nM), whose IC<sub>50</sub>’s are followed by those of CDK9/cyclinK (IC<sub>50</sub>: 38.9 nM), FLT1/VEGFR1 (IC<sub>50</sub>: 19.8 nM), KDR/VEGFR2 (IC<sub>50</sub>: 35.1 nM), ALK (IC<sub>50</sub>: 94.1 nM), and CDK1/cyclinE (IC<sub>50</sub>: 96 nM). Therefore, compound <b>48</b> is identified to be a multiple-kinase inhibitor; inhibition of multiple pathways simultaneously by compound <b>48</b> is beneficial in improving its antitumor efficiency and overcoming drug resistance.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Distribution of kinases inhibited by compound <b>48</b> within the human kinome. The color code for inhibition is indicated. Residual enzymatic activities were determined in single-dose duplicates at compound concentrations of 10 μM. The ATP concentration was 10 μM. Staurosporine served as a positive control. The experiment was performed by Reaction Biology Corp. using a <sup>33</sup>P-radiolabeled assay. (B) Inhibitory activity of compound <b>48</b> against selected kinases using the <sup>33</sup>P-radiolabeled assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01261&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Inspired by the kinase-profiling result, five representative CDK2 and FLT3 inhibitors, <b>35</b>, <b>48</b>, <b>49</b>, <b>50</b>, and <b>51</b>, were further evaluated for inhibitory activities against CDK4/cyclin D1, CDK6/cyclin D1, kinases other than CDK2/cyclinA and FLT3 (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). All the selected compounds showed high inhibitory activities against these kinases with IC<sub>50</sub>’s lower than 10 nM, suggesting that these compounds might be even more potent CDK and FLT3 inhibitors (i.e., <b>50</b>: CDK2 IC<sub>50</sub>: 2.47 nM, CDK4 IC<sub>50</sub>: 0.85 nM, CDK6 IC<sub>50</sub>: 1.96 nM, FLT3 IC<sub>50</sub>: 0.28 nM).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Inhibitory Activities of Compounds <b>35</b>, <b>48</b>, <b>49</b>, <b>50</b>, and <b>51</b> toward CDKs and FLT3 Kinases</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center">compound IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center"><b>35</b></th><th class="colsep0 rowsep0" align="center"><b>48</b></th><th class="colsep0 rowsep0" align="center"><b>49</b></th><th class="colsep0 rowsep0" align="center"><b>50</b></th><th class="colsep0 rowsep0" align="center"><b>51</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK2/cyclin A</td><td class="colsep0 rowsep0" align="char" char="±">3.36 ± 0.26</td><td class="colsep0 rowsep0" align="char" char="±">5.85 ± 0.58</td><td class="colsep0 rowsep0" align="char" char="±">16.5 ± 0.76</td><td class="colsep0 rowsep0" align="char" char="±">2.47 ± 0.21</td><td class="colsep0 rowsep0" align="char" char="±">9.32 ± 0.45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK4/cyclin D1</td><td class="colsep0 rowsep0" align="char" char="±">2.40 ± 0.27</td><td class="colsep0 rowsep0" align="char" char="±">3.33 ± 0.24</td><td class="colsep0 rowsep0" align="char" char="±">5.67 ± 0.30</td><td class="colsep0 rowsep0" align="char" char="±">0.85 ± 0.28</td><td class="colsep0 rowsep0" align="char" char="±">3.10 ± 0.34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK6/cyclin D1</td><td class="colsep0 rowsep0" align="char" char="±">3.88 ± 0.17</td><td class="colsep0 rowsep0" align="char" char="±">4.24 ± 0.23</td><td class="colsep0 rowsep0" align="char" char="±">5.09 ± 0.44</td><td class="colsep0 rowsep0" align="char" char="±">1.96 ± 0.08</td><td class="colsep0 rowsep0" align="char" char="±">4.11 ± 0.29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FLT3</td><td class="colsep0 rowsep0" align="char" char="±">0.62 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">0.60 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">2.56 ± 0.11</td><td class="colsep0 rowsep0" align="char" char="±">0.28 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.47 ± 0.02</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">In the presence of 10 μM ATP and 0.123 μM concentrations of the target compounds. The values are the means ± SD from three independent experiments.</p></div></div></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> In Vitro Cell Assays</h3><div class="NLM_p">All of target compounds (<b>27</b>–<b>62</b>) were evaluated against human-leukemia-cell line MV4-11 (FLT3<sup>ITD</sup>) using the MTT assay after 72 h incubations (see <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Compounds <b>31</b>, <b>36</b>–<b>40</b>, <b>47</b>–<b>48</b>, and <b>50</b>–<b>62</b> showed significant antiproliferative activities against MV4-11, with IC<sub>50</sub> values ranging from 0.0015 to 0.035 μM. Almost all of these derivatives proved to be more antiproliferative than <b>26</b>, which further certifies the rationality of our design strategy. Compounds <b>35</b>, <b>48</b>, and <b>50</b> were selected to evaluate their activities against a panel of cell lines that represent different tumor types, including gastric cancer, leukemia, breast cancer, and colorectal cancer. The growth of all the cell lines was inhibited by the selected compounds, and the 50% growth inhibition (GI<sub>50</sub>) values ranged from 51 to 620 nM (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vitro Growth-Inhibitory Activities of Selected Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center">cell type GI<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">MGC803</th><th class="colsep0 rowsep0" align="center">RS4;11</th><th class="colsep0 rowsep0" align="center">MCF-7</th><th class="colsep0 rowsep0" align="center">HCT-116</th><th class="colsep0 rowsep0" align="center">NCI-H82</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AT-7519</td><td class="colsep0 rowsep0" align="char" char="±">0.21 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.20 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">0.11 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.26 ± 0.13</td><td class="colsep0 rowsep0" align="char" char="±">0.27 ± 0.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="char" char="±">0.21 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.17 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">0.61 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">0.58 ± 0.11</td><td class="colsep0 rowsep0" align="char" char="±">0.29 ± 0.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48</b></td><td class="colsep0 rowsep0" align="char" char="±">0.16 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">0.13 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.62 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">0.37 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.17 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="char" char="±">0.37 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">0.05 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">2.84 ± 0.25</td><td class="colsep0 rowsep0" align="char" char="±">0.09 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">0.11 ± 0.02</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last"><i>n</i> = 3.</p></div></div></div><div class="NLM_p last">With these findings, we submitted <b>35</b>, <b>48</b>, and <b>50</b> to the Developmental Therapeutics Program at the National Cancer Institute (NCI, <a href="http://dtp.nci.nih.gov" class="extLink">http://dtp.nci.nih.gov</a>) to test their selectivities against the NCI60 cancer-cell lines. In this screen, compounds <b>35</b>, <b>48</b>, and <b>50</b> exhibited potent inhibitory activities on all 60 cancer cell lines (<a class="ref internalNav" href="#notes-2" aria-label="Figures S1–S3 in the Supporting Information">Figures S1–S3 in the Supporting Information</a>), with GI<sub>50</sub> < 0.5 μmol/L (the growth inhibition of 50%, calculated by [(Ti – Tz)/(C – Tz)] × 100 = 50, is the drug concentration resulting in a 50% reduction in the net protein increase, as measured by SRB staining in the control cells during the drug incubation). For the great majority of the lines, the LC<sub>50</sub>’s (concentrations of the drugs resulting in 50% reductions in the measured proteins at the end of the drug treatments as compared with those at the beginning, which indicates a net loss of cells following treatment and is calculated by [(Ti – Tz)/Tz] × 100 = −50) were >100 μmol/L (mean LC<sub>50</sub> > 400 μmol/L). In comparison, the lethal concentration of flavopiridol (mean GI<sub>50</sub>: 0.074 μmol/L against NCI60 cell lines), a potent inhibitor of CDKs, reached submicromolar concentrations (LC<sub>50</sub>: 0.904 μmol/L).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(41)</a></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Pharmacokinetics of <b>35</b> and <b>50</b> in Liver Microsomes of Multiple Species</h3><div class="NLM_p">The preliminary metabolic-stability study of compounds <b>35</b> and <b>50</b> were performed by using human liver microsomes (HML), rat liver microsomes (RLM), mouse liver microsomes (MLM), dog liver microsomes (DLM), and monkey liver microsomes (CLM, <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). The terminal half-lives (<i>t</i><sub>1/2</sub>) were moderate in human liver microsomes, rat liver microsomes, mouse liver microsomes, and monkey liver microsomes (ranging between 0.025 and 1.7 h). Compound <b>50</b> was metabolically more stable (<i>t</i><sub>1/2</sub> ranging between 0.25 and 1.7 h) than <b>35</b> (<i>t</i><sub>1/2</sub> shorter than 0.18 h). Given the drastic metabolic instability in the liver-microsomes experiment, compound <b>35</b> was not considered for further study. Some other studies have demonstrated that compounds with pyrimidothiophene rings are metabolically unstable.<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(42, 43)</a> Therefore, this series of compounds has not been considered for further investigation.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetics of Selected Compounds in Liver Microsomes of Multiple Species</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" colspan="2" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">compounds</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>35</b></th><th class="colsep0 rowsep0" align="center"><b>50</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="center">HML</td><td class="colsep0 rowsep0" align="center"><i>R</i><sup>2</sup><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">0.9793</td><td class="colsep0 rowsep0" align="center">0.3209</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">0.138</td><td class="colsep0 rowsep0" align="center">1.717</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">CL<sub>int</sub> (mL/min/kg)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">165.1</td><td class="colsep0 rowsep0" align="center">13.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="center">RLM</td><td class="colsep0 rowsep0" align="center"><i>R</i><sup>2</sup></td><td class="colsep0 rowsep0" align="center">0.8963</td><td class="colsep0 rowsep0" align="center">0.5008</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="center">0.118</td><td class="colsep0 rowsep0" align="center">1.032</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">CL<sub>int</sub> (mL/min/kg)</td><td class="colsep0 rowsep0" align="center">352.4</td><td class="colsep0 rowsep0" align="center">40.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="center">MLM</td><td class="colsep0 rowsep0" align="center"><i>R</i><sup>2</sup></td><td class="colsep0 rowsep0" align="center">0.9056</td><td class="colsep0 rowsep0" align="center">0.9465</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="center">0.12</td><td class="colsep0 rowsep0" align="center">0.66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">CL<sub>int</sub> (mL/min/kg)</td><td class="colsep0 rowsep0" align="center">765.1</td><td class="colsep0 rowsep0" align="center">138.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="center">DLM</td><td class="colsep0 rowsep0" align="center"><i>R</i><sup>2</sup></td><td class="colsep0 rowsep0" align="center">0.9899</td><td class="colsep0 rowsep0" align="center">0.9908</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="center">0.025</td><td class="colsep0 rowsep0" align="center">0.257</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">CL<sub>int</sub> (mL/min/kg)</td><td class="colsep0 rowsep0" align="center">1327.7</td><td class="colsep0 rowsep0" align="center">129.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="center">CLM</td><td class="colsep0 rowsep0" align="center"><i>R</i><sup>2</sup></td><td class="colsep0 rowsep0" align="center">0.9929</td><td class="colsep0 rowsep0" align="center">0.9051</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="center">0.182</td><td class="colsep0 rowsep0" align="center">0.855</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">CL<sub>int</sub> (mL/min/kg)</td><td class="colsep0 rowsep0" align="center">170.9</td><td class="colsep0 rowsep0" align="center">36.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last"><i>R</i><sup>2</sup> is the correlation coefficient of the linear regression for the determination of the kinetic constant.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last"><i>t</i><sub>1/2</sub> is the half-life.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">CL<sub>int</sub> is the intrinsic clearance.</p></div></div></div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Molecular Modeling of Compound <b>50</b> with CDK2 and FLT3</h3><div class="NLM_p">Compound <b>50</b> shows optimal FLT3- and CDK-inhibitory activities, and importantly, it is metabolically stable. Hence, the binding mode of compound <b>50</b> within CDK2 and FLT3 were elucidated using a docking model (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). As is shown in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A, compound <b>50</b> binds to the ATP-binding site of CDK2 in an orientation similar to that of AT-7519 (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B). The pyrazole-3-carboxamide skeleton of compound <b>50</b> forms three conserved hydrogen bonds with the hinge region of CDK2, one between the N1 of pyrazole and GLU81 and the other two between the NH of formamide and the N2 of pyrazole and LEU83 (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A).</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Binding-mode analysis of compound <b>50</b> to CDK2 kinase and FLT3 kinase. (A) Compound <b>50</b> docked into CDK2 kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VU3">2VU3</a>). (B) Overlapping images of compound <b>50</b> (green) and AT7519 (gray) complexed with CDK2. (C) Compound <b>50</b> docked into a homology model of FLT3.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> (D) Chemical structure of compound <b>50</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01261&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The fused heterocycle substituent has complementary packing and hydrophobic interactions with LYS33, VAL18, ASP145, ALA144, and the hydrophobic residue of the ILE10 side chain. The pyrrole NH forms additional polar interactions with the side chains of ASP145. A face-to-face interaction with the adjacent aromatic planes is observed between the pyrimidine and the kinase gatekeeper residue, PHE80. The phenyl ring occupies the small hydrophobic cavity between hinge region and the hydrophilic group. The <i>N</i>-methylpiperazine group sits in a solvent-accessible area that is mainly hydrophobic but lined with several polar residues at the edge (LYS89, ASP86, LEU298, and GLN85).</div><div class="NLM_p last">In <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B, we found that compound <b>50</b> binds to FLT3 in a similar fashion to its binding mode to CDK2 with the core pyrazole-3-carboxamide skeleton forming two conserved hydrogen bonds in the hinge region of FLT3. One is between the N1 of pyrazole and GLU692 and the other is between the N2 of pyrazole and CYS694. The 7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine substituent of <b>50</b> occupies the hydrophobic pocket, and the <i>N</i>-methylpiperazine group extends into the solvent-accessible area (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>C). In general, the docking results further confirm the rationality of our design strategy.</div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> In Vivo Effects of Compound <b>50</b> in sc MV4-11 Tumor Xenografts</h3><div class="NLM_p">On the basis of a desirable set of in vitro properties, compound <b>50</b> was finally selected for further in vivo evaluation. We proceeded to test the antitumor efficacy of compound <b>50</b> in MV4-11-cell-inoculated-xenograft mice.</div><div class="NLM_p">In the MV4-11 model, when the tumor grew to a volume of 200 mm<sup>3</sup>, the mice were grouped and treated intravenously once daily (QD) with 15, 30, or 40 (mg/kg)/d of compound <b>50</b> for 21 days. Another two groups were recruited: one group for negative control, which was given only the vehicle, and another group treated intravenously once daily with 50 (mg/kg)/d of cytarabine as a positive control for 21 days. The group injected with 50 (mg/kg)/d of cytarabine only had reduced tumor-growth rates, and the tumor-growth inhibition was 61.94% on the 21st day, whereas injections of <b>50</b> at 15 (mg/kg)/d induced tumor regression, for which the percent-tumor-regression (PTR) rate was −6.11% on the 21st day (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). Additionally, injections of <b>50</b> at 30 and 40 (mg/kg)/d significantly induced tumor regressions, and the PTRs on the 21st day were 78.95% and 81.33%, respectively (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B–D). Furthermore, <b>50</b> was well tolerated with no overt signs of toxicity or changes in body weight (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A). Experiments in rats demonstrated that <b>50</b> does have significant antitumor activity in vivo compared with cytarabine, which is used as a first-line chemotherapy drug against AML.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Antitumor efficacy of <b>50</b> in the MV4-11-xenograft model. Female nu/nu mice bearing established MV4-11-tumor xenografts were treated by intravenous injection (iv, QD) with <b>50</b> at 15, 30, or 40 (mg/kg)/d, with cytarabine at 50 (mg/kg)/d, or with the vehicle. (A) Body-weight and (B) tumor-size measurements from MV4-11-xenograft mice after <b>50</b> or cytarabine administration. Initial body weights and tumor sizes were set as 100%. (C) Representative photographs of tumors in each group after 15, 30, or 40 (mg/kg)/d of <b>50</b>, 50 (mg/kg)/d of cytarabine, or the vehicle treatment. (D) Comparison of the final tumor weights in each group after the 22 day treatment period. The numbers in columns indicate the mean tumor weight in each group. (*) <i>p</i> < 0.05, (**) <i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01261&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Toxicity Studies</h3><div class="NLM_p">Inspired by the excellent antitumor activity of compound <b>50</b>, we assessed its cytotoxicity on normal lymphocyte cells. Compound <b>50</b> showed little cytotoxicity to normal lymphocyte cells, comparable to those of AC220 (IC<sub>50</sub>: 0.492 μM) and AT7519 (IC<sub>50</sub>: 0.554 μM). To further evaluate the safety of <b>50</b> in vivo, we conducted additional LD<sub>50</sub> tests for AT-7519 and <b>50</b>; groups of ICR mice (half male and half female) were given single doses of compound <b>50</b> or AT7519 by intravenous injections. The survival of the mice was monitored and recorded over 12 days (<a class="ref internalNav" href="#notes-2" aria-label="Table S2">Table S2</a>). The LD<sub>50</sub> values of AT7519 were 32 mg/kg. However, the LD<sub>50</sub> values of <b>50</b> were 185.67 mg/kg, as shown in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>. Compound <b>50</b> exhibited significantly reduced toxicity compared with AT7519.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Median-Lethal-Dose (LD<sub>50</sub>) Values of <b>50</b> and AT7519</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center">LD<sub>50</sub>(mg/kg)</th><th class="colsep0 rowsep0" align="center">95% confidence interval (μmol/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">AT7519</td><td class="colsep0 rowsep0" align="char" char=".">32.00</td><td class="colsep0 rowsep0" align="char" char="−">28.20–36.32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>50</b></td><td class="colsep0 rowsep0" align="char" char=".">185.67</td><td class="colsep0 rowsep0" align="char" char="−">158.57–208.12</td></tr></tbody></table></div></div></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Cellular Mode of Action</h3><div class="NLM_p">To characterize the mode of cell death induced by compound <b>50</b>, biparametric-flow-cytometric analysis with annexin-V and propidium iodide (PI) was performed. Inducing apoptosis is considered as one of the major strategies for antitumor-drug development.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Flow cytometry was used to investigate whether the antiproliferative effect of compound <b>50</b> was caused by the activation of cellular apoptosis in MV4-11 cells. Quantitative analysis of early-apoptotic cells and advanced-apoptotic and necrotic cells was determined via an Annexin V-FITC and PI assay.</div><div class="NLM_p">MV4-11 cells were stimulated with 0.2–2 μM concentrations of compound <b>50</b> for 24 h. DMSO was used as the negative control, and sorafenib was used as the positive control. As shown in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>, the apoptosis induced by compound <b>50</b> was much greater than that of the control, and MV4-11 cells underwent both early apoptosis (Annexin V<sup>+</sup> and PI<sup>–</sup>, lower right) and advanced apoptosis and necrosis (Annexin V<sup>+</sup> and PI<sup>+</sup>, upper right). The results showed that compound <b>50</b> could effectively induce cell apoptosis starting from 0.2 μM with enhanced effects at higher concentrations. The apoptosis ratios of compound <b>50</b> measured at different concentrations were 24.35% (0.2 μM), 41.98% (0.5 μM), 46.34% (1 μM), and 78.30% (2 μM), and the apoptotic effect increased in a dose-dependent manner. From these results, we can conclude that <b>50</b> caused effective apoptotic effects in the MV4-11 cell line and showed an efficiency equivalent to that of sorafenib (75.32% at 2 μM).</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. MV4-11 cells were treated with compound <b>50</b> for 24 h and analyzed by Annexin V and PI staining. The percentage of cells undergoing apoptosis was defined as the sum of early-apoptotic, advanced-apoptotic, and necrotic cells. Upper right: advanced-apoptotic cells and necrotic cells labeled with PI and Annexin. Lower left: fully viable cells. Lower right: early-apoptotic cells labeled with Annexin V but not with PI. (A) DMSO control. (B) Compound <b>50</b>, 0.2 μM. (C) Compound <b>50</b>, 0.5 μM. (D) Compound <b>50</b>, 1 μM. (E) Compound <b>50</b>, 2 μM. (F) Sorafenib, 2 μM. (G) Percentage of apoptotic cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01261&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Furthermore, compound <b>50</b> was measured in MV4-11 and HCT-116 cell lines to determine if its antiproliferative activity was consistent with FLT3- and CDK2-signaling inhibition. The antiproliferative activity of compound <b>50</b> was verified by flow-cytometry analysis of the MV4-11 cell line and HCT-116 colon-cell line, through double staining with propidium iodide and 5-bromo-20-deoxyuridine (BrdU). As is shown in <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>, compound <b>50</b> arrested the cell-cycle progression of the former cell line into the G0 and G1 phases in a dose-dependent manner, which is comparable to action of sorafenib (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>A) in the MV4-11 cell line. Treatment with compound <b>50</b> mainly caused G2- or M-phase arrest in the HCT-116 cell lines (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>B), which could be related to the potent inhibition of CDKs. Overall, compound <b>50</b> arrested the cell cycle of two human-cancer-cell lines as efficiently as AT-7519 and sorafenib, and both cell lines displayed similar patterns of cell-cycle blockades as those with the positive control.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Cancer-cell-growth inhibition and cell-cycle arrest from compound <b>50</b> treatments in MV4-11 and HCT116 cells. (A) Effect of compound <b>50</b> on MV4-11 cell-cycle kinetics. Compound <b>50</b> was added at the concentrations shown to MV4-11 cells 24 h prior to fixation, staining with propidium iodide (PI), and flow-cytometric analysis. (B) Effect of compound <b>50</b> on HCT-116 cell cycles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01261&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We then treated the MV4-11 cell line with increasing doses of compound <b>50</b> for 24 h and immunoblotted the lysates with antibodies against the relative proteins involved in the FLT3-mediated signaling pathway (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>A). Treatment of MV4-11 cells with compound <b>50</b> for 24 h significantly decreased the phosphorylation of FLT3 and that of its downstream mediators STAT5, ERK, and AKT more than treatment with sorafenib did. As shown in <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>B, compound <b>50</b> inhibited Rb<sup>Ser807/811</sup> phosphorylation in a dose-dependent manner, and its efficiency was equal to that of AT7519 at 1 μM. These findings reveal that compound <b>50</b> acts as a highly efficient FLT3 and CDK inhibitor.</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0008.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Western blot analyses. (A) Immunoblots showing the phosphorylation of FLT3, STAT5, ERK, and AKT proteins in MV4-11 cells treated with compound <b>50</b> or sorafenib for 24 h. (B) Immunoblots showing the phosphorylation of the Rb protein in MV4-11 cells treated for 24 h with compound <b>50</b> or AT7519.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01261&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21441" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21441" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Starting from compound <b>26</b>, we have discovered a series of <i>N</i>-(4-methylphenyl)-1-<i>H</i>-pyrazole-3-carboxamide derivatives that are potent FLT3 and CDK inhibitors. The structure–activity-relationship analysis involving substitutions with fused heterocycles that contains pyrimidine and pyridine structures in position 4 of the 1-<i>H</i>-pyrazole-3-carboxamide moiety demonstrated that the 1-<i>H</i>-pyrazole-3-carboxamide moiety was a key strategic group in the improvement of CDK2- and FLT3-inhibitory activities and antiproliferative activities. Compound <b>50</b> showed nanomolar range CDK and FLT3 inhibition and significant cytotoxic effects in NCI60 cancer-cell lines (IC<sub>50</sub> < 1 μM). In addition, <b>50</b> exhibited a high metabolic stability in the liver-microsomal-metabolism assay. The in vivo study in the MV4-11-xenograft model showed that <b>50</b> had a higher antitumor efficacy at a dosage of 15.0 (mg/kg)/d than cytarabine did at a dosage of 50.0 (mg/kg)/d and furthermore that <b>50</b> induced tumor regression when the doses increased to 30.0 (mg/kg)/d or 40.0 (mg/kg)/d. Currently, compound <b>50</b> is in phase I clinical trials in the United States and China as a cancer treatment, and it may represent a promising drug with therapeutic potential for the treatment of AML.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Expermental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76514" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76514" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Procedures</h3><div class="NLM_p last">Unless otherwise specified, reagents were purchased from commercial suppliers and used without further purification. Melting points were determined by an X-4 digital-display micromelting-point apparatus (Beijing Tech Instrument Company, Ltd., Beijing, China). NMR spectra were recorded on a Bruker AVANCE AV-600 spectrometer (800 MHz for <sup>1</sup>H and 150 MHz for <sup>13</sup>C) or a Bruker AVANCE AV-300 spectrometer (300 MHz for <sup>1</sup>H and 75 MHz for <sup>13</sup>C; Bruker, Billerica, MA). Mass spectra were obtained on an Agilent 1100 LC/MSD mass spectrometer (Agilent, Santa Clara, CA) and Micromass Q-tofmicro MS (Waters, Milford, MA). All reactions were monitored by TLC (Silica gel GF254, Merck, Kenilworth, NJ), and spots were visualized with UV light or iodine. The purities of the biologically evaluated compounds were >95% as determined by HPLC.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> General Procedure A for the Synthesis of Compounds <b>2</b>–<b>7</b></h3><div class="NLM_p">4-Nitrobenzyl bromide (46.3 mmol) was dissolved in dichloromethane (100 mL). The solution was added to a mixture of relative amine (47.0 mmol) and triethylamine (70.3 mmol) in dichloromethane (20 mL). The reaction mixture was stirred at room temperature (rt) for 24 h and was extracted with dichloromethane (100 mL × 3). After the removal of the solvent, the residue was crystallized from ethanol, giving a yellow powder. Compounds <b>2</b>–<b>7</b> were used for further reactions without purification.</div><div class="NLM_p">To a suspension of compounds <b>2</b>–<b>7</b> (36.2 mmol) in 95% ethanol (100 mL), 85% NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O (362 mmol), 95% ethanol (100 mL), and iron(III) oxide hydroxide (FeO(OH)/C, 2.0 g) were added and heated to reflux.<a onclick="showRef(event, 'ref40 ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref40 ref45 ref46">(40, 44, 45)</a> When TLC analysis showed the complete conversion of the starting material, the reaction mixture was filtrated through celite, and the filtrate was concentrated in a vacuum. The crude product was purified by silica-gel column chromatography (DCM/MeOH) to yield the title compound as a white solid.</div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 4-(Morpholinomethyl)aniline (<b>8</b>)</h4><div class="NLM_p last">Compound <b>8</b> was prepared according to general procedure A on a 36.2 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (6.0 g, 31 mmol, 86% yield). [M + H]<sup>+</sup>: 193. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 2.32 (s, 4 H), 3.24 (s, 4 H), 3.51 (s, 2 H), 4.92 (s, 2 H), 6.53 (d, 2 H, <i>J</i> = 8.4 Hz), 6.90 (d, 2 H, <i>J</i> = 8.4 Hz).</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 4-((4-Methylpiperazin-1-yl)methyl)aniline (<b>9</b>)</h4><div class="NLM_p last">Compound <b>9</b> was prepared according to general procedure A on a 36.2 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (7.3 g, 34.2 mmol, 94% yield). [M + H]<sup>+</sup>: 206. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.11 (s, 3 H), 2.37 (br, 8 H), 3.50 (s, 2 H), 4.01 (s, 2 H), 7.54 (d, 2 H, <i>J</i> = 8.7 Hz), 8.23 (d, 2 H, <i>J</i> = 8.7 Hz).</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Tert-butyl-4-(4-aminobenzyl)piperazine-1-carboxylate (<b>10</b>)</h4><div class="NLM_p last">Compound <b>10</b> was prepared according to general procedure A on a 36.2 mmol scale. Purification by column chromatography (10% MeOH/DCM) yielded the title compound (8.2 g, 28.1 mmol, 78% yield). [M + H]<sup>+</sup>: 292. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 1.38 (s, 9 H), 2.24–2.26 (m, 4 H), 3.26 (s, 4 H), 3.41 (s, 2 H), 4.92 (s, 2 H), 6.48–6.51 (d, 2 H, <i>J</i> = 8.7 Hz), 6.89–6.92 (d, 2 H, <i>J</i> = 8.7 Hz).</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 4-((4-Methyl-1,4-diazepan-1-yl)methyl)aniline (<b>11</b>)</h4><div class="NLM_p last">Compound <b>11</b> was prepared according to general procedure A on a 36.2 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (4.9 g, 23.1 mmol, 65% yield). [M + H]<sup>+</sup>: 220. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 1.64–1.69 (m, 2 H), 1.81–1.96 (m, 4 H), 2.09–2.15 (m, 2 H), 4.59 (d, 2 H, <i>J</i> = 6.72 Hz), 4.77 (m, 1 H, <i>J</i> = 7.05 Hz), 7.28 (d, 2 H, <i>J</i> = 8.22 Hz), 7.49 (d, 2 H, <i>J</i> = 8.22 Hz), 8.26 (s, 1 H), 8.83 (t, 1 H, <i>J</i> = 6.72 Hz).</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 4-((Diethylamino)methyl)aniline (<b>12</b>)</h4><div class="NLM_p last">Compound <b>12</b> was prepared according to general procedure A on a 36.2 mmol scale. Purification by column chromatography (3% MeOH/DCM) yielded the title compound (2.9 g, 17.1 mmol, 46% yield). [M + H]<sup>+</sup>: 179. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 1.04–1.09 (t, 6 H), 2.61–2.69 (q, 4 H, <i>J</i> = 6.72 Hz), 3.65 (s, 2 H), 5.10 (br, 2 H), 6.52–6.55 (d, 2 H, <i>J</i> = 8.31 Hz), 7.03–7.07 (d, 2 H, <i>J</i> = 8.22 Hz).</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 4-((Cyclopropylamino)methyl)aniline (<b>13</b>)</h4><div class="NLM_p last">Compound <b>13</b> was prepared according to general procedure A on a 36.2 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (3.1 g, 19.8 mmol, 54% yield). [M + H]<sup>+</sup>: 163. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 0.05–0.14 (m, 4 H), 1.76–1.83 (m, 2 H), 3.00 (s, 1 H), 4.64 (d, 2 H, <i>J</i> = 6.72 Hz), 6.26–6.29 (d, <i>J</i> = 8.22 Hz, 2 H), 6.71–6.75 (d, 2 H, <i>J</i> = 8.22 Hz).</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> General Procedure B for the Synthesis of Compounds <b>20</b>–<b>25</b></h3><div class="NLM_p">The mixture of compounds <b>8</b>–<b>13</b> (1 equiv, 18.5 mmol), 4-nitro-1<i>H</i>-pyrazole-3-acid (1.1 equiv, 20.4 mmol), EDC (1.2 equiv, 22.2 mmol), and HOBT (1.2 equiv, 22.2 mmol) in DMF (50 mL) was stirred for 24 h. Ice water (100 mL) was added to the reaction mixture. A large amount of yellow, solid precipitation (compounds <b>3a</b>–<b>f</b>) was acquired. Compounds <b>14</b>–<b>19</b> were used without further purification. Compounds <b>20</b>–<b>25</b> were reduced by the same process as compound <b>8</b>–<b>13</b>; then the resulting compounds <b>20</b>–<b>25</b> were purified by column chromatography on silica gel and eluted with the appropriate solvent.</div><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 4-Amino-<i>N</i>-(4-(morpholinomethyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>20</b>)</h4><div class="NLM_p last">Compound <b>20</b> was prepared according to general procedure B on an 18.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (3.6 g, 12.0 mmol, 65% yield). [M + H]<sup>+</sup>: 302. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.51 (s, 4 H), 3.42 (s, 2 H), 3.61 (s, 4 H), 4.71 (s, 2 H), 7.21–7.26 (m, 3 H), 7.72–7.58 (d, 2 H, <i>J</i> = 8.4 Hz), 9.7 (s, 1 H), 12.7 (s, 1 H);</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 4-Amino-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>21</b>)</h4><div class="NLM_p last">Compound <b>21</b> was prepared according to general procedure B on an 18.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (4.1 g, 15.4 mmol, 76% yield). [M + H]<sup>+</sup>: 315. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.13 (s, 3 H), 2.38 (s, 8 H), 3.43 (s, 2 H), 4.71 (s, 2 H), 7.11–7.24 (m, 3 H), 7.71–7.81 (d, 2 H, <i>J</i> = 8.4 Hz), 9.72 (s, 1 H), 12.71 (s, 1 H).</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Tert-butyl-4-(4-(4-amino-1<i>H</i>-pyrazole-3-carboxamido)benzyl)piperazine-1-carboxylate (<b>22</b>)</h4><div class="NLM_p last">Compound <b>22</b> was prepared according to general procedure B on an 18.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (1.8 g, 4 mmol, 24% yield). [M + H]<sup>+</sup>: 401. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 1.39 (s, 9 H), 2.31 (s, 4 H), 3.43 (s, 2 H), 4.68 (s, 2 H), 7.17–7.20 (d, 2 H, <i>J</i> = 7.71 Hz), 7.22 (s, 1 H), 7.72–7.74 (d, 2 H, <i>J</i> = 7.95 Hz), 9.70 (s, 1 H), 12.75 (s, 1 H).</div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 4-Amino-<i>N</i>-(4-((4-methyl-1,4-diazepan-1-yl)methyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>23</b>)</h4><div class="NLM_p last">Compound <b>23</b> was prepared according to general procedure B on an 18.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (1.3 g, 3.9 mmol, 21% yield). [M + H]<sup>+</sup>: 329.3. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ: 1.66–1.73 (m, 2 H), 2.24 (s, 2 H), 2.51–2.64 (m, 8 H), 3.38 (s, 2 H), 4.73 (br, 2 H), 7.14 (s, 1 H), 7.21–7.24 (d, 2 H, <i>J</i> = 8.37 Hz), 7.68–7.71 (d, 2 H, <i>J</i> = 8.40 Hz), 9.94 (s, 1 H).</div></div><div id="sec5_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 4-Amino-<i>N</i>-(4-((diethylamino)methyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>24</b>)</h4><div class="NLM_p last">Compound <b>24</b> was prepared according to general procedure B on an 18.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (2.0 g, 6.8 mmol, 37% yield). [M + H]<sup>+</sup>: 288. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 1.06 (s, 6 H), 2.52 (s, 2 H), 2.61–2.69 (m, 4 H), 4.70 (d, 2 H, <i>J</i> = 6.72 Hz), 7.18 (s, 1 H, <i>J</i> = 7.05 Hz), 7.32 (d, 2 H, <i>J</i> = 8.22 Hz), 7.76 (d, 2 H, <i>J</i> = 8.22 Hz), 9.76 (s, 1 H), 12.79 (s, 1 H).</div></div><div id="sec5_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 4-Amino-<i>N</i>-(4-((cyclopropylamino)methyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>25</b>)</h4><div class="NLM_p last">Compound <b>25</b> was prepared according to general procedure B on an 18.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (0.9 g, 3.3 mmol, 18% yield). [M + H]<sup>+</sup>: 272. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 0.34–0.36 (m, 4 H), 2.05 (s, 2 H), 3.69 (s, 2 H), 4.70 (s, 2 H), 7.17–7.26 (m, 3 H), 7.69–7.70 (d, 2 H, <i>J</i> = 4.5 Hz), 9.61 (s, 1 H), 12.74 (s, 1 H).</div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> General Procedure C for the Synthesis of Compounds <b>27</b>–<b>62</b></h3><div class="NLM_p">Compounds <b>20</b>–<b>25</b> (1 equiv) and the corresponding chorides (1.2 equiv) in AcOH/H<sub>2</sub>O:1/1 (20 mL) were heated to 50 °C. When TLC analysis showed the complete conversion of the starting material, sodium hydroxide (2 equiv) was added to the mixture. Then, the reaction mixture was extracted with ethyl acetate. After the removal of the solvent, the residue was purified by column chromatography, and the corresponding compound was obtained.</div><div id="sec5_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>-(4-(Morpholinomethyl)phenyl)-4-(quinolin-4-ylamino)-1<i>H</i>-pyrazole-3-carboxamide (<b>27</b>)</h4><div class="NLM_p last">Compound <b>27</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound, (77 mg, 0.18 mmol, 36% yield). Yellow solid; mp 175–279 °C. HPLC analysis: retention time, 5.168 min; peak area, 98.43%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.35 (m, 4 H,), 3.42 (s, 2 H), 3.57 (m, 4 H), 7.00 (d, 1 H, <i>J</i> = 4.8 Hz), 7.25–7.28 (d, <i>J</i> = 7.9 Hz, 2 H), 7.62 (t, <i>J</i> = 8.0 Hz, 1 H), 7.69–7.72 (d, 2 H, <i>J</i> = 7.9 Hz), 7.76 (d, 2 H, <i>J</i> = 8.0 Hz), 7.90 (d, 1 H, <i>J</i> = 8.1 Hz), 8.13 (d, 1 H, <i>J</i> = 8.0 Hz), 8.23 (s, 1 H), 8.6 (d, 1 H, <i>J</i> = 4.8 Hz), 9.9 (br, 1 H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 25.08, 53.10, 62.03, 66.18, 100.71; 118.90, 12 125.24, 125.87, 129.12, 129.31, 132.05, 132.95, 137.33, 145.56, 148.21, 150.78, 161.97, 175.20; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>25</sub>N<sub>6</sub>O<sub>2</sub>: 429.2039, found: 429.2049.</div></div><div id="sec5_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 4-(Isoquinolin-1-ylamino)-<i>N</i>-(4-(morpholinomethyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>28</b>)</h4><div class="NLM_p last">Compound <b>28</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (116 mg, 0.27 mmol, 54% yield). White solid; mp 285–287 °C. HPLC analysis: retention time, 4.109 min; peak area, 100.00%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.38 (s, 4 H), 3.46 (s, 2 H), 3.59 (s, 4 H), 7.19 (d, 1 H, <i>J</i> = 5.8 Hz), 7.31 (d, 2 H, <i>J</i> = 8.1 Hz), 7.75 (dd, 2 H, <i>J</i> = 9.1 Hz), 7.85 (d, 3 H, <i>J</i> = 8.1 Hz), 8.03 (d, 1 H, <i>J</i> = 6.7 Hz), 8.13 (d, 1 H, <i>J</i> = 5.7 Hz), 8.66 (s, 1 H), 10.30 (d, 2 H, <i>J</i> = 6.5 Hz), 13.42 (s, 1 H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 53.09, 62.01, 66.15, 112.04, 117.67, 119.39, 120.40, 120.87, 121.18, 125.84, 127.27, 127.36, 129.47, 130.38, 132.01, 136.68, 137.34, 141.24, 150.48, 163.39; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>24</sub>N<sub>6</sub>O<sub>2</sub>: 429.2039, found: 429.2049.</div></div><div id="sec5_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 4-((6-Bromoquinolin-4-yl)amino)-<i>N</i>-(4-(morpholinomethyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>29</b>)</h4><div class="NLM_p last">Compound <b>29</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (65 mg, 0.13 mmol, 26% yield). Yellow solid; mp 231–235 °C. HPLC analysis: retention time, 4.360 min; peak area, 99.49%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.35 (s, 4 H), 3.43 (s, 2 H), 3.57 (s, 4 H), 6.83–6.86 (d, 1 H, <i>J</i> = 5.13 Hz), 7.24–7.27 (d, 2 H, <i>J</i> = 8.25 Hz), 7.73–7.76 (d, 2 H, <i>J</i> = 8.16 Hz), 7.84 (s, 1 H), 8.28 (s, 1 H), 8.47 (s, 1 H), 8.52 (s, 1 H), 9.38 (s, 1 H), 10.23 (s, 1 H), 13.65 (s, 1 H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 53.16, 62.05, 66.22, 101.52, 118.03, 120.27, 120.48, 122.84, 123.51, 123.89, 129.34, 131.51, 132.44, 132.98, 136.30, 137.36, 146.50, 146.91, 151.30, 161.65; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>24</sub>BrN<sub>6</sub>O<sub>2</sub>: 507.1144, found: 507.1143.</div></div><div id="sec5_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 4-((7-Methoxyquinolin-4-yl)amino)-<i>N</i>-(4-(morpholinomethyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>30</b>)</h4><div class="NLM_p last">Compound <b>30</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (49 mg, 0.11 mmol, 21% yield). Yellow solid; mp 185–187 °C. HPLC analysis: retention time, 3.516 min; peak area, 100.00%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.34 (s, 4 H), 3.42 (s, 2 H), 3.57 (s, 4 H), 3.91 (s, 3 H), 6.88 (d, 1 H, <i>J</i> = 4.2 Hz), 7.28 (s, 4 H), 7.75 (d, 1 H, <i>J</i> = 7.5 Hz), 8.02 (d, 1 H, <i>J</i> = 8.7 Hz), 8.35 (s, 1 H), 8.49 (d, 1 H, <i>J</i> = 4.2 Hz), 9.64 (s, 1 H), 10.31 (s, 1 H), 13.6 (s, 1 H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 21.20, 53.01, 55.27, 61.95, 66.10, 99.63, 107.64, 113.18, 117.31, 120.20, 120.51, 121.66, 125.31, 129.17, 133.08, 133.79, 137.00, 145.94, 149.60, 150.74, 160.00, 162.04; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>27</sub>N<sub>6</sub>O<sub>3</sub>: 459.2145, found: 459.2134.</div></div><div id="sec5_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>N</i>-(4-(Morpholinomethyl)phenyl)-4-(quinazolin-4-ylamino)-1<i>H</i>-pyrazole-3-carboxamide (<b>31</b>)</h4><div class="NLM_p last">Compound <b>31</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (120 mg, 0.28 mmol, 56% yield). Yellow solid; mp 215–217 °C. HPLC analysis: retention time, 4.234 min; peak area, 99.18%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.33 (s, 4 H), 3.17 (s, 2 H), 3.41 (s, 2 H), 3.56 (s, 4 H), 7.27–7.29 (d, 2 H, <i>J</i> = 7.86 Hz), 7.71–7.73 (t, 1 H), 7.79–7.88 (m, 4 H), 7.98–8.00 (1 H, d, <i>J</i> = 7.98 Hz), 8.64 (s, 1 H), 8.73 (s, 1 H), 10.45 (s, 1 H), 10.63 (s, 1 H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 53.23, 62.15, 66.30, 114.65, 120.95, 121.04, 123.94, 127.27, 128.25, 129.29, 132.87, 133.29, 133.44, 137.04, 149.21, 154.91, 155.29, 163.00; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>24</sub>N<sub>7</sub>O<sub>2</sub>: 430.1991, found: 430.2006.</div></div><div id="sec5_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 4-((2-Chloroquinazolin-4-yl)amino)-<i>N</i>-(4-(morpholinomethyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>32</b>)</h4><div class="NLM_p last">Compound <b>32</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (54 mg, 0.12 mmol, 23% yield). Yellow solid; mp 235–237 °C. HPLC analysis: retention time, 3.758 min; peak area, 99.00%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.36 (s, 4 H), 3.45 (s, 2 H), 3.60 (s, 4 H), 7.28–7.31 (d, 2 H, <i>J</i> = 8.28 Hz), 7.72–7.81 (m, 4 H), 7.90–7.95 (s, 1 H, <i>J</i> = 7.35 Hz), 8.0–8.1 (d, 1 H, <i>J</i> = 8.01 Hz), 8.47 (s, 1 H), 10.42 (s, 1 H), 10.87 (s, 1 H), 13.62 (s, 1 H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 162.86, 156.82, 156.23, 150.36, 136.82, 134.21, 133.42, 129.13, 127.45, 127.18, 122.83, 121.58, 120.87, 113.19, 66.17, 62.00, 53.10; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>23</sub>ClN<sub>7</sub>O<sub>2</sub>: 464.1602, found: 464.1602.</div></div><div id="sec5_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>N</i>-(4-(Morpholinomethyl)phenyl)-4-((2-(trifluoromethyl)quinolin-4-yl)amino)-1<i>H</i>-pyrazole-3-carboxamide (<b>33</b>)</h4><div class="NLM_p last">Compound <b>33</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (46 mg, 0.09 mmol, 19% yield). Yellow solid; mp 215–218 °C. HPLC analysis: retention time, 4.386 min; peak area, 100.00%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.45 (s, 4 H), 3.42 (s, 2 H), 3.63 (s, 4 H), 7.18–7.20 (d, 1 H, <i>J</i> = 5.73 Hz), 7.34–7.36 (d, 2 H, <i>J</i> = 6.63 Hz), 7.73–7.76 (m, 2 H), 8.01–8.04 (d, 1 H, <i>J</i> = 6.57 Hz), 8.12–8.14 (d, 1 H, <i>J</i> = 5.73 Hz), 8.66 (s, 1 H), 10.28 (s, 1 H), 10.33 (s, 1 H), 13.48 (s, 1 H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 51.99, 52.82, 65.86, 111.89, 117.55, 119.26, 120.71, 121.05, 125.70, 127.10, 127.20, 129.23, 129.49, 130.20, 136.56, 137.33, 141.09, 150.37, 163.26; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>24</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub>: 497.1913, found: 497.1921.</div></div><div id="sec5_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 4-((6-Methoxyquinazolin-4-yl)amino)-<i>N</i>-(4-(morpholinomethyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>34</b>)</h4><div class="NLM_p last">Compound <b>34</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (85 mg, 0.19 mmol, 37% yield). Yellow solid; mp 251–252 °C. HPLC analysis: retention time, 3.255 min; peak area, 100.00%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.55 (s, 4 H), 3.66 (s, 6 H), 3.97 (s, 3 H), 7.33–7.38 (m, 3 H), 7.55–7.57 (d, 2 H, <i>J</i> = 7.53 Hz), 7.78–7.88 (m, 3 H), 8.60 (s, 1 H), 8.63 (s, 1 H), 10.38 (s, 1 H), 10.42 (s, 1 H), 13.62 (s, 1 H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 52.44, 55.59, 61.20, 65.39, 100.92, 115.07, 120.61, 121.11, 123.41, 123.76, 129.76, 133.08, 137.60, 144.36, 152.63, 154.60, 157.41, 162.77; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>26</sub>N<sub>7</sub>O<sub>3</sub>: 460.2097, found: 460.2096.</div></div><div id="sec5_4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>N</i>-(4-(Morpholinomethyl)phenyl)-4-(thieno[2,3-<i>d</i>]pyrimidin-4-ylamino)-1<i>H</i>-pyrazole-3-carboxamide (<b>35</b>)</h4><div class="NLM_p last">Compound <b>35</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (92 mg, 0.22 mmol, 44% yield). White solid; mp 262–265 °C. HPLC analysis: retention time, 6.105 min; peak area, 98.44%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.35 (s, 4 H), 3.43 (s, 2 H), 3.58 (s, 4 H), 7.27–7.30 (d, 2 H, <i>J</i> = 8.28 Hz), 7.48–7.50 (d, 1 H, <i>J</i> = 5.97 Hz), 7.77–7.82 (m, 3 H), 8.55 (s, 1 H), 8.62 (s, 1 H), 9.99 (s, 1 H), 10.29 (s, 1 H), 13.51 (s, 1 H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 53.10, 62.47, 66.18, 116.49, 117.53, 120.62, 121.10, 123.44, 124.96, 129.10, 133.21, 137.00, 152.96, 153.54, 162.45, 165.97; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>22</sub>N<sub>7</sub>O<sub>2</sub>S: 436.1556, found: 436.1560.</div></div><div id="sec5_4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 4-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-<i>N</i>-(4-(morpholinomethyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>36</b>)</h4><div class="NLM_p last">Compound <b>36</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (138 mg, 0.33 mmol, 66% yield). White solid; mp 213–214 °C. HPLC analysis: retention time, 6.541 min; peak area, 95.47%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.38 (s, 4 H), 3.35 (s, 2 H), 3.60 (s, 4 H), 6.50 (s, 1 H), 7.31 (s, 3 H), 7.79–7.82 (d, 2 H, <i>J</i> = 6.75 Hz), 8.40 (s, 1 H), 8.58 (s, 1 H), 9.53 (s, 1 H), 10.25 (s, 1 H), 11.89 (s, 1 H), 13.45 (s, 1 H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 53.10, 61.94, 66.07, 96.69, 103.07, 120.05, 120.58, 122.98, 124.58, 129.20, 132.26, 137.20, 150.56, 151.16, 151.65, 162.78; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>23</sub>N<sub>8</sub>O<sub>2</sub>: 419.1944, found: 419.1953.</div></div><div id="sec5_4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 4-((6-Ethylthieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)-<i>N</i>-(4-(morpholinomethyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>37</b>)</h4><div class="NLM_p last">Compound <b>37</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (71 mg, 0.15 mmol, 31% yield). White solid; mp 220–222 °C. HPLC analysis: retention time, 5.701 min; peak area, 97.42%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 1.30–1.53 (t, 3 H, <i>J</i> = 7.47 Hz), 2.36 (s, 4 H), 2.95–3.03 (q, 2 H, <i>J</i> = 7.38 Hz), 3.44 (s, 2 H), 3.58 (s, 4 H), 7.17 (s, 1 H), 7.26–7.30 (d, 2 H, <i>J</i> = 8.28 Hz), 7.77–7.80 (d, 2 H, <i>J</i> = 8.10 Hz), 8.55 (s, 1 H), 9.81 (s, 1 H), 10.28 (s, 1 H), 13.49 (s, 1 H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 15.99, 23.05, 53.53, 62.44, 66.59, 113.73, 117.30, 121.25, 121.38, 124.09, 129.71, 131.04, 133.41, 137.56, 146.11, 152.46, 153.43, 163.09, 165.55; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>26</sub>N<sub>7</sub>O<sub>2</sub>S: 464.1869, found: 464.1871.</div></div><div id="sec5_4_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 4-((6-Isopropylthieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)-<i>N</i>-(4-(morpholinomethyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>38</b>)</h4><div class="NLM_p last">Compound <b>38</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (93 mg, 0.20 mmol, 39% yield). White solid; mp 222–224 °C. HPLC analysis: retention time, 4.433 min; peak area, 97.47%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 1.36–1.38 (d, 2 H, <i>J</i> = 6.78 Hz), 2.35 (s, 1 H), 3.35–3.40 (s, 1 H), 3.44 (s, 2 H), 3.58 (s, 4 H), 7.18 (s, 1 H), 7.26–7.29 (d, 2 H, <i>J</i> = 7.35 Hz), 7.76–7.79 (d, 2 H, <i>J</i> = 8.10 Hz), 8.54 (s, 1 H), 9.79 (s, 1 H), 10.28 (s, 1 H), 13.51 (s, 1 H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 13.07, 13.93, 53.09, 62.00, 66.17, 72.31, 116.95, 120.60, 123.81, 129.13, 129.91, 132.39, 133.16, 136.99, 152.32, 152.42, 164.25; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>28</sub>N<sub>7</sub>O<sub>2</sub>S: 478.2025, found: 478.2032.</div></div><div id="sec5_4_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 4-((5-Methylthieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)-<i>N</i>-(4-(morpholinomethyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>39</b>)</h4><div class="NLM_p last">Compound <b>39</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (92 mg, 0.21 mmol, 41% yield). White solid; mp 205–207 °C. HPLC analysis: retention time, 3.568 min; peak area, 96.37%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.35 (s, 4 H), 2.81 (s, 3 H), 3.43 (s, 2 H), 3.58 (s, 4 H), 7.26–7.29 (d, 2 H, <i>J</i> = 8.37 Hz), 7.34 (s, 1 H), 7.76–7.79 (d, 2 H, <i>J</i> = 8.34 Hz), 8.58 (s, 1 H), 8.67 (s, 1 H), 10.14 (s, 1 H), 10.26 (s, 1 H), 13.48 (s, 1 H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 17.75, 53.57, 62.47, 66.64, 116.53, 119.90, 120.73, 121.18, 121.28, 124.22, 129.46, 129.66, 132.94, 133.65, 137.49, 153.71, 153.84, 163.12, 167.64; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>24</sub>N<sub>7</sub>O<sub>2</sub>S: 450.1712, found: 450.1723.</div></div><div id="sec5_4_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>N</i>-(4-(Morpholinomethyl)phenyl)-4-(thieno[3,2-<i>d</i>]pyrimidin-4-ylamino)-1<i>H</i>-pyrazole-3-carboxamide (<b>40</b>)</h4><div class="NLM_p last">Compound <b>40</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (94 mg, 0.21 mmol, 43% yield). White solid; mp 156–158 °C. HPLC analysis: retention time, 3.138 min; peak area, 95.66%.<sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.35 (s, 4 H), 3.43 (s, 2 H), 3.58 (s, 4 H), 7.27–7.30 (d, 2 H, <i>J</i> = 8.28 Hz), 7.52–7.54 (d, 1 H, <i>J</i> = 5.28 Hz), 7.77–7.81 (d, 2 H, <i>J</i> = 8.28 Hz), 8.25–8.27 (d, 1 H, <i>J</i> = 5.31 Hz), 8.57 (s, 1 H), 8.73 (s, 1 H), 9.74 (s, 1 H), 10.30 (s, 1 H), 13.54 (s, 1 H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 53.11, 62.02, 66.18, 101.35, 108.49, 115.23, 120.63, 123.45, 124.83, 129.13, 133.12, 133.26, 133.61, 136.94, 153.27, 154.55, 159.99, 162.58; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>22</sub>N<sub>7</sub>O<sub>2</sub>S: 436.1556, found: 436.1556.</div></div><div id="sec5_4_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 4-((5,6-Dimethylthieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)-<i>N</i>-(4-(morpholinomethyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>41</b>)</h4><div class="NLM_p last">Compound <b>41</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (89 mg, 0.19 mmol, 38% yield). White solid; mp 254–256 °C. HPLC analysis: retention time, 6.625 min; peak area, 95.14%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.35 (s, 4 H), 2.44 (s, 3 H), 2.66 (s, 3 H), 3.43 (s, 2 H), 3.56–3.59 (s, 4 H), 7.27–7.30 (d, 2 H, <i>J</i> = 8.37 Hz), 7.76–7.79 (d, 2 H, <i>J</i> = 8.34 Hz), 8.50 (s, 1 H), 8.63 (s, 1 H), 10.12 (s, 1 H), 10.25 (s, 1 H), 13.46 (s, 1 H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 13.59, 14.46, 53.57, 62.47, 66.63, 117.44, 120.65, 121.10, 124.33, 129.64, 130.38, 131.31, 132.86, 133.58, 137.53, 152.84, 152.89, 163.12, 164.72; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>26</sub>N<sub>7</sub>O<sub>2</sub>S: 464.1869, found: 464.1874.</div></div><div id="sec5_4_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>N</i>-(4-((4-Methylpiperazin-1-yl)methyl)phenyl)-4-(quinolin-4-ylamino)-1<i>H</i>-pyrazole-3-carboxamide (<b>42</b>)</h4><div class="NLM_p last">Compound <b>42</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (44 mg, 0.10 mmol, 19% yield). Yellow solid; mp 224–226 °C. HPLC analysis: retention time, 5.358 min; peak area, 99.76%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.14 (s, 3 H), 2.34 (br, 8 H), 3.41 (s, 2 H), 7.01–7.03 (d, 1 H, <i>J</i> = 5.22 Hz), 7.24–7.27 (d, 2 H, <i>J</i> = 8.25 Hz), 7.67–7.66 (t, 1 H, <i>J</i> = 7.40 Hz), 7.71–7.79 (m, 4 H), 7.92–7.94 (d, 1 H, <i>J</i> = 8.13 Hz), 8.15–8.18 (d, 1 H, <i>J</i> = 8.04 Hz), 8.32 (s, 1 H), 8.56–8.58 (d, 1 H, <i>J</i> = 5.1 Hz), 9.86–10.27 (br, 2 H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 45.69, 52.47, 54.71, 64.65, 100.81, 118.88, 120.19, 120.53, 121.23, 125.32, 125.65, 129.00, 129.15, 129.31, 133.01, 133.67, 137.01, 145.51, 148.16, 150.74, 162.03; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>28</sub>N<sub>7</sub>O: 442.2355, found: 442.2359.</div></div><div id="sec5_4_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 4-(Isoquinolin-1-ylamino)-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>43</b>)</h4><div class="NLM_p last">Compound <b>43</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (48 mg, 0.11 mmol, 22% yield). Yellow solid; mp 224–225 °C. HPLC analysis: retention time, 5.134 min; peak area, 96.60%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 1.99 (s, 3 H), 2.15 (br, 8 H), 3.43 (s, 2 H), 7.17–7.20 (d, 1 H, <i>J</i> = 5.73 Hz), 7.26–7.30 (d, 2 H, <i>J</i> = 8.25 Hz), 7.73–7.75 (t, 2 H, <i>J</i> = 3.55 Hz), 7.79–7.83 (d, 2 H, <i>J</i> = 8.28 Hz), 7.86–7.88 (d, 1 H, <i>J</i> = 6.72 Hz), 7.99–8.02 (d, 1 H, <i>J</i> = 8.10 Hz), 8.11–8.13 (d, 1 H, <i>J</i> = 5.73 Hz), 8.64 (s, 1 H), 10.26 (s, 2 H), 13.38 (s, 1 H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 45.71, 52.48, 54.72, 61.67, 111.87, 117.56, 120.72, 121.05, 125.73, 127.11, 127.20, 129.02, 130.21, 133.72, 136.55, 136.93, 141.09, 150.39, 163.12; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>28</sub>N<sub>7</sub>O: 442.2355, found: 442.2360.</div></div><div id="sec5_4_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 4-((6-Bromoquinolin-4-yl)amino)-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>44</b>)</h4><div class="NLM_p last">Compound <b>44</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (45 mg, 0.09 mmol, 17% yield). Yellow solid; mp 231–235 °C. HPLC analysis: retention time, 4.526 min; peak area, 98.25%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.13 (s, 3 H), 2.33 (br, 8 H), 3.40 (s, 2 H), 6.83–6.84 (d, 1 H, <i>J</i> = 5.13 Hz), 7.21–7.24 (d, 2 H, <i>J</i> = 8.28 Hz), 7.69–7.73 (d, 2 H, <i>J</i> = 8.28 Hz), 7.83 (s, 2 H), 8.27 (s, 1 H), 8.44 (s, 1 H), 8.52 (s, 1 H), 9.31 (s, 1 H), 10.17 (s, 1 H), 13.60 (s, 1 H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 46.15, 52.90, 55.15, 62.10, 101.90, 118.33, 120. 567, 120.84, 123.78, 124.35, 129.51, 132.14, 134.05, 136.22, 137.56, 146.58, 147.57, 151.90, 161.87, 170.80, 172.62; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>27</sub>BrN<sub>7</sub>O: 520.1460, found: 520.1461.</div></div><div id="sec5_4_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 4-((7-Methoxyquinolin-4-yl)amino)-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>45</b>)</h4><div class="NLM_p last">Compound <b>45</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (39 mg, 0.08 mmol, 16.7% yield). Yellow solid; mp 226–228 °C. HPLC analysis: retention time, 6.589 min; peak area, 99.61%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.1 (s, 3 H), 2.35 (br, 8 H), 3.41 (s, 2 H), 3.92 (s, 3 H), 6.88–6.89 (d, 1 H, <i>J</i> = 4.71 Hz), 7.24–7.30 (m, 4 H), 7.74–7.77 (d, 2 H, <i>J</i> = 7.71 Hz), 8.03–8.06 (d, 1 H, <i>J</i> = 8.4 Hz), 8.32 (s, 1 H), 8.50 (s, 1 H), 9.63 (br, 1 H), 10.29 (s, 1 H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 46.10, 52.85, 55.11, 55.81, 62.10, 100.15, 108.57, 113.70, 117.85, 121.05, 122.04, 125.82, 129.55, 134.12, 134.33, 137.46, 145.97, 150.58, 151.71, 160.42, 162.68, 172.62; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>26</sub>H<sub>30</sub>N<sub>7</sub>O<sub>2</sub>: 472.2461, found: 472.2446.</div></div><div id="sec5_4_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 4-((6-Methoxyquinolin-4-yl)amino)-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>46</b>)</h4><div class="NLM_p last">Compound <b>46</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (43 mg, 0.09 mmol, 18.2% yield). Yellow solid; mp 272–274 °C. HPLC analysis: retention time, 3.607 min; peak area, 97.10%.<sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.16 (s, 3 H), 2.35 (br, 8 H), 3.40 (s, 2 H), 3.97 (s, 3 H), 6.87–6.89 (d, 1 H, <i>J</i> = 3.31 Hz), 7.22–7.25 (d, 2 H, <i>J</i> = 8.28 Hz), 7.39–7.43 (m, 1 H), 7.53–7.54 (d, 1 H, <i>J</i> = 2.04 Hz), 7.74–7.77 (d, 2 H, <i>J</i> = 8.28 Hz), 7.84–7.87 (d, 1 H, <i>J</i> = 9.15 Hz), 8.30 (s, 1 H), 8.41–8.43 (d, 1 H, <i>J</i> = 5.16 Hz), 9.34 (br, 1 H), 10.24 (s, 1 H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 46.16, 52.92, 55.16, 56.00, 62.11, 100.47, 101.46, 119.87, 120.78, 120.86, 125.46, 129.54, 131.54, 134.04, 135.27, 137.61, 144.49, 145.72, 149.00, 157.11, 162.34, 162.78, 172.62; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>26</sub>H<sub>30</sub>N<sub>7</sub>O<sub>2</sub>: 472.2461, found: 472.2446.</div></div><div id="sec5_4_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>N</i>-(4-((4-Methylpiperazin-1-yl)methyl)phenyl)-4-(quinazolin-4-ylamino)-1<i>H</i>-pyrazole-3-carboxamide (<b>47</b>)</h4><div class="NLM_p last">Compound <b>47</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (101 mg, 0.23 mmol, 47% yield). Yellow solid; mp 276–278 °C. HPLC analysis: retention time, 3.558 min; peak area, 100.00%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.22 (s, 3 H), 2.42 (br, 8 H), 3.45 (s, 2 H), 7.28–7.30 (d, 2 H, <i>J</i> = 6.0 Hz), 7.75–7.87 (m, 6 H), 8.65 (s, 1 H), 8.76 (s, 1 H), 10.40 (s, 1 H), 10.64 (s, 1 H), 13.60 (s, 1 H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 45.99, 52.75, 55.05, 62.05, 115.00, 121.31, 121.41, 124.28, 127.66, 128.61, 129.55, 133.18, 133.67, 134.26, 137.31, 149.57, 155.27, 155.66, 163.30; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>27</sub>N<sub>8</sub>O: 443.2308, found: 443.2319.</div></div><div id="sec5_4_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> <i>N</i>-(4-((4-Methylpiperazin-1-yl)methyl)phenyl)-4-(thieno[2,3-<i>d</i>]pyrimidin-4-ylamino)-1<i>H</i>-pyrazole-3-carboxamide(<b>48</b>)</h4><div class="NLM_p last">Compound <b>48</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (152 mg, 0.34 mmol, 68% yield). White solid; mp 262–265 °C. HPLC analysis: retention time, 3.904 min; peak area, 98.63%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.15 (s, 1 H), 2.34 (br, 8 H), 3.56 (s, 2 H), 7.24–7.27 (m, 2 H), 7.48–7.51 (d, 1 H, <i>J</i> = 5.88 Hz), 8.54 (s, 1 H), 8.61 (s, 1 H), 9.98 (s, 1 H), 10.28 (s, 1 H), 13.60 (s, 1 H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 45.67, 52.44, 54.68, 61.63, 116.48, 117.56, 120.61, 121 051, 123.41, 124.99, 129.00, 129.19, 132.94, 133.73, 136.90, 152.97, 153.55, 162.36, 165.95; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>25</sub>N<sub>8</sub>OS: 449.1872, found: 449.1880.</div></div><div id="sec5_4_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 4-(Furo[2,3-<i>d</i>]pyrimidin-4-ylamino)-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>49</b>)</h4><div class="NLM_p last">Compound <b>49</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (95 mg, 0.22 mmol, 43% yield). White solid; mp 255–257 °C. HPLC analysis: retention time, 4.625 min; peak area, 100.00%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.14 (s, 3 H), 2.3 (br, 8 H), 3.41 (s, 2 H), 7.10 (s, 1 H, ArH), 7.23–7.26 (d, 2 H, <i>J</i> = 8.3 Hz), 7.75–7.79 (d, 2 H, <i>J</i> = 8.3 Hz), 8.24 (s, 1 H), 8.49–8.52 (d, 2 H, <i>J</i> = 5.64 Hz), 9.70 (s, 1 H), 10.29 (s, 1 H), 13.52 (s, 1 H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 45.54, 52.31, 54.57, 61.57, 101.59, 103.10, 120.24, 120.49, 122.10, 123.28, 129.00, 133.55, 136.99, 142.65, 153.49, 153.71, 162.02, 166.14; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>25</sub>N<sub>8</sub>O<sub>2</sub>: 433.2100, found: 433.2093.</div></div><div id="sec5_4_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 4-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>50</b>)</h4><div class="NLM_p last">Compound <b>50</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (160 mg, 0.37 mmol, 74% yield). White solid; mp 229–230 °C. HPLC analysis: retention time, 3.696 min; peak area, 98.54%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.15 (s, 3 H), 2.35 (br, 8 H), 3.42 (s, 2 H), 6.48 (s, 1 H), 7.24–7.27 (d, 2 H, <i>J</i> = 8.07 Hz), 7.31 (s, 1 H), 7.76–7.79 (d, 2 H, <i>J</i> = 8.22 Hz), 8.38 (s, 1 H), 8.57 (s, 1 H), 9.52 (s, 1 H), 10.28 (s, 1 H), 11.90 (s, 1 H), 13.44 (s, 1 H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 44.65, 51.45, 53.98, 61.25, 96.71, 103.08, 120.57, 121.94, 123.00, 124.70, 129.13, 131.92, 133.06, 137.14, 150.53, 151.18, 151.67, 162.56, 169.17; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>26</sub>N<sub>9</sub>O: 432.2260, found: 432.2271.</div></div><div id="sec5_4_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> <i>N</i>-(4-((4-Methylpiperazin-1-yl)methyl)phenyl)-4-(thieno[3,2-<i>d</i>]pyrimidin-4-ylamino)-1<i>H</i>-pyrazole-3-carboxamide (<b>51</b>)</h4><div class="NLM_p last">Compound <b>51</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (156 mg, 0.35 mmol, 69% yield). White solid; mp 278–280 °C. HPLC analysis: retention time, 4.505 min; peak area, 99.28%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.17 (s, 3 H), 2.36 (br, 8 H), 3.42 (s, 2 H), 7.25–7.28 (d, 2 H, <i>J</i> = 8.46 Hz), 7.52–7.54 (d, 1 H, <i>J</i> = 5.34 Hz), 7.75–7.79 (d, 2 H, <i>J</i> = 8.43 Hz), 8.26–8.28 (d, 1 H, <i>J</i> = 5.37 Hz), 8.56 (s, 1 H), 8.72 (s, 1 H), 9.74 (s, 1 H), 10.35 (s, 1 H), 13.57 (s, 1 H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 46.00, 52.77, 55.05, 62.07, 115.00, 121.11, 122.06, 123.93, 125.32, 129.55, 134.14, 134.20, 137.38, 153.73, 155.06, 160.46, 162.90; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>25</sub>N<sub>8</sub>OS: 449.1872, found: 449.1884.</div></div><div id="sec5_4_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 4-((5,6-Dimethylthieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>52</b>)</h4><div class="NLM_p last">Compound <b>52</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (135 mg, 0.28 mmol, 56% yield). White solid; mp 264–267 °C. HPLC analysis: retention time, 6.249 min; peak area, 96.23%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.23 (s, 3 H), 2.43 (br, 8 H), 2.65 (s, 3 H), 3.44 (s, 2 H), 3.68 (br, 3 H), 7.27 (s, 2 H), 7.79 (s, 2 H), 8.25 (s, 1 H), 8.62 (s, 1 H), 10.11 (s, 1 H), 10.29 (s, 1 H), 13.52 (s, 1 H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 13.02, 13.90, 45.28, 52.06, 54.43, 61.48, 116.90, 120.56, 120.89, 123.76, 123.91, 129.04, 129.80, 132.04, 133.42, 136.99, 152.26, 152.36, 162.50, 164.22; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>29</sub>N<sub>8</sub>OS: 477.2185, found: 477.2193.</div></div><div id="sec5_4_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> <i>N</i>-(4-((4-Methylpiperazin-1-yl)methyl)phenyl)-4-((6-methylthieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)-1<i>H</i>-pyrazole-3-carboxamide (<b>53</b>)</h4><div class="NLM_p last">Compound <b>53</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (147 mg, 0.32 mmol, 64% yield). White solid; mp 254–256 °C. HPLC analysis: retention time, 5.101 min; peak area, 96.47%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 1.98 (s, 3 H), 2.35 (br, 8 H), 2.62 (s, 3 H), 3.42 (s, 2 H), 7.16 (s, 1 H), 7.24–7.28 (d, 2 H, <i>J</i> = 8.07 Hz), 7.76–7.79 (d, 2 H, <i>J</i> = 8.19 Hz), 8.54 (s, 2 H), 9.83 (s, 1 H), 10.27 (s, 1 H), 13.49 (s, 1 H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 15.81, 45.70, 52.47, 54.72, 61.64, 114.80, 117.08, 120.74, 123.72, 128.98, 132.56, 133.80, 136.84, 138.56, 151.78, 152.87, 162.52, 165.40; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>27</sub>N<sub>8</sub>OS: 463.2029, found: 463.2035.</div></div><div id="sec5_4_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> <i>N</i>-(4-((4-Methylpiperazin-1-yl)methyl)phenyl)-4-((5-methylthieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)-1<i>H</i>-pyrazole-3-carboxamide (<b>54</b>)</h4><div class="NLM_p last">Compound <b>54</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (179 mg, 0.39 mmol, 77% yield). White solid; mp 247–249 °C. HPLC analysis: retention time, 4.625 min; peak area, 100.00%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.17 (s, 3 H), 2.36 (br, 8 H), 2.82 (s, 3 H), 3.42 (s, 2 H), 7.28–7.33 (m, 3 H), 7.79 (s, 2 H), 8.59 (s, 1 H), 8.68 (s, 1 H), 10.17 (s, 1 H), 10.30 (s, 1 H), 13.06 (s, 1 H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 17.74, 46.07, 52.85, 55.12, 62.11, 116.52, 119.81, 121.14, 121.49, 124.28, 129.44, 129.51, 132.74, 134.15, 137.39, 153.67, 153.84, 163.02, 167.65; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>27</sub>N<sub>8</sub>OS: 463.2029, found: 463.2035.</div></div><div id="sec5_4_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 4-((6-Isopropylthieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>55</b>)</h4><div class="NLM_p last">Compound <b>55</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (140 mg, 0.29 mmol, 57% yield). White solid; mp 220–222 °C. HPLC analysis: retention time, 12.72 min; peak area, 97.99%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 1.35–1.38 (d, <i>J</i> = 6.78 Hz, 6 H), 2.31 (s, 3 H), 2.46 (s, 4 H), 2.55 (s, 4 H), 3.29–3.39 (m, 1 H), 3.47 (s, 2 H), 7.18 (s, 1 H), 7.26–7.29 (d, 2 H, <i>J</i> = 8.3 Hz), 7.78–7.82 (d, 2 H, <i>J</i> = 8.3 Hz), 8.54–8.55 (m, 2 H), 9.82 (s, 1 H), 10.36 (s, 1 H), 13.61 (s, 1 H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 24.11, 30.08, 44.67, 51.46, 54.01, 64.25, 111.83, 116.58, 120.69, 123.59, 129.12, 133.19, 137.06, 150.98, 152.14, 152.92, 162.34, 164.74; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>31</sub>N<sub>8</sub>OS: 491.2342, found: 491.2359.</div></div><div id="sec5_4_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 4-((6-Ethylthieno[2,3-<i>d</i>]pyrimidin-4-yl)amino)-<i>N</i>-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>56</b>)</h4><div class="NLM_p last">Compound <b>56</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (152 mg, 0.32 mmol, 63% yield). White solid; mp 259–261 °C. HPLC analysis: retention time, 6.032 min; peak area, 96.03%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 1.30–1.35 (t, 3 H, <i>J</i> = 7.47 Hz), 2.15 (s, 3 H), 2.34 (br, 8 H), 2.94–3.02 (q, 2 H, <i>J</i> = 5.83 Hz), 3.42 (s, 2 H), 7.16 (s, 1 H), 7.25–7.28 (d, 2 H, <i>J</i> = 8.31 Hz), 7.77–7.80 (d, 2 H, <i>J</i> = 8.32 Hz), 8.55 (s, 2 H), 10.14 (s, 1 H), 10.28 (s, 1 H), 13.50 (s, 1 H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 15.95, 24.03, 46.20, 52.95, 55.19, 62.13, 113.65, 117.28, 121.20, 121.51, 124.13, 129.47, 133.14, 134.22, 137.36, 146.05, 152.40, 153.38, 162.97, 165.52; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>29</sub>N<sub>8</sub>OS: 477.2185, found: 477.2194.</div></div><div id="sec5_4_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> <i>N</i>-(4-(Piperazin-1-ylmethyl)phenyl)-4-(thieno[2,3-<i>d</i>]pyrimidin-4-ylamino)-1<i>H</i>-pyrazole-3-carboxamide (<b>57</b>)</h4><div class="NLM_p last">Compound <b>57</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (96 mg, 0.22 mmol, 43% yield). White solid; mp 243–245 °C. HPLC analysis: retention time, 3.858 min; peak area, 98.43%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 2.34 (br, 4 H), 2.94 (br, 4 H), 3.18 (s, 1 H), 3.48 (s, 2 H), 7.27–7.30 (d, <i>J</i> = 7.62 Hz, 2 H), 7.50–7.53 (d, <i>J</i> = 5.52 Hz, 1 H), 7.81–7.84 (m, 3 H), 8.54 (s, 1 H), 8.62 (s, 1 H), 10.02 (s, 1 H), 10.43 (s, 1 H) ; <sup>13</sup>C NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 43.69, 50.54, 61.50, 116.47, 117.61, 120.24, 120.58, 121.92, 123.41, 125.00, 129.16, 132.66, 132.85, 137.15, 153.00, 153.56, 158.08, 162.24, 165.93; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>23</sub>N<sub>8</sub>OS: 435.1716, found: 435.1722.</div></div><div id="sec5_4_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> <i>N</i>-(4-((Diethylamino)methyl)phenyl)-4-(thieno[2,3-<i>d</i>]pyrimidin-4-ylamino)-1<i>H</i>-pyrazole-3-carboxamide (<b>58</b>)</h4><div class="NLM_p last">Compound <b>58</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (72 mg, 0.17 mmol, 33% yield). White solid; mp 233–235 °C. HPLC analysis: retention time, 5.505 min; peak area, 96.03%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 1.18–1.29 (m, 6 H), 2.88–2.90 (d, 4 H, <i>J</i> = 7.17 Hz), 4.05 (s, 2 H), 7.52–7.55 (d, 2 H, <i>J</i> = 5.61 Hz), 7.62–7.65 (d, 2 H, <i>J</i> = 8.25 Hz), 7.78–7.80 (d, 1 H, <i>J</i> = 5 0.91 Hz), 7.94–7.97 (d, 2 H, <i>J</i> = 8.28 Hz), 8.54 (s, 1 H), 8.60 (s, 1 H), 9.95 (s, 1 H), 10.51 (s, 1 H), 13.73 (s, 1 H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 8.75, 45.94, 54.72, 116.99, 118.16, 121.11, 121.89, 123.88, 125.52, 125.74, 132.00, 133.72, 139.67, 153.53, 154.06, 163.20, 166.46; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>24</sub>N<sub>7</sub>OS: 422.1763, found: 422.1774.</div></div><div id="sec5_4_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> <i>N</i>-(4-((Cyclopropylamino)methyl)phenyl)-4-(thieno[2,3-<i>d</i>]pyrimidin-4-ylamino)-1<i>H</i>-pyrazole-3-carboxamide (<b>59</b>)</h4><div class="NLM_p last">Compound <b>59</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (10% MeOH/DCM) yielded the title compound (43 mg, 0.11 mmol, 21% yield). White solid; mp 210–213 °C. HPLC analysis: retention time, 3.846 min; peak area, 97.49%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.28 (br, 2 H), 0.35–0.38 (m, 2 H), 2.1 (m, 1 H), 3.72 (s, 2 H), 7.28–7.31 (d, 2 H, <i>J</i> = 8.13 Hz), 7.49–7.51 (d, 2 H, <i>J</i> = 8.25 Hz), 7.76–7.79 (d, 2 H, <i>J</i> = 8.25 Hz), 8.54 (s, 1 H), 8.60 (s, 1 H), 9.98 (s, 1 H), 10.28 (s, 1 H), 13.52 (s, 1 H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 5.97, 29.79, 52.32, 96.76, 103.07, 120.32, 120.44, 122.98, 124.61, 126.29, 127.71, 128.22, 130.28, 131.03, 134.37, 136.13, 136.68, 140.04, 150.55, 151.16, 151.69, 157.66, 162.54; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>20</sub>N<sub>7</sub>OS: 406.1450, found: 406.1437.</div></div><div id="sec5_4_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> <i>N</i>-(4-((4-Methyl-1,4-diazepan-1-yl)methyl)phenyl)-4-(thieno[2,3-<i>d</i>]pyrimidin-4-ylamino)-1<i>H</i>-pyrazole-3-carboxamide (<b>60</b>)</h4><div class="NLM_p last">Compound <b>60</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (58 mg, 0.13 mmol, 25% yield). White solid; mp 241–244 °C. HPLC analysis: retention time, 3.687 min; peak area, 98.39%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 1.71–1.77 (m, 2 H), 2.27 (s, 3 H), 2.53–2.67 (m, 8 H), 3.58 (s, 2 H), 7.29–7.31 (d, 2 H, <i>J</i> = 8.4 Hz), 7.51–7.53 (d, 2 H, <i>J</i> = 6.0 Hz), 7.78–7.82 (t, 3 H), 8.56 (s, 1 H), 8.63 (s, 1 H), 10.00 (s, 1 H), 10.29 (s, 1 H), 13.53 (s, 1 H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 26.99, 46.51, 53.71, 54.12, 56.13, 57.42, 61.47, 94.95, 100.43, 117.83, 120.47, 128.66, 131.03, 134.87, 137.04, 148.05, 153.67, 161.81; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>27</sub>N<sub>8</sub>OS: 463.2029, found: 463.2041.</div></div><div id="sec5_4_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> <i>N</i>-(4-(Piperazin-1-ylmethyl)phenyl)-4-(thieno[2,3-<i>d</i>]pyrimidin-4-ylamino)-1<i>H</i>-pyrazole-3-carboxamide (<b>61</b>)</h4><div class="NLM_p last">Compound <b>61</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (115 mg, 0.28 mmol, 55% yield). White solid; mp 239–242 °C. HPLC analysis: retention time, 5.505 min; peak area, 96.03%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 1.86 (s, 1 H), 2.34 (S, 4 H), 2.77 (s, 4 H), 3.42 (s, 2 H), 6.49–6.51 (d, 1 H, <i>J</i> = 3.45 Hz), 7.26–7.32 (m, 3 H), 7.78–7.81 (d, 2 H, <i>J</i> = 8.40 Hz), 8.40 (s, 1 H), 8.58 (s, 1 H), 9.54 (s, 1 H), 10.30 (s, 1 H), 11.92 (s, 1 H); <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 44.88, 52.98, 62.15, 96.69, 103.07, 111.08, 120.57, 120.75, 122.97, 124.67, 129.08, 131.79, 133.37, 137.01, 150.55, 151.16, 151.69, 161.03, 162.55; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>24</sub>N<sub>9</sub>O: 418.2104, found: 418.2113</div></div><div id="sec5_4_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 4-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-<i>N</i>-(4-((diethylamino)methyl)phenyl)-1<i>H</i>-pyrazole-3-carboxamide (<b>62</b>)</h4><div class="NLM_p last">Compound <b>62</b> was prepared according to general procedure C on a 0.5 mmol scale. Purification by column chromatography (5% MeOH/DCM) yielded the title compound (73 mg, 0.18 mmol, 36% yield). White solid; mp 217–220 °C. HPLC analysis: retention time, 3.334 min; peak area, 99.79%. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 0.95–1.00 (m, 6 H), 2.43–2.49 (q, 4 H, <i>J</i> = 7.98 Hz), 3.50 (s, 2 H), 6.49 (s, 1 H), 7.26–7.29 (d, 2 H, <i>J</i> = 8.64 Hz), 7.29 (s, 1 H), 7.75–7.84 (d, 2 H, <i>J</i> = 8.31 Hz), 8.39 (s, 1 H), 8.57 (s, 1 H), 9.52 (s, 1 H), 10.19 (s, 1 H), 11.87 (s, 1 H), 13.39 (s, 1 H); <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.74, 46.09, 56.55, 98.82, 103.17, 120.27, 120.72, 123.14, 124.70, 128.78, 135.38, 136.84, 150.65, 151.29, 151.76, 162.83; HRMS-EI <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>25</sub>N<sub>8</sub>O: 405.2151, found: 405.2165.</div></div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> Kinase-Inhibition Assay</h3><div class="NLM_p last">The activity of the CDKs and FLT3 were determined using a Hot-SpotSM kinase assay, which was performed by Reaction Biology Corporation (Malvern, PA), as described previously.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(46)</a> Kinase activities were assayed in reaction buffer (20 mM HEPES pH 7.5, 10 mM MgCl<sub>2</sub>, 1 mM EGTA, 0.02% Brij35, 0.02 mg/mL BSA, 0.1 mM Na<sub>3</sub>VO<sub>4</sub>, 2 mM DTT, 1% DMSO) at room temperature at a final ATP concentration of 10 mM. Then compounds, dissolved in 100% DMSO at the indicated doses, were delivered into the kinase reaction mixture by acoustic technology (Echo550, nanoliter range; Labcyte, San Jose, CA) and incubated for 20 min at room temperature. After 10 μM [γ-<sup>33</sup>P] ATP (specific activity 10 Ci/μL) was added to initiate the reaction, the reactions were carried out at 25 °C for 120 min. The kinase activities were detected by the filterbinding method. IC<sub>50</sub> values and curve fits were obtained by Prism (GraphPad Software, La Jolla, CA).</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> Cell-Growth-Inhibition Assay</h3><div class="NLM_p">The human AML cell line MV4-11 was purchased from the American Type Culture Collection (ATCC, Manassas, VA). MV4-11 was cultured in IMDM media (Corning, Corning, NY) with 10% FBS and supplemented with 2% <span class="smallcaps smallerCapital">l</span>-glutamine and 1% penicillin/streptomycin. The MV4-11 cell line was maintained in culture media at 37 °C with 5% CO<sub>2</sub>. The effects of the target compounds on MV4-11 proliferation were performed by Crown Bioscience Inc. (San Diego, CA). Cells were cultured in 96-well culture plates (10 000 cells/well). The compounds at various concentrations were added to the plates. Cell proliferation was determined after treatment with the compounds for 72 h. Cell viability was measured using the CellTiter-Glo assay (Promega, Madison, WI) according to the manufacturer’s instructions, and luminescence was measured in a multilabel reader (Envision2014, PerkinElmer, Waltham, MA). Data were normalized to control groups (DMSO) and represented as the means of three independent measurements with standard errors of <20%. IC<sub>50</sub> values were calculated using Prism 5.0 (GraphPad Software).</div><div class="NLM_p last">The human-cancer-cell lines MCF-7 (ATCC, catalogue no. HTB-22), MGC-803 (ATCC), HCT-116 (ATCC, catalogue no. CCL-247), RS4;11 (ATCC, catalogue no. CRL-1873), and NCI-H82 (ATCC, catalogue no. HTB-175) were obtained from the American Type Culture Collection (Manassas, VA). MCF-7 and HCT-116 were cultured in MEM media (Gibco, Invitrogen, Waltham, MA; catalogue no. 41090) with 10% FBS (Gibco, Invitrogen; catalogue no. 10437-036) and supplemented with 2% <span class="smallcaps smallerCapital">l</span>-glutamine and 1% penicillin/streptomycin. MGC-803 and RS4;11 were cultured in RPMI 1640 (Gibco, Invitrogen; catalogue no. 22400) with 10% FBS (Gibco, Invitrogen; catalogue no. 10437-036) and supplemented with 2% <span class="smallcaps smallerCapital">l</span>-glutamine and 1% penicillin/streptomycin. The cell lines were maintained in culture media at 37 °C with 5% CO<sub>2</sub>. The effects of the target compounds on MCF-7, MGC-803, HCT-116, RS4;11, and NCI-H82 proliferation were performed by Genscript (Nanjing, China). Cells were grown in 384-well culture plates (800 cells/well for MCF-7, MGC-803 and HCT-116 and 2000 cells/well for RS4;11 and NCI-H82). The compounds at various concentrations were added to the plates. Cell proliferation was determined after treatment with the compounds for 72 h. Cell viability was measured using the CellTiter-Glo assay (Promega) according to the manufacturer’s instructions, and luminescence was measured in a multilabel reader (BMG Labtech, Ortenberg, Germany). Data were normalized to control groups (DMSO) and represented as the means of three independent measurements with standard errors of <20%. GI<sub>50</sub> values were calculated using Prism 5.0 (GraphPad Software).</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> Cell-Cycle Assay</h3><div class="NLM_p last">Subconfluent cells were treated with test compounds at different concentrations for 24 h. The cultures were pulse-labeled with 10 μM 5-bromo-2′-deoxyuridine (BrdU) for 30 min at 37 °C prior to harvest. The cells were subsequently washed in PBS, fixed with 70% ethanol, and denatured in 2 M HCl. Following neutralization, the cells were stained with anti-BrdU fluorescein-labeled antibodies, washed, stained with propidium iodide, and analyzed by flow cytometry with a 488 nm laser (Cell Lab Quanta SC, Beckman Coulter, Brea, CA).<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(47)</a> Cell-cycle analyses were made with a FACScan cytometer (FACSCalibun, Becton Dickinson, Franklin Lakes, NJ).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Analysis of P-FLT3, P-STAT5, P-ERK, P-AKT, and P-Rb in Vitro</h3><div class="NLM_p last">To determine the levels of P-FLT3, P-STAT5, P-ERK, P-AKT, and P-Rb, cells were seeded in a 6-well cell-culture plate at a density of 400 000 MV4-11 cells per well in a total volume of 1800 μL and incubated overnight in medium containing 10% fetal bovine serum (Life Technologies, Rockville, MD). Then, 200 μL of one of the serially diluted compounds was added to each well the next day. Cell lysates were harvested after 24 h, and P-FLT3, P-STAT5, P-ERK, P-AKT, and P-Rb were quantified using assay kits for P-STAT5 (Tyr694)/total STAT5 and P-Rb (Ser807)/total Rb (Nanjing keyGen Biotech Company, Nanjing, China) by following the manufacturer’s protocols.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Cell-Apoptosis Assay</h3><div class="NLM_p last">The apoptosis of the MV4-11 cells was determined by an Annexin V-FITC/PI assay.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Annexin V binds to phosphatidylserine, which is exposed on the cell membrane and is one of the earliest indicators of cellular apoptosis. Propidium iodide (PI) is used as a DNA stain for both flow cytometry, which evaluates the cell viability or DNA content in cell-cycle analyses, and microscopy, which visualizes the nucleus and other DNA-containing organelles. It can be used to differentiate necrotic, apoptotic, and normal cells. Cells (2 × 10<sup>5</sup>) were seeded in 6-well plate and were treated with varying concentrations of an inhibitor for 24 h. MV4-11 cells were collected and incubated with FITC-conjugated Annexin V (Nanjin keyGen Biotech Company). The nuclei were then counterstained with PI. After the dual staining, the cells were screened by a FAC Scan flow cytometer (FACS Calibun, Becton Dickinson). The upper left corner of the quadrant represents debris, the lower left is live cells, the upper right is advanced-apoptotic or necrotic cells, and the lower right is apoptotic cells.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Metabolic Stability in Liver Microsomes</h3><div class="NLM_p last">The metabolic stability of compounds <b>35</b> and <b>50</b> in mouse liver microsomes (MLMs), rat liver microsomes (RLMs), dog liver microsomes (DLMs), monkey liver microsomes (CLMs), and human liver microsomes (HLMs) were tested, following the same procedures by WuXi AppTec. Except for the matrix blank, 10 μL of compound <b>35</b> or <b>50</b> or the control working solution was added per well to all the plates (T0, T5, T10, T20, T30, T60, and NCF60). Then, 80 μL/well was added to every plate by an Apricot (Covina, CA), and the mixtures of the microsome solutions and the compounds were incubated at 37 °C for about 10 min. To NCF60, 10 μL of 100 mM potassium phosphate buffer was added per well, and the NCF60 plate was incubated at 37 °C for 1 h. After being prewarmed, 10 μL/well was added to every plate by an Apricot to start the reactions. Reactions were terminated at 5, 10, 20, 30, and 60 min of incubation with a chilled mixture of Tolbutamide and Labetalol (1:1). The mixture was vortexed for 5 min and centrifuged at 4000 rpm for 20 min at 4 °C, and the supernatants were analyzed by LC-MS/MS. The data was analyzed by first-order kinetics to calculate <i>t</i><sub>1/2</sub> and CL.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Cytotoxicity Assays</h3><div class="NLM_p last">Normal human lymphocytes were extracted from human venous blood samples and cultured in RPMI1640 media (Invitrogen, Waltham, MA) with 10% FBS and supplemented with 20% IL-2. The cell lines were maintained in culture media at 37 °C with 5% CO<sub>2</sub>. The effects of target compound <b>50</b>, AT7519, or AC220 on lymphocyte proliferation were determined by Biotech Company (Nanjing, China). Cells were grown in 96-well culture plates (3000 cells/well). Various concentrations of the compounds were added to the plates. Cell proliferation was determined after treatment with the compounds for 72 h. Cell viability was measured using MTT (Promega) according to the manufacturer’s instructions, and luminescence was measured in a multilabel reader (MD Spectramax M3, Molecular Devices, San Jose, CA). The data were normalized to the control groups (DMSO) and represented as the means of three independent measurements with standard errors of <20%. IC<sub>50</sub> values were calculated using Prism 5.0 (GraphPad Software).</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Acute Toxicity</h3><div class="NLM_p last">ICR mice (half male and half female) were purchased from the Comparative Medicine Centre of Yangzhou University. After 16 h of fasting (food but not water was withheld), the mice were weighed and randomly divided into groups (10 mice/group). Various doses of the test compounds were administered by gavage (0.1 mL/10 g), whereas the control groups received solvent only. After the compound was administered, food was withheld for 1 h. Behavioral changes, signs of toxicity or death and the latency of death were observed over a span of 12 days. Because of the lower water solubility of the compounds, acetic acid/sodium acetate buffer (pH 4.5, 7.5%) was chosen as the solvent.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> MV4-11-Xenograft-Tumor Model</h3><div class="NLM_p last">Six-week-old female nu/nu mice were purchased from the Shanghai Experimental Center, Chinese Academy of Sciences (Shanghai, China). All animals were housed in a specific pathogen-free facility and used according to the animal-care regulations of Sundia Meditech Company, Ltd (Shanghai, China). Prior to implantation, cells were harvested during exponential growth. Five million MV4-11 cells in PBS were formulated as a 1:1 mixture with a Matrigel (BD Biosciences, San Jose, CA) and injected into the subcutaneous space on the right flank of each nu/nu mouse. Daily intravenous injections were initiated when MV4-11 tumors had reached sizes of 100–200 mm<sup>3</sup>. The animals were then randomized into treatment groups of 8 mice each for the efficacy studies and dosed with <b>50</b> (0, 15, 30, or 40 (mg/kg)/d) or cytarabine (50 (mg/kg)/d). The compounds were dissolved in a solution of PEG400 (25%), ethanol (3.7%), glucose (5%), and acetic acid/sodium acetate buffer (pH 4.5, 7.5%). Tumor growth was measured every 3 days using Vernier calipers for the duration of the treatment (Sundia Meditech Company, Ltd). The volume was calculated as follows: tumor volume = <i>a</i> × <i>b</i><sup>2</sup>/2, where <i>a</i> was the long diameter, and <i>b</i> was the short diameter. The percentage of tumor-growth inhibition (GI) was calculated as follows: GI = 100% × {1 – [(tumor volume<sub>final</sub> – tumor volume<sub>initial</sub> for the compound-treated group)/(tumor volume<sub>final</sub> – tumor volume<sub>initial</sub> for the vehicle-treated group)]}. The percent tumor regression (PTR) was calculated as follows: PTR = 100% × (tumor volume<sub>initial</sub> – tumor volume<sub>final</sub>)/(tumor volume<sub>initial</sub>).</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Molecular Modeling</h3><div class="NLM_p">The X-ray crystal structure of CDK2 kinase binding to AT-7519 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VU3">2VU3</a>) was retrieved from the Protein Data Bank.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(48)</a> The FLT3 DFG-in conformation was obtained from a DFG-peptide modification based on PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB">1RJB</a>, which was a released FLT3 protein structure with the DFG-out conformation. The modification was made to carry out molecular-dynamics modeling (30 ns) with restraints on DFG peptide to induce a DFG-in mode. Here the restrained molecular dynamics were run using TINKER 4.223 with an amber99 force field.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(49)</a> Then from the trajectory of FLT3 DFG-in conformations, a conformation with the minimum rmsd compared with PDB structure <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB">1RJB</a> was used as our FLT3 DFG-in conformation.</div><div class="NLM_p">Partial atomic charges were calculated using the Gaisteiger–Huckel algorithm, and molecular-energy minimizations were performed using MOE 2014.0901. Compound <b>26</b> was docked into CDK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VU3">2VU3</a>) and the homology-modeling FLT3 (the FLT3 DFG-in conformation) by the dock-ligands module of Discovery Studio 3.0 (Dassault Systèmes BIOVIA, San Diego, CA) with the standard settings. Only poses with low energy conformations and good hydrogen-bond geometries were considered.</div><div class="NLM_p last">Compounds <b>42</b> and <b>50</b> were prepared using the protein-preparation wizard in Maestro with standard settings. Grids of CDK2 and FLT3 were generated using Glide, version 10.2, following the standard procedure recommended by Schrodinger (Cambridge, MA). The conformational ensembles were docked flexibly using Glide with the standard settings in both the standard and extra-precision modes. Only poses with low energy conformations and good hydrogen-bond geometries were considered.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i83"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01261">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42123" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42123" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01261" class="ext-link">10.1021/acs.jmedchem.7b01261</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">IC<sub>50</sub> of compound <b>48</b> against the selected kianses; growth inhibition by <b>35</b>, <b>48</b>, and <b>50</b> in the NCI60-cancer-cell-line panel; <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for the target compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01261/suppl_file/jm7b01261_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular-modeling information CDK2-26 (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01261/suppl_file/jm7b01261_si_002.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular-modeling information CDK2-42, 50, AT-7519 (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01261/suppl_file/jm7b01261_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular-formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01261/suppl_file/jm7b01261_si_004.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Molecular-modeling information FLT3-26 (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01261/suppl_file/jm7b01261_si_005.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular-modeling information FLT3-42, 50 (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01261/suppl_file/jm7b01261_si_006.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01261/suppl_file/jm7b01261_si_001.pdf">jm7b01261_si_001.pdf (7.48 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01261/suppl_file/jm7b01261_si_002.pdb">jm7b01261_si_002.pdb (389.15 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01261/suppl_file/jm7b01261_si_003.pdb">jm7b01261_si_003.pdb (382.67 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01261/suppl_file/jm7b01261_si_004.csv">jm7b01261_si_004.csv (4.53 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01261/suppl_file/jm7b01261_si_005.pdb">jm7b01261_si_005.pdb (340.73 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01261/suppl_file/jm7b01261_si_006.pdb">jm7b01261_si_006.pdb (346.0 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b01261" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45136" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45136" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yadong Chen</span> - <span class="hlFld-Affiliation affiliation">†School
of Sciences and ‡State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#ccb5a8afa4a9a28cafbcb9e2a9a8b9e2afa2"><span class="__cf_email__" data-cfemail="1168757279747f517261643f7475643f727f">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tao Lu</span> - <span class="hlFld-Affiliation affiliation">†School
of Sciences and ‡State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c4a8b1b0f5f2f784f5f2f7eaa7aba9"><span class="__cf_email__" data-cfemail="d6baa3a2e7e0e596e7e0e5f8b5b9bb">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yue Wang</span> - <span class="hlFld-Affiliation affiliation">†School
of Sciences and ‡State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3471-682X" title="Orcid link">http://orcid.org/0000-0002-3471-682X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yanle Zhi</span> - <span class="hlFld-Affiliation affiliation">†School
of Sciences and ‡State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6066-2231" title="Orcid link">http://orcid.org/0000-0001-6066-2231</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qiaomei Jin</span> - <span class="hlFld-Affiliation affiliation">†School
of Sciences and ‡State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuai Lu</span> - <span class="hlFld-Affiliation affiliation">†School
of Sciences and ‡State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guowu Lin</span> - <span class="hlFld-Affiliation affiliation">†School
of Sciences and ‡State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haoliang Yuan</span> - <span class="hlFld-Affiliation affiliation">†School
of Sciences and ‡State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0248-4347" title="Orcid link">http://orcid.org/0000-0003-0248-4347</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Taotao Yang</span> - <span class="hlFld-Affiliation affiliation">†School
of Sciences and ‡State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhanwei Wang</span> - <span class="hlFld-Affiliation affiliation">†School
of Sciences and ‡State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chao Yao</span> - <span class="hlFld-Affiliation affiliation">†School
of Sciences and ‡State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jun Ling</span> - <span class="hlFld-Affiliation affiliation">†School
of Sciences and ‡State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hao Guo</span> - <span class="hlFld-Affiliation affiliation">†School
of Sciences and ‡State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tonghui Li</span> - <span class="hlFld-Affiliation affiliation">†School
of Sciences and ‡State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianlin Jin</span> - <span class="hlFld-Affiliation affiliation">†School
of Sciences and ‡State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Baoquan Li</span> - <span class="hlFld-Affiliation affiliation">†School
of Sciences and ‡State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Zhang</span> - <span class="hlFld-Affiliation affiliation">†School
of Sciences and ‡State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Y.W. and Y.Z. contributed equally to this work. The manuscript was written through contributions of all authors.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ACK-d231e5396-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i87">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06430" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06430" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to the National Natural Science Foundation of China (program no. 81502925) for financial support and to the QingLan Project, which has a grant from Jiangsu Province. This work was financially supported by the Innovation Project for Postgraduates in Jiangsu Province (program no. CX16B-008HH). The Developmental Therapeutics Program at NCI carried out the NCI60 screening of compounds <b>35</b>, <b>48</b>, and <b>50</b>. Figure 3A is reproduced courtesy of Cell Signaling Technology, Inc. (<a href="http://www.cellsignal.com" class="extLink">www.cellsignal.com</a>).<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(50)</a> We also express our gratitude to Dr. Xiazhong Ren, Dr. Huajun Yang, and Dr. Chunlan Dong of Crown Bioscience Corporation and Dr. Jamie Planck of Reaction Biology Corporation (RBC, PA) for their helpful support in the biological evaluations.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i88" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i88"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i89" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i89"> Abbreviations Used</h2><tr><td class="NLM_term">CDK</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase</p></td></tr><tr><td class="NLM_term">FLT3</td><td class="NLM_def"><p class="first last">Fms-like receptor tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">LC<sub>50</sub></td><td class="NLM_def"><p class="first last">lethal concentration 50</p></td></tr><tr><td class="NLM_term">GI<sub>50</sub></td><td class="NLM_def"><p class="first last">50% growth inhibition</p></td></tr><tr><td class="NLM_term">ara-C</td><td class="NLM_def"><p class="first last">cytarabine</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine-kinase inhibitor</p></td></tr><tr><td class="NLM_term">BrdU</td><td class="NLM_def"><p class="first last">5-bromo-20-deoxyuridine</p></td></tr><tr><td class="NLM_term">ITD</td><td class="NLM_def"><p class="first last">internal tandem duplication</p></td></tr><tr><td class="NLM_term">Rb</td><td class="NLM_def"><p class="first last">retinoblastoma</p></td></tr><tr><td class="NLM_term">LD<sub>50</sub></td><td class="NLM_def"><p class="first last">median lethal dose</p></td></tr><tr><td class="NLM_term">GI</td><td class="NLM_def"><p class="first last">percentage of tumor-growth inhibition</p></td></tr><tr><td class="NLM_term">PTR</td><td class="NLM_def"><p class="first last">percent tumor regression</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i90">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57187" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57187" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 50 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Rowe, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tallman, M. S.</span><span> </span><span class="NLM_article-title">How I treat acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">3147</span><span class="NLM_x">–</span> <span class="NLM_lpage">3156</span><span class="refDoi"> DOI: 10.1182/blood-2010-05-260117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1182%2Fblood-2010-05-260117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=20558611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeisLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=3147-3156&author=J.+M.+Roweauthor=M.+S.+Tallman&title=How+I+treat+acute+myeloid+leukemia&doi=10.1182%2Fblood-2010-05-260117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">How I treat acute myeloid leukemia</span></div><div class="casAuthors">Rowe, Jacob M.; Tallman, Martin S.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3147-3156</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">More than one quarter of a million adults throughout the world are diagnosed annually with acute myeloid leukemia (AML).  Despite considerable progress during the past 3 decades in the therapy of AML, two-thirds of young adults and 90% of older adults still die of their disease.  The reported median age has increased over the past few decades, mostly because of a greater willingness of physicians to diagnose and treat older patients, and now is 72 years.  The greatest challenge is in this age group.  However, much improvement in therapy is needed for all adults with AML.  Recent advances in allogeneic transplantation, a better understanding of prognostic factors, and development of targeted agents have only modestly improved overall outcome when large populations of patients are considered.  Although an explosion in knowledge about the mol. pathogenesis of AML has outpaced treatment advances, such insights hold promise for the development of new therapies directed at specific mol. abnormalities that perturb malignant cell survival pathways.  The current approach in 2010 to the management of this disease is presented through a discussion of illustrative cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowwHCAKmWidLVg90H21EOLACvtfcHk0ljdOXAOP6L88w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeisLvM&md5=0ed950fa5646cae2522ea653fc74d733</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-05-260117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-05-260117%26sid%3Dliteratum%253Aachs%26aulast%3DRowe%26aufirst%3DJ.%2BM.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26atitle%3DHow%2520I%2520treat%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26spage%3D3147%26epage%3D3156%26doi%3D10.1182%2Fblood-2010-05-260117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Quintás-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravandi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu-Dumlao, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faderl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borthakur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Manero, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span> </span><span class="NLM_article-title">Epigenetic Therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">4840</span><span class="NLM_x">–</span> <span class="NLM_lpage">4845</span><span class="refDoi"> DOI: 10.1182/blood-2012-06-436055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1182%2Fblood-2012-06-436055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2012&pages=4840-4845&author=A.+Quint%C3%A1s-Cardamaauthor=F.+Ravandiauthor=T.+Liu-Dumlaoauthor=M.+Brandtauthor=S.+Faderlauthor=S.+Pierceauthor=G.+Borthakurauthor=G.+Garcia-Maneroauthor=J.+Cortesauthor=H.+Kantarjian&title=Epigenetic+Therapy+is+associated+with+similar+survival+compared+with+intensive+chemotherapy+in+older+patients+with+newly+diagnosed+acute+myeloid+leukemia&doi=10.1182%2Fblood-2012-06-436055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1182%2Fblood-2012-06-436055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2012-06-436055%26sid%3Dliteratum%253Aachs%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DA.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DLiu-Dumlao%26aufirst%3DT.%26aulast%3DBrandt%26aufirst%3DM.%26aulast%3DFaderl%26aufirst%3DS.%26aulast%3DPierce%26aufirst%3DS.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DEpigenetic%2520Therapy%2520is%2520associated%2520with%2520similar%2520survival%2520compared%2520with%2520intensive%2520chemotherapy%2520in%2520older%2520patients%2520with%2520newly%2520diagnosed%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2012%26volume%3D120%26spage%3D4840%26epage%3D4845%26doi%3D10.1182%2Fblood-2012-06-436055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">FLT3 tyrosine kinase inhibitors</span> <span class="citation_source-journal">Int. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">100</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span><span class="refDoi"> DOI: 10.1532/IJH97.05079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1532%2FIJH97.05079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=16146839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGntL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2005&pages=100-107&author=M.+Levisauthor=D.+Small&title=FLT3+tyrosine+kinase+inhibitors&doi=10.1532%2FIJH97.05079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 tyrosine kinase inhibitors</span></div><div class="casAuthors">Levis, Mark; Small, Donald</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Hematology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">100-107</span>CODEN:
                <span class="NLM_cas:coden">IJHEEY</span>;
        ISSN:<span class="NLM_cas:issn">0925-5710</span>.
    
            (<span class="NLM_cas:orgname">Carden Jennings Publishing</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase FLT3 is an important regulatory mol. in hematopoiesis and is expressed on the blasts in most cases of acute leukemia.  Activating mutations of this receptor are present in roughly 30% of acute myeloid leukemia (AML) patients and are assocd. with a distinctly worse clin. outcome.  Efforts to target this mutation and improve outcomes in this subgroup of AML patients have led to the investigation of several novel small-mol. FLT3 tyrosine kinase inhibitors.  These compds. derive from a wide variety of chem. classes and differ significantly, both in their potency and in their selectivity.  In this review, we discuss the results of preclin., clin., and correlative lab. studies of FLT3 inhibitors in demonstrating how this field represents a truly translational enterprise with multiple ongoing interactions between the lab. and the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF4BnW93Jv2rVg90H21EOLACvtfcHk0ljdOXAOP6L88w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGntL%252FN&md5=75bdd31913d422c3a42551ee048e4f1e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1532%2FIJH97.05079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1532%252FIJH97.05079%26sid%3Dliteratum%253Aachs%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DFLT3%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DInt.%2520J.%2520Hematol.%26date%3D2005%26volume%3D82%26spage%3D100%26epage%3D107%26doi%3D10.1532%2FIJH97.05079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Kikushige, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimoto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niiro, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takenaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagafuji, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, M.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Human FLT3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">180</span><span class="NLM_x">, </span> <span class="NLM_fpage">7358</span><span class="NLM_x">–</span> <span class="NLM_lpage">7367</span><span class="refDoi"> DOI: 10.4049/jimmunol.180.11.7358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.4049%2Fjimmunol.180.11.7358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=18490735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtVanurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2008&pages=7358-7367&author=Y.+Kikushigeauthor=G.+Yoshimotoauthor=T.+Miyamotoauthor=T.+Iinoauthor=Y.+Moriauthor=H.+Iwasakiauthor=H.+Niiroauthor=K.+Takenakaauthor=K.+Nagafujiauthor=M.+Harada&title=Human+FLT3+is+expressed+at+the+hematopoietic+stem+cell+and+the+granulocyte%2Fmacrophage+progenitor+stages+to+maintain+cell+survival&doi=10.4049%2Fjimmunol.180.11.7358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Human Flt3 Is Expressed at the Hematopoietic Stem Cell and the Granulocyte/Macrophage Progenitor Stages to Maintain Cell Survival</span></div><div class="casAuthors">Kikushige, Yoshikane; Yoshimoto, Goichi; Miyamoto, Toshihiro; Iino, Tadafumi; Mori, Yasuo; Iwasaki, Hiromi; Niiro, Hiroaki; Takenaka, Katsuto; Nagafuji, Koji; Harada, Mine; Ishikawa, Fumihiko; Akashi, Koichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7358-7367</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">FLT3/FLK2, a member of the receptor tyrosine kinase family, plays a crit. role in maintenance of hematopoietic homeostasis, and the constitutively active form of the FLT3 mutation is one of the most common genetic abnormalities in acute myelogenous leukemia.  In murine hematopoiesis, Flt3 is not expressed in self-renewing hematopoietic stem cells, but its expression is restricted to the multipotent and the lymphoid progenitor stages at which cells are incapable of self-renewal.  The authors extensively analyzed the expression of Flt3 in human (h) hematopoiesis.  Strikingly, in both the bone marrow and the cord blood, the human hematopoietic stem cell population capable of long-term reconstitution in xenogeneic hosts uniformly expressed Flt3.  Furthermore, human Flt3 is expressed not only in early lymphoid progenitors, but also in progenitors continuously along the granulocyte/macrophage pathway, including the common myeloid progenitor and the granulocyte/macrophage progenitor.  The authors further found that human Flt3 signaling prevents stem and progenitors from spontaneous apoptotic cell death at least through up-regulating Mcl-1, an indispensable survival factor for hematopoiesis.  Thus, the distribution of Flt3 expression is considerably different in human and mouse hematopoiesis, and human FLT3 signaling might play an important role in cell survival, esp. at stem and progenitor cells that are crit. cellular targets for acute myelogenous leukemia transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKXcrR-KQExrVg90H21EOLACvtfcHk0liX4gi8re3Wtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtVanurs%253D&md5=3ff9bbe7a42c4ce0a87017014f7c3c2b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.180.11.7358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.180.11.7358%26sid%3Dliteratum%253Aachs%26aulast%3DKikushige%26aufirst%3DY.%26aulast%3DYoshimoto%26aufirst%3DG.%26aulast%3DMiyamoto%26aufirst%3DT.%26aulast%3DIino%26aufirst%3DT.%26aulast%3DMori%26aufirst%3DY.%26aulast%3DIwasaki%26aufirst%3DH.%26aulast%3DNiiro%26aufirst%3DH.%26aulast%3DTakenaka%26aufirst%3DK.%26aulast%3DNagafuji%26aufirst%3DK.%26aulast%3DHarada%26aufirst%3DM.%26atitle%3DHuman%2520FLT3%2520is%2520expressed%2520at%2520the%2520hematopoietic%2520stem%2520cell%2520and%2520the%2520granulocyte%252Fmacrophage%2520progenitor%2520stages%2520to%2520maintain%2520cell%2520survival%26jtitle%3DJ.%2520Immunol.%26date%3D2008%26volume%3D180%26spage%3D7358%26epage%3D7367%26doi%3D10.4049%2Fjimmunol.180.11.7358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Oubari, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amirizade, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammadpour, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakhlestani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarif, M. N.</span><span> </span><span class="NLM_article-title">The important role of FLT3-L in ex vivo expansion of hematopoietic stem cells following co-culture with mesenchymal stem cells</span> <span class="citation_source-journal">Cell J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">210</span><span class="refDoi"> DOI: 10.22074/cellj.2016.3715</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.22074%2Fcellj.2016.3715" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2014&pages=201-210&author=F.+Oubariauthor=N.+Amirizadeauthor=H.+Mohammadpourauthor=M.+Nakhlestaniauthor=M.+N.+Zarif&title=The+important+role+of+FLT3-L+in+ex+vivo+expansion+of+hematopoietic+stem+cells+following+co-culture+with+mesenchymal+stem+cells&doi=10.22074%2Fcellj.2016.3715"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.22074%2Fcellj.2016.3715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.22074%252Fcellj.2016.3715%26sid%3Dliteratum%253Aachs%26aulast%3DOubari%26aufirst%3DF.%26aulast%3DAmirizade%26aufirst%3DN.%26aulast%3DMohammadpour%26aufirst%3DH.%26aulast%3DNakhlestani%26aufirst%3DM.%26aulast%3DZarif%26aufirst%3DM.%2BN.%26atitle%3DThe%2520important%2520role%2520of%2520FLT3-L%2520in%2520ex%2520vivo%2520expansion%2520of%2520hematopoietic%2520stem%2520cells%2520following%2520co-culture%2520with%2520mesenchymal%2520stem%2520cells%26jtitle%3DCell%2520J.%26date%3D2014%26volume%3D17%26spage%3D201%26epage%3D210%26doi%3D10.22074%2Fcellj.2016.3715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Kottaridis, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frew, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langabeer, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belton, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheatley, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowen, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnett, A. K.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">1752</span><span class="NLM_x">–</span> <span class="NLM_lpage">1759</span><span class="refDoi"> DOI: 10.1182/blood.V98.6.1752</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1182%2Fblood.V98.6.1752" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=1752-1759&author=P.+D.+Kottaridisauthor=R.+E.+Galeauthor=M.+E.+Frewauthor=G.+Harrisonauthor=S.+E.+Langabeerauthor=A.+A.+Beltonauthor=H.+Walkerauthor=K.+Wheatleyauthor=D.+T.+Bowenauthor=A.+K.+Burnett&title=The+presence+of+a+FLT3+internal+tandem+duplication+in+patients+with+acute+myeloid+leukemia+%28AML%29+adds+important+prognostic+information+to+cytogenetic+risk+group+and+response+to+the+first+cycle+of+chemotherapy%3A+analysis+of+854+patients+from+the+United+Kingdom+Medical+Research+Council+AML+10+and+12+trials&doi=10.1182%2Fblood.V98.6.1752"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1182%2Fblood.V98.6.1752&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V98.6.1752%26sid%3Dliteratum%253Aachs%26aulast%3DKottaridis%26aufirst%3DP.%2BD.%26aulast%3DGale%26aufirst%3DR.%2BE.%26aulast%3DFrew%26aufirst%3DM.%2BE.%26aulast%3DHarrison%26aufirst%3DG.%26aulast%3DLangabeer%26aufirst%3DS.%2BE.%26aulast%3DBelton%26aufirst%3DA.%2BA.%26aulast%3DWalker%26aufirst%3DH.%26aulast%3DWheatley%26aufirst%3DK.%26aulast%3DBowen%26aufirst%3DD.%2BT.%26aulast%3DBurnett%26aufirst%3DA.%2BK.%26atitle%3DThe%2520presence%2520of%2520a%2520FLT3%2520internal%2520tandem%2520duplication%2520in%2520patients%2520with%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%2520adds%2520important%2520prognostic%2520information%2520to%2520cytogenetic%2520risk%2520group%2520and%2520response%2520to%2520the%2520first%2520cycle%2520of%2520chemotherapy%253A%2520analysis%2520of%2520854%2520patients%2520from%2520the%2520United%2520Kingdom%2520Medical%2520Research%2520Council%2520AML%252010%2520and%252012%2520trials%26jtitle%3DBlood%26date%3D2001%26volume%3D98%26spage%3D1752%26epage%3D1759%26doi%3D10.1182%2Fblood.V98.6.1752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Yamamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyawaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yagasaki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimazaki, C.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">2434</span><span class="NLM_x">–</span> <span class="NLM_lpage">2439</span><span class="refDoi"> DOI: 10.1182/blood.V97.8.2434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1182%2Fblood.V97.8.2434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=11290608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFOgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2001&pages=2434-2439&author=Y.+Yamamotoauthor=H.+Kiyoiauthor=Y.+Nakanoauthor=R.+Suzukiauthor=Y.+Koderaauthor=S.+Miyawakiauthor=N.+Asouauthor=K.+Kuriyamaauthor=F.+Yagasakiauthor=C.+Shimazaki&title=Activating+mutation+of+D835+within+the+activation+loop+of+FLT3+in+human+hematologic+malignancies&doi=10.1182%2Fblood.V97.8.2434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies</span></div><div class="casAuthors">Yamamoto, Yukiya; Kiyoi, Hitoshi; Nakano, Yasuyuki; Suzuki, Ritsuro; Kodera, Yoshihisa; Miyawaki, Shuichi; Asou, Norio; Kuriyama, Kazutaka; Yagasaki, Fumiharu; Shimazaki, Chihiro; Akiyama, Hideki; Saito, Kenji; Nishimura, Miki; Motoji, Toshiko; Shinagawa, Katsuji; Takeshita, Akihiro; Saito, Hidehiko; Ueda, Ryuzo; Ohno, Ryuzo; Naoe, Tomoki</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2434-2439</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Mutations of receptor tyrosine kinases are implicated in the constitutive activation and development of human malignancy.  An internal tandem duplication (ITD) of the juxtamembrane (JM) domain-coding sequence of the FLT3 gene (FLT3/ITD) is found in 20% of patients with acute myeloid leukemia (AML) and is strongly assocd. with leukocytosis and a poor prognosis.  On the other hand, mutations of the c-KIT gene, which have been found in mast cell leukemia and AML, are clustered in 2 distinct regions, the JM domain and D816 within the activation loop.  This study was designed to analyze the mutation of D835 of FLT3, which corresponds to D816 of c-KIT, in a large series of human hematol. malignancies.  Several kinds of missense mutations were found in 30 of the 429 (7.0%) AML cases, 1 of the 29 (3.4%) myelodysplastic syndrome (MDS) cases, and 1 of the 36 (2.8%) acute lymphocytic leukemia patients.  The D835Y mutation was most frequently found (22 of the 32 D835 mutations), followed by the D835V (5), and D835H (1), D835E (1), and D835N (1) mutations.  Of note is that D835 mutations occurred independently of FLT3/ITD.  An anal. in the 201 patients newly diagnosed with AML (excluding M3) revealed that, in contrast to the FLT3/ITD mutation, D835 mutations were not significantly related to the leukocytosis, but tended to worsen disease-free survival.  All D835-mutant FLT3 were constitutively tyrosine-phosphorylated and transformed 32D cells, suggesting these mutations were constitutively active.  These results demonstrate that the FLT3 gene is the target most frequently mutated to become constitutively active in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrydJnPT47K17Vg90H21EOLACvtfcHk0lg1KvraAwUMsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFOgtbk%253D&md5=646e1b1a04c570f4094e7d83723d47fb</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1182%2Fblood.V97.8.2434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V97.8.2434%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DKodera%26aufirst%3DY.%26aulast%3DMiyawaki%26aufirst%3DS.%26aulast%3DAsou%26aufirst%3DN.%26aulast%3DKuriyama%26aufirst%3DK.%26aulast%3DYagasaki%26aufirst%3DF.%26aulast%3DShimazaki%26aufirst%3DC.%26atitle%3DActivating%2520mutation%2520of%2520D835%2520within%2520the%2520activation%2520loop%2520of%2520FLT3%2520in%2520human%2520hematologic%2520malignancies%26jtitle%3DBlood%26date%3D2001%26volume%3D97%26spage%3D2434%26epage%3D2439%26doi%3D10.1182%2Fblood.V97.8.2434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allebach, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tse, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldwin, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones-Bolin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dionne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">3885</span><span class="NLM_x">–</span> <span class="NLM_lpage">3891</span><span class="refDoi"> DOI: 10.1182/blood.V99.11.3885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1182%2Fblood.V99.11.3885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=12010785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BD38XktFyrsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=3885-3891&author=M.+Levisauthor=J.+Allebachauthor=K.+F.+Tseauthor=R.+Zhengauthor=B.+R.+Baldwinauthor=B.+D.+Smithauthor=S.+Jones-Bolinauthor=B.+Ruggeriauthor=C.+Dionneauthor=D.+Small&title=A+FLT3-targeted+tyrosine+kinase+inhibitor+is+cytotoxic+to+leukemia+cells+in+vitro+and+in+vivo&doi=10.1182%2Fblood.V99.11.3885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo</span></div><div class="casAuthors">Levis, Mark; Allebach, Jeffrey; Tse, Kam-Fai; Zheng, Rui; Baldwin, Brenda R.; Smith, B. Douglas; Jones-Bolin, Susan; Ruggeri, Bruce; Dionne, Craig; Small, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3885-3891</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Constitutively activating internal tandem duplication (ITD) and point mutations of the receptor tyrosine kinase FLT3 are present in ≤41% of patients with acute myeloid leukemia (AML).  These FLT3/ITD mutations are likely to be important because their presence is assocd. with a poor prognosis.  Both types of mutations appear to activate the tyrosine kinase activity of FLT3.  The authors describe here the identification and characterization of the indolocarbazole deriv. CEP-701 as a FLT3 inhibitor.  This drug potently and selectively inhibits autophosphorylation of wild-type and constitutively activated mutant FLT3 in vitro in FLT3/ITD-transfected cells and in human FLT3-expressing myeloid leukemia-derived cell lines.  The authors demonstrate that CEP-701 induces a cytotoxic effect on cells in a dose-responsive fashion that parallels the inhibition of FLT3.  STAT5 and ERK1/2, downstream targets of FLT3 in the signaling pathway, are inhibited in response to FLT3 inhibition.  In primary leukemia blasts from AML patients harboring FLT3/ITD mutations, FLT3 is also inhibited, with an assocd. cytotoxic response.  Finally, using a mouse model of FLT3/ITD leukemia, the authors demonstrate that the drug inhibits FLT3 phosphorylation in vivo and prolongs survival.  These findings form the basis for a planned clin. trial of CEP-701 in patients with AML harboring FLT3-activating mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXL7nbYZzBSrVg90H21EOLACvtfcHk0lhFG8MgzeKNPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktFyrsr0%253D&md5=3808e2bf314d769c9ae1c11324df4aba</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1182%2Fblood.V99.11.3885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V99.11.3885%26sid%3Dliteratum%253Aachs%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DAllebach%26aufirst%3DJ.%26aulast%3DTse%26aufirst%3DK.%2BF.%26aulast%3DZheng%26aufirst%3DR.%26aulast%3DBaldwin%26aufirst%3DB.%2BR.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DJones-Bolin%26aufirst%3DS.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DDionne%26aufirst%3DC.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DA%2520FLT3-targeted%2520tyrosine%2520kinase%2520inhibitor%2520is%2520cytotoxic%2520to%2520leukemia%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2002%26volume%3D99%26spage%3D3885%26epage%3D3891%26doi%3D10.1182%2Fblood.V99.11.3885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Kiyoi, H.</span><span> </span><span class="NLM_article-title">Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1605</span><span class="NLM_x">–</span> <span class="NLM_lpage">1609</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1997&pages=1605-1609&author=H.+Kiyoi&title=Internal+tandem+duplication+of+the+FLT3+gene+is+preferentially+seen+in+acute+myeloid+leukemia+and+myelodysplastic+syndrome+among+various+hematological+malignancies.+A+study+on+a+large+series+of+patients+and+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKiyoi%26aufirst%3DH.%26atitle%3DInternal%2520tandem%2520duplication%2520of%2520the%2520FLT3%2520gene%2520is%2520preferentially%2520seen%2520in%2520acute%2520myeloid%2520leukemia%2520and%2520myelodysplastic%2520syndrome%2520among%2520various%2520hematological%2520malignancies.%2520A%2520study%2520on%2520a%2520large%2520series%2520of%2520patients%2520and%2520cell%2520lines%26jtitle%3DLeukemia%26date%3D1997%26volume%3D11%26spage%3D1605%26epage%3D1609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Meshinchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirewalt, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweetser, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tjoa, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radich, J. P.</span><span> </span><span class="NLM_article-title">Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span><span class="refDoi"> DOI: 10.1182/blood.V97.1.89</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1182%2Fblood.V97.1.89" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2001&pages=89-94&author=S.+Meshinchiauthor=W.+G.+Woodsauthor=D.+L.+Stirewaltauthor=D.+A.+Sweetserauthor=J.+D.+Buckleyauthor=T.+K.+Tjoaauthor=I.+D.+Bernsteinauthor=J.+P.+Radich&title=Prevalence+and+prognostic+significance+of+Flt3+internal+tandem+duplication+in+pediatric+acute+myeloid+leukemia&doi=10.1182%2Fblood.V97.1.89"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1182%2Fblood.V97.1.89&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V97.1.89%26sid%3Dliteratum%253Aachs%26aulast%3DMeshinchi%26aufirst%3DS.%26aulast%3DWoods%26aufirst%3DW.%2BG.%26aulast%3DStirewalt%26aufirst%3DD.%2BL.%26aulast%3DSweetser%26aufirst%3DD.%2BA.%26aulast%3DBuckley%26aufirst%3DJ.%2BD.%26aulast%3DTjoa%26aufirst%3DT.%2BK.%26aulast%3DBernstein%26aufirst%3DI.%2BD.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26atitle%3DPrevalence%2520and%2520prognostic%2520significance%2520of%2520Flt3%2520internal%2520tandem%2520duplication%2520in%2520pediatric%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2001%26volume%3D97%26spage%3D89%26epage%3D94%26doi%3D10.1182%2Fblood.V97.1.89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Smith, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dun, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panicker, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mashkani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Don, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, J.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">47465</span><span class="NLM_x">–</span> <span class="NLM_lpage">47478</span><span class="refDoi"> DOI: 10.18632/oncotarget.10167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.18632%2Foncotarget.10167" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=47465-47478&author=A.+M.+Smithauthor=M.+D.+Dunauthor=E.+M.+Leeauthor=C.+Harrisonauthor=R.+Kahlauthor=H.+Flanaganauthor=N.+Panickerauthor=B.+Mashkaniauthor=A.+S.+Donauthor=J.+Morris&title=Activation+of+protein+phosphatase+2A+in+FLT3%2B+acute+myeloid+leukemia+cells+enhances+the+cytotoxicity+of+FLT3+tyrosine+kinase+inhibitors&doi=10.18632%2Foncotarget.10167"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.10167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.10167%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DDun%26aufirst%3DM.%2BD.%26aulast%3DLee%26aufirst%3DE.%2BM.%26aulast%3DHarrison%26aufirst%3DC.%26aulast%3DKahl%26aufirst%3DR.%26aulast%3DFlanagan%26aufirst%3DH.%26aulast%3DPanicker%26aufirst%3DN.%26aulast%3DMashkani%26aufirst%3DB.%26aulast%3DDon%26aufirst%3DA.%2BS.%26aulast%3DMorris%26aufirst%3DJ.%26atitle%3DActivation%2520of%2520protein%2520phosphatase%25202A%2520in%2520FLT3%252B%2520acute%2520myeloid%2520leukemia%2520cells%2520enhances%2520the%2520cytotoxicity%2520of%2520FLT3%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D47465%26epage%3D47478%26doi%3D10.18632%2Foncotarget.10167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Wiernik, P. H.</span><span> </span><span class="NLM_article-title">FLT3 inhibitors for the treatment of acute myeloid leukemia</span> <span class="citation_source-journal">Clin. Adv. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">436</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=20733555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A280%3ADC%252BC3cjmvFCgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=429-436&author=P.+H.+Wiernik&title=FLT3+inhibitors+for+the+treatment+of+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 inhibitors for the treatment of acute myeloid leukemia</span></div><div class="casAuthors">Wiernik Peter H</div><div class="citationInfo"><span class="NLM_cas:title">Clinical advances in hematology & oncology : H&O</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">429-36, 444</span>
        ISSN:<span class="NLM_cas:issn">1543-0790</span>.
    </div><div class="casAbstract">The fms-like receptor tyrosine kinase-3 (FLT3), which is important for the normal development of hematopoietic stem cells and cells of the immune system, is frequently mutated in patients with acute myeloid leukemia (AML).  FLT3 is, therefore, a potential therapeutic target in AML.  Recently, FLT3 inhibitors have shown therapeutic activity in AML patients with FLT3 mutations.  Sorafenib and sunitinib were the first FLT3 inhibitors to be studied in the clinic and have the most clinically relevant data.  Limited data are available for midostaurin (PKC412), lestaurtinib (CEP-701), tandutinib (MLN518), AC220, and KW-2449.  It is likely that optimal application of these agents will involve combinations of inhibitors and combinations of inhibitors and chemotherapy, potentially with a mammalian target of rapamycin inhibitor such as everolimus or temsirolimus.  This review discusses the theoretical rationale for the use of these agents and summarizes the relevant clinical data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZEiX89cbR_l1C8OJBvdfbfW6udTcc2ea6C5fX3z7Uxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjmvFCgtg%253D%253D&md5=79a23ac07439bcd8edaa748451fd35d8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWiernik%26aufirst%3DP.%2BH.%26atitle%3DFLT3%2520inhibitors%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DClin.%2520Adv.%2520Hematol.%2520Oncol.%26date%3D2010%26volume%3D8%26spage%3D429%26epage%3D436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Grunwald, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span> </span><span class="NLM_article-title">FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance</span> <span class="citation_source-journal">Int. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">683</span><span class="NLM_x">–</span> <span class="NLM_lpage">694</span><span class="refDoi"> DOI: 10.1007/s12185-013-1334-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1007%2Fs12185-013-1334-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=23613268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC3sXps1ynt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2013&pages=683-694&author=M.+R.+Grunwaldauthor=M.+J.+Levis&title=FLT3+inhibitors+for+acute+myeloid+leukemia%3A+a+review+of+their+efficacy+and+mechanisms+of+resistance&doi=10.1007%2Fs12185-013-1334-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance</span></div><div class="casAuthors">Grunwald, Michael R.; Levis, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Hematology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">683-694</span>CODEN:
                <span class="NLM_cas:coden">IJHEEY</span>;
        ISSN:<span class="NLM_cas:issn">0925-5710</span>.
    
            (<span class="NLM_cas:orgname">Springer Japan</span>)
        </div><div class="casAbstract">A review.  Since the Food and Drug Administration approval of imatinib for treatment of chronic myeloid leukemia in 2001, tyrosine kinase inhibitors (TKIs) have become a mainstay in the care of many malignancies.  In acute myeloid leukemia (AML), activating mutations in the FMS-like tyrosine kinase 3 (FLT3) gene result in survival and proliferation of leukemic blasts and are assocd. with adverse prognosis.  Therefore, the FLT3 receptor is an appealing target for inhibition.  Multiple small mol. TKIs are currently in development for FLT3-mutated AML, and agents are beginning to show promising efficacy.  In other malignancies, the development of resistance to TKIs during the course of therapy has proven to be a challenge, and thus far, in clin. trials of FLT3 TKIs, resistance to inhibition represents a significant barrier to successful FLT3 inhibition.  Understanding the mechanisms of resistance and overcoming these obstacles to target inhibition will be central to the success of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLGvQhRtVOcLVg90H21EOLACvtfcHk0liuareQNL6UPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXps1ynt7Y%253D&md5=f760866dbcd953c09143e0290fbffe3c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs12185-013-1334-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12185-013-1334-8%26sid%3Dliteratum%253Aachs%26aulast%3DGrunwald%26aufirst%3DM.%2BR.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26atitle%3DFLT3%2520inhibitors%2520for%2520acute%2520myeloid%2520leukemia%253A%2520a%2520review%2520of%2520their%2520efficacy%2520and%2520mechanisms%2520of%2520resistance%26jtitle%3DInt.%2520J.%2520Hematol.%26date%3D2013%26volume%3D97%26spage%3D683%26epage%3D694%26doi%3D10.1007%2Fs12185-013-1334-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Boulahjar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouach, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lozach, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guguen-Guillouzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Guevel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akssira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillaumet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Routier, S.</span><span> </span><span class="NLM_article-title">Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">274</span><span class="NLM_x">–</span> <span class="NLM_lpage">287</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2015.06.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1016%2Fj.ejmech.2015.06.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=26142492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCqsbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2015&pages=274-287&author=R.+Boulahjarauthor=A.+Ouachauthor=S.+Bourgauthor=P.+Bonnetauthor=O.+Lozachauthor=L.+Meijerauthor=C.+Guguen-Guillouzoauthor=R.+Le+Guevelauthor=S.+Lazarauthor=M.+Akssiraauthor=Y.+Troinauthor=G.+Guillaumetauthor=S.+Routier&title=Advances+in+tetrahydropyrido%5B1%2C2-a%5Disoindolone+%28valmerins%29+series%3A+Potent+glycogen+synthase+kinase+3+and+cyclin+dependent+kinase+5+inhibitors&doi=10.1016%2Fj.ejmech.2015.06.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors</span></div><div class="casAuthors">Boulahjar, Rajaa; Ouach, Aziz; Bourg, Stephane; Bonnet, Pascal; Lozach, Olivier; Meijer, Laurent; Guguen-Guillouzo, Christiane; Le Guevel, Remy; Lazar, Said; Akssira, Mohamed; Troin, Yves; Guillaumet, Gerald; Routier, Sylvain</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">274-287</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">An efficient synthetic strategy was developed to modulate the structure of the tetrahydropyridine isoindolone (Valmerin) skeleton.  A library of more than 30 novel final structures was generated.  Biol. activities on CDK5 and GSK3 as well as cellular effects on cancer cell lines were measured for each novel compd.  Addnl. docking studies were performed to support medicinal chem. efforts.  A strong GSK3/CDK5 dual inhibitor (I, IC50 GSK3/CDK5 32/84 nM) was obtained.  A set of highly selective GSK3 inhibitors was synthesized by fine-tuning structural modifications (II, IC50 GSK3/CDK5 32/320 nM).  Antiproliferative effects on cells were correlated with the in vitro kinase activities and the best effects were obtained with lung and colon cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNKc6ssVA1k7Vg90H21EOLACvtfcHk0lhSfQsT1ydhnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCqsbrK&md5=5385782f450d6914ddc149004d5facce</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.06.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.06.046%26sid%3Dliteratum%253Aachs%26aulast%3DBoulahjar%26aufirst%3DR.%26aulast%3DOuach%26aufirst%3DA.%26aulast%3DBourg%26aufirst%3DS.%26aulast%3DBonnet%26aufirst%3DP.%26aulast%3DLozach%26aufirst%3DO.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DGuguen-Guillouzo%26aufirst%3DC.%26aulast%3DLe%2BGuevel%26aufirst%3DR.%26aulast%3DLazar%26aufirst%3DS.%26aulast%3DAkssira%26aufirst%3DM.%26aulast%3DTroin%26aufirst%3DY.%26aulast%3DGuillaumet%26aufirst%3DG.%26aulast%3DRoutier%26aufirst%3DS.%26atitle%3DAdvances%2520in%2520tetrahydropyrido%255B1%252C2-a%255Disoindolone%2520%2528valmerins%2529%2520series%253A%2520Potent%2520glycogen%2520synthase%2520kinase%25203%2520and%2520cyclin%2520dependent%2520kinase%25205%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D101%26spage%3D274%26epage%3D287%26doi%3D10.1016%2Fj.ejmech.2015.06.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">Cell cycle, CDKs and cancer: a changing paradigm</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">166</span><span class="refDoi"> DOI: 10.1038/nrc2602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1038%2Fnrc2602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=19238148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=153-166&author=M.+Malumbresauthor=M.+Barbacid&title=Cell+cycle%2C+CDKs+and+cancer%3A+a+changing+paradigm&doi=10.1038%2Fnrc2602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle, CDKs and cancer: a changing paradigm</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-166</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor-assocd. cell cycle defects are often mediated by alterations in cyclin-dependent kinase (CDK) activity.  Misregulated CDKs induce unscheduled proliferation as well as genomic and chromosomal instability.  According to current models, mammalian CDKs are essential for driving each cell cycle phase, so therapeutic strategies that block CDK activity are unlikely to selectively target tumor cells.  However, recent genetic evidence has revealed that, whereas CDK1 is required for the cell cycle, interphase CDKs are only essential for proliferation of specialized cells.  Emerging evidence suggests that tumor cells may also require specific interphase CDKs for proliferation.  Thus, selective CDK inhibition may provide therapeutic benefit against certain human neoplasias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzlIKlbCPWnLVg90H21EOLACvtfcHk0lhSfQsT1ydhnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D&md5=2a7eb34b2381e288b3f43ec1bffc0aec</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnrc2602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2602%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCell%2520cycle%252C%2520CDKs%2520and%2520cancer%253A%2520a%2520changing%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D153%26epage%3D166%26doi%3D10.1038%2Fnrc2602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Diaz-Padilla, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duran, I.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase inhibitors as potential targeted anticancer agents</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">586</span><span class="NLM_x">–</span> <span class="NLM_lpage">594</span><span class="refDoi"> DOI: 10.1007/s10637-009-9236-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1007%2Fs10637-009-9236-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=586-594&author=I.+Diaz-Padillaauthor=L.+L.+Siuauthor=I.+Duran&title=Cyclin-dependent+kinase+inhibitors+as+potential+targeted+anticancer+agents&doi=10.1007%2Fs10637-009-9236-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs10637-009-9236-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-009-9236-6%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz-Padilla%26aufirst%3DI.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26aulast%3DDuran%26aufirst%3DI.%26atitle%3DCyclin-dependent%2520kinase%2520inhibitors%2520as%2520potential%2520targeted%2520anticancer%2520agents%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2009%26volume%3D27%26spage%3D586%26epage%3D594%26doi%3D10.1007%2Fs10637-009-9236-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">Cell cycle kinases in cancer</span> <span class="citation_source-journal">Curr. Opin. Genet. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">60</span><span class="NLM_x">–</span> <span class="NLM_lpage">65</span><span class="refDoi"> DOI: 10.1016/j.gde.2006.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1016%2Fj.gde.2006.12.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=60-65&author=M.+Malumbresauthor=M.+Barbacid&title=Cell+cycle+kinases+in+cancer&doi=10.1016%2Fj.gde.2006.12.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.gde.2006.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gde.2006.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCell%2520cycle%2520kinases%2520in%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D2007%26volume%3D17%26spage%3D60%26epage%3D65%26doi%3D10.1016%2Fj.gde.2006.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eksterowicz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribble, M. W.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alba, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connors, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeGraffenreid, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deignan, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duquette, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huard, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaizerman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lively, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMinn, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihalic, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pattabiraman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piper, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Queva, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ragains, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suchomel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibault, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanska, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wehn, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weidner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamb, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickramasinghe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, J. C.</span><span> </span><span class="NLM_article-title">Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3430</span><span class="NLM_x">–</span> <span class="NLM_lpage">3449</span><span class="refDoi"> DOI: 10.1021/jm500118j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500118j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3430-3449&author=Z.+Liauthor=X.+Wangauthor=J.+Eksterowiczauthor=M.+W.+Gribbleauthor=G.+Q.+Albaauthor=M.+Ayresauthor=T.+J.+Carlsonauthor=A.+Chenauthor=X.+Chenauthor=R.+Choauthor=R.+V.+Connorsauthor=M.+DeGraffenreidauthor=J.+T.+Deignanauthor=J.+Duquetteauthor=P.+Fanauthor=B.+Fisherauthor=J.+Fuauthor=J.+N.+Huardauthor=J.+Kaizermanauthor=K.+S.+Keeganauthor=C.+Liauthor=K.+Liauthor=Y.+Liauthor=L.+Liangauthor=W.+Liuauthor=S.+E.+Livelyauthor=M.+C.+Loauthor=J.+Maauthor=D.+L.+McMinnauthor=J.+T.+Mihalicauthor=K.+Modiauthor=R.+Ngoauthor=K.+Pattabiramanauthor=D.+E.+Piperauthor=C.+Quevaauthor=M.+L.+Ragainsauthor=J.+Suchomelauthor=S.+Thibaultauthor=N.+Walkerauthor=X.+Wangauthor=Z.+Wangauthor=M.+Wanskaauthor=P.+M.+Wehnauthor=M.+F.+Weidnerauthor=A.+J.+Zhangauthor=X.+Zhaoauthor=A.+Kambauthor=D.+Wickramasingheauthor=K.+Daiauthor=L.+R.+McGeeauthor=J.+C.+Medina&title=Discovery+of+AMG+925%2C+a+FLT3+and+CDK4+dual+kinase+inhibitor+with+preferential+affinity+for+the+activated+state+of+FLT3&doi=10.1021%2Fjm500118j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3</span></div><div class="casAuthors">Li, Zhihong; Wang, Xianghong; Eksterowicz, John; Gribble, Michael W.; Alba, Grace Q.; Ayres, Merrill; Carlson, Timothy J.; Chen, Ada; Chen, Xiaoqi; Cho, Robert; Connors, Richard V.; DeGraffenreid, Michael; Deignan, Jeffrey T.; Duquette, Jason; Fan, Pingchen; Fisher, Benjamin; Fu, Jiasheng; Huard, Justin N.; Kaizerman, Jacob; Keegan, Kathleen S.; Li, Cong; Li, Kexue; Li, Yunxiao; Liang, Lingming; Liu, Wen; Lively, Sarah E.; Lo, Mei-Chu; Ma, Ji; McMinn, Dustin L.; Mihalic, Jeffrey T.; Modi, Kriti; Ngo, Rachel; Pattabiraman, Kanaka; Piper, Derek E.; Queva, Christophe; Ragains, Mark L.; Suchomel, Julia; Thibault, Steve; Walker, Nigel; Wang, Xiaodong; Wang, Zhulun; Wanska, Malgorzata; Wehn, Paul M.; Weidner, Margaret F.; Zhang, Alex J.; Zhao, Xiaoning; Kamb, Alexander; Wickramasinghe, Dineli; Dai, Kang; McGee, Lawrence R.; Medina, Julio C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3430-3449</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors describe the structural optimization of a lead compd. that exhibits dual inhibitory activities against FLT3 and CDK4.  A series of pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine derivs. was synthesized, and SAR anal., using cell-based assays, led to the discovery of AMG 925 (I), a potent and orally bioavailable dual inhibitor of CDK4 and FLT3, including many FLT3 mutants reported to date.  Compd. I inhibits the proliferation of a panel of human tumor cell lines including Colo205 (Rb+) and U937 (FLT3WT) and induced cell death in MOLM13 (FLT3ITD) and even in MOLM13 (FLT3ITD, D835Y), which exhibits resistance to a no. of FLT3 inhibitors currently under clin. development.  At well-tolerated doses, compd. I leads to significant growth inhibition of MOLM13 xenografts in nude mice, and the activity correlates with inhibition of STAT5 and Rb phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcJdjH0aU8KrVg90H21EOLACvtfcHk0lhr-B4tMIBzBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D&md5=4047a6ea068dbde57896da520fbdf0d3</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm500118j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500118j%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DGribble%26aufirst%3DM.%2BW.%26aulast%3DAlba%26aufirst%3DG.%2BQ.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DCarlson%26aufirst%3DT.%2BJ.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCho%26aufirst%3DR.%26aulast%3DConnors%26aufirst%3DR.%2BV.%26aulast%3DDeGraffenreid%26aufirst%3DM.%26aulast%3DDeignan%26aufirst%3DJ.%2BT.%26aulast%3DDuquette%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DHuard%26aufirst%3DJ.%2BN.%26aulast%3DKaizerman%26aufirst%3DJ.%26aulast%3DKeegan%26aufirst%3DK.%2BS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLively%26aufirst%3DS.%2BE.%26aulast%3DLo%26aufirst%3DM.%2BC.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DMcMinn%26aufirst%3DD.%2BL.%26aulast%3DMihalic%26aufirst%3DJ.%2BT.%26aulast%3DModi%26aufirst%3DK.%26aulast%3DNgo%26aufirst%3DR.%26aulast%3DPattabiraman%26aufirst%3DK.%26aulast%3DPiper%26aufirst%3DD.%2BE.%26aulast%3DQueva%26aufirst%3DC.%26aulast%3DRagains%26aufirst%3DM.%2BL.%26aulast%3DSuchomel%26aufirst%3DJ.%26aulast%3DThibault%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWanska%26aufirst%3DM.%26aulast%3DWehn%26aufirst%3DP.%2BM.%26aulast%3DWeidner%26aufirst%3DM.%2BF.%26aulast%3DZhang%26aufirst%3DA.%2BJ.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DKamb%26aufirst%3DA.%26aulast%3DWickramasinghe%26aufirst%3DD.%26aulast%3DDai%26aufirst%3DK.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520of%2520AMG%2520925%252C%2520a%2520FLT3%2520and%2520CDK4%2520dual%2520kinase%2520inhibitor%2520with%2520preferential%2520affinity%2520for%2520the%2520activated%2520state%2520of%2520FLT3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3430%26epage%3D3449%26doi%3D10.1021%2Fjm500118j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Rosnet, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bühring, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchetto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rappold, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavagna, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sainty, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnoulet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabannon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannum, C.</span><span> </span><span class="NLM_article-title">Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">238</span><span class="NLM_x">–</span> <span class="NLM_lpage">248</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1996&pages=238-248&author=O.+Rosnetauthor=H.+J.+B%C3%BChringauthor=S.+Marchettoauthor=I.+Rappoldauthor=C.+Lavagnaauthor=D.+Saintyauthor=C.+Arnouletauthor=C.+Chabannonauthor=L.+Kanzauthor=C.+Hannum&title=Human+FLT3%2FFLK2+receptor+tyrosine+kinase+is+expressed+at+the+surface+of+normal+and+malignant+hematopoietic+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRosnet%26aufirst%3DO.%26aulast%3DB%25C3%25BChring%26aufirst%3DH.%2BJ.%26aulast%3DMarchetto%26aufirst%3DS.%26aulast%3DRappold%26aufirst%3DI.%26aulast%3DLavagna%26aufirst%3DC.%26aulast%3DSainty%26aufirst%3DD.%26aulast%3DArnoulet%26aufirst%3DC.%26aulast%3DChabannon%26aufirst%3DC.%26aulast%3DKanz%26aufirst%3DL.%26aulast%3DHannum%26aufirst%3DC.%26atitle%3DHuman%2520FLT3%252FFLK2%2520receptor%2520tyrosine%2520kinase%2520is%2520expressed%2520at%2520the%2520surface%2520of%2520normal%2520and%2520malignant%2520hematopoietic%2520cells%26jtitle%3DLeukemia%26date%3D1996%26volume%3D10%26spage%3D238%26epage%3D248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Drexler, H. G.</span><span> </span><span class="NLM_article-title">Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">845</span><span class="NLM_x">–</span> <span class="NLM_lpage">859</span><span class="refDoi"> DOI: 10.1038/sj.leu.2401043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1038%2Fsj.leu.2401043" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1998&pages=845-859&author=H.+G.+Drexler&title=Review+of+alterations+of+the+cyclin-dependent+kinase+inhibitor+INK4+family+genes+p15%2C+p16%2C+p18+and+p19+in+human+leukemia-lymphoma+cells&doi=10.1038%2Fsj.leu.2401043"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2401043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2401043%26sid%3Dliteratum%253Aachs%26aulast%3DDrexler%26aufirst%3DH.%2BG.%26atitle%3DReview%2520of%2520alterations%2520of%2520the%2520cyclin-dependent%2520kinase%2520inhibitor%2520INK4%2520family%2520genes%2520p15%252C%2520p16%252C%2520p18%2520and%2520p19%2520in%2520human%2520leukemia-lymphoma%2520cells%26jtitle%3DLeukemia%26date%3D1998%26volume%3D12%26spage%3D845%26epage%3D859%26doi%3D10.1038%2Fsj.leu.2401043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Estey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Döhner, H.</span><span> </span><span class="NLM_article-title">Acute myeloid leukaemia</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x">, </span> <span class="NLM_fpage">1894</span><span class="NLM_x">–</span> <span class="NLM_lpage">1907</span><span class="refDoi"> DOI: 10.1016/S0140-6736(06)69780-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1016%2FS0140-6736%2806%2969780-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=17126723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A280%3ADC%252BD28novFKitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2006&pages=1894-1907&author=E.+Esteyauthor=H.+D%C3%B6hner&title=Acute+myeloid+leukaemia&doi=10.1016%2FS0140-6736%2806%2969780-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Acute myeloid leukaemia</span></div><div class="casAuthors">Estey Elihu; Dohner Hartmut</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">9550</span>),
    <span class="NLM_cas:pages">1894-907</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haemopoietic progenitor cells and the most common malignant myeloid disorder in adults.  The median age at presentation for patients with AML is 70 years.  In the past few years, research in molecular biology has been instrumental in deciphering the pathogenesis of the disease.  Genetic defects are thought to be the most important factors in determining the response to chemotherapy and outcome.  Whereas significant progress has been made in the treatment of younger adults, the prospects for elderly patients have remained dismal, with median survival times of only a few months.  This difference is related to comorbidities associated with ageing and to disease biology.  Current efforts in clinical research focus on the assessment of targeted therapies.  Such new approaches will probably lead to an increase in the cure rate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS2ttizzpYcl3p3bfzSLaX5fW6udTcc2eYM-OfwoP0-a7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28novFKitw%253D%253D&md5=d4b1be3bbc0a3793e687ee30cfe1ba56</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2806%2969780-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252806%252969780-8%26sid%3Dliteratum%253Aachs%26aulast%3DEstey%26aufirst%3DE.%26aulast%3DD%25C3%25B6hner%26aufirst%3DH.%26atitle%3DAcute%2520myeloid%2520leukaemia%26jtitle%3DLancet%26date%3D2006%26volume%3D368%26spage%3D1894%26epage%3D1907%26doi%3D10.1016%2FS0140-6736%2806%2969780-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Kindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipka, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, T.</span><span> </span><span class="NLM_article-title">FLT3 as a therapeutic target in AML: still challenging after all these years</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">5089</span><span class="NLM_x">–</span> <span class="NLM_lpage">5102</span><span class="refDoi"> DOI: 10.1182/blood-2010-04-261867</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1182%2Fblood-2010-04-261867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=20705759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotV0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=5089-5102&author=T.+Kindlerauthor=D.+B.+Lipkaauthor=T.+Fischer&title=FLT3+as+a+therapeutic+target+in+AML%3A+still+challenging+after+all+these+years&doi=10.1182%2Fblood-2010-04-261867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 as a therapeutic target in AML: still challenging after all these years</span></div><div class="casAuthors">Kindler, Thomas; Lipka, Daniel B.; Fischer, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5089-5102</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Mutations within the FMS-like tyrosine kinase 3 (FLT3) gene on chromosome 13q12 have been detected in up to 35% of acute myeloid leukemia (AML) patients and represent one of the most frequently identified genetic alterations in AML.  Over the last years, FLT3 has emerged as a promising mol. target in therapy of AML.  Here, we review results of clin. trials and of correlative lab. studies using small mol. FLT3 tyrosine kinase inhibitors (TKIs) in AML patients.  We also review mechanisms of primary and secondary drug resistance to FLT3-TKI, and from the data currently available we summarize lessons learned from FLT3-TKI monotherapy.  Finally, for using FLT3 as a mol. target, we discuss novel strategies to overcome treatment failure and to improve FLT3 inhibitor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR_j_VWZ2CirVg90H21EOLACvtfcHk0lhHIbhQulHOPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotV0%253D&md5=131b2a645450c17defcb63a7be4262c9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-04-261867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-04-261867%26sid%3Dliteratum%253Aachs%26aulast%3DKindler%26aufirst%3DT.%26aulast%3DLipka%26aufirst%3DD.%2BB.%26aulast%3DFischer%26aufirst%3DT.%26atitle%3DFLT3%2520as%2520a%2520therapeutic%2520target%2520in%2520AML%253A%2520still%2520challenging%2520after%2520all%2520these%2520years%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26spage%3D5089%26epage%3D5102%26doi%3D10.1182%2Fblood-2010-04-261867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Bavetsias, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crumpler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avery, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atrash, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faisal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosmopoulou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheldrake, P. W.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8721</span><span class="NLM_x">–</span> <span class="NLM_lpage">8734</span><span class="refDoi"> DOI: 10.1021/jm300952s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300952s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8721-8734&author=V.+Bavetsiasauthor=S.+Crumplerauthor=C.+Sunauthor=S.+Averyauthor=B.+Atrashauthor=A.+Faisalauthor=A.+Mooreauthor=M.+Kosmopoulouauthor=N.+Brownauthor=P.+W.+Sheldrake&title=Optimization+of+imidazo%5B4%2C5-b%5Dpyridine-based+kinase+inhibitors%3A+identification+of+a+dual+FLT3%2FAurora+kinase+inhibitor+as+an+orally+bioavailable+preclinical+development+candidate+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1021%2Fjm300952s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm300952s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300952s%26sid%3Dliteratum%253Aachs%26aulast%3DBavetsias%26aufirst%3DV.%26aulast%3DCrumpler%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DAvery%26aufirst%3DS.%26aulast%3DAtrash%26aufirst%3DB.%26aulast%3DFaisal%26aufirst%3DA.%26aulast%3DMoore%26aufirst%3DA.%26aulast%3DKosmopoulou%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DN.%26aulast%3DSheldrake%26aufirst%3DP.%2BW.%26atitle%3DOptimization%2520of%2520imidazo%255B4%252C5-b%255Dpyridine-based%2520kinase%2520inhibitors%253A%2520identification%2520of%2520a%2520dual%2520FLT3%252FAurora%2520kinase%2520inhibitor%2520as%2520an%2520orally%2520bioavailable%2520preclinical%2520development%2520candidate%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8721%26epage%3D8734%26doi%3D10.1021%2Fjm300952s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Heathcote, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroll, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Periyasamy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alikian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanneganti, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jogalekar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheiper, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbazanges, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brackow, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siwicka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pace, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuchter, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liotta, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freemont, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aboagye, E. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coombes, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, S.</span><span> </span><span class="NLM_article-title">A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8508</span><span class="NLM_x">–</span> <span class="NLM_lpage">8522</span><span class="refDoi"> DOI: 10.1021/jm100732t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100732t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8508-8522&author=D.+A.+Heathcoteauthor=H.+Patelauthor=S.+H.+Krollauthor=P.+Hazelauthor=M.+Periyasamyauthor=M.+Alikianauthor=S.+K.+Kannegantiauthor=A.+S.+Jogalekarauthor=B.+Scheiperauthor=M.+Barbazangesauthor=A.+Blumauthor=J.+Brackowauthor=A.+Siwickaauthor=R.+D.+Paceauthor=M.+J.+Fuchterauthor=J.+P.+Snyderauthor=D.+C.+Liottaauthor=P.+S.+Freemontauthor=E.+O.+Aboagyeauthor=R.+C.+Coombesauthor=A.+G.+Barrettauthor=S.+Ali&title=A+novel+pyrazolo%5B1%2C5-a%5Dpyrimidine+is+a+potent+inhibitor+of+cyclin-dependent+protein+kinases+1%2C+2%2C+and+9%2C+which+demonstrates+antitumor+effects+in+human+tumor+xenografts+following+oral+administration&doi=10.1021%2Fjm100732t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Pyrazolo[1,5-a]pyrimidine is a Potent Inhibitor of Cyclin-Dependent Protein Kinases 1, 2, and 9, Which Demonstrates Antitumor Effects in Human Tumor Xenografts Following Oral Administration</span></div><div class="casAuthors">Heathcote, Dean A.; Patel, Hetal; Kroll, Sebastian H. B.; Hazel, Pascale; Periyasamy, Manikandan; Alikian, Mary; Kanneganti, Seshu K.; Jogalekar, Ashutosh S.; Scheiper, Bodo; Barbazanges, Marion; Blum, Andreas; Brackow, Jan; Siwicka, Alekasandra; Pace, Robert D. M.; Fuchter, Matthew J.; Snyder, James P.; Liotta, Dennis C.; Freemont, Paul. S.; Aboagye, Eric O.; Coombes, R. Charles; Barrett, Anthony G. M.; Ali, Simak</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8508-8522</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent protein kinases (CDKs) are central to the appropriate regulation of cell proliferation, apoptosis, and gene expression.  Abnormalities in CDK activity and regulation are common features of cancer, making CDK family members attractive targets for the development of anticancer drugs.  Here, we report the identification of a pyrazolo[1,5-a]pyrimidine derived compd., 4k (BS-194, I), as a selective and potent CDK inhibitor, which inhibits CDK2, CDK1, CDK5, CDK7, and CDK9 (IC50 = 3, 30, 30, 250, and 90 nmol/L, resp.).  Cell-based studies showed inhibition of the phosphorylation of CDK substrates, Rb and the RNA polymerase II C-terminal domain, down-regulation of cyclins A, E, and D1, and cell cycle block in the S and G2/M phases.  Consistent with these findings, 4k demonstrated potent antiproliferative activity in 60 cancer cell lines tested (mean GI50 = 280 nmol/L).  Pharmacokinetic studies showed that 4k is orally bioavailable, with an elimination half-life of 178 min following oral dosing in mice.  When administered at a concn. of 25 mg/kg orally, 4k inhibited human tumor xenografts and suppressed CDK substrate phosphorylation.  These findings identify 4k as a novel, potent CDK selective inhibitor with potential for oral delivery in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUJPhLKEWwBLVg90H21EOLACvtfcHk0liYfetyzDAYng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL%252FJ&md5=b84f41ab0cbf298a9ac248bc0a9d0d73</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm100732t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100732t%26sid%3Dliteratum%253Aachs%26aulast%3DHeathcote%26aufirst%3DD.%2BA.%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DKroll%26aufirst%3DS.%2BH.%26aulast%3DHazel%26aufirst%3DP.%26aulast%3DPeriyasamy%26aufirst%3DM.%26aulast%3DAlikian%26aufirst%3DM.%26aulast%3DKanneganti%26aufirst%3DS.%2BK.%26aulast%3DJogalekar%26aufirst%3DA.%2BS.%26aulast%3DScheiper%26aufirst%3DB.%26aulast%3DBarbazanges%26aufirst%3DM.%26aulast%3DBlum%26aufirst%3DA.%26aulast%3DBrackow%26aufirst%3DJ.%26aulast%3DSiwicka%26aufirst%3DA.%26aulast%3DPace%26aufirst%3DR.%2BD.%26aulast%3DFuchter%26aufirst%3DM.%2BJ.%26aulast%3DSnyder%26aufirst%3DJ.%2BP.%26aulast%3DLiotta%26aufirst%3DD.%2BC.%26aulast%3DFreemont%26aufirst%3DP.%2BS.%26aulast%3DAboagye%26aufirst%3DE.%2BO.%26aulast%3DCoombes%26aufirst%3DR.%2BC.%26aulast%3DBarrett%26aufirst%3DA.%2BG.%26aulast%3DAli%26aufirst%3DS.%26atitle%3DA%2520novel%2520pyrazolo%255B1%252C5-a%255Dpyrimidine%2520is%2520a%2520potent%2520inhibitor%2520of%2520cyclin-dependent%2520protein%2520kinases%25201%252C%25202%252C%2520and%25209%252C%2520which%2520demonstrates%2520antitumor%2520effects%2520in%2520human%2520tumor%2520xenografts%2520following%2520oral%2520administration%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8508%26epage%3D8522%26doi%3D10.1021%2Fjm100732t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Wyatt, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodhead, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulstridge, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devine, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Early, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltell, R. E.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Identification of N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-Ray crystallography and structure based drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4986</span><span class="NLM_x">–</span> <span class="NLM_lpage">4999</span><span class="refDoi"> DOI: 10.1021/jm800382h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800382h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4986-4999&author=P.+G.+Wyattauthor=A.+J.+Woodheadauthor=V.+Berdiniauthor=J.+A.+Boulstridgeauthor=M.+G.+Carrauthor=D.+M.+Crossauthor=D.+J.+Davisauthor=L.+A.+Devineauthor=T.+R.+Earlyauthor=R.+E.+Feltell&title=Identification+of+N-%284-Piperidinyl%29-4-%282%2C6-dichlorobenzoylamino%29-1H-pyrazole-3-carboxamide+%28AT7519%29%2C+a+novel+cyclin+dependent+kinase+inhibitor+using+fragment-based+X-Ray+crystallography+and+structure+based+drug+design&doi=10.1021%2Fjm800382h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm800382h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800382h%26sid%3Dliteratum%253Aachs%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DBoulstridge%26aufirst%3DJ.%2BA.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DCross%26aufirst%3DD.%2BM.%26aulast%3DDavis%26aufirst%3DD.%2BJ.%26aulast%3DDevine%26aufirst%3DL.%2BA.%26aulast%3DEarly%26aufirst%3DT.%2BR.%26aulast%3DFeltell%26aufirst%3DR.%2BE.%26atitle%3DIdentification%2520of%2520N-%25284-Piperidinyl%2529-4-%25282%252C6-dichlorobenzoylamino%2529-1H-pyrazole-3-carboxamide%2520%2528AT7519%2529%252C%2520a%2520novel%2520cyclin%2520dependent%2520kinase%2520inhibitor%2520using%2520fragment-based%2520X-Ray%2520crystallography%2520and%2520structure%2520based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4986%26epage%3D4999%26doi%3D10.1021%2Fjm800382h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Flynn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andritsos, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maddocks, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaglowski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hessler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grever, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Im, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1524</span><span class="NLM_x">–</span> <span class="NLM_lpage">1529</span><span class="refDoi"> DOI: 10.1038/leu.2015.31</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1038%2Fleu.2015.31" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=25708835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsFersrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=1524-1529&author=J.+Flynnauthor=J.+Jonesauthor=A.+J.+Johnsonauthor=L.+Andritsosauthor=K.+Maddocksauthor=S.+Jaglowskiauthor=J.+Hesslerauthor=M.+R.+Greverauthor=E.+Imauthor=H.+Zhou&title=Dinaciclib+is+a+novel+cyclin-dependent+kinase+inhibitor+with+significant+clinical+activity+in+relapsed+and+refractory+chronic+lymphocytic+leukemia&doi=10.1038%2Fleu.2015.31"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia</span></div><div class="casAuthors">Flynn, J.; Jones, J.; Johnson, A. J.; Andritsos, L.; Maddocks, K.; Jaglowski, S.; Hessler, J.; Grever, M. R.; Im, E.; Zhou, H.; Zhu, Y.; Zhang, D.; Small, K.; Bannerji, R.; Byrd, J. C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1524-1529</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Dinaciclib (SCH727965) is a selective CDKi chosen for clin. development based upon a favorable therapeutic index in cancer xenograft models.  We performed a phase I dose escalation study of dinaciclib in relapsed and refractory chronic lymphocytic leukemia (CLL) patients with intact organ function and WBC<200 × 109 /l.  Five sep. dose levels (5 mg/m2, 7 mg/m2, 10 mg/m2, 14 mg/m2 and 17 mg/m2) were explored dosing on a weekly schedule × 3 with 1 wk off (4-wk cycles) using a std. 3+3 design with expansion cohorts to optimize safety.  Fifty-two patients were enrolled with relapsed and refractory CLL.  Escalation through cohorts occurred with two dose-limiting toxicity (DLTs) at the 17 mg/m2 dose (tumor lysis syndrome (TLS) and pneumonia).  The phase II expansion occurred at 14 mg/m2 with 16 patients receiving this dose with one DLT (TLS).  Addnl. stepped up dosing to the max. tolerated dose was examd. in 19 patients at this dose.  Adverse events included cytopenias, transient lab. abnormalities and TLS.  Responses occurred in 28 (54%) of patients independent of del(17)(p13.1) with a median progression-free survival of 481 days.  Dinaciclib is clin. active in relapsed CLL including those patients with high risk del(17)(p13.1) disease and warrants future study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY8zLFNmk5-bVg90H21EOLACvtfcHk0lgiH0W7ulCqvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsFersrY%253D&md5=5f53b49e419f68563500fee211221c29</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.31%26sid%3Dliteratum%253Aachs%26aulast%3DFlynn%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DAndritsos%26aufirst%3DL.%26aulast%3DMaddocks%26aufirst%3DK.%26aulast%3DJaglowski%26aufirst%3DS.%26aulast%3DHessler%26aufirst%3DJ.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DIm%26aufirst%3DE.%26aulast%3DZhou%26aufirst%3DH.%26atitle%3DDinaciclib%2520is%2520a%2520novel%2520cyclin-dependent%2520kinase%2520inhibitor%2520with%2520significant%2520clinical%2520activity%2520in%2520relapsed%2520and%2520refractory%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DLeukemia%26date%3D2015%26volume%3D29%26spage%3D1524%26epage%3D1529%26doi%3D10.1038%2Fleu.2015.31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Patel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senderowicz, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinto, D.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Igishi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raffeld, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quintanilla-Martinez, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ensley, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sausville, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutkind, J. S.</span><span> </span><span class="NLM_article-title">Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">1674</span><span class="NLM_x">–</span> <span class="NLM_lpage">1681</span><span class="refDoi"> DOI: 10.1172/JCI3661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1172%2FJCI3661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=9802881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADyaK1cXnt1Oqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1998&pages=1674-1681&author=V.+Patelauthor=A.+M.+Senderowiczauthor=D.+Pintoauthor=T.+Igishiauthor=M.+Raffeldauthor=L.+Quintanilla-Martinezauthor=J.+F.+Ensleyauthor=E.+A.+Sausvilleauthor=J.+S.+Gutkind&title=Flavopiridol%2C+a+novel+cyclin-dependent+kinase+inhibitor%2C+suppresses+the+growth+of+head+and+neck+squamous+cell+carcinomas+by+inducing+apoptosis&doi=10.1172%2FJCI3661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis</span></div><div class="casAuthors">Patel, Vyomesh; Senderowicz, Adrian M.; Pinto, Decio, Jr.; Igishi, Tadashi; Raffeld, Mark; Quintanilla-Martinez, Leticia; Ensley, John F.; Sausville, Edward A.; Gutkind, J. Silvio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1674-1681</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Flavopiridol (HMR 1275) has been identified recently as a novel antineoplastic agent in the primary screen conducted by the Developmental Therapeutics Program, National Cancer Institute.  Flavopiridol inhibits most cyclin-dependent kinases (cdks) and displays unique anticancer properties.  Here, we investigated whether this compd. was effective against head and neck squamous cell carcinomas (HNSCC).  Exposure of HNSCC cells to flavopiridol diminished cdc2 and cdk2 activity and potently inhibited cell proliferation (IC50 43-83 nM), which was concomitant with the appearance of cells with a sub-G1 DNA content.  Moreover, DNA fragmentation and TUNEL (terminal deoxynucleotidyl transferase-mediated nick end labeling) reaction confirmed that flavopiridol induces apoptosis in all cell lines, even on certain HNSCC cells that are insensitive to apoptosis to DNA-damaging agents (γ-irradn. and bleomycin).  A tumorigenic HNSCC cell line was used to assess the effect of flavopiridol in vivo.  Treatment (5 mg/kg per day, i.p.) for 5 d led to the appearance of apoptotic cells in the tumor xenografts and caused a 60-70% redn. in tumor size, which was sustained over a period of 10 wk.  Flavopiridol treatment also resulted in a remarkable redn. of cyclin D1 expression in HNSCC cells and tumor xenografts.  Our data indicate that flavopiridol exerts antitumor activity in HNSCC, and thus it can be considered a suitable candidate drug for testing in the treatment of refractory carcinomas of the head and neck.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-lF748dX347Vg90H21EOLACvtfcHk0lje4LeUKzi70w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnt1Oqtrc%253D&md5=549f97c62f21c1b194856d237823a2b7</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1172%2FJCI3661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI3661%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DSenderowicz%26aufirst%3DA.%2BM.%26aulast%3DPinto%26aufirst%3DD.%26aulast%3DIgishi%26aufirst%3DT.%26aulast%3DRaffeld%26aufirst%3DM.%26aulast%3DQuintanilla-Martinez%26aufirst%3DL.%26aulast%3DEnsley%26aufirst%3DJ.%2BF.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DGutkind%26aufirst%3DJ.%2BS.%26atitle%3DFlavopiridol%252C%2520a%2520novel%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520suppresses%2520the%2520growth%2520of%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinomas%2520by%2520inducing%2520apoptosis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1998%26volume%3D102%26spage%3D1674%26epage%3D1681%26doi%3D10.1172%2FJCI3661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novotnydiermayr, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheong, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">236</span><span class="NLM_x">–</span> <span class="NLM_lpage">243</span><span class="refDoi"> DOI: 10.1038/leu.2011.218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1038%2Fleu.2011.218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=21860433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFGgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=236-243&author=K.+C.+Gohauthor=V.+Novotnydiermayrauthor=S.+Hartauthor=L.+C.+Ongauthor=Y.+K.+Lohauthor=A.+Cheongauthor=Y.+C.+Tanauthor=C.+Huauthor=R.+Jayaramanauthor=A.+D.+William&title=TG02%2C+a+novel+oral+multi-kinase+inhibitor+of+CDKs%2C+JAK2+and+FLT3+with+potent+anti-leukemic+properties&doi=10.1038%2Fleu.2011.218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties</span></div><div class="casAuthors">Goh, K. C.; Novotny-Diermayr, V.; Hart, S.; Ong, L. C.; Loh, Y. K.; Cheong, A.; Tan, Y. C.; Hu, C.; Jayaraman, R.; William, A. D.; Sun, E. T.; Dymock, B. W.; Ong, K. H.; Ethirajulu, K.; Burrows, F.; Wood, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-243</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3.  It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs.  TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis.  Primary cultures of progenitor cells derived from acute myeloid leukemia (AML) and polycythemia vera patients are very sensitive to TG02.  Comparison with ref. inhibitors that block only one of the main targets of TG02 demonstrate the benefit of combined CDK and JAK2/FLT3 inhibition in cell lines as well as primary cells.  In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling.  TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60).  These data demonstrate that TG02 is active in various models of leukemia and provide a rationale for the ongoing clin. evaluation of TG02 in patients with advanced leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMelEE91r_BrVg90H21EOLACvtfcHk0lje4LeUKzi70w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFGgtLc%253D&md5=30af7dc302f9c421924b5b0062e82655</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.218%26sid%3Dliteratum%253Aachs%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DNovotnydiermayr%26aufirst%3DV.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DLoh%26aufirst%3DY.%2BK.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26atitle%3DTG02%252C%2520a%2520novel%2520oral%2520multi-kinase%2520inhibitor%2520of%2520CDKs%252C%2520JAK2%2520and%2520FLT3%2520with%2520potent%2520anti-leukemic%2520properties%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D236%26epage%3D243%26doi%3D10.1038%2Fleu.2011.218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Joshi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rathos, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahajan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenoy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatia, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chile, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sivakumar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiebig, H.-H.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">P276–00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">926</span><span class="NLM_x">–</span> <span class="NLM_lpage">934</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1158%2F1535-7163.MCT-06-0614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=17363487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2nur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=926-934&author=K.+Joshiauthor=M.+J.+Rathosauthor=P.+Mahajanauthor=V.+Waghauthor=S.+Shenoyauthor=D.+Bhatiaauthor=S.+Chileauthor=M.+Sivakumarauthor=A.+Maierauthor=H.-H.+Fiebig&title=P276%E2%80%9300%2C+a+novel+cyclin-dependent+inhibitor+induces+G1-G2+arrest%2C+shows+antitumor+activity+on+cisplatin-resistant+cells+and+significant+in+vivo+efficacy+in+tumor+models&doi=10.1158%2F1535-7163.MCT-06-0614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models</span></div><div class="casAuthors">Joshi, Kalpana S.; Rathos, Maggie J.; Mahajan, Pravin; Wagh, Vilas; Shenoy, Satyendra; Bhatia, Dimple; Chile, Shailaja; Sivakumar, Meenakshi; Maier, Armin; Fiebig, Heinz-Herbert; Sharma, Somesh</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">926-934</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">P276-00, a flavone that inhibits cyclin-dependent kinases, has been identified by us recently as a novel antineoplastic agent.  In this study, we have selected a panel of human tumor cell lines and xenografts to allow detn. of selectivity and efficacy of P276-00.  When tested against a panel of 16 cisplatin-sensitive and cisplatin-resistant cell lines, the antiproliferative potential of P276-00 was found to be ∼30-fold higher than cisplatin.  Studies to show tumor sensitivity using clonogenic assay in 22 human xenografts indicated that P276-00 was ∼26-fold more potent than cisplatin, and further, it was also found to be active against cisplatin-resistant tumors of central nervous system, melanoma, prostate, and renal cancers.  Further, we studied the effects of P276-00 on cell cycle progression by flow cytometry using asynchronous and synchronous population of tumor and normal cells.  Asynchronous population of human prostate carcinoma (PC-3) and human promyelocytic leukemia (HL-60) cells when exposed to P276-00 showed arrest of slow-growing PC-3 cells in G2-M with no significant apoptosis obsd. up to 72 h.  Unlike PC-3, significant apoptosis was seen in fast-growing HL-60 cells at 6 h.  However, synchronized human non-small cell lung carcinoma (H-460) and human normal lung fibroblast (WI-38) cells showed arrest of cells in G1.  H-460 cells undergo apoptosis, which increases with longer exposure to the compd. and also after exposure to P276-00 for 48 h followed by recovery.  In contrast, the normal cells (WI-38) remain arrested in G1 with no significant apoptosis up to 72 h of exposure and also after 48 h of P276-00 treatment followed by recovery, confirming our previous results that P276-00 was less effective against normal cells compared with cancer cells.  After promising in vitro results, P276-00 was checked for in vivo efficacy in murine tumor and human xenograft models.  Growth inhibition of murine colon cancer (CA-51) was significant when P276-00 was administered i.p. at 50 mg/kg daily for 20 treatments.  However, in murine lung carcinoma model (Lewis lung), an increased dose of 60 mg/kg (30 mg/kg twice daily) administered every alternate day i.p. for seven treatments showed significant inhibition in the growth.  Further studies were undertaken to establish the efficacy profile of P276-00 in human tumor xenograft models.  In the two xenograft models studied, P276-00 showed potent in vivo antitumor potential.  Compd. P276-00 at a dose of 35 mg/kg administered daily via the i.p. route for 10 days showed significant (P < 0.05) inhibition in the growth of human colon carcinoma HCT-116 xenograft.  Furthermore, P276-00 at a dose of 50 mg/kg once daily and 30 mg/kg twice daily administered via i.p. route for 20 treatments significantly (P < 0.05) inhibited growth of human non-small cell lung carcinoma H-460 xenograft.  Thus, the in vitro cellular potency, together with in vivo antitumor activity, confirms the potential of P276-00, a cyclin-dependent kinase inhibitor as an anticancer mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogJ_J7_PmrDrVg90H21EOLACvtfcHk0liN98BMXSfTYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2nur4%253D&md5=04e65ada85eb38521909544a4e16a739</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0614%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DK.%26aulast%3DRathos%26aufirst%3DM.%2BJ.%26aulast%3DMahajan%26aufirst%3DP.%26aulast%3DWagh%26aufirst%3DV.%26aulast%3DShenoy%26aufirst%3DS.%26aulast%3DBhatia%26aufirst%3DD.%26aulast%3DChile%26aufirst%3DS.%26aulast%3DSivakumar%26aufirst%3DM.%26aulast%3DMaier%26aufirst%3DA.%26aulast%3DFiebig%26aufirst%3DH.-H.%26atitle%3DP276%25E2%2580%259300%252C%2520a%2520novel%2520cyclin-dependent%2520inhibitor%2520induces%2520G1-G2%2520arrest%252C%2520shows%2520antitumor%2520activity%2520on%2520cisplatin-resistant%2520cells%2520and%2520significant%2520in%2520vivo%2520efficacy%2520in%2520tumor%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D926%26epage%3D934%26doi%3D10.1158%2F1535-7163.MCT-06-0614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Toogood, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repine, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanderWel, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodfuehrer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barvian, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2388</span><span class="NLM_x">–</span> <span class="NLM_lpage">2406</span><span class="refDoi"> DOI: 10.1021/jm049354h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049354h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2388-2406&author=P.+L.+Toogoodauthor=P.+J.+Harveyauthor=J.+T.+Repineauthor=D.+J.+Sheehanauthor=S.+N.+VanderWelauthor=H.+Zhouauthor=P.+R.+Kellerauthor=D.+J.+McNamaraauthor=D.+Sherryauthor=T.+Zhuauthor=J.+Brodfuehrerauthor=C.+Choiauthor=M.+R.+Barvianauthor=D.+W.+Fry&title=Discovery+of+a+potent+and+selective+inhibitor+of+cyclin-dependent+kinase+4%2F6&doi=10.1021%2Fjm049354h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6</span></div><div class="casAuthors">Toogood, Peter L.; Harvey, Patricia J.; Repine, Joseph T.; Sheehan, Derek J.; VanderWel, Scott N.; Zhou, Hairong; Keller, Paul R.; McNamara, Dennis J.; Sherry, Debra; Zhu, Tong; Brodfuehrer, Joanne; Choi, Chung; Barvian, Mark R.; Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2388-2406</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A pharmacol. approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small mol. inhibitors has the potential to provide novel cancer therapies for clin. use.  Achieving high levels of selectivity for Cdk4/6, vs. other ATP-dependent kinases, presents a significant challenge.  The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks.  It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro.  This selectivity profile is recapitulated in cells where the most selective inhibitors create a G1 block at concns. up to 100-fold the IC50 for cell proliferation.  On the basis of its selectivity profile and pharmacokinetic profile, compd. I (PD 0332991) was identified as a drug candidate for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX577J5U0r97Vg90H21EOLACvtfcHk0liN98BMXSfTYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D&md5=23cbe58426ff1975695712db7c1b128a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm049354h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049354h%26sid%3Dliteratum%253Aachs%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DRepine%26aufirst%3DJ.%2BT.%26aulast%3DSheehan%26aufirst%3DD.%2BJ.%26aulast%3DVanderWel%26aufirst%3DS.%2BN.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DSherry%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520cyclin-dependent%2520kinase%25204%252F6%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2388%26epage%3D2406%26doi%3D10.1021%2Fjm049354h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Infante, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witteveen, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerecitano, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribrag, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chugh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakraborty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parasuraman, S.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Abstract A276: Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">A276</span><span class="refDoi"> DOI: 10.1158/1535-7163.TARG-13-A276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1158%2F1535-7163.TARG-13-A276" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=A276&author=J.+R.+Infanteauthor=G.+I.+Shapiroauthor=P.+O.+Witteveenauthor=J.+F.+Gerecitanoauthor=V.+Ribragauthor=R.+Chughauthor=A.+Chakrabortyauthor=A.+Matanoauthor=X.+Zhaoauthor=S.+Parasuraman&title=Abstract+A276%3A+Phase+1+multicenter%2C+open+label%2C+dose-escalation+study+of+LEE011%2C+an+oral+inhibitor+of+cyclin-dependent+kinase+4%2F6%2C+in+patients+with+advanced+solid+tumors+or+lymphomas&doi=10.1158%2F1535-7163.TARG-13-A276"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.TARG-13-A276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.TARG-13-A276%26sid%3Dliteratum%253Aachs%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DWitteveen%26aufirst%3DP.%2BO.%26aulast%3DGerecitano%26aufirst%3DJ.%2BF.%26aulast%3DRibrag%26aufirst%3DV.%26aulast%3DChugh%26aufirst%3DR.%26aulast%3DChakraborty%26aufirst%3DA.%26aulast%3DMatano%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DParasuraman%26aufirst%3DS.%26atitle%3DAbstract%2520A276%253A%2520Phase%25201%2520multicenter%252C%2520open%2520label%252C%2520dose-escalation%2520study%2520of%2520LEE011%252C%2520an%2520oral%2520inhibitor%2520of%2520cyclin-dependent%2520kinase%25204%252F6%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%2520or%2520lymphomas%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3DA276%26doi%3D10.1158%2F1535-7163.TARG-13-A276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Sanchezmartinez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelbert, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shannon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Dios, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staton, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ajamie, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawada, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishart, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raub, T. J.</span><span> </span><span class="NLM_article-title">Abstract B234: LY2835219, a potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) that crosses the blood-brain barrier and demonstrates in vivo activity against intracranial human brain tumor xenografts</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">B234</span><span class="refDoi"> DOI: 10.1158/1535-7163.TARG-11-B234</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1158%2F1535-7163.TARG-11-B234" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=B234&author=C.+Sanchezmartinezauthor=L.+M.+Gelbertauthor=H.+Shannonauthor=A.+De+Diosauthor=B.+A.+Statonauthor=R.+T.+Ajamieauthor=G.+Sawadaauthor=G.+N.+Wishartauthor=T.+J.+Raub&title=Abstract+B234%3A+LY2835219%2C+a+potent+oral+inhibitor+of+the+cyclin-dependent+kinases+4+and+6+%28CDK4%2F6%29+that+crosses+the+blood-brain+barrier+and+demonstrates+in+vivo+activity+against+intracranial+human+brain+tumor+xenografts&doi=10.1158%2F1535-7163.TARG-11-B234"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.TARG-11-B234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.TARG-11-B234%26sid%3Dliteratum%253Aachs%26aulast%3DSanchezmartinez%26aufirst%3DC.%26aulast%3DGelbert%26aufirst%3DL.%2BM.%26aulast%3DShannon%26aufirst%3DH.%26aulast%3DDe%2BDios%26aufirst%3DA.%26aulast%3DStaton%26aufirst%3DB.%2BA.%26aulast%3DAjamie%26aufirst%3DR.%2BT.%26aulast%3DSawada%26aufirst%3DG.%26aulast%3DWishart%26aufirst%3DG.%2BN.%26aulast%3DRaub%26aufirst%3DT.%2BJ.%26atitle%3DAbstract%2520B234%253A%2520LY2835219%252C%2520a%2520potent%2520oral%2520inhibitor%2520of%2520the%2520cyclin-dependent%2520kinases%25204%2520and%25206%2520%2528CDK4%252F6%2529%2520that%2520crosses%2520the%2520blood-brain%2520barrier%2520and%2520demonstrates%2520in%2520vivo%2520activity%2520against%2520intracranial%2520human%2520brain%2520tumor%2520xenografts%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3DB234%26doi%3D10.1158%2F1535-7163.TARG-11-B234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Cicenas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalyan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorokinas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jatulyte, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valiunas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaupinis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valius, M.</span><span> </span><span class="NLM_article-title">Highlights of the latest advances in research on CDK inhibitors</span> <span class="citation_source-journal">Cancers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2224</span><span class="NLM_x">–</span> <span class="NLM_lpage">2242</span><span class="refDoi"> DOI: 10.3390/cancers6042224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.3390%2Fcancers6042224" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=2224-2242&author=J.+Cicenasauthor=K.+Kalyanauthor=A.+Sorokinasauthor=A.+Jatulyteauthor=D.+Valiunasauthor=A.+Kaupinisauthor=M.+Valius&title=Highlights+of+the+latest+advances+in+research+on+CDK+inhibitors&doi=10.3390%2Fcancers6042224"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.3390%2Fcancers6042224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers6042224%26sid%3Dliteratum%253Aachs%26aulast%3DCicenas%26aufirst%3DJ.%26aulast%3DKalyan%26aufirst%3DK.%26aulast%3DSorokinas%26aufirst%3DA.%26aulast%3DJatulyte%26aufirst%3DA.%26aulast%3DValiunas%26aufirst%3DD.%26aulast%3DKaupinis%26aufirst%3DA.%26aulast%3DValius%26aufirst%3DM.%26atitle%3DHighlights%2520of%2520the%2520latest%2520advances%2520in%2520research%2520on%2520CDK%2520inhibitors%26jtitle%3DCancers%26date%3D2014%26volume%3D6%26spage%3D2224%26epage%3D2242%26doi%3D10.3390%2Fcancers6042224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Rizzolio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuccinardi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucchetti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, A.</span><span> </span><span class="NLM_article-title">CDK Inhibitors: From the bench to clinical trials</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">279</span><span class="NLM_x">–</span> <span class="NLM_lpage">290</span><span class="refDoi"> DOI: 10.2174/138945010790711978</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.2174%2F138945010790711978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=20210753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkt1emsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=279-290&author=F.+Rizzolioauthor=T.+Tuccinardiauthor=I.+Caligiuriauthor=C.+Lucchettiauthor=A.+Giordano&title=CDK+Inhibitors%3A+From+the+bench+to+clinical+trials&doi=10.2174%2F138945010790711978"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">CDK inhibitors: from the bench to clinical trials</span></div><div class="casAuthors">Rizzolio, Flavio; Tuccinardi, Tiziano; Caligiuri, Isabella; Lucchetti, Chiara; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">279-290</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cell cycle deregulation is one of the first steps that transform normal cells into tumor cells.  CDKs are a family of proteins devoted to controlling cell cycle entry, progression and exit.  Studies from animal models show a tissue-specific essentiality of the single CDKs.  In cancer cells, mis-regulation of CDK function is a common event.  For this reason the pioneer compd. Flavopiridol was developed and many new drugs are currently under development.  ATP and the last generation of non-ATP competitive inhibitors are now emerging as one of the most potentially powerful target therapies.  Many clin. trials are ongoing, as either a single agent or in combination with the classical cytotoxic agents.  In this review, we discuss new strategies and methods to design more potent, selective and specific CDK inhibitors, starting from evidence emerging from animal and cancer cell models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6pyjusDph6rVg90H21EOLACvtfcHk0litEZs1-lmuOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkt1emsrw%253D&md5=9c5986f6a899a379bdf87ae4aa506746</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.2174%2F138945010790711978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945010790711978%26sid%3Dliteratum%253Aachs%26aulast%3DRizzolio%26aufirst%3DF.%26aulast%3DTuccinardi%26aufirst%3DT.%26aulast%3DCaligiuri%26aufirst%3DI.%26aulast%3DLucchetti%26aufirst%3DC.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DCDK%2520Inhibitors%253A%2520From%2520the%2520bench%2520to%2520clinical%2520trials%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2010%26volume%3D11%26spage%3D279%26epage%3D290%26doi%3D10.2174%2F138945010790711978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Asghar, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witkiewicz, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, E. S.</span><span> </span><span class="NLM_article-title">The history and future of targeting cyclin-dependent kinases in cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">146</span><span class="refDoi"> DOI: 10.1038/nrd4504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1038%2Fnrd4504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=25633797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvVCrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=130-146&author=U.+Asgharauthor=A.+K.+Witkiewiczauthor=N.+C.+Turnerauthor=E.+S.+Knudsen&title=The+history+and+future+of+targeting+cyclin-dependent+kinases+in+cancer+therapy&doi=10.1038%2Fnrd4504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The history and future of targeting cyclin-dependent kinases in cancer therapy</span></div><div class="casAuthors">Asghar, Uzma; Witkiewicz, Agnieszka K.; Turner, Nicholas C.; Knudsen, Erik S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-146</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer represents a pathol. manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies.  In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle.  Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events.  Translating this knowledge into successful clin. development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clin. trials.  Here, we review the biol. of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clin. results of CDK inhibitors.  We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clin. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ_utd-yiEZLVg90H21EOLACvtfcHk0litEZs1-lmuOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvVCrtLc%253D&md5=113bcd2e99a8267119d180670d3c7761</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnrd4504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4504%26sid%3Dliteratum%253Aachs%26aulast%3DAsghar%26aufirst%3DU.%26aulast%3DWitkiewicz%26aufirst%3DA.%2BK.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DKnudsen%26aufirst%3DE.%2BS.%26atitle%3DThe%2520history%2520and%2520future%2520of%2520targeting%2520cyclin-dependent%2520kinases%2520in%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D130%26epage%3D146%26doi%3D10.1038%2Fnrd4504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaser, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duchemin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusewitt, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briesewitz, R.</span><span> </span><span class="NLM_article-title">Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">2075</span><span class="NLM_x">–</span> <span class="NLM_lpage">2083</span><span class="refDoi"> DOI: 10.1182/blood-2007-02-071266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1182%2Fblood-2007-02-071266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=17537993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVGjtbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=2075-2083&author=L.+Wangauthor=J.+Wangauthor=B.+W.+Blaserauthor=A.+M.+Ducheminauthor=D.+F.+Kusewittauthor=T.+Liuauthor=M.+A.+Caligiuriauthor=R.+Briesewitz&title=Pharmacologic+inhibition+of+CDK4%2F6%3A+mechanistic+evidence+for+selective+activity+or+acquired+resistance+in+acute+myeloid+leukemia&doi=10.1182%2Fblood-2007-02-071266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia</span></div><div class="casAuthors">Wang, Lisheng; Wang, Jie; Blaser, Bradley W.; Duchemin, Anne-Marie; Kusewitt, Donna F.; Liu, Tom; Caligiuri, Michael A.; Briesewitz, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2075-2083</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Entry into the cell cycle is mediated by cyclin-dependent kinase 4/6 (CDK4/6) activation, followed by CDK2 activation.  We found that pharmacol. inhibition of the Flt3 internal tandem duplication (ITD), a mutated receptor tyrosine kinase commonly found in patients with acute myelogenous leukemia (AML), led to the down-regulation of cyclin D2 and D3 followed by retinoblastoma protein (pRb) dephosphorylation and G1 cell-cycle arrest.  This implicated the D-cyclin-CDK4/6 complex as a downstream effector of Flt3 ITD signaling.  Indeed, single-agent PD0332991, a selective CDK4/6 inhibitor, caused sustained cell-cycle arrest in Flt3 ITD AML cell lines and prolonged survival in an in vivo model of Flt3 ITD AML.  PD0332991 caused an initial cell-cycle arrest in well-established Flt3 wild-type (wt) AML cell lines, but this was overcome by down-regulation of p27Kip and reactivation of CDK2.  This acquired resistance was not obsd. in a Flt3 ITD and a Flt3 wt sample from a patient with primary AML.  In summary, the mechanism of cell-cycle arrest after treatment of Flt3 ITD AML with a Flt3 inhibitor involves down-regulation of cyclin D2 and D3.  As such, CDK4/6 can be a therapeutic target in Flt3 ITD AML but also in primary Flt3 wt AML.  Finally, acquired resistance to CDK4/6 inhibition can arise through activation CDK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiH_wOIP8jJLVg90H21EOLACvtfcHk0litEZs1-lmuOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVGjtbbK&md5=5f68ef6deacf3789e428731722f8c5ff</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-02-071266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-02-071266%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBlaser%26aufirst%3DB.%2BW.%26aulast%3DDuchemin%26aufirst%3DA.%2BM.%26aulast%3DKusewitt%26aufirst%3DD.%2BF.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DBriesewitz%26aufirst%3DR.%26atitle%3DPharmacologic%2520inhibition%2520of%2520CDK4%252F6%253A%2520mechanistic%2520evidence%2520for%2520selective%2520activity%2520or%2520acquired%2520resistance%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D2075%26epage%3D2083%26doi%3D10.1182%2Fblood-2007-02-071266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, T.</span><span> </span><span class="NLM_article-title">Synthesis and structure of the β-carboline derivatives and their binding intensity with cyclin-dependent kinase 2</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">435</span><span class="NLM_x">–</span> <span class="NLM_lpage">441</span><span class="refDoi"> DOI: 10.1248/cpb.60.435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1248%2Fcpb.60.435" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2012&pages=435-441&author=Y.+Wangauthor=Q.+Jinauthor=G.+Linauthor=T.+Yangauthor=Z.+Wangauthor=Y.+Luauthor=Y.+Tangauthor=L.+Liuauthor=T.+Lu&title=Synthesis+and+structure+of+the+%CE%B2-carboline+derivatives+and+their+binding+intensity+with+cyclin-dependent+kinase+2&doi=10.1248%2Fcpb.60.435"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1248%2Fcpb.60.435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.60.435%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DT.%26atitle%3DSynthesis%2520and%2520structure%2520of%2520the%2520%25CE%25B2-carboline%2520derivatives%2520and%2520their%2520binding%2520intensity%2520with%2520cyclin-dependent%2520kinase%25202%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2012%26volume%3D60%26spage%3D435%26epage%3D441%26doi%3D10.1248%2Fcpb.60.435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Jin, Q. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, T.</span><span> </span><span class="NLM_article-title">Synthesis, characterization, DNA binding ability and cytotoxicity of the novel platinum(II), copper(II), cobalt(II) and nickel(II) complexes with 3-(1 H -benzo[ d ]imidazol-2-yl)- β -carboline</span> <span class="citation_source-journal">Inorg. Chim. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">421</span><span class="NLM_x">, </span> <span class="NLM_fpage">91</span><span class="NLM_x">–</span> <span class="NLM_lpage">99</span><span class="refDoi"> DOI: 10.1016/j.ica.2014.05.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1016%2Fj.ica.2014.05.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Cku7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=421&publication_year=2014&pages=91-99&author=Q.+M.+Jinauthor=Y.+Luauthor=J.+L.+Jinauthor=H.+Guoauthor=G.+W.+Linauthor=Y.+Wangauthor=T.+Lu&title=Synthesis%2C+characterization%2C+DNA+binding+ability+and+cytotoxicity+of+the+novel+platinum%28II%29%2C+copper%28II%29%2C+cobalt%28II%29+and+nickel%28II%29+complexes+with+3-%281+H+-benzo%5B+d+%5Dimidazol-2-yl%29-+%CE%B2+-carboline&doi=10.1016%2Fj.ica.2014.05.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, characterization, DNA binding ability and cytotoxicity of the novel platinum(II), copper(II), cobalt(II) and nickel(II) complexes with 3-(1H-benzo[d]imidazol-2-yl)-β-carboline</span></div><div class="casAuthors">Jin, Qiao-Mei; Lu, Yi; Jin, Jian-Lin; Guo, Hao; Lin, Guo-Wu; Wang, Yue; Lu, Tao</div><div class="citationInfo"><span class="NLM_cas:title">Inorganica Chimica Acta</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">421</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">91-99</span>CODEN:
                <span class="NLM_cas:coden">ICHAA3</span>;
        ISSN:<span class="NLM_cas:issn">0020-1693</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">3-(1H-benzo[d]imidazol-2-yl)-β-carbolin (Y-5, C18H12N4, 5) and its Pt(II), Cu(II), Co(II) and Ni(II) complexes 1-4 were synthesized and characterized by 1H NMR, MS, IR, elemental analyses and TG.  The complexes are Pt(C18H12N4)Cl2.DMF (1), Cu(C18H12N4)Cl2.2H2O (2), Co(C18H12N4)2Cl2.2H2O (3), and Ni(C18H12N4)Cl2.2H2O (4).  Crystal structure of Y-5 and its Pt(II) complex are reported.  The DNA binding and DNA cleavage ability of complexes with Cu(II) ion and Pt(II) ion as the metal center showed enhanced activities than that of the other two, which were evaluated by absorption spectra, EB displacement expts. and agarose gel electrophoresis.  Assay on the cytotoxicity of the above complexes against A549 and Hela tumor cells and Helf normal cells revealed that the complexes 1 and 2 are toxic against tumor cells but relatively safe to normal cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr15oiIWuruLVg90H21EOLACvtfcHk0lhsDRl2H4SmaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Cku7rJ&md5=b50fc1bb101c523e27d11daf0a00a31a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ica.2014.05.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ica.2014.05.036%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DQ.%2BM.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%2BL.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DG.%2BW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DT.%26atitle%3DSynthesis%252C%2520characterization%252C%2520DNA%2520binding%2520ability%2520and%2520cytotoxicity%2520of%2520the%2520novel%2520platinum%2528II%2529%252C%2520copper%2528II%2529%252C%2520cobalt%2528II%2529%2520and%2520nickel%2528II%2529%2520complexes%2520with%25203-%25281%2520H%2520-benzo%255B%2520d%2520%255Dimidazol-2-yl%2529-%2520%25CE%25B2%2520-carboline%26jtitle%3DInorg.%2520Chim.%2520Acta%26date%3D2014%26volume%3D421%26spage%3D91%26epage%3D99%26doi%3D10.1016%2Fj.ica.2014.05.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Lin, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Q. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, T.</span><span> </span><span class="NLM_article-title">Synthesis, structures and the biological activity study on the metal complexes of 2-(4-aminophenyl)benzothiazole derivative</span> <span class="citation_source-journal">Inorg. Chim. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">382</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">–</span> <span class="NLM_lpage">42</span><span class="refDoi"> DOI: 10.1016/j.ica.2011.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1016%2Fj.ica.2011.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFGnu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2012&pages=35-42&author=G.+W.+Linauthor=Y.+Wangauthor=Q.+M.+Jinauthor=T.+T.+Yangauthor=J.+M.+Songauthor=Y.+Luauthor=Q.+J.+Huangauthor=K.+Songauthor=J.+Zhouauthor=T.+Lu&title=Synthesis%2C+structures+and+the+biological+activity+study+on+the+metal+complexes+of+2-%284-aminophenyl%29benzothiazole+derivative&doi=10.1016%2Fj.ica.2011.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, structures and the biological activity study on the metal complexes of 2-(4-aminophenyl)benzothiazole derivative</span></div><div class="casAuthors">Lin, Guo-Wu; Wang, Yue; Jin, Qiao-Mei; Yang, Tao-Tao; Song, Jie-Mei; Lu, Yi; Huang, Qing-Jie; Song, Ke; Zhou, Jun; Lu, Tao</div><div class="citationInfo"><span class="NLM_cas:title">Inorganica Chimica Acta</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35-42</span>CODEN:
                <span class="NLM_cas:coden">ICHAA3</span>;
        ISSN:<span class="NLM_cas:issn">0020-1693</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">(2-(4-(Benzothiazole)phenyl)carbamoylmethyl)iminodiacetic acid (ZL-5) was synthesized and then its three metal complexes were prepd. with structures detd. by 1H NMR or x-ray.  In all complexes, ZL-5 is deprotonated to generate the neutral complex unit and acts as a tetradentate ligand, providing iminodiacetic N atom and three O atoms to bond with metal ions.  Meanwhile the authors studied on the interaction of complexes with DNA by UV spectrum and fluorescent spectrum.  Also the cleavage abilities of the complexes on plasmid pBR 322 DNA were studied by gel electrophoresis.  The authors deduce the Co(II) complex 1 with the largest planar structure has the strongest DNA binding ability mainly by the intercalation mode, while the Cu(II) complex 2 with the coordinated H2O cut the DNA most effectively.  And in the oxidative cleavage process of all complexes, the hydroxyl radical is produced which can be captured by DMSO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAGxHUkxdxarVg90H21EOLACvtfcHk0lhsDRl2H4SmaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFGnu78%253D&md5=bccd140e1cbc1437fd706ac135d85909</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.ica.2011.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ica.2011.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DG.%2BW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DQ.%2BM.%26aulast%3DYang%26aufirst%3DT.%2BT.%26aulast%3DSong%26aufirst%3DJ.%2BM.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DQ.%2BJ.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DT.%26atitle%3DSynthesis%252C%2520structures%2520and%2520the%2520biological%2520activity%2520study%2520on%2520the%2520metal%2520complexes%2520of%25202-%25284-aminophenyl%2529benzothiazole%2520derivative%26jtitle%3DInorg.%2520Chim.%2520Acta%26date%3D2012%26volume%3D382%26spage%3D35%26epage%3D42%26doi%3D10.1016%2Fj.ica.2011.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span> </span><span class="NLM_article-title">Novel 1H-pyrazole-3-carboxamide derivatives: synthesis, anticancer evaluation and identification of their DNA-binding interaction</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">238</span><span class="NLM_x">–</span> <span class="NLM_lpage">246</span><span class="refDoi"> DOI: 10.1248/cpb.c13-00676</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1248%2Fcpb.c13-00676" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=24365978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVSgu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2014&pages=238-246&author=Y.+Luauthor=T.+Ranauthor=G.+Linauthor=Q.+Jinauthor=J.+Jinauthor=H.+Liauthor=H.+Guoauthor=T.+Luauthor=Y.+Wang&title=Novel+1H-pyrazole-3-carboxamide+derivatives%3A+synthesis%2C+anticancer+evaluation+and+identification+of+their+DNA-binding+interaction&doi=10.1248%2Fcpb.c13-00676"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 1H-pyrazole-3-carboxamide derivatives: synthesis, anticancer evaluation and identification of their DNA-binding interaction</span></div><div class="casAuthors">Lu, Yi; Ran, Ting; Lin, Guowu; Jin, Qiaomei; Jin, Jianling; Li, Hongmei; Guo, Hao; Lu, Tao; Wang, Yue</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">238-246</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">Four novel 1H-pyrazole-3-carboxamides I (R = cyclopropylaminocarbonyl, benzoyl, pyridin-4-ylmethyl, X = NMe; R = cyclopropylaminocarbonyl, X = O) were synthesized, and their antiproliferative effect on cancer cells, kinase inhibition, and in particular, the DNA-binding interactions were investigated to interpret the antitumor mechanisms.  A DNA minor groove binding model was developed, and the binding energy was predicted for these compds.  In consistence with the prediction, the binding ability was detd. by the electronic absorption spectroscopy under physiol. conditions, and further verified by viscosity measurements.  Compd. I [R = cyclopropylaminocarbonyl; X = NMe; (II)] exerted the highest DNA-binding affinity (K = 1.06x105 M-1) and showed more than 50% decrease of the emission intensity of the ethidium bromide-calf thymus DNA (EB-CT-DNA) complex in fluorescence spectra, suggesting that it could strongly affect the DNA conformation.  Furthermore, compd. II showed the cleavage activity upon the supercoiled plasmid pBR322 DNA in the pBR322 DNA cleavage assay.  These studies suggested that DNA may serve as a potential target to these pyrazole derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsjjzMFPJ9b7Vg90H21EOLACvtfcHk0lhbfC0lKJpF6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVSgu74%253D&md5=bf837d90cd59ef638de41c08e49f488c</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1248%2Fcpb.c13-00676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.c13-00676%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DRan%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DNovel%25201H-pyrazole-3-carboxamide%2520derivatives%253A%2520synthesis%252C%2520anticancer%2520evaluation%2520and%2520identification%2520of%2520their%2520DNA-binding%2520interaction%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2014%26volume%3D62%26spage%3D238%26epage%3D246%26doi%3D10.1248%2Fcpb.c13-00676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Heathcote, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroll, S. H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Periyasamy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alikian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanneganti, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jogalekar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheiper, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbazanges, M.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">A Novel Pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8508</span><span class="NLM_x">–</span> <span class="NLM_lpage">8522</span><span class="refDoi"> DOI: 10.1021/jm100732t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100732t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8508-8522&author=D.+A.+Heathcoteauthor=H.+Patelauthor=S.+H.+B.+Krollauthor=P.+Hazelauthor=M.+Periyasamyauthor=M.+Alikianauthor=S.+K.+Kannegantiauthor=A.+S.+Jogalekarauthor=B.+Scheiperauthor=M.+Barbazanges&title=A+Novel+Pyrazolo%5B1%2C5-a%5Dpyrimidine+is+a+potent+inhibitor+of+cyclin-dependent+protein+kinases+1%2C+2%2C+and+9%2C+which+demonstrates+antitumor+effects+in+human+tumor+xenografts+following+oral+administration&doi=10.1021%2Fjm100732t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Pyrazolo[1,5-a]pyrimidine is a Potent Inhibitor of Cyclin-Dependent Protein Kinases 1, 2, and 9, Which Demonstrates Antitumor Effects in Human Tumor Xenografts Following Oral Administration</span></div><div class="casAuthors">Heathcote, Dean A.; Patel, Hetal; Kroll, Sebastian H. B.; Hazel, Pascale; Periyasamy, Manikandan; Alikian, Mary; Kanneganti, Seshu K.; Jogalekar, Ashutosh S.; Scheiper, Bodo; Barbazanges, Marion; Blum, Andreas; Brackow, Jan; Siwicka, Alekasandra; Pace, Robert D. M.; Fuchter, Matthew J.; Snyder, James P.; Liotta, Dennis C.; Freemont, Paul. S.; Aboagye, Eric O.; Coombes, R. Charles; Barrett, Anthony G. M.; Ali, Simak</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8508-8522</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent protein kinases (CDKs) are central to the appropriate regulation of cell proliferation, apoptosis, and gene expression.  Abnormalities in CDK activity and regulation are common features of cancer, making CDK family members attractive targets for the development of anticancer drugs.  Here, we report the identification of a pyrazolo[1,5-a]pyrimidine derived compd., 4k (BS-194, I), as a selective and potent CDK inhibitor, which inhibits CDK2, CDK1, CDK5, CDK7, and CDK9 (IC50 = 3, 30, 30, 250, and 90 nmol/L, resp.).  Cell-based studies showed inhibition of the phosphorylation of CDK substrates, Rb and the RNA polymerase II C-terminal domain, down-regulation of cyclins A, E, and D1, and cell cycle block in the S and G2/M phases.  Consistent with these findings, 4k demonstrated potent antiproliferative activity in 60 cancer cell lines tested (mean GI50 = 280 nmol/L).  Pharmacokinetic studies showed that 4k is orally bioavailable, with an elimination half-life of 178 min following oral dosing in mice.  When administered at a concn. of 25 mg/kg orally, 4k inhibited human tumor xenografts and suppressed CDK substrate phosphorylation.  These findings identify 4k as a novel, potent CDK selective inhibitor with potential for oral delivery in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUJPhLKEWwBLVg90H21EOLACvtfcHk0lhbfC0lKJpF6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL%252FJ&md5=b84f41ab0cbf298a9ac248bc0a9d0d73</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm100732t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100732t%26sid%3Dliteratum%253Aachs%26aulast%3DHeathcote%26aufirst%3DD.%2BA.%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DKroll%26aufirst%3DS.%2BH.%2BB.%26aulast%3DHazel%26aufirst%3DP.%26aulast%3DPeriyasamy%26aufirst%3DM.%26aulast%3DAlikian%26aufirst%3DM.%26aulast%3DKanneganti%26aufirst%3DS.%2BK.%26aulast%3DJogalekar%26aufirst%3DA.%2BS.%26aulast%3DScheiper%26aufirst%3DB.%26aulast%3DBarbazanges%26aufirst%3DM.%26atitle%3DA%2520Novel%2520Pyrazolo%255B1%252C5-a%255Dpyrimidine%2520is%2520a%2520potent%2520inhibitor%2520of%2520cyclin-dependent%2520protein%2520kinases%25201%252C%25202%252C%2520and%25209%252C%2520which%2520demonstrates%2520antitumor%2520effects%2520in%2520human%2520tumor%2520xenografts%2520following%2520oral%2520administration%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8508%26epage%3D8522%26doi%3D10.1021%2Fjm100732t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Wood, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noetzel, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engers, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollinger, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melancon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarr, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregro, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamsal, A.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Discovery and optimization of a novel series of highly CNS penetrant M 4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3- d ]pyrimidine core</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3029</span><span class="NLM_x">–</span> <span class="NLM_lpage">3033</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1016%2Fj.bmcl.2016.05.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=3029-3033&author=M.+R.+Woodauthor=M.+J.+Noetzelauthor=J.+L.+Engersauthor=K.+A.+Bollingerauthor=B.+J.+Melanconauthor=J.+C.+Tarrauthor=C.+Hanauthor=M.+Westauthor=A.+R.+Gregroauthor=A.+Lamsal&title=Discovery+and+optimization+of+a+novel+series+of+highly+CNS+penetrant+M+4+PAMs+based+on+a+5%2C6-dimethyl-4-%28piperidin-1-yl%29thieno%5B2%2C3-+d+%5Dpyrimidine+core&doi=10.1016%2Fj.bmcl.2016.05.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DM.%2BR.%26aulast%3DNoetzel%26aufirst%3DM.%2BJ.%26aulast%3DEngers%26aufirst%3DJ.%2BL.%26aulast%3DBollinger%26aufirst%3DK.%2BA.%26aulast%3DMelancon%26aufirst%3DB.%2BJ.%26aulast%3DTarr%26aufirst%3DJ.%2BC.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DWest%26aufirst%3DM.%26aulast%3DGregro%26aufirst%3DA.%2BR.%26aulast%3DLamsal%26aufirst%3DA.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520a%2520novel%2520series%2520of%2520highly%2520CNS%2520penetrant%2520M%25204%2520PAMs%2520based%2520on%2520a%25205%252C6-dimethyl-4-%2528piperidin-1-yl%2529thieno%255B2%252C3-%2520d%2520%255Dpyrimidine%2520core%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D3029%26epage%3D3033%26doi%3D10.1016%2Fj.bmcl.2016.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Shook, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarty, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbay, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alford, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rassnick, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scannevin, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, K.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Substituted thieno[2,3-d ]pyrimidines as adenosine A 2A receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">2688</span><span class="NLM_x">–</span> <span class="NLM_lpage">2691</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.02.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1016%2Fj.bmcl.2013.02.078" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=2688-2691&author=B.+C.+Shookauthor=D.+Chakravartyauthor=J.+K.+Barbayauthor=A.+Wangauthor=K.+Leonardauthor=V.+Alfordauthor=M.+T.+Powellauthor=S.+Rassnickauthor=R.+H.+Scannevinauthor=K.+Carroll&title=Substituted+thieno%5B2%2C3-d+%5Dpyrimidines+as+adenosine+A+2A+receptor+antagonists&doi=10.1016%2Fj.bmcl.2013.02.078"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.02.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.02.078%26sid%3Dliteratum%253Aachs%26aulast%3DShook%26aufirst%3DB.%2BC.%26aulast%3DChakravarty%26aufirst%3DD.%26aulast%3DBarbay%26aufirst%3DJ.%2BK.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DLeonard%26aufirst%3DK.%26aulast%3DAlford%26aufirst%3DV.%26aulast%3DPowell%26aufirst%3DM.%2BT.%26aulast%3DRassnick%26aufirst%3DS.%26aulast%3DScannevin%26aufirst%3DR.%2BH.%26aulast%3DCarroll%26aufirst%3DK.%26atitle%3DSubstituted%2520thieno%255B2%252C3-d%2520%255Dpyrimidines%2520as%2520adenosine%2520A%25202A%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D2688%26epage%3D2691%26doi%3D10.1016%2Fj.bmcl.2013.02.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Carbain, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anscombe, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Echalier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endicott, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golding, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haggerty, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardcastle, I. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewsbury, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roche, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span> </span><span class="NLM_article-title">8-Substituted O(6)-cyclohexylmethylguanine CDK2 inhibitors: using structure-based inhibitor design to optimize an alternative binding mode</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span><span class="refDoi"> DOI: 10.1021/jm401555v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401555v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=56-70&author=B.+Carbainauthor=D.+J.+Patersonauthor=E.+Anscombeauthor=A.+J.+Campbellauthor=C.+Canoauthor=A.+Echalierauthor=J.+A.+Endicottauthor=B.+T.+Goldingauthor=K.+Haggertyauthor=I.+R.+Hardcastleauthor=P.+J.+Jewsburyauthor=D.+R.+Newellauthor=M.+E.+Nobleauthor=C.+Rocheauthor=L.+Z.+Wangauthor=R.+J.+Griffin&title=8-Substituted+O%286%29-cyclohexylmethylguanine+CDK2+inhibitors%3A+using+structure-based+inhibitor+design+to+optimize+an+alternative+binding+mode&doi=10.1021%2Fjm401555v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm401555v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401555v%26sid%3Dliteratum%253Aachs%26aulast%3DCarbain%26aufirst%3DB.%26aulast%3DPaterson%26aufirst%3DD.%2BJ.%26aulast%3DAnscombe%26aufirst%3DE.%26aulast%3DCampbell%26aufirst%3DA.%2BJ.%26aulast%3DCano%26aufirst%3DC.%26aulast%3DEchalier%26aufirst%3DA.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DHaggerty%26aufirst%3DK.%26aulast%3DHardcastle%26aufirst%3DI.%2BR.%26aulast%3DJewsbury%26aufirst%3DP.%2BJ.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26aulast%3DRoche%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26atitle%3D8-Substituted%2520O%25286%2529-cyclohexylmethylguanine%2520CDK2%2520inhibitors%253A%2520using%2520structure-based%2520inhibitor%2520design%2520to%2520optimize%2520an%2520alternative%2520binding%2520mode%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D56%26epage%3D70%26doi%3D10.1021%2Fjm401555v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Lauwiner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rys, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissmann, J.</span><span> </span><span class="NLM_article-title">Reduction of aromatic nitro compounds with hydrazine hydrate in the presence of an iron oxide hydroxide catalyst. I. The reduction of mono substituted nitrobenzenes with hydrazine hydrate in the presence of ferrihydrite</span> <span class="citation_source-journal">Appl. Catal., A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">172</span><span class="NLM_x">, </span> <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span><span class="refDoi"> DOI: 10.1016/S0926-860X(98)00110-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1016%2FS0926-860X%2898%2900110-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADyaK1cXlslWmsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=1998&pages=141-148&author=M.+Lauwinerauthor=P.+Rysauthor=J.+Wissmann&title=Reduction+of+aromatic+nitro+compounds+with+hydrazine+hydrate+in+the+presence+of+an+iron+oxide+hydroxide+catalyst.+I.+The+reduction+of+mono+substituted+nitrobenzenes+with+hydrazine+hydrate+in+the+presence+of+ferrihydrite&doi=10.1016%2FS0926-860X%2898%2900110-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Reduction of aromatic nitro compounds with hydrazine hydrate in the presence of an iron oxide hydroxide catalyst. I. The reduction of monosubstituted nitrobenzenes with hydrazine hydrate in the presence of ferrihydrite</span></div><div class="casAuthors">Lauwiner, Max; Rys, Paul; Wissmann, Jorg</div><div class="citationInfo"><span class="NLM_cas:title">Applied Catalysis, A: General</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">141-148</span>CODEN:
                <span class="NLM_cas:coden">ACAGE4</span>;
        ISSN:<span class="NLM_cas:issn">0926-860X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A great variety of monosubstituted PhNO2 derivs. was reduced in good yield to the corresponding anilines with N2H4.H2O in the presence of an Fe oxide hydroxide catalyst prepd. by pptn. from an aq. Fe(III) soln. with NaOH.  The dependence of the redn. rate on the nature and the position of addnl. substituents other than the nitro group was detd. by measuring the reaction kinetics.  The rate is enhanced by electron-withdrawing substituents and decreased by electron-donating groups, which results in a pos. slope of ρ = 0.546 for the Hammett plot.  Competitive redn. expts. with mixts. of 2 differently substituted PhNO2 derivs. revealed that the nitro compd. with the more electron-attracting substituent is reduced first.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2y6E_uUTcJrVg90H21EOLACvtfcHk0lhRXTyKf5524w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlslWmsb0%253D&md5=5bca64ef7634fec257c8338565c4ec55</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2FS0926-860X%2898%2900110-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0926-860X%252898%252900110-0%26sid%3Dliteratum%253Aachs%26aulast%3DLauwiner%26aufirst%3DM.%26aulast%3DRys%26aufirst%3DP.%26aulast%3DWissmann%26aufirst%3DJ.%26atitle%3DReduction%2520of%2520aromatic%2520nitro%2520compounds%2520with%2520hydrazine%2520hydrate%2520in%2520the%2520presence%2520of%2520an%2520iron%2520oxide%2520hydroxide%2520catalyst.%2520I.%2520The%2520reduction%2520of%2520mono%2520substituted%2520nitrobenzenes%2520with%2520hydrazine%2520hydrate%2520in%2520the%2520presence%2520of%2520ferrihydrite%26jtitle%3DAppl.%2520Catal.%252C%2520A%26date%3D1998%26volume%3D172%26spage%3D141%26epage%3D148%26doi%3D10.1016%2FS0926-860X%2898%2900110-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Yang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, W.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">581</span><span class="NLM_x">–</span> <span class="NLM_lpage">596</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2014.10.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1016%2Fj.ejmech.2014.10.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=25462267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOjtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2015&pages=581-596&author=W.+Yangauthor=Y.+Chenauthor=X.+Zhouauthor=Y.+Guauthor=W.+Qianauthor=F.+Zhangauthor=W.+Hanauthor=T.+Luauthor=W.+Tang&title=Design%2C+synthesis+and+biological+evaluation+of+bis-aryl+ureas+and+amides+based+on+2-amino-3-purinylpyridine+scaffold+as+DFG-out+B-Raf+kinase+inhibitors&doi=10.1016%2Fj.ejmech.2014.10.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors</span></div><div class="casAuthors">Yang, Weimin; Chen, Yadong; Zhou, Xiang; Gu, Yazhou; Qian, Wenqi; Zhang, Fan; Han, Wei; Lu, Tao; Tang, Weifang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">581-596</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">By combining the scaffolds of UI-125 and Sorafenib, a series of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine moiety were designed and synthesized as novel DFG-out B-RafV600E inhibitors.  Several of these compds. displayed potent antiproliferative activities against melanoma A375 (B-RafV600E) cell lines with IC50 values of 3.190, 2.276, 1.856, 1.632 μM and 1.839 μM, resp., comparable with the pos. control Vemurafenib (IC50 = 3.32 μM).  Selected compds. were tested for the ERK inhibition in human melanoma A375 (B-RafV600E) and SK-MEL-2 (B-RafWT) cell lines by Western blot.  The results revealed that our compds. inhibited the proliferation of melanoma A375 cells (B-RafV600E) through ERK pathway, without paradoxical activation of ERK in melanoma SK-MEL-2 cells (B-RafWT).  Eventually, two compds. were selected to confirm their inhibitory effects on tumor growth in A375 xenograft models in mice.  Compd. I exhibited equiv. antitumor efficacy in vivo (T/C = 44.37%), compared to Sorafenib (T/C = 37.35%), by 23-day repetitive administration of a single dose of 50 mg/kg without significant body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq84bBDYugz1bVg90H21EOLACvtfcHk0lhUqZ9fdnH33Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOjtL7I&md5=6a65e09b0121c8f2f32facbfeae8f86b</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.10.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.10.039%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DQian%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520bis-aryl%2520ureas%2520and%2520amides%2520based%2520on%25202-amino-3-purinylpyridine%2520scaffold%2520as%2520DFG-out%2520B-Raf%2520kinase%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D89%26spage%3D581%26epage%3D596%26doi%3D10.1016%2Fj.ejmech.2014.10.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Jorda, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Havlícek, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNae, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walkinshaw, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Šturc, A. n.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navrátilová, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuzma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistrík, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bártek, J.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Pyrazolo [4, 3-d] pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2980</span><span class="NLM_x">–</span> <span class="NLM_lpage">2993</span><span class="refDoi"> DOI: 10.1021/jm200064p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200064p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2980-2993&author=R.+Jordaauthor=L.+Havl%C3%ADcekauthor=I.+W.+McNaeauthor=M.+D.+Walkinshawauthor=J.+Vollerauthor=A.+n.+%C5%A0turcauthor=J.+Navr%C3%A1tilov%C3%A1author=M.+Kuzmaauthor=M.+Mistr%C3%ADkauthor=J.+B%C3%A1rtek&title=Pyrazolo+%5B4%2C+3-d%5D+pyrimidine+bioisostere+of+roscovitine%3A+evaluation+of+a+novel+selective+inhibitor+of+cyclin-dependent+kinases+with+antiproliferative+activity&doi=10.1021%2Fjm200064p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm200064p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200064p%26sid%3Dliteratum%253Aachs%26aulast%3DJorda%26aufirst%3DR.%26aulast%3DHavl%25C3%25ADcek%26aufirst%3DL.%26aulast%3DMcNae%26aufirst%3DI.%2BW.%26aulast%3DWalkinshaw%26aufirst%3DM.%2BD.%26aulast%3DVoller%26aufirst%3DJ.%26aulast%3D%25C5%25A0turc%26aufirst%3DA.%2Bn.%26aulast%3DNavr%25C3%25A1tilov%25C3%25A1%26aufirst%3DJ.%26aulast%3DKuzma%26aufirst%3DM.%26aulast%3DMistr%25C3%25ADk%26aufirst%3DM.%26aulast%3DB%25C3%25A1rtek%26aufirst%3DJ.%26atitle%3DPyrazolo%2520%255B4%252C%25203-d%255D%2520pyrimidine%2520bioisostere%2520of%2520roscovitine%253A%2520evaluation%2520of%2520a%2520novel%2520selective%2520inhibitor%2520of%2520cyclin-dependent%2520kinases%2520with%2520antiproliferative%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2980%26epage%3D2993%26doi%3D10.1021%2Fjm200064p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Wyatt, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodhead, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulstridge, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devine, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Early, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltell, R. E.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4986</span><span class="NLM_x">–</span> <span class="NLM_lpage">4999</span><span class="refDoi"> DOI: 10.1021/jm800382h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800382h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4986-4999&author=P.+G.+Wyattauthor=A.+J.+Woodheadauthor=V.+Berdiniauthor=J.+A.+Boulstridgeauthor=M.+G.+Carrauthor=D.+M.+Crossauthor=D.+J.+Davisauthor=L.+A.+Devineauthor=T.+R.+Earlyauthor=R.+E.+Feltell&title=Identification+of+N-%284-piperidinyl%29-4-%282%2C6-dichlorobenzoylamino%29-1H-pyrazole-3-carboxamide+%28AT7519%29%2C+a+novel+cyclin+dependent+kinase+inhibitor+using+fragment-based+X-ray+crystallography+and+structure+based+drug+design&doi=10.1021%2Fjm800382h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm800382h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800382h%26sid%3Dliteratum%253Aachs%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DBoulstridge%26aufirst%3DJ.%2BA.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DCross%26aufirst%3DD.%2BM.%26aulast%3DDavis%26aufirst%3DD.%2BJ.%26aulast%3DDevine%26aufirst%3DL.%2BA.%26aulast%3DEarly%26aufirst%3DT.%2BR.%26aulast%3DFeltell%26aufirst%3DR.%2BE.%26atitle%3DIdentification%2520of%2520N-%25284-piperidinyl%2529-4-%25282%252C6-dichlorobenzoylamino%2529-1H-pyrazole-3-carboxamide%2520%2528AT7519%2529%252C%2520a%2520novel%2520cyclin%2520dependent%2520kinase%2520inhibitor%2520using%2520fragment-based%2520X-ray%2520crystallography%2520and%2520structure%2520based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4986%26epage%3D4999%26doi%3D10.1021%2Fjm800382h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Hornak, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strockbine, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roitberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmerling, C.</span><span> </span><span class="NLM_article-title">Comparison of multiple Amber force fields and development of improved protein backbone parameters</span> <span class="citation_source-journal">Proteins: Struct., Funct., Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">712</span><span class="NLM_x">–</span> <span class="NLM_lpage">725</span><span class="refDoi"> DOI: 10.1002/prot.21123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1002%2Fprot.21123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=16981200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWqt7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2006&pages=712-725&author=V.+Hornakauthor=R.+Abelauthor=A.+Okurauthor=B.+Strockbineauthor=A.+Roitbergauthor=C.+Simmerling&title=Comparison+of+multiple+Amber+force+fields+and+development+of+improved+protein+backbone+parameters&doi=10.1002%2Fprot.21123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of multiple Amber force fields and development of improved protein backbone parameters</span></div><div class="casAuthors">Hornak, Viktor; Abel, Robert; Okur, Asim; Strockbine, Bentley; Roitberg, Adrian; Simmerling, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Bioinformatics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">712-725</span>CODEN:
                <span class="NLM_cas:coden">PSFBAF</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The ff94 force field that is commonly assocd. with the Amber simulation package is one of the most widely used parameter sets for biomol. simulation.  After a decade of extensive use and testing, limitations in this force field, such as over-stabilization of α-helixes, were reported by the authors and other researchers.  This led to a no. of attempts to improve these parameters, resulting in a variety of "Amber" force fields and significant difficulty in detg. which should be used for a particular application.  The authors show that several of these continue to suffer from inadequate balance between different secondary structure elements.  In addn., the approach used in most of these studies neglected to account for the existence in Amber of two sets of backbone .vphi./ψ dihedral terms.  This led to parameter sets that provide unreasonable conformational preferences for glycine.  The authors report here an effort to improve the .vphi./ψ dihedral terms in the ff99 energy function.  Dihedral term parameters are based on fitting the energies of multiple conformations of glycine and alanine tetrapeptides from high level ab initio quantum mech. calcns.  The new parameters for backbone dihedrals replace those in the existing ff99 force field.  This parameter set, which the authors denote ff99SB, achieves a better balance of secondary structure elements as judged by improved distribution of backbone dihedrals for glycine and alanine with respect to PDB survey data.  It also accomplishes improved agreement with published exptl. data for conformational preferences of short alanine peptides and better accord with exptl. NMR relaxation data of test protein systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmoASzza-Gd7Vg90H21EOLACvtfcHk0ljkWazeF2_9-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWqt7fM&md5=de683a26eca9e83ae524726e97ac22fa</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1002%2Fprot.21123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.21123%26sid%3Dliteratum%253Aachs%26aulast%3DHornak%26aufirst%3DV.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DOkur%26aufirst%3DA.%26aulast%3DStrockbine%26aufirst%3DB.%26aulast%3DRoitberg%26aufirst%3DA.%26aulast%3DSimmerling%26aufirst%3DC.%26atitle%3DComparison%2520of%2520multiple%2520Amber%2520force%2520fields%2520and%2520development%2520of%2520improved%2520protein%2520backbone%2520parameters%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2006%26volume%3D65%26spage%3D712%26epage%3D725%26doi%3D10.1002%2Fprot.21123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Matthieu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thierry, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonathan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafael, N.</span><span> </span><span class="NLM_article-title">Kinome Render: a stand-alone and web-accessible tool to annotate the human protein kinome tree</span> <span class="citation_source-journal">Peerj</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">e126</span><span class="refDoi"> DOI: 10.7717/peerj.126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.7717%2Fpeerj.126" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=e126&author=C.+Matthieuauthor=C.+Thierryauthor=B.+Jonathanauthor=N.+Rafael&title=Kinome+Render%3A+a+stand-alone+and+web-accessible+tool+to+annotate+the+human+protein+kinome+tree&doi=10.7717%2Fpeerj.126"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.7717%2Fpeerj.126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7717%252Fpeerj.126%26sid%3Dliteratum%253Aachs%26aulast%3DMatthieu%26aufirst%3DC.%26aulast%3DThierry%26aufirst%3DC.%26aulast%3DJonathan%26aufirst%3DB.%26aulast%3DRafael%26aufirst%3DN.%26atitle%3DKinome%2520Render%253A%2520a%2520stand-alone%2520and%2520web-accessible%2520tool%2520to%2520annotate%2520the%2520human%2520protein%2520kinome%2520tree%26jtitle%3DPeerj%26date%3D2013%26volume%3D1%26spage%3De126%26doi%3D10.7717%2Fpeerj.126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref100':['cit100']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 33 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Junwei Wang, Xiang Pan, Yi Song, Jian Liu, Fei Ma, Ping Wang, Yan Liu, Lin Zhao, Di Kang, <span class="NLM_string-name hlFld-ContribAuthor">Lihong Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Potent and Selective FLT3 Inhibitor (Z)-N-(5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-4-methyl-1H-pyrrol-3-yl)-3-(pyrrolidin-1-yl)propanamide with Improved Drug-like Properties and Superior Efficacy in FLT3-ITD-Positive Acute Myeloid Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (8)
                                     , 4870-4890. <a href="https://doi.org/10.1021/acs.jmedchem.0c02247" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02247</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02247&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02247%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BPotent%252Band%252BSelective%252BFLT3%252BInhibitor%252B%252528Z%252529-N-%2525285-%252528%2525285-Fluoro-2-oxoindolin-3-ylidene%252529methyl%252529-4-methyl-1H-pyrrol-3-yl%252529-3-%252528pyrrolidin-1-yl%252529propanamide%252Bwith%252BImproved%252BDrug-like%252BProperties%252Band%252BSuperior%252BEfficacy%252Bin%252BFLT3-ITD-Positive%252BAcute%252BMyeloid%252BLeukemia%26aulast%3DWang%26aufirst%3DJunwei%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D28122020%26date%3D02042021%26volume%3D64%26issue%3D8%26spage%3D4870%26epage%3D4890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhijie Wang, Jiongheng Cai, Jie Cheng, Wenqianzi Yang, Yifan Zhu, Hongmei Li, Tao Lu, Yadong Chen, <span class="NLM_string-name hlFld-ContribAuthor">Shuai Lu</span>. </span><span class="cited-content_cbyCitation_article-title">FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (6)
                                     , 2878-2900. <a href="https://doi.org/10.1021/acs.jmedchem.0c01851" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01851</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01851%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFLT3%252BInhibitors%252Bin%252BAcute%252BMyeloid%252BLeukemia%25253A%252BChallenges%252Band%252BRecent%252BDevelopments%252Bin%252BOvercoming%252BResistance%26aulast%3DWang%26aufirst%3DZhijie%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D23102020%26date%3D10032021%26volume%3D64%26issue%3D6%26spage%3D2878%26epage%3D2900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yue Zhong, Run-Ze Qiu, Shan-Liang Sun, Chao Zhao, Tian-Yuan Fan, Min Chen, Nian-Guang Li, <span class="NLM_string-name hlFld-ContribAuthor">Zhi-Hao Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12403-12428. <a href="https://doi.org/10.1021/acs.jmedchem.0c00696" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00696</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00696&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00696%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BFms-like%252BTyrosine%252BKinase%252B3%252BInhibitors%25253A%252BAn%252BAttractive%252Band%252BEfficient%252BMethod%252Bfor%252Bthe%252BTreatment%252Bof%252BAcute%252BMyeloid%252BLeukemia%26aulast%3DZhong%26aufirst%3DYue%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26042020%26date%3D21072020%26date%3D13072020%26volume%3D63%26issue%3D21%26spage%3D12403%26epage%3D12428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yuqin Zhu, Yuxiang Ma, Weidong Zu, Jianing Song, Hua Wang, You Zhong, Hongmei Li, Yanmin Zhang, Qianqian Gao, Bo Kong, Junyu Xu, Fei Jiang, Xinren Wang, Shuwen Li, Chenhe Liu, Haichun Liu, Tao Lu, <span class="NLM_string-name hlFld-ContribAuthor">Yadong Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of N-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine Derivatives as Novel, Potent, and Selective NF-κB Inducing Kinase (NIK) Inhibitors for the Treatment of Psoriasis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (13)
                                     , 6748-6773. <a href="https://doi.org/10.1021/acs.jmedchem.0c00055" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00055%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BN-Phenyl-7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidin-4-amine%252BDerivatives%252Bas%252BNovel%25252C%252BPotent%25252C%252Band%252BSelective%252BNF-%2525CE%2525BAB%252BInducing%252BKinase%252B%252528NIK%252529%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BPsoriasis%26aulast%3DZhu%26aufirst%3DYuqin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D12012020%26date%3D16062020%26date%3D01062020%26volume%3D63%26issue%3D13%26spage%3D6748%26epage%3D6773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yang Wang, Xing Chen, Yaoyao Yan, Xiaochen Zhu, Mingming Liu, <span class="NLM_string-name hlFld-ContribAuthor">Xinhua Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and SARs of 5-Chloro-N4-phenyl-N2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives as Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (6)
                                     , 3327-3347. <a href="https://doi.org/10.1021/acs.jmedchem.9b02121" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b02121</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b02121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b02121%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BSARs%252Bof%252B5-Chloro-N4-phenyl-N2-%252528pyridin-2-yl%252529pyrimidine-2%25252C4-diamine%252BDerivatives%252Bas%252BOral%252BAvailable%252Band%252BDual%252BCDK%252B6%252Band%252B9%252BInhibitors%252Bwith%252BPotent%252BAntitumor%252BActivity%26aulast%3DWang%26aufirst%3DYang%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D20122019%26date%3D12032020%26date%3D04032020%26volume%3D63%26issue%3D6%26spage%3D3327%26epage%3D3347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Guirong You, Kai Wang, Xiaodan Wang, Guodong Wang, Jian Sun, Guiyun Duan, <span class="NLM_string-name hlFld-ContribAuthor">Chengcai Xia</span>. </span><span class="cited-content_cbyCitation_article-title">Visible-Light-Mediated Nickel(II)-Catalyzed C–N Cross-Coupling in Water: Green and Regioselective Access for the Synthesis of Pyrazole-Containing Compounds. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (13)
                                     , 4005-4009. <a href="https://doi.org/10.1021/acs.orglett.8b01395" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b01395</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b01395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b01395%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DVisible-Light-Mediated%252BNickel%252528II%252529-Catalyzed%252BC%2525E2%252580%252593N%252BCross-Coupling%252Bin%252BWater%25253A%252BGreen%252Band%252BRegioselective%252BAccess%252Bfor%252Bthe%252BSynthesis%252Bof%252BPyrazole-Containing%252BCompounds%26aulast%3DYou%26aufirst%3DGuirong%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D18052018%26date%3D26062018%26volume%3D20%26issue%3D13%26spage%3D4005%26epage%3D4009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Zhong</span>, <span class="hlFld-ContribAuthor ">Yueshan  Li</span>, <span class="hlFld-ContribAuthor ">Liang  Xiong</span>, <span class="hlFld-ContribAuthor ">Wenjing  Wang</span>, <span class="hlFld-ContribAuthor ">Ming  Wu</span>, <span class="hlFld-ContribAuthor ">Ting  Yuan</span>, <span class="hlFld-ContribAuthor ">Wei  Yang</span>, <span class="hlFld-ContribAuthor ">Chenyu  Tian</span>, <span class="hlFld-ContribAuthor ">Zhuang  Miao</span>, <span class="hlFld-ContribAuthor ">Tianqi  Wang</span>, <span class="hlFld-ContribAuthor ">Shengyong  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. </span><span class="cited-content_cbyCitation_journal-name">Signal Transduction and Targeted Therapy</span><span> <strong>2021,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41392-021-00572-w" title="DOI URL">https://doi.org/10.1038/s41392-021-00572-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41392-021-00572-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41392-021-00572-w%26sid%3Dliteratum%253Aachs%26jtitle%3DSignal%2520Transduction%2520and%2520Targeted%2520Therapy%26atitle%3DSmall%252Bmolecules%252Bin%252Btargeted%252Bcancer%252Btherapy%25253A%252Badvances%25252C%252Bchallenges%25252C%252Band%252Bfuture%252Bperspectives%26aulast%3DZhong%26aufirst%3DLei%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cen  Zhao</span>, <span class="hlFld-ContribAuthor ">Dawei  Yang</span>, <span class="hlFld-ContribAuthor ">Yuchen  Ye</span>, <span class="hlFld-ContribAuthor ">Zhenzhong  Chen</span>, <span class="hlFld-ContribAuthor ">Tifan  Sun</span>, <span class="hlFld-ContribAuthor ">Jiawei  Zhao</span>, <span class="hlFld-ContribAuthor ">Kai  Zhao</span>, <span class="hlFld-ContribAuthor ">Na  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of Pim-2 kinase by LT-171-861 promotes DNA damage and exhibits enhanced lethal effects with PARP inhibitor in multiple myeloma. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2021,</strong> <em>190 </em>, 114648. <a href="https://doi.org/10.1016/j.bcp.2021.114648" title="DOI URL">https://doi.org/10.1016/j.bcp.2021.114648</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2021.114648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2021.114648%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DInhibition%252Bof%252BPim-2%252Bkinase%252Bby%252BLT-171-861%252Bpromotes%252BDNA%252Bdamage%252Band%252Bexhibits%252Benhanced%252Blethal%252Beffects%252Bwith%252BPARP%252Binhibitor%252Bin%252Bmultiple%252Bmyeloma%26aulast%3DZhao%26aufirst%3DCen%26date%3D2021%26volume%3D190%26spage%3D114648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanhui  Qiao</span>, <span class="hlFld-ContribAuthor ">Yating  Chen</span>, <span class="hlFld-ContribAuthor ">Shuhua  Zhang</span>, <span class="hlFld-ContribAuthor ">Qiuping  Huang</span>, <span class="hlFld-ContribAuthor ">Yujie  Zhang</span>, <span class="hlFld-ContribAuthor ">Guangzhao  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Six novel complexes based on 5-Acetoxy-1-(6-chloro-pyridin-2-yl)-1H-pyrazole-3-carboxylic acid methyl ester derivatives: Syntheses, crystal structures, and anti-cancer activity. </span><span class="cited-content_cbyCitation_journal-name">Arabian Journal of Chemistry</span><span> <strong>2021,</strong> <em>14 </em>
                                    (7)
                                     , 103237. <a href="https://doi.org/10.1016/j.arabjc.2021.103237" title="DOI URL">https://doi.org/10.1016/j.arabjc.2021.103237</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.arabjc.2021.103237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.arabjc.2021.103237%26sid%3Dliteratum%253Aachs%26jtitle%3DArabian%2520Journal%2520of%2520Chemistry%26atitle%3DSix%252Bnovel%252Bcomplexes%252Bbased%252Bon%252B5-Acetoxy-1-%2525286-chloro-pyridin-2-yl%252529-1H-pyrazole-3-carboxylic%252Bacid%252Bmethyl%252Bester%252Bderivatives%25253A%252BSyntheses%25252C%252Bcrystal%252Bstructures%25252C%252Band%252Banti-cancer%252Bactivity%26aulast%3DQiao%26aufirst%3DYanhui%26date%3D2021%26volume%3D14%26issue%3D7%26spage%3D103237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  Richter</span>, <span class="hlFld-ContribAuthor ">Nina  Schoenwaelder</span>, <span class="hlFld-ContribAuthor ">Sina  Sender</span>, <span class="hlFld-ContribAuthor ">Christian  Junghanss</span>, <span class="hlFld-ContribAuthor ">Claudia  Maletzki</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies—Current Understanding, (Pre-)Clinical Application and Promising Approaches. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (10)
                                     , 2497. <a href="https://doi.org/10.3390/cancers13102497" title="DOI URL">https://doi.org/10.3390/cancers13102497</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13102497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13102497%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DCyclin-Dependent%252BKinase%252BInhibitors%252Bin%252BHematological%252BMalignancies%2525E2%252580%252594Current%252BUnderstanding%25252C%252B%252528Pre-%252529Clinical%252BApplication%252Band%252BPromising%252BApproaches%26aulast%3DRichter%26aufirst%3DAnna%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D10%26spage%3D2497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fateme  Moradi Moraddahande</span>, <span class="hlFld-ContribAuthor ">Mona  Shameli Houjghan</span>, <span class="hlFld-ContribAuthor ">Amir-Mohammad  Yousefi</span>, <span class="hlFld-ContribAuthor ">Ava  Safaroghli-Azar</span>, <span class="hlFld-ContribAuthor ">Atieh  Pourbagheri-Sigaroodi</span>, <span class="hlFld-ContribAuthor ">Davood  Bashash</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitor of Multi-cyclin-dependent Kinases (AT7519) Reduced Survival of U937 Leukemic Cells and Enhanced Anti-leukemic Effect of Vincristine: A Highlight to CDK Inhibition Efficacy in Acute Leukemia. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Cancer Management</span><span> <strong>2021,</strong> <em>14 </em>
                                    (2)
                                     <a href="https://doi.org/10.5812/ijcm.101366" title="DOI URL">https://doi.org/10.5812/ijcm.101366</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5812/ijcm.101366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5812%2Fijcm.101366%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Cancer%2520Management%26atitle%3DInhibitor%252Bof%252BMulti-cyclin-dependent%252BKinases%252B%252528AT7519%252529%252BReduced%252BSurvival%252Bof%252BU937%252BLeukemic%252BCells%252Band%252BEnhanced%252BAnti-leukemic%252BEffect%252Bof%252BVincristine%25253A%252BA%252BHighlight%252Bto%252BCDK%252BInhibition%252BEfficacy%252Bin%252BAcute%252BLeukemia%26aulast%3DMoradi%2BMoraddahande%26aufirst%3DFateme%26date%3D2021%26date%3D2021%26volume%3D14%26issue%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuchao  Ma</span>, <span class="hlFld-ContribAuthor ">Ben  Ouyang</span>, <span class="hlFld-ContribAuthor ">Linan  Wang</span>, <span class="hlFld-ContribAuthor ">Lei  Yao</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Biological Evaluation of 3-Aryl-4-alkylpyrazol-5-amines Based on the Target Fishing. </span><span class="cited-content_cbyCitation_journal-name">Current Computer-Aided Drug Design</span><span> <strong>2020,</strong> <em>16 </em>
                                    (5)
                                     , 564-570. <a href="https://doi.org/10.2174/1573409915666191003123900" title="DOI URL">https://doi.org/10.2174/1573409915666191003123900</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1573409915666191003123900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1573409915666191003123900%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Computer-Aided%2520Drug%2520Design%26atitle%3DDesign%252Band%252BBiological%252BEvaluation%252Bof%252B3-Aryl-4-alkylpyrazol-5-amines%252BBased%252Bon%252Bthe%252BTarget%252BFishing%26aulast%3DMa%26aufirst%3DShuchao%26date%3D2020%26volume%3D16%26issue%3D5%26spage%3D564%26epage%3D570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anthony  Feral</span>, <span class="hlFld-ContribAuthor ">Guillaume  Laconde</span>, <span class="hlFld-ContribAuthor ">Muriel  Amblard</span>, <span class="hlFld-ContribAuthor ">Nicolas  Masurier</span>. </span><span class="cited-content_cbyCitation_article-title">PROteolysis TArgetting Chimeras (PROTACs) Strategy Applied to Kinases: Recent Advances. </span><span class="cited-content_cbyCitation_journal-name">Advanced Therapeutics</span><span> <strong>2020,</strong> <em>3 </em>
                                    (11)
                                     , 2000148. <a href="https://doi.org/10.1002/adtp.202000148" title="DOI URL">https://doi.org/10.1002/adtp.202000148</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adtp.202000148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadtp.202000148%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Therapeutics%26atitle%3DPROteolysis%252BTArgetting%252BChimeras%252B%252528PROTACs%252529%252BStrategy%252BApplied%252Bto%252BKinases%25253A%252BRecent%252BAdvances%26aulast%3DFeral%26aufirst%3DAnthony%26date%3D2020%26date%3D2020%26volume%3D3%26issue%3D11%26spage%3D2000148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yingxiu  Li</span>, <span class="hlFld-ContribAuthor ">Peng  Wang</span>, <span class="hlFld-ContribAuthor ">Cong  Chen</span>, <span class="hlFld-ContribAuthor ">Tianyu  Ye</span>, <span class="hlFld-ContribAuthor ">Yufei  Han</span>, <span class="hlFld-ContribAuthor ">Yunlei  Hou</span>, <span class="hlFld-ContribAuthor ">Yajing  Liu</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Mingze  Qin</span>, <span class="hlFld-ContribAuthor ">Yanfang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and rational design of 2-aminopyrimidine-based derivatives targeting Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>104 </em>, 104361. <a href="https://doi.org/10.1016/j.bioorg.2020.104361" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104361</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104361%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiscovery%252Band%252Brational%252Bdesign%252Bof%252B2-aminopyrimidine-based%252Bderivatives%252Btargeting%252BJanus%252Bkinase%252B2%252B%252528JAK2%252529%252Band%252BFMS-like%252Btyrosine%252Bkinase%252B3%252B%252528FLT3%252529%26aulast%3DLi%26aufirst%3DYingxiu%26date%3D2020%26volume%3D104%26spage%3D104361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingli  Sun</span>, <span class="hlFld-ContribAuthor ">Lei  Wang</span>, <span class="hlFld-ContribAuthor ">Lulu  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhiming  Wang</span>, <span class="hlFld-ContribAuthor ">Pinhua  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Visible‐Light Photoredox Catalyzed C−N Coupling of Quinoxaline‐2(1
              H
              )‐ones with Azoles without External Photosensitizer. </span><span class="cited-content_cbyCitation_journal-name">ChemCatChem</span><span> <strong>2020,</strong> <em>12 </em>
                                    (20)
                                     , 5261-5268. <a href="https://doi.org/10.1002/cctc.202000459" title="DOI URL">https://doi.org/10.1002/cctc.202000459</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cctc.202000459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcctc.202000459%26sid%3Dliteratum%253Aachs%26jtitle%3DChemCatChem%26atitle%3DVisible%2525E2%252580%252590Light%252BPhotoredox%252BCatalyzed%252BC%2525E2%252588%252592N%252BCoupling%252Bof%252BQuinoxaline%2525E2%252580%2525902%2525281%252BH%252B%252529%2525E2%252580%252590ones%252Bwith%252BAzoles%252Bwithout%252BExternal%252BPhotosensitizer%26aulast%3DSun%26aufirst%3DMingli%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D20%26spage%3D5261%26epage%3D5268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Binyan  Lin</span>, <span class="hlFld-ContribAuthor ">Yongxu  Li</span>, <span class="hlFld-ContribAuthor ">Tiepeng  Wang</span>, <span class="hlFld-ContribAuthor ">Yangmin  Qiu</span>, <span class="hlFld-ContribAuthor ">Zhenzhong  Chen</span>, <span class="hlFld-ContribAuthor ">Kai  Zhao</span>, <span class="hlFld-ContribAuthor ">Na  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">CRMP2 is a therapeutic target that suppresses the aggressiveness of breast cancer cells by stabilizing RECK. </span><span class="cited-content_cbyCitation_journal-name">Oncogene</span><span> <strong>2020,</strong> <em>39 </em>
                                    (37)
                                     , 6024-6040. <a href="https://doi.org/10.1038/s41388-020-01412-x" title="DOI URL">https://doi.org/10.1038/s41388-020-01412-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41388-020-01412-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41388-020-01412-x%26sid%3Dliteratum%253Aachs%26jtitle%3DOncogene%26atitle%3DCRMP2%252Bis%252Ba%252Btherapeutic%252Btarget%252Bthat%252Bsuppresses%252Bthe%252Baggressiveness%252Bof%252Bbreast%252Bcancer%252Bcells%252Bby%252Bstabilizing%252BRECK%26aulast%3DLin%26aufirst%3DBinyan%26date%3D2020%26date%3D2020%26volume%3D39%26issue%3D37%26spage%3D6024%26epage%3D6040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bharat  Goel</span>, <span class="hlFld-ContribAuthor ">Nancy  Tripathi</span>, <span class="hlFld-ContribAuthor ">Nivedita  Bhardwaj</span>, <span class="hlFld-ContribAuthor ">Shreyans K.  Jain</span>. </span><span class="cited-content_cbyCitation_article-title">Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (17)
                                     , 1535-1563. <a href="https://doi.org/10.2174/1568026620666200516152756" title="DOI URL">https://doi.org/10.2174/1568026620666200516152756</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026620666200516152756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026620666200516152756%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecule%252BCDK%252BInhibitors%252Bfor%252Bthe%252BTherapeutic%252BManagement%252Bof%252BCancer%26aulast%3DGoel%26aufirst%3DBharat%26date%3D2020%26volume%3D20%26issue%3D17%26spage%3D1535%26epage%3D1563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Erik B  Faber</span>, <span class="hlFld-ContribAuthor ">Nan  Wang</span>, <span class="hlFld-ContribAuthor ">Gunda I  Georg</span>. </span><span class="cited-content_cbyCitation_article-title">Review of rationale and progress toward targeting cyclin-dependent kinase 2 (CDK2) for male contraception†. </span><span class="cited-content_cbyCitation_journal-name">Biology of Reproduction</span><span> <strong>2020,</strong> <em>103 </em>
                                    (2)
                                     , 357-367. <a href="https://doi.org/10.1093/biolre/ioaa107" title="DOI URL">https://doi.org/10.1093/biolre/ioaa107</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/biolre/ioaa107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fbiolre%2Fioaa107%26sid%3Dliteratum%253Aachs%26jtitle%3DBiology%2520of%2520Reproduction%26atitle%3DReview%252Bof%252Brationale%252Band%252Bprogress%252Btoward%252Btargeting%252Bcyclin-dependent%252Bkinase%252B2%252B%252528CDK2%252529%252Bfor%252Bmale%252Bcontraception%2525E2%252580%2525A0%26aulast%3DFaber%26aufirst%3DErik%2BB%26date%3D2020%26date%3D2020%26volume%3D103%26issue%3D2%26spage%3D357%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lexian  Tong</span>, <span class="hlFld-ContribAuthor ">Xuemei  Li</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>, <span class="hlFld-ContribAuthor ">Tao  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in FLT3 inhibitors for acute myeloid leukemia. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (10)
                                     , 961-981. <a href="https://doi.org/10.4155/fmc-2019-0365" title="DOI URL">https://doi.org/10.4155/fmc-2019-0365</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0365%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252BFLT3%252Binhibitors%252Bfor%252Bacute%252Bmyeloid%252Bleukemia%26aulast%3DTong%26aufirst%3DLexian%26date%3D2020%26volume%3D12%26issue%3D10%26spage%3D961%26epage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunhui  Cheng</span>, <span class="hlFld-ContribAuthor ">Fan  Yun</span>, <span class="hlFld-ContribAuthor ">Sadeeq  Ullah</span>, <span class="hlFld-ContribAuthor ">Qipeng  Yuan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>189 </em>, 112073. <a href="https://doi.org/10.1016/j.ejmech.2020.112073" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112073</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112073%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bcyclin-dependent%252Bkinase%252B%252528CDK%252529%252Band%252Bhistone%252Bdeacetylase%252B%252528HDAC%252529%252Bdual%252Binhibitors%252Bwith%252Bpotent%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%252Banticancer%252Bactivity%26aulast%3DCheng%26aufirst%3DChunhui%26date%3D2020%26volume%3D189%26spage%3D112073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiuji  Cui</span>, <span class="hlFld-ContribAuthor ">Shuai  Lu</span>, <span class="hlFld-ContribAuthor ">Bingwei  Ni</span>, <span class="hlFld-ContribAuthor ">Xian  Zeng</span>, <span class="hlFld-ContribAuthor ">Ying  Tan</span>, <span class="hlFld-ContribAuthor ">Ya Dong  Chen</span>, <span class="hlFld-ContribAuthor ">Hongping  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Improved Prediction of Aqueous Solubility of Novel Compounds by Going Deeper With Deep Learning. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2020,</strong> <em>10 </em><a href="https://doi.org/10.3389/fonc.2020.00121" title="DOI URL">https://doi.org/10.3389/fonc.2020.00121</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2020.00121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2020.00121%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DImproved%252BPrediction%252Bof%252BAqueous%252BSolubility%252Bof%252BNovel%252BCompounds%252Bby%252BGoing%252BDeeper%252BWith%252BDeep%252BLearning%26aulast%3DCui%26aufirst%3DQiuji%26date%3D2020%26date%3D2020%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fei  Zhou</span>, <span class="hlFld-ContribAuthor ">Luyu  Chen</span>, <span class="hlFld-ContribAuthor ">Chaoguo  Cao</span>, <span class="hlFld-ContribAuthor ">Jiang  Yu</span>, <span class="hlFld-ContribAuthor ">Xiaojiao  Luo</span>, <span class="hlFld-ContribAuthor ">Peiting  Zhou</span>, <span class="hlFld-ContribAuthor ">Lifeng  Zhao</span>, <span class="hlFld-ContribAuthor ">Wu  Du</span>, <span class="hlFld-ContribAuthor ">Jijun  Cheng</span>, <span class="hlFld-ContribAuthor ">Yongmei  Xie</span>, <span class="hlFld-ContribAuthor ">Yuanwei  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Development of selective mono or dual PROTAC degrader probe of CDK isoforms. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>187 </em>, 111952. <a href="https://doi.org/10.1016/j.ejmech.2019.111952" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111952</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111952%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252Bselective%252Bmono%252Bor%252Bdual%252BPROTAC%252Bdegrader%252Bprobe%252Bof%252BCDK%252Bisoforms%26aulast%3DZhou%26aufirst%3DFei%26date%3D2020%26volume%3D187%26spage%3D111952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiyin  Bao</span>, <span class="hlFld-ContribAuthor ">Haichun  Liu</span>, <span class="hlFld-ContribAuthor ">Yanle  Zhi</span>, <span class="hlFld-ContribAuthor ">Wenqianzi  Yang</span>, <span class="hlFld-ContribAuthor ">Jiawei  Zhang</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Yue  Wang</span>, <span class="hlFld-ContribAuthor ">Shuai  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of benzo[d]oxazole derivatives as the potent type-I FLT3-ITD inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>94 </em>, 103248. <a href="https://doi.org/10.1016/j.bioorg.2019.103248" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103248</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103248%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bbenzo%25255Bd%25255Doxazole%252Bderivatives%252Bas%252Bthe%252Bpotent%252Btype-I%252BFLT3-ITD%252Binhibitors%26aulast%3DBao%26aufirst%3DJiyin%26date%3D2020%26volume%3D94%26spage%3D103248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyi  Jiang</span>, <span class="hlFld-ContribAuthor ">Ji  Yu</span>, <span class="hlFld-ContribAuthor ">Zhongxia  Zhou</span>, <span class="hlFld-ContribAuthor ">Jacob  Kongsted</span>, <span class="hlFld-ContribAuthor ">Yuning  Song</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular design opportunities presented by solvent‐exposed regions of target proteins. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (6)
                                     , 2194-2238. <a href="https://doi.org/10.1002/med.21581" title="DOI URL">https://doi.org/10.1002/med.21581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21581%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DMolecular%252Bdesign%252Bopportunities%252Bpresented%252Bby%252Bsolvent%2525E2%252580%252590exposed%252Bregions%252Bof%252Btarget%252Bproteins%26aulast%3DJiang%26aufirst%3DXiangyi%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D6%26spage%3D2194%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanle  Zhi</span>, <span class="hlFld-ContribAuthor ">Zhijie  Wang</span>, <span class="hlFld-ContribAuthor ">Chao  Yao</span>, <span class="hlFld-ContribAuthor ">Baoquan  Li</span>, <span class="hlFld-ContribAuthor ">Hao  Heng</span>, <span class="hlFld-ContribAuthor ">Jiongheng  Cai</span>, <span class="hlFld-ContribAuthor ">Li  Xiang</span>, <span class="hlFld-ContribAuthor ">Yue  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Shuai  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of 4-(Heterocyclic Substituted Amino)-1H-Pyrazole-3-Carboxamide Derivatives and Their Potent Activity against Acute Myeloid Leukemia (AML). </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2019,</strong> <em>20 </em>
                                    (22)
                                     , 5739. <a href="https://doi.org/10.3390/ijms20225739" title="DOI URL">https://doi.org/10.3390/ijms20225739</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms20225739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms20225739%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252B4-%252528Heterocyclic%252BSubstituted%252BAmino%252529-1H-Pyrazole-3-Carboxamide%252BDerivatives%252Band%252BTheir%252BPotent%252BActivity%252Bagainst%252BAcute%252BMyeloid%252BLeukemia%252B%252528AML%252529%26aulast%3DZhi%26aufirst%3DYanle%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D22%26spage%3D5739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Concepción  Sánchez-Martínez</span>, <span class="hlFld-ContribAuthor ">María José  Lallena</span>, <span class="hlFld-ContribAuthor ">Sonia Gutiérrez  Sanfeliciano</span>, <span class="hlFld-ContribAuthor ">Alfonso  de Dios</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (20)
                                     , 126637. <a href="https://doi.org/10.1016/j.bmcl.2019.126637" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126637</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126637%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DCyclin%252Bdependent%252Bkinase%252B%252528CDK%252529%252Binhibitors%252Bas%252Banticancer%252Bdrugs%25253A%252BRecent%252Badvances%252B%2525282015%2525E2%252580%2525932019%252529%26aulast%3DS%25C3%25A1nchez-Mart%25C3%25ADnez%26aufirst%3DConcepci%25C3%25B3n%26date%3D2019%26volume%3D29%26issue%3D20%26spage%3D126637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Heng</span>, <span class="hlFld-ContribAuthor ">Zhijie  Wang</span>, <span class="hlFld-ContribAuthor ">Hongmei  Li</span>, <span class="hlFld-ContribAuthor ">Yatian  Huang</span>, <span class="hlFld-ContribAuthor ">Qingyuan  Lan</span>, <span class="hlFld-ContribAuthor ">Xiaoxing  Guo</span>, <span class="hlFld-ContribAuthor ">Liang  Zhang</span>, <span class="hlFld-ContribAuthor ">Yanle  Zhi</span>, <span class="hlFld-ContribAuthor ">Jiongheng  Cai</span>, <span class="hlFld-ContribAuthor ">Tianren  Qin</span>, <span class="hlFld-ContribAuthor ">Li  Xiang</span>, <span class="hlFld-ContribAuthor ">Shuxian  Wang</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Shuai  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>176 </em>, 248-267. <a href="https://doi.org/10.1016/j.ejmech.2019.05.021" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.05.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.05.021%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCombining%252Bstructure-%252Band%252Bproperty-based%252Boptimization%252Bto%252Bidentify%252Bselective%252BFLT3-ITD%252Binhibitors%252Bwith%252Bgood%252Bantitumor%252Befficacy%252Bin%252BAML%252Bcell%252Binoculated%252Bmouse%252Bxenograft%252Bmodel%26aulast%3DHeng%26aufirst%3DHao%26date%3D2019%26volume%3D176%26spage%3D248%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rong-Hong  Hsiao</span>, <span class="hlFld-ContribAuthor ">Ching-Chun  Tseng</span>, <span class="hlFld-ContribAuthor ">Jia-Jun  Xie</span>, <span class="hlFld-ContribAuthor ">Shuo-En  Tsai</span>, <span class="hlFld-ContribAuthor ">Naoto  Uramaru</span>, <span class="hlFld-ContribAuthor ">Ching-Ya  Lin</span>, <span class="hlFld-ContribAuthor ">Ching-Yuh  Chern</span>, <span class="hlFld-ContribAuthor ">Fung Fuh  Wong</span>. </span><span class="cited-content_cbyCitation_article-title">Selective synthesis of functionalized pyrazoles from 5-amino-1H-pyrazole-4-carbaldehydes with sodium nitrite: 5-Amino-4-nitrosopyrazoles and pyrazole-4-carbaldehydes. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2019,</strong> <em>75 </em>
                                    (33)
                                     , 4561-4569. <a href="https://doi.org/10.1016/j.tet.2019.06.048" title="DOI URL">https://doi.org/10.1016/j.tet.2019.06.048</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2019.06.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2019.06.048%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DSelective%252Bsynthesis%252Bof%252Bfunctionalized%252Bpyrazoles%252Bfrom%252B5-amino-1H-pyrazole-4-carbaldehydes%252Bwith%252Bsodium%252Bnitrite%25253A%252B5-Amino-4-nitrosopyrazoles%252Band%252Bpyrazole-4-carbaldehydes%26aulast%3DHsiao%26aufirst%3DRong-Hong%26date%3D2019%26volume%3D75%26issue%3D33%26spage%3D4561%26epage%3D4569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Han-Qing  Wu</span>, <span class="hlFld-ContribAuthor ">Kai  Yang</span>, <span class="hlFld-ContribAuthor ">Xiao-Yun  Chen</span>, <span class="hlFld-ContribAuthor ">Mani  Arulkumar</span>, <span class="hlFld-ContribAuthor ">Neng  Wang</span>, <span class="hlFld-ContribAuthor ">Si-Hong  Chen</span>, <span class="hlFld-ContribAuthor ">Zhao-Yang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">A 3,4-dihalo-2(5
              H
              )-furanone initiated ring-opening reaction of DABCO in the absence of a metal catalyst and additive and its application in a one-pot two-step reaction. </span><span class="cited-content_cbyCitation_journal-name">Green Chemistry</span><span> <strong>2019,</strong> <em>21 </em>
                                    (14)
                                     , 3782-3788. <a href="https://doi.org/10.1039/C9GC01740B" title="DOI URL">https://doi.org/10.1039/C9GC01740B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9GC01740B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9GC01740B%26sid%3Dliteratum%253Aachs%26jtitle%3DGreen%2520Chemistry%26atitle%3DA%252B3%25252C4-dihalo-2%2525285%252BH%252B%252529-furanone%252Binitiated%252Bring-opening%252Breaction%252Bof%252BDABCO%252Bin%252Bthe%252Babsence%252Bof%252Ba%252Bmetal%252Bcatalyst%252Band%252Badditive%252Band%252Bits%252Bapplication%252Bin%252Ba%252Bone-pot%252Btwo-step%252Breaction%26aulast%3DWu%26aufirst%3DHan-Qing%26date%3D2019%26date%3D2019%26volume%3D21%26issue%3D14%26spage%3D3782%26epage%3D3788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Julhash U.  Kazi</span>, <span class="hlFld-ContribAuthor ">Lars  Rönnstrand</span>. </span><span class="cited-content_cbyCitation_article-title">FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications. </span><span class="cited-content_cbyCitation_journal-name">Physiological Reviews</span><span> <strong>2019,</strong> <em>99 </em>
                                    (3)
                                     , 1433-1466. <a href="https://doi.org/10.1152/physrev.00029.2018" title="DOI URL">https://doi.org/10.1152/physrev.00029.2018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1152/physrev.00029.2018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1152%2Fphysrev.00029.2018%26sid%3Dliteratum%253Aachs%26jtitle%3DPhysiological%2520Reviews%26atitle%3DFMS-like%252BTyrosine%252BKinase%252B3%25252FFLT3%25253A%252BFrom%252BBasic%252BScience%252Bto%252BClinical%252BImplications%26aulast%3DKazi%26aufirst%3DJulhash%2BU.%26date%3D2019%26volume%3D99%26issue%3D3%26spage%3D1433%26epage%3D1466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  Kusakiewicz-Dawid</span>, <span class="hlFld-ContribAuthor ">Monika  Porada</span>, <span class="hlFld-ContribAuthor ">Błażej  Dziuk</span>, <span class="hlFld-ContribAuthor ">Dawid  Siodłak</span>. </span><span class="cited-content_cbyCitation_article-title">Annular Tautomerism of 3(5)-Disubstituted-1H-pyrazoles with Ester and Amide Groups. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (14)
                                     , 2632. <a href="https://doi.org/10.3390/molecules24142632" title="DOI URL">https://doi.org/10.3390/molecules24142632</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24142632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24142632%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DAnnular%252BTautomerism%252Bof%252B3%2525285%252529-Disubstituted-1H-pyrazoles%252Bwith%252BEster%252Band%252BAmide%252BGroups%26aulast%3DKusakiewicz-Dawid%26aufirst%3DAnna%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D14%26spage%3D2632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Heng</span>, <span class="hlFld-ContribAuthor ">Yanle  Zhi</span>, <span class="hlFld-ContribAuthor ">Haoliang  Yuan</span>, <span class="hlFld-ContribAuthor ">Zhijie  Wang</span>, <span class="hlFld-ContribAuthor ">Hongmei  Li</span>, <span class="hlFld-ContribAuthor ">Shuxian  Wang</span>, <span class="hlFld-ContribAuthor ">Jieyi  Tian</span>, <span class="hlFld-ContribAuthor ">Haichun  Liu</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Ting  Ran</span>, <span class="hlFld-ContribAuthor ">Shuai  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a highly selective FLT3 inhibitor with specific proliferation inhibition against AML cells harboring FLT3-ITD mutation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>163 </em>, 195-206. <a href="https://doi.org/10.1016/j.ejmech.2018.11.063" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.11.063</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.11.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.11.063%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252Bhighly%252Bselective%252BFLT3%252Binhibitor%252Bwith%252Bspecific%252Bproliferation%252Binhibition%252Bagainst%252BAML%252Bcells%252Bharboring%252BFLT3-ITD%252Bmutation%26aulast%3DHeng%26aufirst%3DHao%26date%3D2019%26volume%3D163%26spage%3D195%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jieping  Li</span>, <span class="hlFld-ContribAuthor ">Li  Yang</span>, <span class="hlFld-ContribAuthor ">Rui  Shen</span>, <span class="hlFld-ContribAuthor ">Li  Gong</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Tian</span>, <span class="hlFld-ContribAuthor ">Huarong  Qiu</span>, <span class="hlFld-ContribAuthor ">Zhe  Shi</span>, <span class="hlFld-ContribAuthor ">Lichen  Gao</span>, <span class="hlFld-ContribAuthor ">Hongwu  Sun</span>, <span class="hlFld-ContribAuthor ">Guangsen  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Self-nanoemulsifying system improves oral absorption and enhances anti-acute myeloid leukemia activity of berberine. </span><span class="cited-content_cbyCitation_journal-name">Journal of Nanobiotechnology</span><span> <strong>2018,</strong> <em>16 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12951-018-0402-x" title="DOI URL">https://doi.org/10.1186/s12951-018-0402-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12951-018-0402-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12951-018-0402-x%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Nanobiotechnology%26atitle%3DSelf-nanoemulsifying%252Bsystem%252Bimproves%252Boral%252Babsorption%252Band%252Benhances%252Banti-acute%252Bmyeloid%252Bleukemia%252Bactivity%252Bof%252Bberberine%26aulast%3DLi%26aufirst%3DJieping%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01261&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Molecular docking analysis of compound <b>26</b> to CDK2 kinase and FLT3 kinase. (A) Chemical structure of <b>26</b>. (B) Compound <b>26</b> docked into CDK2 kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VU3">2VU3</a>). (C) Compound <b>26</b> docked into a homology model of FLT3.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01261&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Routes of Compounds <b>27</b>–<b>62</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01261&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) relative amine, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>; (b) FeO(OH)/C, 80% NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O, 95% EtOH; (c) 4-nitropyrazole-3-carboxylic acid, EDC·HCl, HOBt, DMF, room temperature; (d) FeO(OH)/C, 80% NH<sub>2</sub>NH<sub>2</sub>·H<sub>2</sub>O, 95% EtOH; (e) <b>R<sup>2</sup></b>–Cl, AcOH/H<sub>2</sub>O, 50 °C.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Binding-mode analysis of compound <b>42</b> to CDK2 kinase and FLT3 kinase. (A) Compound <b>42</b> docked into CDK2 kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VU3">2VU3</a>). (B) Compound <b>42</b> docked into the homology model of FLT3.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01261&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Distribution of kinases inhibited by compound <b>48</b> within the human kinome. The color code for inhibition is indicated. Residual enzymatic activities were determined in single-dose duplicates at compound concentrations of 10 μM. The ATP concentration was 10 μM. Staurosporine served as a positive control. The experiment was performed by Reaction Biology Corp. using a <sup>33</sup>P-radiolabeled assay. (B) Inhibitory activity of compound <b>48</b> against selected kinases using the <sup>33</sup>P-radiolabeled assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01261&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Binding-mode analysis of compound <b>50</b> to CDK2 kinase and FLT3 kinase. (A) Compound <b>50</b> docked into CDK2 kinase (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VU3">2VU3</a>). (B) Overlapping images of compound <b>50</b> (green) and AT7519 (gray) complexed with CDK2. (C) Compound <b>50</b> docked into a homology model of FLT3.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> (D) Chemical structure of compound <b>50</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01261&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Antitumor efficacy of <b>50</b> in the MV4-11-xenograft model. Female nu/nu mice bearing established MV4-11-tumor xenografts were treated by intravenous injection (iv, QD) with <b>50</b> at 15, 30, or 40 (mg/kg)/d, with cytarabine at 50 (mg/kg)/d, or with the vehicle. (A) Body-weight and (B) tumor-size measurements from MV4-11-xenograft mice after <b>50</b> or cytarabine administration. Initial body weights and tumor sizes were set as 100%. (C) Representative photographs of tumors in each group after 15, 30, or 40 (mg/kg)/d of <b>50</b>, 50 (mg/kg)/d of cytarabine, or the vehicle treatment. (D) Comparison of the final tumor weights in each group after the 22 day treatment period. The numbers in columns indicate the mean tumor weight in each group. (*) <i>p</i> < 0.05, (**) <i>p</i> < 0.01.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01261&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. MV4-11 cells were treated with compound <b>50</b> for 24 h and analyzed by Annexin V and PI staining. The percentage of cells undergoing apoptosis was defined as the sum of early-apoptotic, advanced-apoptotic, and necrotic cells. Upper right: advanced-apoptotic cells and necrotic cells labeled with PI and Annexin. Lower left: fully viable cells. Lower right: early-apoptotic cells labeled with Annexin V but not with PI. (A) DMSO control. (B) Compound <b>50</b>, 0.2 μM. (C) Compound <b>50</b>, 0.5 μM. (D) Compound <b>50</b>, 1 μM. (E) Compound <b>50</b>, 2 μM. (F) Sorafenib, 2 μM. (G) Percentage of apoptotic cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01261&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Cancer-cell-growth inhibition and cell-cycle arrest from compound <b>50</b> treatments in MV4-11 and HCT116 cells. (A) Effect of compound <b>50</b> on MV4-11 cell-cycle kinetics. Compound <b>50</b> was added at the concentrations shown to MV4-11 cells 24 h prior to fixation, staining with propidium iodide (PI), and flow-cytometric analysis. (B) Effect of compound <b>50</b> on HCT-116 cell cycles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01261&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/medium/jm-2017-01261s_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0008.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Western blot analyses. (A) Immunoblots showing the phosphorylation of FLT3, STAT5, ERK, and AKT proteins in MV4-11 cells treated with compound <b>50</b> or sorafenib for 24 h. (B) Immunoblots showing the phosphorylation of the Rb protein in MV4-11 cells treated for 24 h with compound <b>50</b> or AT7519.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-4/acs.jmedchem.7b01261/20180215/images/large/jm-2017-01261s_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01261&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i90">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74261" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74261" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 50 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Rowe, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tallman, M. S.</span><span> </span><span class="NLM_article-title">How I treat acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">3147</span><span class="NLM_x">–</span> <span class="NLM_lpage">3156</span><span class="refDoi"> DOI: 10.1182/blood-2010-05-260117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1182%2Fblood-2010-05-260117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=20558611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeisLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=3147-3156&author=J.+M.+Roweauthor=M.+S.+Tallman&title=How+I+treat+acute+myeloid+leukemia&doi=10.1182%2Fblood-2010-05-260117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">How I treat acute myeloid leukemia</span></div><div class="casAuthors">Rowe, Jacob M.; Tallman, Martin S.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3147-3156</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">More than one quarter of a million adults throughout the world are diagnosed annually with acute myeloid leukemia (AML).  Despite considerable progress during the past 3 decades in the therapy of AML, two-thirds of young adults and 90% of older adults still die of their disease.  The reported median age has increased over the past few decades, mostly because of a greater willingness of physicians to diagnose and treat older patients, and now is 72 years.  The greatest challenge is in this age group.  However, much improvement in therapy is needed for all adults with AML.  Recent advances in allogeneic transplantation, a better understanding of prognostic factors, and development of targeted agents have only modestly improved overall outcome when large populations of patients are considered.  Although an explosion in knowledge about the mol. pathogenesis of AML has outpaced treatment advances, such insights hold promise for the development of new therapies directed at specific mol. abnormalities that perturb malignant cell survival pathways.  The current approach in 2010 to the management of this disease is presented through a discussion of illustrative cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowwHCAKmWidLVg90H21EOLACvtfcHk0lhUviiDyW-tEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeisLvM&md5=0ed950fa5646cae2522ea653fc74d733</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-05-260117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-05-260117%26sid%3Dliteratum%253Aachs%26aulast%3DRowe%26aufirst%3DJ.%2BM.%26aulast%3DTallman%26aufirst%3DM.%2BS.%26atitle%3DHow%2520I%2520treat%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26spage%3D3147%26epage%3D3156%26doi%3D10.1182%2Fblood-2010-05-260117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Quintás-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravandi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu-Dumlao, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faderl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borthakur, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Manero, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span> </span><span class="NLM_article-title">Epigenetic Therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">4840</span><span class="NLM_x">–</span> <span class="NLM_lpage">4845</span><span class="refDoi"> DOI: 10.1182/blood-2012-06-436055</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1182%2Fblood-2012-06-436055" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2012&pages=4840-4845&author=A.+Quint%C3%A1s-Cardamaauthor=F.+Ravandiauthor=T.+Liu-Dumlaoauthor=M.+Brandtauthor=S.+Faderlauthor=S.+Pierceauthor=G.+Borthakurauthor=G.+Garcia-Maneroauthor=J.+Cortesauthor=H.+Kantarjian&title=Epigenetic+Therapy+is+associated+with+similar+survival+compared+with+intensive+chemotherapy+in+older+patients+with+newly+diagnosed+acute+myeloid+leukemia&doi=10.1182%2Fblood-2012-06-436055"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1182%2Fblood-2012-06-436055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2012-06-436055%26sid%3Dliteratum%253Aachs%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DA.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DLiu-Dumlao%26aufirst%3DT.%26aulast%3DBrandt%26aufirst%3DM.%26aulast%3DFaderl%26aufirst%3DS.%26aulast%3DPierce%26aufirst%3DS.%26aulast%3DBorthakur%26aufirst%3DG.%26aulast%3DGarcia-Manero%26aufirst%3DG.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DEpigenetic%2520Therapy%2520is%2520associated%2520with%2520similar%2520survival%2520compared%2520with%2520intensive%2520chemotherapy%2520in%2520older%2520patients%2520with%2520newly%2520diagnosed%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2012%26volume%3D120%26spage%3D4840%26epage%3D4845%26doi%3D10.1182%2Fblood-2012-06-436055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">FLT3 tyrosine kinase inhibitors</span> <span class="citation_source-journal">Int. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">100</span><span class="NLM_x">–</span> <span class="NLM_lpage">107</span><span class="refDoi"> DOI: 10.1532/IJH97.05079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1532%2FIJH97.05079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=16146839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGntL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2005&pages=100-107&author=M.+Levisauthor=D.+Small&title=FLT3+tyrosine+kinase+inhibitors&doi=10.1532%2FIJH97.05079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 tyrosine kinase inhibitors</span></div><div class="casAuthors">Levis, Mark; Small, Donald</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Hematology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">100-107</span>CODEN:
                <span class="NLM_cas:coden">IJHEEY</span>;
        ISSN:<span class="NLM_cas:issn">0925-5710</span>.
    
            (<span class="NLM_cas:orgname">Carden Jennings Publishing</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase FLT3 is an important regulatory mol. in hematopoiesis and is expressed on the blasts in most cases of acute leukemia.  Activating mutations of this receptor are present in roughly 30% of acute myeloid leukemia (AML) patients and are assocd. with a distinctly worse clin. outcome.  Efforts to target this mutation and improve outcomes in this subgroup of AML patients have led to the investigation of several novel small-mol. FLT3 tyrosine kinase inhibitors.  These compds. derive from a wide variety of chem. classes and differ significantly, both in their potency and in their selectivity.  In this review, we discuss the results of preclin., clin., and correlative lab. studies of FLT3 inhibitors in demonstrating how this field represents a truly translational enterprise with multiple ongoing interactions between the lab. and the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF4BnW93Jv2rVg90H21EOLACvtfcHk0lglcLDO_itEKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGntL%252FN&md5=75bdd31913d422c3a42551ee048e4f1e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1532%2FIJH97.05079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1532%252FIJH97.05079%26sid%3Dliteratum%253Aachs%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DFLT3%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DInt.%2520J.%2520Hematol.%26date%3D2005%26volume%3D82%26spage%3D100%26epage%3D107%26doi%3D10.1532%2FIJH97.05079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Kikushige, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimoto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwasaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niiro, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takenaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagafuji, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, M.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Human FLT3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">180</span><span class="NLM_x">, </span> <span class="NLM_fpage">7358</span><span class="NLM_x">–</span> <span class="NLM_lpage">7367</span><span class="refDoi"> DOI: 10.4049/jimmunol.180.11.7358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.4049%2Fjimmunol.180.11.7358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=18490735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtVanurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2008&pages=7358-7367&author=Y.+Kikushigeauthor=G.+Yoshimotoauthor=T.+Miyamotoauthor=T.+Iinoauthor=Y.+Moriauthor=H.+Iwasakiauthor=H.+Niiroauthor=K.+Takenakaauthor=K.+Nagafujiauthor=M.+Harada&title=Human+FLT3+is+expressed+at+the+hematopoietic+stem+cell+and+the+granulocyte%2Fmacrophage+progenitor+stages+to+maintain+cell+survival&doi=10.4049%2Fjimmunol.180.11.7358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Human Flt3 Is Expressed at the Hematopoietic Stem Cell and the Granulocyte/Macrophage Progenitor Stages to Maintain Cell Survival</span></div><div class="casAuthors">Kikushige, Yoshikane; Yoshimoto, Goichi; Miyamoto, Toshihiro; Iino, Tadafumi; Mori, Yasuo; Iwasaki, Hiromi; Niiro, Hiroaki; Takenaka, Katsuto; Nagafuji, Koji; Harada, Mine; Ishikawa, Fumihiko; Akashi, Koichi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7358-7367</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">FLT3/FLK2, a member of the receptor tyrosine kinase family, plays a crit. role in maintenance of hematopoietic homeostasis, and the constitutively active form of the FLT3 mutation is one of the most common genetic abnormalities in acute myelogenous leukemia.  In murine hematopoiesis, Flt3 is not expressed in self-renewing hematopoietic stem cells, but its expression is restricted to the multipotent and the lymphoid progenitor stages at which cells are incapable of self-renewal.  The authors extensively analyzed the expression of Flt3 in human (h) hematopoiesis.  Strikingly, in both the bone marrow and the cord blood, the human hematopoietic stem cell population capable of long-term reconstitution in xenogeneic hosts uniformly expressed Flt3.  Furthermore, human Flt3 is expressed not only in early lymphoid progenitors, but also in progenitors continuously along the granulocyte/macrophage pathway, including the common myeloid progenitor and the granulocyte/macrophage progenitor.  The authors further found that human Flt3 signaling prevents stem and progenitors from spontaneous apoptotic cell death at least through up-regulating Mcl-1, an indispensable survival factor for hematopoiesis.  Thus, the distribution of Flt3 expression is considerably different in human and mouse hematopoiesis, and human FLT3 signaling might play an important role in cell survival, esp. at stem and progenitor cells that are crit. cellular targets for acute myelogenous leukemia transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKXcrR-KQExrVg90H21EOLACvtfcHk0lglcLDO_itEKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtVanurs%253D&md5=3ff9bbe7a42c4ce0a87017014f7c3c2b</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.180.11.7358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.180.11.7358%26sid%3Dliteratum%253Aachs%26aulast%3DKikushige%26aufirst%3DY.%26aulast%3DYoshimoto%26aufirst%3DG.%26aulast%3DMiyamoto%26aufirst%3DT.%26aulast%3DIino%26aufirst%3DT.%26aulast%3DMori%26aufirst%3DY.%26aulast%3DIwasaki%26aufirst%3DH.%26aulast%3DNiiro%26aufirst%3DH.%26aulast%3DTakenaka%26aufirst%3DK.%26aulast%3DNagafuji%26aufirst%3DK.%26aulast%3DHarada%26aufirst%3DM.%26atitle%3DHuman%2520FLT3%2520is%2520expressed%2520at%2520the%2520hematopoietic%2520stem%2520cell%2520and%2520the%2520granulocyte%252Fmacrophage%2520progenitor%2520stages%2520to%2520maintain%2520cell%2520survival%26jtitle%3DJ.%2520Immunol.%26date%3D2008%26volume%3D180%26spage%3D7358%26epage%3D7367%26doi%3D10.4049%2Fjimmunol.180.11.7358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Oubari, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amirizade, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammadpour, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakhlestani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarif, M. N.</span><span> </span><span class="NLM_article-title">The important role of FLT3-L in ex vivo expansion of hematopoietic stem cells following co-culture with mesenchymal stem cells</span> <span class="citation_source-journal">Cell J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">210</span><span class="refDoi"> DOI: 10.22074/cellj.2016.3715</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.22074%2Fcellj.2016.3715" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2014&pages=201-210&author=F.+Oubariauthor=N.+Amirizadeauthor=H.+Mohammadpourauthor=M.+Nakhlestaniauthor=M.+N.+Zarif&title=The+important+role+of+FLT3-L+in+ex+vivo+expansion+of+hematopoietic+stem+cells+following+co-culture+with+mesenchymal+stem+cells&doi=10.22074%2Fcellj.2016.3715"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.22074%2Fcellj.2016.3715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.22074%252Fcellj.2016.3715%26sid%3Dliteratum%253Aachs%26aulast%3DOubari%26aufirst%3DF.%26aulast%3DAmirizade%26aufirst%3DN.%26aulast%3DMohammadpour%26aufirst%3DH.%26aulast%3DNakhlestani%26aufirst%3DM.%26aulast%3DZarif%26aufirst%3DM.%2BN.%26atitle%3DThe%2520important%2520role%2520of%2520FLT3-L%2520in%2520ex%2520vivo%2520expansion%2520of%2520hematopoietic%2520stem%2520cells%2520following%2520co-culture%2520with%2520mesenchymal%2520stem%2520cells%26jtitle%3DCell%2520J.%26date%3D2014%26volume%3D17%26spage%3D201%26epage%3D210%26doi%3D10.22074%2Fcellj.2016.3715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Kottaridis, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frew, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langabeer, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belton, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheatley, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bowen, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burnett, A. K.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">1752</span><span class="NLM_x">–</span> <span class="NLM_lpage">1759</span><span class="refDoi"> DOI: 10.1182/blood.V98.6.1752</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1182%2Fblood.V98.6.1752" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2001&pages=1752-1759&author=P.+D.+Kottaridisauthor=R.+E.+Galeauthor=M.+E.+Frewauthor=G.+Harrisonauthor=S.+E.+Langabeerauthor=A.+A.+Beltonauthor=H.+Walkerauthor=K.+Wheatleyauthor=D.+T.+Bowenauthor=A.+K.+Burnett&title=The+presence+of+a+FLT3+internal+tandem+duplication+in+patients+with+acute+myeloid+leukemia+%28AML%29+adds+important+prognostic+information+to+cytogenetic+risk+group+and+response+to+the+first+cycle+of+chemotherapy%3A+analysis+of+854+patients+from+the+United+Kingdom+Medical+Research+Council+AML+10+and+12+trials&doi=10.1182%2Fblood.V98.6.1752"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1182%2Fblood.V98.6.1752&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V98.6.1752%26sid%3Dliteratum%253Aachs%26aulast%3DKottaridis%26aufirst%3DP.%2BD.%26aulast%3DGale%26aufirst%3DR.%2BE.%26aulast%3DFrew%26aufirst%3DM.%2BE.%26aulast%3DHarrison%26aufirst%3DG.%26aulast%3DLangabeer%26aufirst%3DS.%2BE.%26aulast%3DBelton%26aufirst%3DA.%2BA.%26aulast%3DWalker%26aufirst%3DH.%26aulast%3DWheatley%26aufirst%3DK.%26aulast%3DBowen%26aufirst%3DD.%2BT.%26aulast%3DBurnett%26aufirst%3DA.%2BK.%26atitle%3DThe%2520presence%2520of%2520a%2520FLT3%2520internal%2520tandem%2520duplication%2520in%2520patients%2520with%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%2520adds%2520important%2520prognostic%2520information%2520to%2520cytogenetic%2520risk%2520group%2520and%2520response%2520to%2520the%2520first%2520cycle%2520of%2520chemotherapy%253A%2520analysis%2520of%2520854%2520patients%2520from%2520the%2520United%2520Kingdom%2520Medical%2520Research%2520Council%2520AML%252010%2520and%252012%2520trials%26jtitle%3DBlood%26date%3D2001%26volume%3D98%26spage%3D1752%26epage%3D1759%26doi%3D10.1182%2Fblood.V98.6.1752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Yamamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyoi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakano, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodera, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyawaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asou, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yagasaki, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimazaki, C.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">2434</span><span class="NLM_x">–</span> <span class="NLM_lpage">2439</span><span class="refDoi"> DOI: 10.1182/blood.V97.8.2434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1182%2Fblood.V97.8.2434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=11290608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFOgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2001&pages=2434-2439&author=Y.+Yamamotoauthor=H.+Kiyoiauthor=Y.+Nakanoauthor=R.+Suzukiauthor=Y.+Koderaauthor=S.+Miyawakiauthor=N.+Asouauthor=K.+Kuriyamaauthor=F.+Yagasakiauthor=C.+Shimazaki&title=Activating+mutation+of+D835+within+the+activation+loop+of+FLT3+in+human+hematologic+malignancies&doi=10.1182%2Fblood.V97.8.2434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies</span></div><div class="casAuthors">Yamamoto, Yukiya; Kiyoi, Hitoshi; Nakano, Yasuyuki; Suzuki, Ritsuro; Kodera, Yoshihisa; Miyawaki, Shuichi; Asou, Norio; Kuriyama, Kazutaka; Yagasaki, Fumiharu; Shimazaki, Chihiro; Akiyama, Hideki; Saito, Kenji; Nishimura, Miki; Motoji, Toshiko; Shinagawa, Katsuji; Takeshita, Akihiro; Saito, Hidehiko; Ueda, Ryuzo; Ohno, Ryuzo; Naoe, Tomoki</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2434-2439</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Mutations of receptor tyrosine kinases are implicated in the constitutive activation and development of human malignancy.  An internal tandem duplication (ITD) of the juxtamembrane (JM) domain-coding sequence of the FLT3 gene (FLT3/ITD) is found in 20% of patients with acute myeloid leukemia (AML) and is strongly assocd. with leukocytosis and a poor prognosis.  On the other hand, mutations of the c-KIT gene, which have been found in mast cell leukemia and AML, are clustered in 2 distinct regions, the JM domain and D816 within the activation loop.  This study was designed to analyze the mutation of D835 of FLT3, which corresponds to D816 of c-KIT, in a large series of human hematol. malignancies.  Several kinds of missense mutations were found in 30 of the 429 (7.0%) AML cases, 1 of the 29 (3.4%) myelodysplastic syndrome (MDS) cases, and 1 of the 36 (2.8%) acute lymphocytic leukemia patients.  The D835Y mutation was most frequently found (22 of the 32 D835 mutations), followed by the D835V (5), and D835H (1), D835E (1), and D835N (1) mutations.  Of note is that D835 mutations occurred independently of FLT3/ITD.  An anal. in the 201 patients newly diagnosed with AML (excluding M3) revealed that, in contrast to the FLT3/ITD mutation, D835 mutations were not significantly related to the leukocytosis, but tended to worsen disease-free survival.  All D835-mutant FLT3 were constitutively tyrosine-phosphorylated and transformed 32D cells, suggesting these mutations were constitutively active.  These results demonstrate that the FLT3 gene is the target most frequently mutated to become constitutively active in AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrydJnPT47K17Vg90H21EOLACvtfcHk0li7Mmd2lpcqLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFOgtbk%253D&md5=646e1b1a04c570f4094e7d83723d47fb</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1182%2Fblood.V97.8.2434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V97.8.2434%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DKiyoi%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DY.%26aulast%3DSuzuki%26aufirst%3DR.%26aulast%3DKodera%26aufirst%3DY.%26aulast%3DMiyawaki%26aufirst%3DS.%26aulast%3DAsou%26aufirst%3DN.%26aulast%3DKuriyama%26aufirst%3DK.%26aulast%3DYagasaki%26aufirst%3DF.%26aulast%3DShimazaki%26aufirst%3DC.%26atitle%3DActivating%2520mutation%2520of%2520D835%2520within%2520the%2520activation%2520loop%2520of%2520FLT3%2520in%2520human%2520hematologic%2520malignancies%26jtitle%3DBlood%26date%3D2001%26volume%3D97%26spage%3D2434%26epage%3D2439%26doi%3D10.1182%2Fblood.V97.8.2434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Levis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allebach, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tse, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldwin, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones-Bolin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dionne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Small, D.</span><span> </span><span class="NLM_article-title">A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">3885</span><span class="NLM_x">–</span> <span class="NLM_lpage">3891</span><span class="refDoi"> DOI: 10.1182/blood.V99.11.3885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1182%2Fblood.V99.11.3885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=12010785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BD38XktFyrsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=3885-3891&author=M.+Levisauthor=J.+Allebachauthor=K.+F.+Tseauthor=R.+Zhengauthor=B.+R.+Baldwinauthor=B.+D.+Smithauthor=S.+Jones-Bolinauthor=B.+Ruggeriauthor=C.+Dionneauthor=D.+Small&title=A+FLT3-targeted+tyrosine+kinase+inhibitor+is+cytotoxic+to+leukemia+cells+in+vitro+and+in+vivo&doi=10.1182%2Fblood.V99.11.3885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo</span></div><div class="casAuthors">Levis, Mark; Allebach, Jeffrey; Tse, Kam-Fai; Zheng, Rui; Baldwin, Brenda R.; Smith, B. Douglas; Jones-Bolin, Susan; Ruggeri, Bruce; Dionne, Craig; Small, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3885-3891</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Constitutively activating internal tandem duplication (ITD) and point mutations of the receptor tyrosine kinase FLT3 are present in ≤41% of patients with acute myeloid leukemia (AML).  These FLT3/ITD mutations are likely to be important because their presence is assocd. with a poor prognosis.  Both types of mutations appear to activate the tyrosine kinase activity of FLT3.  The authors describe here the identification and characterization of the indolocarbazole deriv. CEP-701 as a FLT3 inhibitor.  This drug potently and selectively inhibits autophosphorylation of wild-type and constitutively activated mutant FLT3 in vitro in FLT3/ITD-transfected cells and in human FLT3-expressing myeloid leukemia-derived cell lines.  The authors demonstrate that CEP-701 induces a cytotoxic effect on cells in a dose-responsive fashion that parallels the inhibition of FLT3.  STAT5 and ERK1/2, downstream targets of FLT3 in the signaling pathway, are inhibited in response to FLT3 inhibition.  In primary leukemia blasts from AML patients harboring FLT3/ITD mutations, FLT3 is also inhibited, with an assocd. cytotoxic response.  Finally, using a mouse model of FLT3/ITD leukemia, the authors demonstrate that the drug inhibits FLT3 phosphorylation in vivo and prolongs survival.  These findings form the basis for a planned clin. trial of CEP-701 in patients with AML harboring FLT3-activating mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXL7nbYZzBSrVg90H21EOLACvtfcHk0lglZrpVLHjxWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktFyrsr0%253D&md5=3808e2bf314d769c9ae1c11324df4aba</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1182%2Fblood.V99.11.3885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V99.11.3885%26sid%3Dliteratum%253Aachs%26aulast%3DLevis%26aufirst%3DM.%26aulast%3DAllebach%26aufirst%3DJ.%26aulast%3DTse%26aufirst%3DK.%2BF.%26aulast%3DZheng%26aufirst%3DR.%26aulast%3DBaldwin%26aufirst%3DB.%2BR.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DJones-Bolin%26aufirst%3DS.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DDionne%26aufirst%3DC.%26aulast%3DSmall%26aufirst%3DD.%26atitle%3DA%2520FLT3-targeted%2520tyrosine%2520kinase%2520inhibitor%2520is%2520cytotoxic%2520to%2520leukemia%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBlood%26date%3D2002%26volume%3D99%26spage%3D3885%26epage%3D3891%26doi%3D10.1182%2Fblood.V99.11.3885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Kiyoi, H.</span><span> </span><span class="NLM_article-title">Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1605</span><span class="NLM_x">–</span> <span class="NLM_lpage">1609</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1997&pages=1605-1609&author=H.+Kiyoi&title=Internal+tandem+duplication+of+the+FLT3+gene+is+preferentially+seen+in+acute+myeloid+leukemia+and+myelodysplastic+syndrome+among+various+hematological+malignancies.+A+study+on+a+large+series+of+patients+and+cell+lines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKiyoi%26aufirst%3DH.%26atitle%3DInternal%2520tandem%2520duplication%2520of%2520the%2520FLT3%2520gene%2520is%2520preferentially%2520seen%2520in%2520acute%2520myeloid%2520leukemia%2520and%2520myelodysplastic%2520syndrome%2520among%2520various%2520hematological%2520malignancies.%2520A%2520study%2520on%2520a%2520large%2520series%2520of%2520patients%2520and%2520cell%2520lines%26jtitle%3DLeukemia%26date%3D1997%26volume%3D11%26spage%3D1605%26epage%3D1609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Meshinchi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stirewalt, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweetser, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buckley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tjoa, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radich, J. P.</span><span> </span><span class="NLM_article-title">Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span><span class="refDoi"> DOI: 10.1182/blood.V97.1.89</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1182%2Fblood.V97.1.89" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2001&pages=89-94&author=S.+Meshinchiauthor=W.+G.+Woodsauthor=D.+L.+Stirewaltauthor=D.+A.+Sweetserauthor=J.+D.+Buckleyauthor=T.+K.+Tjoaauthor=I.+D.+Bernsteinauthor=J.+P.+Radich&title=Prevalence+and+prognostic+significance+of+Flt3+internal+tandem+duplication+in+pediatric+acute+myeloid+leukemia&doi=10.1182%2Fblood.V97.1.89"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1182%2Fblood.V97.1.89&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V97.1.89%26sid%3Dliteratum%253Aachs%26aulast%3DMeshinchi%26aufirst%3DS.%26aulast%3DWoods%26aufirst%3DW.%2BG.%26aulast%3DStirewalt%26aufirst%3DD.%2BL.%26aulast%3DSweetser%26aufirst%3DD.%2BA.%26aulast%3DBuckley%26aufirst%3DJ.%2BD.%26aulast%3DTjoa%26aufirst%3DT.%2BK.%26aulast%3DBernstein%26aufirst%3DI.%2BD.%26aulast%3DRadich%26aufirst%3DJ.%2BP.%26atitle%3DPrevalence%2520and%2520prognostic%2520significance%2520of%2520Flt3%2520internal%2520tandem%2520duplication%2520in%2520pediatric%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2001%26volume%3D97%26spage%3D89%26epage%3D94%26doi%3D10.1182%2Fblood.V97.1.89" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Smith, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dun, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahl, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panicker, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mashkani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Don, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, J.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">47465</span><span class="NLM_x">–</span> <span class="NLM_lpage">47478</span><span class="refDoi"> DOI: 10.18632/oncotarget.10167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.18632%2Foncotarget.10167" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=47465-47478&author=A.+M.+Smithauthor=M.+D.+Dunauthor=E.+M.+Leeauthor=C.+Harrisonauthor=R.+Kahlauthor=H.+Flanaganauthor=N.+Panickerauthor=B.+Mashkaniauthor=A.+S.+Donauthor=J.+Morris&title=Activation+of+protein+phosphatase+2A+in+FLT3%2B+acute+myeloid+leukemia+cells+enhances+the+cytotoxicity+of+FLT3+tyrosine+kinase+inhibitors&doi=10.18632%2Foncotarget.10167"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.10167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.10167%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DDun%26aufirst%3DM.%2BD.%26aulast%3DLee%26aufirst%3DE.%2BM.%26aulast%3DHarrison%26aufirst%3DC.%26aulast%3DKahl%26aufirst%3DR.%26aulast%3DFlanagan%26aufirst%3DH.%26aulast%3DPanicker%26aufirst%3DN.%26aulast%3DMashkani%26aufirst%3DB.%26aulast%3DDon%26aufirst%3DA.%2BS.%26aulast%3DMorris%26aufirst%3DJ.%26atitle%3DActivation%2520of%2520protein%2520phosphatase%25202A%2520in%2520FLT3%252B%2520acute%2520myeloid%2520leukemia%2520cells%2520enhances%2520the%2520cytotoxicity%2520of%2520FLT3%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D47465%26epage%3D47478%26doi%3D10.18632%2Foncotarget.10167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Wiernik, P. H.</span><span> </span><span class="NLM_article-title">FLT3 inhibitors for the treatment of acute myeloid leukemia</span> <span class="citation_source-journal">Clin. Adv. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">436</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=20733555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A280%3ADC%252BC3cjmvFCgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=429-436&author=P.+H.+Wiernik&title=FLT3+inhibitors+for+the+treatment+of+acute+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 inhibitors for the treatment of acute myeloid leukemia</span></div><div class="casAuthors">Wiernik Peter H</div><div class="citationInfo"><span class="NLM_cas:title">Clinical advances in hematology & oncology : H&O</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">429-36, 444</span>
        ISSN:<span class="NLM_cas:issn">1543-0790</span>.
    </div><div class="casAbstract">The fms-like receptor tyrosine kinase-3 (FLT3), which is important for the normal development of hematopoietic stem cells and cells of the immune system, is frequently mutated in patients with acute myeloid leukemia (AML).  FLT3 is, therefore, a potential therapeutic target in AML.  Recently, FLT3 inhibitors have shown therapeutic activity in AML patients with FLT3 mutations.  Sorafenib and sunitinib were the first FLT3 inhibitors to be studied in the clinic and have the most clinically relevant data.  Limited data are available for midostaurin (PKC412), lestaurtinib (CEP-701), tandutinib (MLN518), AC220, and KW-2449.  It is likely that optimal application of these agents will involve combinations of inhibitors and combinations of inhibitors and chemotherapy, potentially with a mammalian target of rapamycin inhibitor such as everolimus or temsirolimus.  This review discusses the theoretical rationale for the use of these agents and summarizes the relevant clinical data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZEiX89cbR_l1C8OJBvdfbfW6udTcc2eY7PyFN98pk1rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjmvFCgtg%253D%253D&md5=79a23ac07439bcd8edaa748451fd35d8</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWiernik%26aufirst%3DP.%2BH.%26atitle%3DFLT3%2520inhibitors%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DClin.%2520Adv.%2520Hematol.%2520Oncol.%26date%3D2010%26volume%3D8%26spage%3D429%26epage%3D436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Grunwald, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span> </span><span class="NLM_article-title">FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance</span> <span class="citation_source-journal">Int. J. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">683</span><span class="NLM_x">–</span> <span class="NLM_lpage">694</span><span class="refDoi"> DOI: 10.1007/s12185-013-1334-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1007%2Fs12185-013-1334-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=23613268" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC3sXps1ynt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2013&pages=683-694&author=M.+R.+Grunwaldauthor=M.+J.+Levis&title=FLT3+inhibitors+for+acute+myeloid+leukemia%3A+a+review+of+their+efficacy+and+mechanisms+of+resistance&doi=10.1007%2Fs12185-013-1334-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance</span></div><div class="casAuthors">Grunwald, Michael R.; Levis, Mark J.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Hematology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">683-694</span>CODEN:
                <span class="NLM_cas:coden">IJHEEY</span>;
        ISSN:<span class="NLM_cas:issn">0925-5710</span>.
    
            (<span class="NLM_cas:orgname">Springer Japan</span>)
        </div><div class="casAbstract">A review.  Since the Food and Drug Administration approval of imatinib for treatment of chronic myeloid leukemia in 2001, tyrosine kinase inhibitors (TKIs) have become a mainstay in the care of many malignancies.  In acute myeloid leukemia (AML), activating mutations in the FMS-like tyrosine kinase 3 (FLT3) gene result in survival and proliferation of leukemic blasts and are assocd. with adverse prognosis.  Therefore, the FLT3 receptor is an appealing target for inhibition.  Multiple small mol. TKIs are currently in development for FLT3-mutated AML, and agents are beginning to show promising efficacy.  In other malignancies, the development of resistance to TKIs during the course of therapy has proven to be a challenge, and thus far, in clin. trials of FLT3 TKIs, resistance to inhibition represents a significant barrier to successful FLT3 inhibition.  Understanding the mechanisms of resistance and overcoming these obstacles to target inhibition will be central to the success of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLGvQhRtVOcLVg90H21EOLACvtfcHk0lg5-IYYebdMSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXps1ynt7Y%253D&md5=f760866dbcd953c09143e0290fbffe3c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs12185-013-1334-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12185-013-1334-8%26sid%3Dliteratum%253Aachs%26aulast%3DGrunwald%26aufirst%3DM.%2BR.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26atitle%3DFLT3%2520inhibitors%2520for%2520acute%2520myeloid%2520leukemia%253A%2520a%2520review%2520of%2520their%2520efficacy%2520and%2520mechanisms%2520of%2520resistance%26jtitle%3DInt.%2520J.%2520Hematol.%26date%3D2013%26volume%3D97%26spage%3D683%26epage%3D694%26doi%3D10.1007%2Fs12185-013-1334-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Boulahjar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ouach, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonnet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lozach, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guguen-Guillouzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Guevel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akssira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillaumet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Routier, S.</span><span> </span><span class="NLM_article-title">Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">274</span><span class="NLM_x">–</span> <span class="NLM_lpage">287</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2015.06.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1016%2Fj.ejmech.2015.06.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=26142492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCqsbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2015&pages=274-287&author=R.+Boulahjarauthor=A.+Ouachauthor=S.+Bourgauthor=P.+Bonnetauthor=O.+Lozachauthor=L.+Meijerauthor=C.+Guguen-Guillouzoauthor=R.+Le+Guevelauthor=S.+Lazarauthor=M.+Akssiraauthor=Y.+Troinauthor=G.+Guillaumetauthor=S.+Routier&title=Advances+in+tetrahydropyrido%5B1%2C2-a%5Disoindolone+%28valmerins%29+series%3A+Potent+glycogen+synthase+kinase+3+and+cyclin+dependent+kinase+5+inhibitors&doi=10.1016%2Fj.ejmech.2015.06.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors</span></div><div class="casAuthors">Boulahjar, Rajaa; Ouach, Aziz; Bourg, Stephane; Bonnet, Pascal; Lozach, Olivier; Meijer, Laurent; Guguen-Guillouzo, Christiane; Le Guevel, Remy; Lazar, Said; Akssira, Mohamed; Troin, Yves; Guillaumet, Gerald; Routier, Sylvain</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">274-287</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">An efficient synthetic strategy was developed to modulate the structure of the tetrahydropyridine isoindolone (Valmerin) skeleton.  A library of more than 30 novel final structures was generated.  Biol. activities on CDK5 and GSK3 as well as cellular effects on cancer cell lines were measured for each novel compd.  Addnl. docking studies were performed to support medicinal chem. efforts.  A strong GSK3/CDK5 dual inhibitor (I, IC50 GSK3/CDK5 32/84 nM) was obtained.  A set of highly selective GSK3 inhibitors was synthesized by fine-tuning structural modifications (II, IC50 GSK3/CDK5 32/320 nM).  Antiproliferative effects on cells were correlated with the in vitro kinase activities and the best effects were obtained with lung and colon cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNKc6ssVA1k7Vg90H21EOLACvtfcHk0lg5-IYYebdMSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCqsbrK&md5=5385782f450d6914ddc149004d5facce</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.06.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.06.046%26sid%3Dliteratum%253Aachs%26aulast%3DBoulahjar%26aufirst%3DR.%26aulast%3DOuach%26aufirst%3DA.%26aulast%3DBourg%26aufirst%3DS.%26aulast%3DBonnet%26aufirst%3DP.%26aulast%3DLozach%26aufirst%3DO.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DGuguen-Guillouzo%26aufirst%3DC.%26aulast%3DLe%2BGuevel%26aufirst%3DR.%26aulast%3DLazar%26aufirst%3DS.%26aulast%3DAkssira%26aufirst%3DM.%26aulast%3DTroin%26aufirst%3DY.%26aulast%3DGuillaumet%26aufirst%3DG.%26aulast%3DRoutier%26aufirst%3DS.%26atitle%3DAdvances%2520in%2520tetrahydropyrido%255B1%252C2-a%255Disoindolone%2520%2528valmerins%2529%2520series%253A%2520Potent%2520glycogen%2520synthase%2520kinase%25203%2520and%2520cyclin%2520dependent%2520kinase%25205%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D101%26spage%3D274%26epage%3D287%26doi%3D10.1016%2Fj.ejmech.2015.06.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">Cell cycle, CDKs and cancer: a changing paradigm</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">166</span><span class="refDoi"> DOI: 10.1038/nrc2602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1038%2Fnrc2602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=19238148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=153-166&author=M.+Malumbresauthor=M.+Barbacid&title=Cell+cycle%2C+CDKs+and+cancer%3A+a+changing+paradigm&doi=10.1038%2Fnrc2602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle, CDKs and cancer: a changing paradigm</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-166</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor-assocd. cell cycle defects are often mediated by alterations in cyclin-dependent kinase (CDK) activity.  Misregulated CDKs induce unscheduled proliferation as well as genomic and chromosomal instability.  According to current models, mammalian CDKs are essential for driving each cell cycle phase, so therapeutic strategies that block CDK activity are unlikely to selectively target tumor cells.  However, recent genetic evidence has revealed that, whereas CDK1 is required for the cell cycle, interphase CDKs are only essential for proliferation of specialized cells.  Emerging evidence suggests that tumor cells may also require specific interphase CDKs for proliferation.  Thus, selective CDK inhibition may provide therapeutic benefit against certain human neoplasias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzlIKlbCPWnLVg90H21EOLACvtfcHk0lj53FJnPmLYXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D&md5=2a7eb34b2381e288b3f43ec1bffc0aec</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnrc2602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2602%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCell%2520cycle%252C%2520CDKs%2520and%2520cancer%253A%2520a%2520changing%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D153%26epage%3D166%26doi%3D10.1038%2Fnrc2602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Diaz-Padilla, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duran, I.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase inhibitors as potential targeted anticancer agents</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">586</span><span class="NLM_x">–</span> <span class="NLM_lpage">594</span><span class="refDoi"> DOI: 10.1007/s10637-009-9236-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1007%2Fs10637-009-9236-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=586-594&author=I.+Diaz-Padillaauthor=L.+L.+Siuauthor=I.+Duran&title=Cyclin-dependent+kinase+inhibitors+as+potential+targeted+anticancer+agents&doi=10.1007%2Fs10637-009-9236-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2Fs10637-009-9236-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-009-9236-6%26sid%3Dliteratum%253Aachs%26aulast%3DDiaz-Padilla%26aufirst%3DI.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26aulast%3DDuran%26aufirst%3DI.%26atitle%3DCyclin-dependent%2520kinase%2520inhibitors%2520as%2520potential%2520targeted%2520anticancer%2520agents%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2009%26volume%3D27%26spage%3D586%26epage%3D594%26doi%3D10.1007%2Fs10637-009-9236-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">Cell cycle kinases in cancer</span> <span class="citation_source-journal">Curr. Opin. Genet. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">60</span><span class="NLM_x">–</span> <span class="NLM_lpage">65</span><span class="refDoi"> DOI: 10.1016/j.gde.2006.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1016%2Fj.gde.2006.12.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=60-65&author=M.+Malumbresauthor=M.+Barbacid&title=Cell+cycle+kinases+in+cancer&doi=10.1016%2Fj.gde.2006.12.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.gde.2006.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gde.2006.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCell%2520cycle%2520kinases%2520in%2520cancer%26jtitle%3DCurr.%2520Opin.%2520Genet.%2520Dev.%26date%3D2007%26volume%3D17%26spage%3D60%26epage%3D65%26doi%3D10.1016%2Fj.gde.2006.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Li, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eksterowicz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribble, M. W.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alba, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connors, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeGraffenreid, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deignan, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duquette, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huard, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaizerman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lively, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMinn, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihalic, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pattabiraman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piper, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Queva, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ragains, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suchomel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thibault, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanska, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wehn, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weidner, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamb, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickramasinghe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGee, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, J. C.</span><span> </span><span class="NLM_article-title">Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3430</span><span class="NLM_x">–</span> <span class="NLM_lpage">3449</span><span class="refDoi"> DOI: 10.1021/jm500118j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500118j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3430-3449&author=Z.+Liauthor=X.+Wangauthor=J.+Eksterowiczauthor=M.+W.+Gribbleauthor=G.+Q.+Albaauthor=M.+Ayresauthor=T.+J.+Carlsonauthor=A.+Chenauthor=X.+Chenauthor=R.+Choauthor=R.+V.+Connorsauthor=M.+DeGraffenreidauthor=J.+T.+Deignanauthor=J.+Duquetteauthor=P.+Fanauthor=B.+Fisherauthor=J.+Fuauthor=J.+N.+Huardauthor=J.+Kaizermanauthor=K.+S.+Keeganauthor=C.+Liauthor=K.+Liauthor=Y.+Liauthor=L.+Liangauthor=W.+Liuauthor=S.+E.+Livelyauthor=M.+C.+Loauthor=J.+Maauthor=D.+L.+McMinnauthor=J.+T.+Mihalicauthor=K.+Modiauthor=R.+Ngoauthor=K.+Pattabiramanauthor=D.+E.+Piperauthor=C.+Quevaauthor=M.+L.+Ragainsauthor=J.+Suchomelauthor=S.+Thibaultauthor=N.+Walkerauthor=X.+Wangauthor=Z.+Wangauthor=M.+Wanskaauthor=P.+M.+Wehnauthor=M.+F.+Weidnerauthor=A.+J.+Zhangauthor=X.+Zhaoauthor=A.+Kambauthor=D.+Wickramasingheauthor=K.+Daiauthor=L.+R.+McGeeauthor=J.+C.+Medina&title=Discovery+of+AMG+925%2C+a+FLT3+and+CDK4+dual+kinase+inhibitor+with+preferential+affinity+for+the+activated+state+of+FLT3&doi=10.1021%2Fjm500118j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3</span></div><div class="casAuthors">Li, Zhihong; Wang, Xianghong; Eksterowicz, John; Gribble, Michael W.; Alba, Grace Q.; Ayres, Merrill; Carlson, Timothy J.; Chen, Ada; Chen, Xiaoqi; Cho, Robert; Connors, Richard V.; DeGraffenreid, Michael; Deignan, Jeffrey T.; Duquette, Jason; Fan, Pingchen; Fisher, Benjamin; Fu, Jiasheng; Huard, Justin N.; Kaizerman, Jacob; Keegan, Kathleen S.; Li, Cong; Li, Kexue; Li, Yunxiao; Liang, Lingming; Liu, Wen; Lively, Sarah E.; Lo, Mei-Chu; Ma, Ji; McMinn, Dustin L.; Mihalic, Jeffrey T.; Modi, Kriti; Ngo, Rachel; Pattabiraman, Kanaka; Piper, Derek E.; Queva, Christophe; Ragains, Mark L.; Suchomel, Julia; Thibault, Steve; Walker, Nigel; Wang, Xiaodong; Wang, Zhulun; Wanska, Malgorzata; Wehn, Paul M.; Weidner, Margaret F.; Zhang, Alex J.; Zhao, Xiaoning; Kamb, Alexander; Wickramasinghe, Dineli; Dai, Kang; McGee, Lawrence R.; Medina, Julio C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3430-3449</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The authors describe the structural optimization of a lead compd. that exhibits dual inhibitory activities against FLT3 and CDK4.  A series of pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine derivs. was synthesized, and SAR anal., using cell-based assays, led to the discovery of AMG 925 (I), a potent and orally bioavailable dual inhibitor of CDK4 and FLT3, including many FLT3 mutants reported to date.  Compd. I inhibits the proliferation of a panel of human tumor cell lines including Colo205 (Rb+) and U937 (FLT3WT) and induced cell death in MOLM13 (FLT3ITD) and even in MOLM13 (FLT3ITD, D835Y), which exhibits resistance to a no. of FLT3 inhibitors currently under clin. development.  At well-tolerated doses, compd. I leads to significant growth inhibition of MOLM13 xenografts in nude mice, and the activity correlates with inhibition of STAT5 and Rb phosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcJdjH0aU8KrVg90H21EOLACvtfcHk0lgfD0vcTJB-4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktl2itLg%253D&md5=4047a6ea068dbde57896da520fbdf0d3</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm500118j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500118j%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DGribble%26aufirst%3DM.%2BW.%26aulast%3DAlba%26aufirst%3DG.%2BQ.%26aulast%3DAyres%26aufirst%3DM.%26aulast%3DCarlson%26aufirst%3DT.%2BJ.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCho%26aufirst%3DR.%26aulast%3DConnors%26aufirst%3DR.%2BV.%26aulast%3DDeGraffenreid%26aufirst%3DM.%26aulast%3DDeignan%26aufirst%3DJ.%2BT.%26aulast%3DDuquette%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DFu%26aufirst%3DJ.%26aulast%3DHuard%26aufirst%3DJ.%2BN.%26aulast%3DKaizerman%26aufirst%3DJ.%26aulast%3DKeegan%26aufirst%3DK.%2BS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLively%26aufirst%3DS.%2BE.%26aulast%3DLo%26aufirst%3DM.%2BC.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DMcMinn%26aufirst%3DD.%2BL.%26aulast%3DMihalic%26aufirst%3DJ.%2BT.%26aulast%3DModi%26aufirst%3DK.%26aulast%3DNgo%26aufirst%3DR.%26aulast%3DPattabiraman%26aufirst%3DK.%26aulast%3DPiper%26aufirst%3DD.%2BE.%26aulast%3DQueva%26aufirst%3DC.%26aulast%3DRagains%26aufirst%3DM.%2BL.%26aulast%3DSuchomel%26aufirst%3DJ.%26aulast%3DThibault%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DWanska%26aufirst%3DM.%26aulast%3DWehn%26aufirst%3DP.%2BM.%26aulast%3DWeidner%26aufirst%3DM.%2BF.%26aulast%3DZhang%26aufirst%3DA.%2BJ.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DKamb%26aufirst%3DA.%26aulast%3DWickramasinghe%26aufirst%3DD.%26aulast%3DDai%26aufirst%3DK.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520of%2520AMG%2520925%252C%2520a%2520FLT3%2520and%2520CDK4%2520dual%2520kinase%2520inhibitor%2520with%2520preferential%2520affinity%2520for%2520the%2520activated%2520state%2520of%2520FLT3%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3430%26epage%3D3449%26doi%3D10.1021%2Fjm500118j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Rosnet, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bühring, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchetto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rappold, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lavagna, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sainty, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnoulet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chabannon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanz, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannum, C.</span><span> </span><span class="NLM_article-title">Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">238</span><span class="NLM_x">–</span> <span class="NLM_lpage">248</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1996&pages=238-248&author=O.+Rosnetauthor=H.+J.+B%C3%BChringauthor=S.+Marchettoauthor=I.+Rappoldauthor=C.+Lavagnaauthor=D.+Saintyauthor=C.+Arnouletauthor=C.+Chabannonauthor=L.+Kanzauthor=C.+Hannum&title=Human+FLT3%2FFLK2+receptor+tyrosine+kinase+is+expressed+at+the+surface+of+normal+and+malignant+hematopoietic+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRosnet%26aufirst%3DO.%26aulast%3DB%25C3%25BChring%26aufirst%3DH.%2BJ.%26aulast%3DMarchetto%26aufirst%3DS.%26aulast%3DRappold%26aufirst%3DI.%26aulast%3DLavagna%26aufirst%3DC.%26aulast%3DSainty%26aufirst%3DD.%26aulast%3DArnoulet%26aufirst%3DC.%26aulast%3DChabannon%26aufirst%3DC.%26aulast%3DKanz%26aufirst%3DL.%26aulast%3DHannum%26aufirst%3DC.%26atitle%3DHuman%2520FLT3%252FFLK2%2520receptor%2520tyrosine%2520kinase%2520is%2520expressed%2520at%2520the%2520surface%2520of%2520normal%2520and%2520malignant%2520hematopoietic%2520cells%26jtitle%3DLeukemia%26date%3D1996%26volume%3D10%26spage%3D238%26epage%3D248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Drexler, H. G.</span><span> </span><span class="NLM_article-title">Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">845</span><span class="NLM_x">–</span> <span class="NLM_lpage">859</span><span class="refDoi"> DOI: 10.1038/sj.leu.2401043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1038%2Fsj.leu.2401043" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1998&pages=845-859&author=H.+G.+Drexler&title=Review+of+alterations+of+the+cyclin-dependent+kinase+inhibitor+INK4+family+genes+p15%2C+p16%2C+p18+and+p19+in+human+leukemia-lymphoma+cells&doi=10.1038%2Fsj.leu.2401043"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fsj.leu.2401043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.leu.2401043%26sid%3Dliteratum%253Aachs%26aulast%3DDrexler%26aufirst%3DH.%2BG.%26atitle%3DReview%2520of%2520alterations%2520of%2520the%2520cyclin-dependent%2520kinase%2520inhibitor%2520INK4%2520family%2520genes%2520p15%252C%2520p16%252C%2520p18%2520and%2520p19%2520in%2520human%2520leukemia-lymphoma%2520cells%26jtitle%3DLeukemia%26date%3D1998%26volume%3D12%26spage%3D845%26epage%3D859%26doi%3D10.1038%2Fsj.leu.2401043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Estey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Döhner, H.</span><span> </span><span class="NLM_article-title">Acute myeloid leukaemia</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x">, </span> <span class="NLM_fpage">1894</span><span class="NLM_x">–</span> <span class="NLM_lpage">1907</span><span class="refDoi"> DOI: 10.1016/S0140-6736(06)69780-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1016%2FS0140-6736%2806%2969780-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=17126723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A280%3ADC%252BD28novFKitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2006&pages=1894-1907&author=E.+Esteyauthor=H.+D%C3%B6hner&title=Acute+myeloid+leukaemia&doi=10.1016%2FS0140-6736%2806%2969780-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Acute myeloid leukaemia</span></div><div class="casAuthors">Estey Elihu; Dohner Hartmut</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">9550</span>),
    <span class="NLM_cas:pages">1894-907</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haemopoietic progenitor cells and the most common malignant myeloid disorder in adults.  The median age at presentation for patients with AML is 70 years.  In the past few years, research in molecular biology has been instrumental in deciphering the pathogenesis of the disease.  Genetic defects are thought to be the most important factors in determining the response to chemotherapy and outcome.  Whereas significant progress has been made in the treatment of younger adults, the prospects for elderly patients have remained dismal, with median survival times of only a few months.  This difference is related to comorbidities associated with ageing and to disease biology.  Current efforts in clinical research focus on the assessment of targeted therapies.  Such new approaches will probably lead to an increase in the cure rate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS2ttizzpYcl3p3bfzSLaX5fW6udTcc2ebW70K99ygwh7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28novFKitw%253D%253D&md5=d4b1be3bbc0a3793e687ee30cfe1ba56</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2806%2969780-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252806%252969780-8%26sid%3Dliteratum%253Aachs%26aulast%3DEstey%26aufirst%3DE.%26aulast%3DD%25C3%25B6hner%26aufirst%3DH.%26atitle%3DAcute%2520myeloid%2520leukaemia%26jtitle%3DLancet%26date%3D2006%26volume%3D368%26spage%3D1894%26epage%3D1907%26doi%3D10.1016%2FS0140-6736%2806%2969780-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Kindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipka, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, T.</span><span> </span><span class="NLM_article-title">FLT3 as a therapeutic target in AML: still challenging after all these years</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">5089</span><span class="NLM_x">–</span> <span class="NLM_lpage">5102</span><span class="refDoi"> DOI: 10.1182/blood-2010-04-261867</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1182%2Fblood-2010-04-261867" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=20705759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotV0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=5089-5102&author=T.+Kindlerauthor=D.+B.+Lipkaauthor=T.+Fischer&title=FLT3+as+a+therapeutic+target+in+AML%3A+still+challenging+after+all+these+years&doi=10.1182%2Fblood-2010-04-261867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">FLT3 as a therapeutic target in AML: still challenging after all these years</span></div><div class="casAuthors">Kindler, Thomas; Lipka, Daniel B.; Fischer, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5089-5102</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Mutations within the FMS-like tyrosine kinase 3 (FLT3) gene on chromosome 13q12 have been detected in up to 35% of acute myeloid leukemia (AML) patients and represent one of the most frequently identified genetic alterations in AML.  Over the last years, FLT3 has emerged as a promising mol. target in therapy of AML.  Here, we review results of clin. trials and of correlative lab. studies using small mol. FLT3 tyrosine kinase inhibitors (TKIs) in AML patients.  We also review mechanisms of primary and secondary drug resistance to FLT3-TKI, and from the data currently available we summarize lessons learned from FLT3-TKI monotherapy.  Finally, for using FLT3 as a mol. target, we discuss novel strategies to overcome treatment failure and to improve FLT3 inhibitor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR_j_VWZ2CirVg90H21EOLACvtfcHk0ljPNCuhcjAyFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotV0%253D&md5=131b2a645450c17defcb63a7be4262c9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1182%2Fblood-2010-04-261867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2010-04-261867%26sid%3Dliteratum%253Aachs%26aulast%3DKindler%26aufirst%3DT.%26aulast%3DLipka%26aufirst%3DD.%2BB.%26aulast%3DFischer%26aufirst%3DT.%26atitle%3DFLT3%2520as%2520a%2520therapeutic%2520target%2520in%2520AML%253A%2520still%2520challenging%2520after%2520all%2520these%2520years%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26spage%3D5089%26epage%3D5102%26doi%3D10.1182%2Fblood-2010-04-261867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Bavetsias, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crumpler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avery, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atrash, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faisal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosmopoulou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheldrake, P. W.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">8721</span><span class="NLM_x">–</span> <span class="NLM_lpage">8734</span><span class="refDoi"> DOI: 10.1021/jm300952s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300952s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8721-8734&author=V.+Bavetsiasauthor=S.+Crumplerauthor=C.+Sunauthor=S.+Averyauthor=B.+Atrashauthor=A.+Faisalauthor=A.+Mooreauthor=M.+Kosmopoulouauthor=N.+Brownauthor=P.+W.+Sheldrake&title=Optimization+of+imidazo%5B4%2C5-b%5Dpyridine-based+kinase+inhibitors%3A+identification+of+a+dual+FLT3%2FAurora+kinase+inhibitor+as+an+orally+bioavailable+preclinical+development+candidate+for+the+treatment+of+acute+myeloid+leukemia&doi=10.1021%2Fjm300952s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm300952s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300952s%26sid%3Dliteratum%253Aachs%26aulast%3DBavetsias%26aufirst%3DV.%26aulast%3DCrumpler%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DAvery%26aufirst%3DS.%26aulast%3DAtrash%26aufirst%3DB.%26aulast%3DFaisal%26aufirst%3DA.%26aulast%3DMoore%26aufirst%3DA.%26aulast%3DKosmopoulou%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DN.%26aulast%3DSheldrake%26aufirst%3DP.%2BW.%26atitle%3DOptimization%2520of%2520imidazo%255B4%252C5-b%255Dpyridine-based%2520kinase%2520inhibitors%253A%2520identification%2520of%2520a%2520dual%2520FLT3%252FAurora%2520kinase%2520inhibitor%2520as%2520an%2520orally%2520bioavailable%2520preclinical%2520development%2520candidate%2520for%2520the%2520treatment%2520of%2520acute%2520myeloid%2520leukemia%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8721%26epage%3D8734%26doi%3D10.1021%2Fjm300952s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Heathcote, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroll, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Periyasamy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alikian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanneganti, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jogalekar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheiper, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbazanges, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blum, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brackow, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siwicka, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pace, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuchter, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liotta, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freemont, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aboagye, E. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coombes, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, S.</span><span> </span><span class="NLM_article-title">A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8508</span><span class="NLM_x">–</span> <span class="NLM_lpage">8522</span><span class="refDoi"> DOI: 10.1021/jm100732t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100732t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8508-8522&author=D.+A.+Heathcoteauthor=H.+Patelauthor=S.+H.+Krollauthor=P.+Hazelauthor=M.+Periyasamyauthor=M.+Alikianauthor=S.+K.+Kannegantiauthor=A.+S.+Jogalekarauthor=B.+Scheiperauthor=M.+Barbazangesauthor=A.+Blumauthor=J.+Brackowauthor=A.+Siwickaauthor=R.+D.+Paceauthor=M.+J.+Fuchterauthor=J.+P.+Snyderauthor=D.+C.+Liottaauthor=P.+S.+Freemontauthor=E.+O.+Aboagyeauthor=R.+C.+Coombesauthor=A.+G.+Barrettauthor=S.+Ali&title=A+novel+pyrazolo%5B1%2C5-a%5Dpyrimidine+is+a+potent+inhibitor+of+cyclin-dependent+protein+kinases+1%2C+2%2C+and+9%2C+which+demonstrates+antitumor+effects+in+human+tumor+xenografts+following+oral+administration&doi=10.1021%2Fjm100732t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Pyrazolo[1,5-a]pyrimidine is a Potent Inhibitor of Cyclin-Dependent Protein Kinases 1, 2, and 9, Which Demonstrates Antitumor Effects in Human Tumor Xenografts Following Oral Administration</span></div><div class="casAuthors">Heathcote, Dean A.; Patel, Hetal; Kroll, Sebastian H. B.; Hazel, Pascale; Periyasamy, Manikandan; Alikian, Mary; Kanneganti, Seshu K.; Jogalekar, Ashutosh S.; Scheiper, Bodo; Barbazanges, Marion; Blum, Andreas; Brackow, Jan; Siwicka, Alekasandra; Pace, Robert D. M.; Fuchter, Matthew J.; Snyder, James P.; Liotta, Dennis C.; Freemont, Paul. S.; Aboagye, Eric O.; Coombes, R. Charles; Barrett, Anthony G. M.; Ali, Simak</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8508-8522</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent protein kinases (CDKs) are central to the appropriate regulation of cell proliferation, apoptosis, and gene expression.  Abnormalities in CDK activity and regulation are common features of cancer, making CDK family members attractive targets for the development of anticancer drugs.  Here, we report the identification of a pyrazolo[1,5-a]pyrimidine derived compd., 4k (BS-194, I), as a selective and potent CDK inhibitor, which inhibits CDK2, CDK1, CDK5, CDK7, and CDK9 (IC50 = 3, 30, 30, 250, and 90 nmol/L, resp.).  Cell-based studies showed inhibition of the phosphorylation of CDK substrates, Rb and the RNA polymerase II C-terminal domain, down-regulation of cyclins A, E, and D1, and cell cycle block in the S and G2/M phases.  Consistent with these findings, 4k demonstrated potent antiproliferative activity in 60 cancer cell lines tested (mean GI50 = 280 nmol/L).  Pharmacokinetic studies showed that 4k is orally bioavailable, with an elimination half-life of 178 min following oral dosing in mice.  When administered at a concn. of 25 mg/kg orally, 4k inhibited human tumor xenografts and suppressed CDK substrate phosphorylation.  These findings identify 4k as a novel, potent CDK selective inhibitor with potential for oral delivery in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUJPhLKEWwBLVg90H21EOLACvtfcHk0lgMw9bTregoGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL%252FJ&md5=b84f41ab0cbf298a9ac248bc0a9d0d73</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm100732t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100732t%26sid%3Dliteratum%253Aachs%26aulast%3DHeathcote%26aufirst%3DD.%2BA.%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DKroll%26aufirst%3DS.%2BH.%26aulast%3DHazel%26aufirst%3DP.%26aulast%3DPeriyasamy%26aufirst%3DM.%26aulast%3DAlikian%26aufirst%3DM.%26aulast%3DKanneganti%26aufirst%3DS.%2BK.%26aulast%3DJogalekar%26aufirst%3DA.%2BS.%26aulast%3DScheiper%26aufirst%3DB.%26aulast%3DBarbazanges%26aufirst%3DM.%26aulast%3DBlum%26aufirst%3DA.%26aulast%3DBrackow%26aufirst%3DJ.%26aulast%3DSiwicka%26aufirst%3DA.%26aulast%3DPace%26aufirst%3DR.%2BD.%26aulast%3DFuchter%26aufirst%3DM.%2BJ.%26aulast%3DSnyder%26aufirst%3DJ.%2BP.%26aulast%3DLiotta%26aufirst%3DD.%2BC.%26aulast%3DFreemont%26aufirst%3DP.%2BS.%26aulast%3DAboagye%26aufirst%3DE.%2BO.%26aulast%3DCoombes%26aufirst%3DR.%2BC.%26aulast%3DBarrett%26aufirst%3DA.%2BG.%26aulast%3DAli%26aufirst%3DS.%26atitle%3DA%2520novel%2520pyrazolo%255B1%252C5-a%255Dpyrimidine%2520is%2520a%2520potent%2520inhibitor%2520of%2520cyclin-dependent%2520protein%2520kinases%25201%252C%25202%252C%2520and%25209%252C%2520which%2520demonstrates%2520antitumor%2520effects%2520in%2520human%2520tumor%2520xenografts%2520following%2520oral%2520administration%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8508%26epage%3D8522%26doi%3D10.1021%2Fjm100732t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Wyatt, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodhead, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulstridge, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devine, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Early, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltell, R. E.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Identification of N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-Ray crystallography and structure based drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4986</span><span class="NLM_x">–</span> <span class="NLM_lpage">4999</span><span class="refDoi"> DOI: 10.1021/jm800382h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800382h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4986-4999&author=P.+G.+Wyattauthor=A.+J.+Woodheadauthor=V.+Berdiniauthor=J.+A.+Boulstridgeauthor=M.+G.+Carrauthor=D.+M.+Crossauthor=D.+J.+Davisauthor=L.+A.+Devineauthor=T.+R.+Earlyauthor=R.+E.+Feltell&title=Identification+of+N-%284-Piperidinyl%29-4-%282%2C6-dichlorobenzoylamino%29-1H-pyrazole-3-carboxamide+%28AT7519%29%2C+a+novel+cyclin+dependent+kinase+inhibitor+using+fragment-based+X-Ray+crystallography+and+structure+based+drug+design&doi=10.1021%2Fjm800382h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm800382h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800382h%26sid%3Dliteratum%253Aachs%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DBoulstridge%26aufirst%3DJ.%2BA.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DCross%26aufirst%3DD.%2BM.%26aulast%3DDavis%26aufirst%3DD.%2BJ.%26aulast%3DDevine%26aufirst%3DL.%2BA.%26aulast%3DEarly%26aufirst%3DT.%2BR.%26aulast%3DFeltell%26aufirst%3DR.%2BE.%26atitle%3DIdentification%2520of%2520N-%25284-Piperidinyl%2529-4-%25282%252C6-dichlorobenzoylamino%2529-1H-pyrazole-3-carboxamide%2520%2528AT7519%2529%252C%2520a%2520novel%2520cyclin%2520dependent%2520kinase%2520inhibitor%2520using%2520fragment-based%2520X-Ray%2520crystallography%2520and%2520structure%2520based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4986%26epage%3D4999%26doi%3D10.1021%2Fjm800382h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Flynn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andritsos, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maddocks, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaglowski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hessler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grever, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Im, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1524</span><span class="NLM_x">–</span> <span class="NLM_lpage">1529</span><span class="refDoi"> DOI: 10.1038/leu.2015.31</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1038%2Fleu.2015.31" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=25708835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsFersrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=1524-1529&author=J.+Flynnauthor=J.+Jonesauthor=A.+J.+Johnsonauthor=L.+Andritsosauthor=K.+Maddocksauthor=S.+Jaglowskiauthor=J.+Hesslerauthor=M.+R.+Greverauthor=E.+Imauthor=H.+Zhou&title=Dinaciclib+is+a+novel+cyclin-dependent+kinase+inhibitor+with+significant+clinical+activity+in+relapsed+and+refractory+chronic+lymphocytic+leukemia&doi=10.1038%2Fleu.2015.31"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia</span></div><div class="casAuthors">Flynn, J.; Jones, J.; Johnson, A. J.; Andritsos, L.; Maddocks, K.; Jaglowski, S.; Hessler, J.; Grever, M. R.; Im, E.; Zhou, H.; Zhu, Y.; Zhang, D.; Small, K.; Bannerji, R.; Byrd, J. C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1524-1529</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Dinaciclib (SCH727965) is a selective CDKi chosen for clin. development based upon a favorable therapeutic index in cancer xenograft models.  We performed a phase I dose escalation study of dinaciclib in relapsed and refractory chronic lymphocytic leukemia (CLL) patients with intact organ function and WBC<200 × 109 /l.  Five sep. dose levels (5 mg/m2, 7 mg/m2, 10 mg/m2, 14 mg/m2 and 17 mg/m2) were explored dosing on a weekly schedule × 3 with 1 wk off (4-wk cycles) using a std. 3+3 design with expansion cohorts to optimize safety.  Fifty-two patients were enrolled with relapsed and refractory CLL.  Escalation through cohorts occurred with two dose-limiting toxicity (DLTs) at the 17 mg/m2 dose (tumor lysis syndrome (TLS) and pneumonia).  The phase II expansion occurred at 14 mg/m2 with 16 patients receiving this dose with one DLT (TLS).  Addnl. stepped up dosing to the max. tolerated dose was examd. in 19 patients at this dose.  Adverse events included cytopenias, transient lab. abnormalities and TLS.  Responses occurred in 28 (54%) of patients independent of del(17)(p13.1) with a median progression-free survival of 481 days.  Dinaciclib is clin. active in relapsed CLL including those patients with high risk del(17)(p13.1) disease and warrants future study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY8zLFNmk5-bVg90H21EOLACvtfcHk0lgjkWYRy-vNaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsFersrY%253D&md5=5f53b49e419f68563500fee211221c29</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.31%26sid%3Dliteratum%253Aachs%26aulast%3DFlynn%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DAndritsos%26aufirst%3DL.%26aulast%3DMaddocks%26aufirst%3DK.%26aulast%3DJaglowski%26aufirst%3DS.%26aulast%3DHessler%26aufirst%3DJ.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DIm%26aufirst%3DE.%26aulast%3DZhou%26aufirst%3DH.%26atitle%3DDinaciclib%2520is%2520a%2520novel%2520cyclin-dependent%2520kinase%2520inhibitor%2520with%2520significant%2520clinical%2520activity%2520in%2520relapsed%2520and%2520refractory%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DLeukemia%26date%3D2015%26volume%3D29%26spage%3D1524%26epage%3D1529%26doi%3D10.1038%2Fleu.2015.31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Patel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senderowicz, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinto, D.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Igishi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raffeld, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quintanilla-Martinez, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ensley, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sausville, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutkind, J. S.</span><span> </span><span class="NLM_article-title">Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">1674</span><span class="NLM_x">–</span> <span class="NLM_lpage">1681</span><span class="refDoi"> DOI: 10.1172/JCI3661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1172%2FJCI3661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=9802881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADyaK1cXnt1Oqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1998&pages=1674-1681&author=V.+Patelauthor=A.+M.+Senderowiczauthor=D.+Pintoauthor=T.+Igishiauthor=M.+Raffeldauthor=L.+Quintanilla-Martinezauthor=J.+F.+Ensleyauthor=E.+A.+Sausvilleauthor=J.+S.+Gutkind&title=Flavopiridol%2C+a+novel+cyclin-dependent+kinase+inhibitor%2C+suppresses+the+growth+of+head+and+neck+squamous+cell+carcinomas+by+inducing+apoptosis&doi=10.1172%2FJCI3661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis</span></div><div class="casAuthors">Patel, Vyomesh; Senderowicz, Adrian M.; Pinto, Decio, Jr.; Igishi, Tadashi; Raffeld, Mark; Quintanilla-Martinez, Leticia; Ensley, John F.; Sausville, Edward A.; Gutkind, J. Silvio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1674-1681</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Flavopiridol (HMR 1275) has been identified recently as a novel antineoplastic agent in the primary screen conducted by the Developmental Therapeutics Program, National Cancer Institute.  Flavopiridol inhibits most cyclin-dependent kinases (cdks) and displays unique anticancer properties.  Here, we investigated whether this compd. was effective against head and neck squamous cell carcinomas (HNSCC).  Exposure of HNSCC cells to flavopiridol diminished cdc2 and cdk2 activity and potently inhibited cell proliferation (IC50 43-83 nM), which was concomitant with the appearance of cells with a sub-G1 DNA content.  Moreover, DNA fragmentation and TUNEL (terminal deoxynucleotidyl transferase-mediated nick end labeling) reaction confirmed that flavopiridol induces apoptosis in all cell lines, even on certain HNSCC cells that are insensitive to apoptosis to DNA-damaging agents (γ-irradn. and bleomycin).  A tumorigenic HNSCC cell line was used to assess the effect of flavopiridol in vivo.  Treatment (5 mg/kg per day, i.p.) for 5 d led to the appearance of apoptotic cells in the tumor xenografts and caused a 60-70% redn. in tumor size, which was sustained over a period of 10 wk.  Flavopiridol treatment also resulted in a remarkable redn. of cyclin D1 expression in HNSCC cells and tumor xenografts.  Our data indicate that flavopiridol exerts antitumor activity in HNSCC, and thus it can be considered a suitable candidate drug for testing in the treatment of refractory carcinomas of the head and neck.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-lF748dX347Vg90H21EOLACvtfcHk0lgjkWYRy-vNaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnt1Oqtrc%253D&md5=549f97c62f21c1b194856d237823a2b7</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1172%2FJCI3661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI3661%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DV.%26aulast%3DSenderowicz%26aufirst%3DA.%2BM.%26aulast%3DPinto%26aufirst%3DD.%26aulast%3DIgishi%26aufirst%3DT.%26aulast%3DRaffeld%26aufirst%3DM.%26aulast%3DQuintanilla-Martinez%26aufirst%3DL.%26aulast%3DEnsley%26aufirst%3DJ.%2BF.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DGutkind%26aufirst%3DJ.%2BS.%26atitle%3DFlavopiridol%252C%2520a%2520novel%2520cyclin-dependent%2520kinase%2520inhibitor%252C%2520suppresses%2520the%2520growth%2520of%2520head%2520and%2520neck%2520squamous%2520cell%2520carcinomas%2520by%2520inducing%2520apoptosis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1998%26volume%3D102%26spage%3D1674%26epage%3D1681%26doi%3D10.1172%2FJCI3661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novotnydiermayr, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheong, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">236</span><span class="NLM_x">–</span> <span class="NLM_lpage">243</span><span class="refDoi"> DOI: 10.1038/leu.2011.218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1038%2Fleu.2011.218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=21860433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFGgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=236-243&author=K.+C.+Gohauthor=V.+Novotnydiermayrauthor=S.+Hartauthor=L.+C.+Ongauthor=Y.+K.+Lohauthor=A.+Cheongauthor=Y.+C.+Tanauthor=C.+Huauthor=R.+Jayaramanauthor=A.+D.+William&title=TG02%2C+a+novel+oral+multi-kinase+inhibitor+of+CDKs%2C+JAK2+and+FLT3+with+potent+anti-leukemic+properties&doi=10.1038%2Fleu.2011.218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties</span></div><div class="casAuthors">Goh, K. C.; Novotny-Diermayr, V.; Hart, S.; Ong, L. C.; Loh, Y. K.; Cheong, A.; Tan, Y. C.; Hu, C.; Jayaraman, R.; William, A. D.; Sun, E. T.; Dymock, B. W.; Ong, K. H.; Ethirajulu, K.; Burrows, F.; Wood, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-243</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3.  It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs.  TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis.  Primary cultures of progenitor cells derived from acute myeloid leukemia (AML) and polycythemia vera patients are very sensitive to TG02.  Comparison with ref. inhibitors that block only one of the main targets of TG02 demonstrate the benefit of combined CDK and JAK2/FLT3 inhibition in cell lines as well as primary cells.  In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling.  TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60).  These data demonstrate that TG02 is active in various models of leukemia and provide a rationale for the ongoing clin. evaluation of TG02 in patients with advanced leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMelEE91r_BrVg90H21EOLACvtfcHk0lhB8RQZQg_4GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFGgtLc%253D&md5=30af7dc302f9c421924b5b0062e82655</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.218%26sid%3Dliteratum%253Aachs%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DNovotnydiermayr%26aufirst%3DV.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DOng%26aufirst%3DL.%2BC.%26aulast%3DLoh%26aufirst%3DY.%2BK.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DTan%26aufirst%3DY.%2BC.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26atitle%3DTG02%252C%2520a%2520novel%2520oral%2520multi-kinase%2520inhibitor%2520of%2520CDKs%252C%2520JAK2%2520and%2520FLT3%2520with%2520potent%2520anti-leukemic%2520properties%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26spage%3D236%26epage%3D243%26doi%3D10.1038%2Fleu.2011.218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Joshi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rathos, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahajan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenoy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatia, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chile, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sivakumar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiebig, H.-H.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">P276–00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">926</span><span class="NLM_x">–</span> <span class="NLM_lpage">934</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1158%2F1535-7163.MCT-06-0614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=17363487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2nur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=926-934&author=K.+Joshiauthor=M.+J.+Rathosauthor=P.+Mahajanauthor=V.+Waghauthor=S.+Shenoyauthor=D.+Bhatiaauthor=S.+Chileauthor=M.+Sivakumarauthor=A.+Maierauthor=H.-H.+Fiebig&title=P276%E2%80%9300%2C+a+novel+cyclin-dependent+inhibitor+induces+G1-G2+arrest%2C+shows+antitumor+activity+on+cisplatin-resistant+cells+and+significant+in+vivo+efficacy+in+tumor+models&doi=10.1158%2F1535-7163.MCT-06-0614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models</span></div><div class="casAuthors">Joshi, Kalpana S.; Rathos, Maggie J.; Mahajan, Pravin; Wagh, Vilas; Shenoy, Satyendra; Bhatia, Dimple; Chile, Shailaja; Sivakumar, Meenakshi; Maier, Armin; Fiebig, Heinz-Herbert; Sharma, Somesh</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">926-934</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">P276-00, a flavone that inhibits cyclin-dependent kinases, has been identified by us recently as a novel antineoplastic agent.  In this study, we have selected a panel of human tumor cell lines and xenografts to allow detn. of selectivity and efficacy of P276-00.  When tested against a panel of 16 cisplatin-sensitive and cisplatin-resistant cell lines, the antiproliferative potential of P276-00 was found to be ∼30-fold higher than cisplatin.  Studies to show tumor sensitivity using clonogenic assay in 22 human xenografts indicated that P276-00 was ∼26-fold more potent than cisplatin, and further, it was also found to be active against cisplatin-resistant tumors of central nervous system, melanoma, prostate, and renal cancers.  Further, we studied the effects of P276-00 on cell cycle progression by flow cytometry using asynchronous and synchronous population of tumor and normal cells.  Asynchronous population of human prostate carcinoma (PC-3) and human promyelocytic leukemia (HL-60) cells when exposed to P276-00 showed arrest of slow-growing PC-3 cells in G2-M with no significant apoptosis obsd. up to 72 h.  Unlike PC-3, significant apoptosis was seen in fast-growing HL-60 cells at 6 h.  However, synchronized human non-small cell lung carcinoma (H-460) and human normal lung fibroblast (WI-38) cells showed arrest of cells in G1.  H-460 cells undergo apoptosis, which increases with longer exposure to the compd. and also after exposure to P276-00 for 48 h followed by recovery.  In contrast, the normal cells (WI-38) remain arrested in G1 with no significant apoptosis up to 72 h of exposure and also after 48 h of P276-00 treatment followed by recovery, confirming our previous results that P276-00 was less effective against normal cells compared with cancer cells.  After promising in vitro results, P276-00 was checked for in vivo efficacy in murine tumor and human xenograft models.  Growth inhibition of murine colon cancer (CA-51) was significant when P276-00 was administered i.p. at 50 mg/kg daily for 20 treatments.  However, in murine lung carcinoma model (Lewis lung), an increased dose of 60 mg/kg (30 mg/kg twice daily) administered every alternate day i.p. for seven treatments showed significant inhibition in the growth.  Further studies were undertaken to establish the efficacy profile of P276-00 in human tumor xenograft models.  In the two xenograft models studied, P276-00 showed potent in vivo antitumor potential.  Compd. P276-00 at a dose of 35 mg/kg administered daily via the i.p. route for 10 days showed significant (P < 0.05) inhibition in the growth of human colon carcinoma HCT-116 xenograft.  Furthermore, P276-00 at a dose of 50 mg/kg once daily and 30 mg/kg twice daily administered via i.p. route for 20 treatments significantly (P < 0.05) inhibited growth of human non-small cell lung carcinoma H-460 xenograft.  Thus, the in vitro cellular potency, together with in vivo antitumor activity, confirms the potential of P276-00, a cyclin-dependent kinase inhibitor as an anticancer mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogJ_J7_PmrDrVg90H21EOLACvtfcHk0lhB8RQZQg_4GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2nur4%253D&md5=04e65ada85eb38521909544a4e16a739</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0614%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DK.%26aulast%3DRathos%26aufirst%3DM.%2BJ.%26aulast%3DMahajan%26aufirst%3DP.%26aulast%3DWagh%26aufirst%3DV.%26aulast%3DShenoy%26aufirst%3DS.%26aulast%3DBhatia%26aufirst%3DD.%26aulast%3DChile%26aufirst%3DS.%26aulast%3DSivakumar%26aufirst%3DM.%26aulast%3DMaier%26aufirst%3DA.%26aulast%3DFiebig%26aufirst%3DH.-H.%26atitle%3DP276%25E2%2580%259300%252C%2520a%2520novel%2520cyclin-dependent%2520inhibitor%2520induces%2520G1-G2%2520arrest%252C%2520shows%2520antitumor%2520activity%2520on%2520cisplatin-resistant%2520cells%2520and%2520significant%2520in%2520vivo%2520efficacy%2520in%2520tumor%2520models%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D926%26epage%3D934%26doi%3D10.1158%2F1535-7163.MCT-06-0614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Toogood, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repine, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanderWel, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodfuehrer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barvian, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2388</span><span class="NLM_x">–</span> <span class="NLM_lpage">2406</span><span class="refDoi"> DOI: 10.1021/jm049354h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049354h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2388-2406&author=P.+L.+Toogoodauthor=P.+J.+Harveyauthor=J.+T.+Repineauthor=D.+J.+Sheehanauthor=S.+N.+VanderWelauthor=H.+Zhouauthor=P.+R.+Kellerauthor=D.+J.+McNamaraauthor=D.+Sherryauthor=T.+Zhuauthor=J.+Brodfuehrerauthor=C.+Choiauthor=M.+R.+Barvianauthor=D.+W.+Fry&title=Discovery+of+a+potent+and+selective+inhibitor+of+cyclin-dependent+kinase+4%2F6&doi=10.1021%2Fjm049354h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6</span></div><div class="casAuthors">Toogood, Peter L.; Harvey, Patricia J.; Repine, Joseph T.; Sheehan, Derek J.; VanderWel, Scott N.; Zhou, Hairong; Keller, Paul R.; McNamara, Dennis J.; Sherry, Debra; Zhu, Tong; Brodfuehrer, Joanne; Choi, Chung; Barvian, Mark R.; Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2388-2406</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A pharmacol. approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small mol. inhibitors has the potential to provide novel cancer therapies for clin. use.  Achieving high levels of selectivity for Cdk4/6, vs. other ATP-dependent kinases, presents a significant challenge.  The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks.  It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro.  This selectivity profile is recapitulated in cells where the most selective inhibitors create a G1 block at concns. up to 100-fold the IC50 for cell proliferation.  On the basis of its selectivity profile and pharmacokinetic profile, compd. I (PD 0332991) was identified as a drug candidate for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX577J5U0r97Vg90H21EOLACvtfcHk0lhvolXOnP00ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D&md5=23cbe58426ff1975695712db7c1b128a</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm049354h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049354h%26sid%3Dliteratum%253Aachs%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DRepine%26aufirst%3DJ.%2BT.%26aulast%3DSheehan%26aufirst%3DD.%2BJ.%26aulast%3DVanderWel%26aufirst%3DS.%2BN.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DSherry%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520cyclin-dependent%2520kinase%25204%252F6%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2388%26epage%3D2406%26doi%3D10.1021%2Fjm049354h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Infante, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witteveen, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerecitano, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribrag, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chugh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakraborty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parasuraman, S.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Abstract A276: Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">A276</span><span class="refDoi"> DOI: 10.1158/1535-7163.TARG-13-A276</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1158%2F1535-7163.TARG-13-A276" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=A276&author=J.+R.+Infanteauthor=G.+I.+Shapiroauthor=P.+O.+Witteveenauthor=J.+F.+Gerecitanoauthor=V.+Ribragauthor=R.+Chughauthor=A.+Chakrabortyauthor=A.+Matanoauthor=X.+Zhaoauthor=S.+Parasuraman&title=Abstract+A276%3A+Phase+1+multicenter%2C+open+label%2C+dose-escalation+study+of+LEE011%2C+an+oral+inhibitor+of+cyclin-dependent+kinase+4%2F6%2C+in+patients+with+advanced+solid+tumors+or+lymphomas&doi=10.1158%2F1535-7163.TARG-13-A276"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.TARG-13-A276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.TARG-13-A276%26sid%3Dliteratum%253Aachs%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DWitteveen%26aufirst%3DP.%2BO.%26aulast%3DGerecitano%26aufirst%3DJ.%2BF.%26aulast%3DRibrag%26aufirst%3DV.%26aulast%3DChugh%26aufirst%3DR.%26aulast%3DChakraborty%26aufirst%3DA.%26aulast%3DMatano%26aufirst%3DA.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DParasuraman%26aufirst%3DS.%26atitle%3DAbstract%2520A276%253A%2520Phase%25201%2520multicenter%252C%2520open%2520label%252C%2520dose-escalation%2520study%2520of%2520LEE011%252C%2520an%2520oral%2520inhibitor%2520of%2520cyclin-dependent%2520kinase%25204%252F6%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%2520or%2520lymphomas%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3DA276%26doi%3D10.1158%2F1535-7163.TARG-13-A276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Sanchezmartinez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gelbert, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shannon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Dios, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staton, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ajamie, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawada, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishart, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raub, T. J.</span><span> </span><span class="NLM_article-title">Abstract B234: LY2835219, a potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) that crosses the blood-brain barrier and demonstrates in vivo activity against intracranial human brain tumor xenografts</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">B234</span><span class="refDoi"> DOI: 10.1158/1535-7163.TARG-11-B234</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1158%2F1535-7163.TARG-11-B234" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=B234&author=C.+Sanchezmartinezauthor=L.+M.+Gelbertauthor=H.+Shannonauthor=A.+De+Diosauthor=B.+A.+Statonauthor=R.+T.+Ajamieauthor=G.+Sawadaauthor=G.+N.+Wishartauthor=T.+J.+Raub&title=Abstract+B234%3A+LY2835219%2C+a+potent+oral+inhibitor+of+the+cyclin-dependent+kinases+4+and+6+%28CDK4%2F6%29+that+crosses+the+blood-brain+barrier+and+demonstrates+in+vivo+activity+against+intracranial+human+brain+tumor+xenografts&doi=10.1158%2F1535-7163.TARG-11-B234"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.TARG-11-B234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.TARG-11-B234%26sid%3Dliteratum%253Aachs%26aulast%3DSanchezmartinez%26aufirst%3DC.%26aulast%3DGelbert%26aufirst%3DL.%2BM.%26aulast%3DShannon%26aufirst%3DH.%26aulast%3DDe%2BDios%26aufirst%3DA.%26aulast%3DStaton%26aufirst%3DB.%2BA.%26aulast%3DAjamie%26aufirst%3DR.%2BT.%26aulast%3DSawada%26aufirst%3DG.%26aulast%3DWishart%26aufirst%3DG.%2BN.%26aulast%3DRaub%26aufirst%3DT.%2BJ.%26atitle%3DAbstract%2520B234%253A%2520LY2835219%252C%2520a%2520potent%2520oral%2520inhibitor%2520of%2520the%2520cyclin-dependent%2520kinases%25204%2520and%25206%2520%2528CDK4%252F6%2529%2520that%2520crosses%2520the%2520blood-brain%2520barrier%2520and%2520demonstrates%2520in%2520vivo%2520activity%2520against%2520intracranial%2520human%2520brain%2520tumor%2520xenografts%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3DB234%26doi%3D10.1158%2F1535-7163.TARG-11-B234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Cicenas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalyan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorokinas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jatulyte, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valiunas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaupinis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valius, M.</span><span> </span><span class="NLM_article-title">Highlights of the latest advances in research on CDK inhibitors</span> <span class="citation_source-journal">Cancers</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">2224</span><span class="NLM_x">–</span> <span class="NLM_lpage">2242</span><span class="refDoi"> DOI: 10.3390/cancers6042224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.3390%2Fcancers6042224" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=2224-2242&author=J.+Cicenasauthor=K.+Kalyanauthor=A.+Sorokinasauthor=A.+Jatulyteauthor=D.+Valiunasauthor=A.+Kaupinisauthor=M.+Valius&title=Highlights+of+the+latest+advances+in+research+on+CDK+inhibitors&doi=10.3390%2Fcancers6042224"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.3390%2Fcancers6042224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers6042224%26sid%3Dliteratum%253Aachs%26aulast%3DCicenas%26aufirst%3DJ.%26aulast%3DKalyan%26aufirst%3DK.%26aulast%3DSorokinas%26aufirst%3DA.%26aulast%3DJatulyte%26aufirst%3DA.%26aulast%3DValiunas%26aufirst%3DD.%26aulast%3DKaupinis%26aufirst%3DA.%26aulast%3DValius%26aufirst%3DM.%26atitle%3DHighlights%2520of%2520the%2520latest%2520advances%2520in%2520research%2520on%2520CDK%2520inhibitors%26jtitle%3DCancers%26date%3D2014%26volume%3D6%26spage%3D2224%26epage%3D2242%26doi%3D10.3390%2Fcancers6042224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Rizzolio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuccinardi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucchetti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, A.</span><span> </span><span class="NLM_article-title">CDK Inhibitors: From the bench to clinical trials</span> <span class="citation_source-journal">Curr. Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">279</span><span class="NLM_x">–</span> <span class="NLM_lpage">290</span><span class="refDoi"> DOI: 10.2174/138945010790711978</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.2174%2F138945010790711978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=20210753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkt1emsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=279-290&author=F.+Rizzolioauthor=T.+Tuccinardiauthor=I.+Caligiuriauthor=C.+Lucchettiauthor=A.+Giordano&title=CDK+Inhibitors%3A+From+the+bench+to+clinical+trials&doi=10.2174%2F138945010790711978"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">CDK inhibitors: from the bench to clinical trials</span></div><div class="casAuthors">Rizzolio, Flavio; Tuccinardi, Tiziano; Caligiuri, Isabella; Lucchetti, Chiara; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">279-290</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cell cycle deregulation is one of the first steps that transform normal cells into tumor cells.  CDKs are a family of proteins devoted to controlling cell cycle entry, progression and exit.  Studies from animal models show a tissue-specific essentiality of the single CDKs.  In cancer cells, mis-regulation of CDK function is a common event.  For this reason the pioneer compd. Flavopiridol was developed and many new drugs are currently under development.  ATP and the last generation of non-ATP competitive inhibitors are now emerging as one of the most potentially powerful target therapies.  Many clin. trials are ongoing, as either a single agent or in combination with the classical cytotoxic agents.  In this review, we discuss new strategies and methods to design more potent, selective and specific CDK inhibitors, starting from evidence emerging from animal and cancer cell models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6pyjusDph6rVg90H21EOLACvtfcHk0lipaXqdEhDwKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkt1emsrw%253D&md5=9c5986f6a899a379bdf87ae4aa506746</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.2174%2F138945010790711978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138945010790711978%26sid%3Dliteratum%253Aachs%26aulast%3DRizzolio%26aufirst%3DF.%26aulast%3DTuccinardi%26aufirst%3DT.%26aulast%3DCaligiuri%26aufirst%3DI.%26aulast%3DLucchetti%26aufirst%3DC.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DCDK%2520Inhibitors%253A%2520From%2520the%2520bench%2520to%2520clinical%2520trials%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2010%26volume%3D11%26spage%3D279%26epage%3D290%26doi%3D10.2174%2F138945010790711978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Asghar, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witkiewicz, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knudsen, E. S.</span><span> </span><span class="NLM_article-title">The history and future of targeting cyclin-dependent kinases in cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">146</span><span class="refDoi"> DOI: 10.1038/nrd4504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1038%2Fnrd4504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=25633797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvVCrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=130-146&author=U.+Asgharauthor=A.+K.+Witkiewiczauthor=N.+C.+Turnerauthor=E.+S.+Knudsen&title=The+history+and+future+of+targeting+cyclin-dependent+kinases+in+cancer+therapy&doi=10.1038%2Fnrd4504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">The history and future of targeting cyclin-dependent kinases in cancer therapy</span></div><div class="casAuthors">Asghar, Uzma; Witkiewicz, Agnieszka K.; Turner, Nicholas C.; Knudsen, Erik S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-146</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer represents a pathol. manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies.  In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle.  Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events.  Translating this knowledge into successful clin. development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clin. trials.  Here, we review the biol. of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clin. results of CDK inhibitors.  We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clin. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ_utd-yiEZLVg90H21EOLACvtfcHk0lipaXqdEhDwKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvVCrtLc%253D&md5=113bcd2e99a8267119d180670d3c7761</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnrd4504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4504%26sid%3Dliteratum%253Aachs%26aulast%3DAsghar%26aufirst%3DU.%26aulast%3DWitkiewicz%26aufirst%3DA.%2BK.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DKnudsen%26aufirst%3DE.%2BS.%26atitle%3DThe%2520history%2520and%2520future%2520of%2520targeting%2520cyclin-dependent%2520kinases%2520in%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D130%26epage%3D146%26doi%3D10.1038%2Fnrd4504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaser, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duchemin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusewitt, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Briesewitz, R.</span><span> </span><span class="NLM_article-title">Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">2075</span><span class="NLM_x">–</span> <span class="NLM_lpage">2083</span><span class="refDoi"> DOI: 10.1182/blood-2007-02-071266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1182%2Fblood-2007-02-071266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=17537993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVGjtbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=2075-2083&author=L.+Wangauthor=J.+Wangauthor=B.+W.+Blaserauthor=A.+M.+Ducheminauthor=D.+F.+Kusewittauthor=T.+Liuauthor=M.+A.+Caligiuriauthor=R.+Briesewitz&title=Pharmacologic+inhibition+of+CDK4%2F6%3A+mechanistic+evidence+for+selective+activity+or+acquired+resistance+in+acute+myeloid+leukemia&doi=10.1182%2Fblood-2007-02-071266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia</span></div><div class="casAuthors">Wang, Lisheng; Wang, Jie; Blaser, Bradley W.; Duchemin, Anne-Marie; Kusewitt, Donna F.; Liu, Tom; Caligiuri, Michael A.; Briesewitz, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2075-2083</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Entry into the cell cycle is mediated by cyclin-dependent kinase 4/6 (CDK4/6) activation, followed by CDK2 activation.  We found that pharmacol. inhibition of the Flt3 internal tandem duplication (ITD), a mutated receptor tyrosine kinase commonly found in patients with acute myelogenous leukemia (AML), led to the down-regulation of cyclin D2 and D3 followed by retinoblastoma protein (pRb) dephosphorylation and G1 cell-cycle arrest.  This implicated the D-cyclin-CDK4/6 complex as a downstream effector of Flt3 ITD signaling.  Indeed, single-agent PD0332991, a selective CDK4/6 inhibitor, caused sustained cell-cycle arrest in Flt3 ITD AML cell lines and prolonged survival in an in vivo model of Flt3 ITD AML.  PD0332991 caused an initial cell-cycle arrest in well-established Flt3 wild-type (wt) AML cell lines, but this was overcome by down-regulation of p27Kip and reactivation of CDK2.  This acquired resistance was not obsd. in a Flt3 ITD and a Flt3 wt sample from a patient with primary AML.  In summary, the mechanism of cell-cycle arrest after treatment of Flt3 ITD AML with a Flt3 inhibitor involves down-regulation of cyclin D2 and D3.  As such, CDK4/6 can be a therapeutic target in Flt3 ITD AML but also in primary Flt3 wt AML.  Finally, acquired resistance to CDK4/6 inhibition can arise through activation CDK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiH_wOIP8jJLVg90H21EOLACvtfcHk0lgPzcsK53f7Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVGjtbbK&md5=5f68ef6deacf3789e428731722f8c5ff</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1182%2Fblood-2007-02-071266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2007-02-071266%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBlaser%26aufirst%3DB.%2BW.%26aulast%3DDuchemin%26aufirst%3DA.%2BM.%26aulast%3DKusewitt%26aufirst%3DD.%2BF.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DBriesewitz%26aufirst%3DR.%26atitle%3DPharmacologic%2520inhibition%2520of%2520CDK4%252F6%253A%2520mechanistic%2520evidence%2520for%2520selective%2520activity%2520or%2520acquired%2520resistance%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D2075%26epage%3D2083%26doi%3D10.1182%2Fblood-2007-02-071266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, T.</span><span> </span><span class="NLM_article-title">Synthesis and structure of the β-carboline derivatives and their binding intensity with cyclin-dependent kinase 2</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">435</span><span class="NLM_x">–</span> <span class="NLM_lpage">441</span><span class="refDoi"> DOI: 10.1248/cpb.60.435</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1248%2Fcpb.60.435" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2012&pages=435-441&author=Y.+Wangauthor=Q.+Jinauthor=G.+Linauthor=T.+Yangauthor=Z.+Wangauthor=Y.+Luauthor=Y.+Tangauthor=L.+Liuauthor=T.+Lu&title=Synthesis+and+structure+of+the+%CE%B2-carboline+derivatives+and+their+binding+intensity+with+cyclin-dependent+kinase+2&doi=10.1248%2Fcpb.60.435"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1248%2Fcpb.60.435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.60.435%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DT.%26atitle%3DSynthesis%2520and%2520structure%2520of%2520the%2520%25CE%25B2-carboline%2520derivatives%2520and%2520their%2520binding%2520intensity%2520with%2520cyclin-dependent%2520kinase%25202%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2012%26volume%3D60%26spage%3D435%26epage%3D441%26doi%3D10.1248%2Fcpb.60.435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Jin, Q. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, T.</span><span> </span><span class="NLM_article-title">Synthesis, characterization, DNA binding ability and cytotoxicity of the novel platinum(II), copper(II), cobalt(II) and nickel(II) complexes with 3-(1 H -benzo[ d ]imidazol-2-yl)- β -carboline</span> <span class="citation_source-journal">Inorg. Chim. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">421</span><span class="NLM_x">, </span> <span class="NLM_fpage">91</span><span class="NLM_x">–</span> <span class="NLM_lpage">99</span><span class="refDoi"> DOI: 10.1016/j.ica.2014.05.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1016%2Fj.ica.2014.05.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1Cku7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=421&publication_year=2014&pages=91-99&author=Q.+M.+Jinauthor=Y.+Luauthor=J.+L.+Jinauthor=H.+Guoauthor=G.+W.+Linauthor=Y.+Wangauthor=T.+Lu&title=Synthesis%2C+characterization%2C+DNA+binding+ability+and+cytotoxicity+of+the+novel+platinum%28II%29%2C+copper%28II%29%2C+cobalt%28II%29+and+nickel%28II%29+complexes+with+3-%281+H+-benzo%5B+d+%5Dimidazol-2-yl%29-+%CE%B2+-carboline&doi=10.1016%2Fj.ica.2014.05.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, characterization, DNA binding ability and cytotoxicity of the novel platinum(II), copper(II), cobalt(II) and nickel(II) complexes with 3-(1H-benzo[d]imidazol-2-yl)-β-carboline</span></div><div class="casAuthors">Jin, Qiao-Mei; Lu, Yi; Jin, Jian-Lin; Guo, Hao; Lin, Guo-Wu; Wang, Yue; Lu, Tao</div><div class="citationInfo"><span class="NLM_cas:title">Inorganica Chimica Acta</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">421</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">91-99</span>CODEN:
                <span class="NLM_cas:coden">ICHAA3</span>;
        ISSN:<span class="NLM_cas:issn">0020-1693</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">3-(1H-benzo[d]imidazol-2-yl)-β-carbolin (Y-5, C18H12N4, 5) and its Pt(II), Cu(II), Co(II) and Ni(II) complexes 1-4 were synthesized and characterized by 1H NMR, MS, IR, elemental analyses and TG.  The complexes are Pt(C18H12N4)Cl2.DMF (1), Cu(C18H12N4)Cl2.2H2O (2), Co(C18H12N4)2Cl2.2H2O (3), and Ni(C18H12N4)Cl2.2H2O (4).  Crystal structure of Y-5 and its Pt(II) complex are reported.  The DNA binding and DNA cleavage ability of complexes with Cu(II) ion and Pt(II) ion as the metal center showed enhanced activities than that of the other two, which were evaluated by absorption spectra, EB displacement expts. and agarose gel electrophoresis.  Assay on the cytotoxicity of the above complexes against A549 and Hela tumor cells and Helf normal cells revealed that the complexes 1 and 2 are toxic against tumor cells but relatively safe to normal cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpr15oiIWuruLVg90H21EOLACvtfcHk0lgPzcsK53f7Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1Cku7rJ&md5=b50fc1bb101c523e27d11daf0a00a31a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ica.2014.05.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ica.2014.05.036%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DQ.%2BM.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%2BL.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DG.%2BW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DT.%26atitle%3DSynthesis%252C%2520characterization%252C%2520DNA%2520binding%2520ability%2520and%2520cytotoxicity%2520of%2520the%2520novel%2520platinum%2528II%2529%252C%2520copper%2528II%2529%252C%2520cobalt%2528II%2529%2520and%2520nickel%2528II%2529%2520complexes%2520with%25203-%25281%2520H%2520-benzo%255B%2520d%2520%255Dimidazol-2-yl%2529-%2520%25CE%25B2%2520-carboline%26jtitle%3DInorg.%2520Chim.%2520Acta%26date%3D2014%26volume%3D421%26spage%3D91%26epage%3D99%26doi%3D10.1016%2Fj.ica.2014.05.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Lin, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Q. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, T.</span><span> </span><span class="NLM_article-title">Synthesis, structures and the biological activity study on the metal complexes of 2-(4-aminophenyl)benzothiazole derivative</span> <span class="citation_source-journal">Inorg. Chim. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">382</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">–</span> <span class="NLM_lpage">42</span><span class="refDoi"> DOI: 10.1016/j.ica.2011.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1016%2Fj.ica.2011.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFGnu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2012&pages=35-42&author=G.+W.+Linauthor=Y.+Wangauthor=Q.+M.+Jinauthor=T.+T.+Yangauthor=J.+M.+Songauthor=Y.+Luauthor=Q.+J.+Huangauthor=K.+Songauthor=J.+Zhouauthor=T.+Lu&title=Synthesis%2C+structures+and+the+biological+activity+study+on+the+metal+complexes+of+2-%284-aminophenyl%29benzothiazole+derivative&doi=10.1016%2Fj.ica.2011.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, structures and the biological activity study on the metal complexes of 2-(4-aminophenyl)benzothiazole derivative</span></div><div class="casAuthors">Lin, Guo-Wu; Wang, Yue; Jin, Qiao-Mei; Yang, Tao-Tao; Song, Jie-Mei; Lu, Yi; Huang, Qing-Jie; Song, Ke; Zhou, Jun; Lu, Tao</div><div class="citationInfo"><span class="NLM_cas:title">Inorganica Chimica Acta</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35-42</span>CODEN:
                <span class="NLM_cas:coden">ICHAA3</span>;
        ISSN:<span class="NLM_cas:issn">0020-1693</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">(2-(4-(Benzothiazole)phenyl)carbamoylmethyl)iminodiacetic acid (ZL-5) was synthesized and then its three metal complexes were prepd. with structures detd. by 1H NMR or x-ray.  In all complexes, ZL-5 is deprotonated to generate the neutral complex unit and acts as a tetradentate ligand, providing iminodiacetic N atom and three O atoms to bond with metal ions.  Meanwhile the authors studied on the interaction of complexes with DNA by UV spectrum and fluorescent spectrum.  Also the cleavage abilities of the complexes on plasmid pBR 322 DNA were studied by gel electrophoresis.  The authors deduce the Co(II) complex 1 with the largest planar structure has the strongest DNA binding ability mainly by the intercalation mode, while the Cu(II) complex 2 with the coordinated H2O cut the DNA most effectively.  And in the oxidative cleavage process of all complexes, the hydroxyl radical is produced which can be captured by DMSO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAGxHUkxdxarVg90H21EOLACvtfcHk0ljQcXQoupxFUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFGnu78%253D&md5=bccd140e1cbc1437fd706ac135d85909</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.ica.2011.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ica.2011.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DG.%2BW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DQ.%2BM.%26aulast%3DYang%26aufirst%3DT.%2BT.%26aulast%3DSong%26aufirst%3DJ.%2BM.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DQ.%2BJ.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DT.%26atitle%3DSynthesis%252C%2520structures%2520and%2520the%2520biological%2520activity%2520study%2520on%2520the%2520metal%2520complexes%2520of%25202-%25284-aminophenyl%2529benzothiazole%2520derivative%26jtitle%3DInorg.%2520Chim.%2520Acta%26date%3D2012%26volume%3D382%26spage%3D35%26epage%3D42%26doi%3D10.1016%2Fj.ica.2011.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span> </span><span class="NLM_article-title">Novel 1H-pyrazole-3-carboxamide derivatives: synthesis, anticancer evaluation and identification of their DNA-binding interaction</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">238</span><span class="NLM_x">–</span> <span class="NLM_lpage">246</span><span class="refDoi"> DOI: 10.1248/cpb.c13-00676</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1248%2Fcpb.c13-00676" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=24365978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVSgu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2014&pages=238-246&author=Y.+Luauthor=T.+Ranauthor=G.+Linauthor=Q.+Jinauthor=J.+Jinauthor=H.+Liauthor=H.+Guoauthor=T.+Luauthor=Y.+Wang&title=Novel+1H-pyrazole-3-carboxamide+derivatives%3A+synthesis%2C+anticancer+evaluation+and+identification+of+their+DNA-binding+interaction&doi=10.1248%2Fcpb.c13-00676"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 1H-pyrazole-3-carboxamide derivatives: synthesis, anticancer evaluation and identification of their DNA-binding interaction</span></div><div class="casAuthors">Lu, Yi; Ran, Ting; Lin, Guowu; Jin, Qiaomei; Jin, Jianling; Li, Hongmei; Guo, Hao; Lu, Tao; Wang, Yue</div><div class="citationInfo"><span class="NLM_cas:title">Chemical & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">238-246</span>CODEN:
                <span class="NLM_cas:coden">CPBTAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-2363</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">Four novel 1H-pyrazole-3-carboxamides I (R = cyclopropylaminocarbonyl, benzoyl, pyridin-4-ylmethyl, X = NMe; R = cyclopropylaminocarbonyl, X = O) were synthesized, and their antiproliferative effect on cancer cells, kinase inhibition, and in particular, the DNA-binding interactions were investigated to interpret the antitumor mechanisms.  A DNA minor groove binding model was developed, and the binding energy was predicted for these compds.  In consistence with the prediction, the binding ability was detd. by the electronic absorption spectroscopy under physiol. conditions, and further verified by viscosity measurements.  Compd. I [R = cyclopropylaminocarbonyl; X = NMe; (II)] exerted the highest DNA-binding affinity (K = 1.06x105 M-1) and showed more than 50% decrease of the emission intensity of the ethidium bromide-calf thymus DNA (EB-CT-DNA) complex in fluorescence spectra, suggesting that it could strongly affect the DNA conformation.  Furthermore, compd. II showed the cleavage activity upon the supercoiled plasmid pBR322 DNA in the pBR322 DNA cleavage assay.  These studies suggested that DNA may serve as a potential target to these pyrazole derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsjjzMFPJ9b7Vg90H21EOLACvtfcHk0ljQcXQoupxFUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVSgu74%253D&md5=bf837d90cd59ef638de41c08e49f488c</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1248%2Fcpb.c13-00676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.c13-00676%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DRan%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DJin%26aufirst%3DQ.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DNovel%25201H-pyrazole-3-carboxamide%2520derivatives%253A%2520synthesis%252C%2520anticancer%2520evaluation%2520and%2520identification%2520of%2520their%2520DNA-binding%2520interaction%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D2014%26volume%3D62%26spage%3D238%26epage%3D246%26doi%3D10.1248%2Fcpb.c13-00676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Heathcote, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroll, S. H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Periyasamy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alikian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanneganti, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jogalekar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheiper, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbazanges, M.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">A Novel Pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8508</span><span class="NLM_x">–</span> <span class="NLM_lpage">8522</span><span class="refDoi"> DOI: 10.1021/jm100732t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100732t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8508-8522&author=D.+A.+Heathcoteauthor=H.+Patelauthor=S.+H.+B.+Krollauthor=P.+Hazelauthor=M.+Periyasamyauthor=M.+Alikianauthor=S.+K.+Kannegantiauthor=A.+S.+Jogalekarauthor=B.+Scheiperauthor=M.+Barbazanges&title=A+Novel+Pyrazolo%5B1%2C5-a%5Dpyrimidine+is+a+potent+inhibitor+of+cyclin-dependent+protein+kinases+1%2C+2%2C+and+9%2C+which+demonstrates+antitumor+effects+in+human+tumor+xenografts+following+oral+administration&doi=10.1021%2Fjm100732t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Pyrazolo[1,5-a]pyrimidine is a Potent Inhibitor of Cyclin-Dependent Protein Kinases 1, 2, and 9, Which Demonstrates Antitumor Effects in Human Tumor Xenografts Following Oral Administration</span></div><div class="casAuthors">Heathcote, Dean A.; Patel, Hetal; Kroll, Sebastian H. B.; Hazel, Pascale; Periyasamy, Manikandan; Alikian, Mary; Kanneganti, Seshu K.; Jogalekar, Ashutosh S.; Scheiper, Bodo; Barbazanges, Marion; Blum, Andreas; Brackow, Jan; Siwicka, Alekasandra; Pace, Robert D. M.; Fuchter, Matthew J.; Snyder, James P.; Liotta, Dennis C.; Freemont, Paul. S.; Aboagye, Eric O.; Coombes, R. Charles; Barrett, Anthony G. M.; Ali, Simak</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8508-8522</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent protein kinases (CDKs) are central to the appropriate regulation of cell proliferation, apoptosis, and gene expression.  Abnormalities in CDK activity and regulation are common features of cancer, making CDK family members attractive targets for the development of anticancer drugs.  Here, we report the identification of a pyrazolo[1,5-a]pyrimidine derived compd., 4k (BS-194, I), as a selective and potent CDK inhibitor, which inhibits CDK2, CDK1, CDK5, CDK7, and CDK9 (IC50 = 3, 30, 30, 250, and 90 nmol/L, resp.).  Cell-based studies showed inhibition of the phosphorylation of CDK substrates, Rb and the RNA polymerase II C-terminal domain, down-regulation of cyclins A, E, and D1, and cell cycle block in the S and G2/M phases.  Consistent with these findings, 4k demonstrated potent antiproliferative activity in 60 cancer cell lines tested (mean GI50 = 280 nmol/L).  Pharmacokinetic studies showed that 4k is orally bioavailable, with an elimination half-life of 178 min following oral dosing in mice.  When administered at a concn. of 25 mg/kg orally, 4k inhibited human tumor xenografts and suppressed CDK substrate phosphorylation.  These findings identify 4k as a novel, potent CDK selective inhibitor with potential for oral delivery in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUJPhLKEWwBLVg90H21EOLACvtfcHk0ljQcXQoupxFUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL%252FJ&md5=b84f41ab0cbf298a9ac248bc0a9d0d73</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm100732t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100732t%26sid%3Dliteratum%253Aachs%26aulast%3DHeathcote%26aufirst%3DD.%2BA.%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DKroll%26aufirst%3DS.%2BH.%2BB.%26aulast%3DHazel%26aufirst%3DP.%26aulast%3DPeriyasamy%26aufirst%3DM.%26aulast%3DAlikian%26aufirst%3DM.%26aulast%3DKanneganti%26aufirst%3DS.%2BK.%26aulast%3DJogalekar%26aufirst%3DA.%2BS.%26aulast%3DScheiper%26aufirst%3DB.%26aulast%3DBarbazanges%26aufirst%3DM.%26atitle%3DA%2520Novel%2520Pyrazolo%255B1%252C5-a%255Dpyrimidine%2520is%2520a%2520potent%2520inhibitor%2520of%2520cyclin-dependent%2520protein%2520kinases%25201%252C%25202%252C%2520and%25209%252C%2520which%2520demonstrates%2520antitumor%2520effects%2520in%2520human%2520tumor%2520xenografts%2520following%2520oral%2520administration%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8508%26epage%3D8522%26doi%3D10.1021%2Fjm100732t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Wood, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noetzel, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engers, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollinger, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melancon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarr, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregro, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamsal, A.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Discovery and optimization of a novel series of highly CNS penetrant M 4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3- d ]pyrimidine core</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3029</span><span class="NLM_x">–</span> <span class="NLM_lpage">3033</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1016%2Fj.bmcl.2016.05.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=3029-3033&author=M.+R.+Woodauthor=M.+J.+Noetzelauthor=J.+L.+Engersauthor=K.+A.+Bollingerauthor=B.+J.+Melanconauthor=J.+C.+Tarrauthor=C.+Hanauthor=M.+Westauthor=A.+R.+Gregroauthor=A.+Lamsal&title=Discovery+and+optimization+of+a+novel+series+of+highly+CNS+penetrant+M+4+PAMs+based+on+a+5%2C6-dimethyl-4-%28piperidin-1-yl%29thieno%5B2%2C3-+d+%5Dpyrimidine+core&doi=10.1016%2Fj.bmcl.2016.05.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DM.%2BR.%26aulast%3DNoetzel%26aufirst%3DM.%2BJ.%26aulast%3DEngers%26aufirst%3DJ.%2BL.%26aulast%3DBollinger%26aufirst%3DK.%2BA.%26aulast%3DMelancon%26aufirst%3DB.%2BJ.%26aulast%3DTarr%26aufirst%3DJ.%2BC.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DWest%26aufirst%3DM.%26aulast%3DGregro%26aufirst%3DA.%2BR.%26aulast%3DLamsal%26aufirst%3DA.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520a%2520novel%2520series%2520of%2520highly%2520CNS%2520penetrant%2520M%25204%2520PAMs%2520based%2520on%2520a%25205%252C6-dimethyl-4-%2528piperidin-1-yl%2529thieno%255B2%252C3-%2520d%2520%255Dpyrimidine%2520core%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D3029%26epage%3D3033%26doi%3D10.1016%2Fj.bmcl.2016.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Shook, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarty, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbay, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alford, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rassnick, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scannevin, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, K.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Substituted thieno[2,3-d ]pyrimidines as adenosine A 2A receptor antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">2688</span><span class="NLM_x">–</span> <span class="NLM_lpage">2691</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2013.02.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1016%2Fj.bmcl.2013.02.078" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=2688-2691&author=B.+C.+Shookauthor=D.+Chakravartyauthor=J.+K.+Barbayauthor=A.+Wangauthor=K.+Leonardauthor=V.+Alfordauthor=M.+T.+Powellauthor=S.+Rassnickauthor=R.+H.+Scannevinauthor=K.+Carroll&title=Substituted+thieno%5B2%2C3-d+%5Dpyrimidines+as+adenosine+A+2A+receptor+antagonists&doi=10.1016%2Fj.bmcl.2013.02.078"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.02.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.02.078%26sid%3Dliteratum%253Aachs%26aulast%3DShook%26aufirst%3DB.%2BC.%26aulast%3DChakravarty%26aufirst%3DD.%26aulast%3DBarbay%26aufirst%3DJ.%2BK.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DLeonard%26aufirst%3DK.%26aulast%3DAlford%26aufirst%3DV.%26aulast%3DPowell%26aufirst%3DM.%2BT.%26aulast%3DRassnick%26aufirst%3DS.%26aulast%3DScannevin%26aufirst%3DR.%2BH.%26aulast%3DCarroll%26aufirst%3DK.%26atitle%3DSubstituted%2520thieno%255B2%252C3-d%2520%255Dpyrimidines%2520as%2520adenosine%2520A%25202A%2520receptor%2520antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D2688%26epage%3D2691%26doi%3D10.1016%2Fj.bmcl.2013.02.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Carbain, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anscombe, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Echalier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endicott, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golding, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haggerty, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardcastle, I. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewsbury, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roche, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span> </span><span class="NLM_article-title">8-Substituted O(6)-cyclohexylmethylguanine CDK2 inhibitors: using structure-based inhibitor design to optimize an alternative binding mode</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">70</span><span class="refDoi"> DOI: 10.1021/jm401555v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401555v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=56-70&author=B.+Carbainauthor=D.+J.+Patersonauthor=E.+Anscombeauthor=A.+J.+Campbellauthor=C.+Canoauthor=A.+Echalierauthor=J.+A.+Endicottauthor=B.+T.+Goldingauthor=K.+Haggertyauthor=I.+R.+Hardcastleauthor=P.+J.+Jewsburyauthor=D.+R.+Newellauthor=M.+E.+Nobleauthor=C.+Rocheauthor=L.+Z.+Wangauthor=R.+J.+Griffin&title=8-Substituted+O%286%29-cyclohexylmethylguanine+CDK2+inhibitors%3A+using+structure-based+inhibitor+design+to+optimize+an+alternative+binding+mode&doi=10.1021%2Fjm401555v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm401555v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401555v%26sid%3Dliteratum%253Aachs%26aulast%3DCarbain%26aufirst%3DB.%26aulast%3DPaterson%26aufirst%3DD.%2BJ.%26aulast%3DAnscombe%26aufirst%3DE.%26aulast%3DCampbell%26aufirst%3DA.%2BJ.%26aulast%3DCano%26aufirst%3DC.%26aulast%3DEchalier%26aufirst%3DA.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DGolding%26aufirst%3DB.%2BT.%26aulast%3DHaggerty%26aufirst%3DK.%26aulast%3DHardcastle%26aufirst%3DI.%2BR.%26aulast%3DJewsbury%26aufirst%3DP.%2BJ.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DNoble%26aufirst%3DM.%2BE.%26aulast%3DRoche%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DL.%2BZ.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26atitle%3D8-Substituted%2520O%25286%2529-cyclohexylmethylguanine%2520CDK2%2520inhibitors%253A%2520using%2520structure-based%2520inhibitor%2520design%2520to%2520optimize%2520an%2520alternative%2520binding%2520mode%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D56%26epage%3D70%26doi%3D10.1021%2Fjm401555v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Lauwiner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rys, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissmann, J.</span><span> </span><span class="NLM_article-title">Reduction of aromatic nitro compounds with hydrazine hydrate in the presence of an iron oxide hydroxide catalyst. I. The reduction of mono substituted nitrobenzenes with hydrazine hydrate in the presence of ferrihydrite</span> <span class="citation_source-journal">Appl. Catal., A</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">172</span><span class="NLM_x">, </span> <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span><span class="refDoi"> DOI: 10.1016/S0926-860X(98)00110-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1016%2FS0926-860X%2898%2900110-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADyaK1cXlslWmsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=1998&pages=141-148&author=M.+Lauwinerauthor=P.+Rysauthor=J.+Wissmann&title=Reduction+of+aromatic+nitro+compounds+with+hydrazine+hydrate+in+the+presence+of+an+iron+oxide+hydroxide+catalyst.+I.+The+reduction+of+mono+substituted+nitrobenzenes+with+hydrazine+hydrate+in+the+presence+of+ferrihydrite&doi=10.1016%2FS0926-860X%2898%2900110-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Reduction of aromatic nitro compounds with hydrazine hydrate in the presence of an iron oxide hydroxide catalyst. I. The reduction of monosubstituted nitrobenzenes with hydrazine hydrate in the presence of ferrihydrite</span></div><div class="casAuthors">Lauwiner, Max; Rys, Paul; Wissmann, Jorg</div><div class="citationInfo"><span class="NLM_cas:title">Applied Catalysis, A: General</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">141-148</span>CODEN:
                <span class="NLM_cas:coden">ACAGE4</span>;
        ISSN:<span class="NLM_cas:issn">0926-860X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A great variety of monosubstituted PhNO2 derivs. was reduced in good yield to the corresponding anilines with N2H4.H2O in the presence of an Fe oxide hydroxide catalyst prepd. by pptn. from an aq. Fe(III) soln. with NaOH.  The dependence of the redn. rate on the nature and the position of addnl. substituents other than the nitro group was detd. by measuring the reaction kinetics.  The rate is enhanced by electron-withdrawing substituents and decreased by electron-donating groups, which results in a pos. slope of ρ = 0.546 for the Hammett plot.  Competitive redn. expts. with mixts. of 2 differently substituted PhNO2 derivs. revealed that the nitro compd. with the more electron-attracting substituent is reduced first.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2y6E_uUTcJrVg90H21EOLACvtfcHk0livKzHL_tGYbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlslWmsb0%253D&md5=5bca64ef7634fec257c8338565c4ec55</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2FS0926-860X%2898%2900110-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0926-860X%252898%252900110-0%26sid%3Dliteratum%253Aachs%26aulast%3DLauwiner%26aufirst%3DM.%26aulast%3DRys%26aufirst%3DP.%26aulast%3DWissmann%26aufirst%3DJ.%26atitle%3DReduction%2520of%2520aromatic%2520nitro%2520compounds%2520with%2520hydrazine%2520hydrate%2520in%2520the%2520presence%2520of%2520an%2520iron%2520oxide%2520hydroxide%2520catalyst.%2520I.%2520The%2520reduction%2520of%2520mono%2520substituted%2520nitrobenzenes%2520with%2520hydrazine%2520hydrate%2520in%2520the%2520presence%2520of%2520ferrihydrite%26jtitle%3DAppl.%2520Catal.%252C%2520A%26date%3D1998%26volume%3D172%26spage%3D141%26epage%3D148%26doi%3D10.1016%2FS0926-860X%2898%2900110-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Yang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, W.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">89</span><span class="NLM_x">, </span> <span class="NLM_fpage">581</span><span class="NLM_x">–</span> <span class="NLM_lpage">596</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2014.10.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1016%2Fj.ejmech.2014.10.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=25462267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslOjtL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2015&pages=581-596&author=W.+Yangauthor=Y.+Chenauthor=X.+Zhouauthor=Y.+Guauthor=W.+Qianauthor=F.+Zhangauthor=W.+Hanauthor=T.+Luauthor=W.+Tang&title=Design%2C+synthesis+and+biological+evaluation+of+bis-aryl+ureas+and+amides+based+on+2-amino-3-purinylpyridine+scaffold+as+DFG-out+B-Raf+kinase+inhibitors&doi=10.1016%2Fj.ejmech.2014.10.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors</span></div><div class="casAuthors">Yang, Weimin; Chen, Yadong; Zhou, Xiang; Gu, Yazhou; Qian, Wenqi; Zhang, Fan; Han, Wei; Lu, Tao; Tang, Weifang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">581-596</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">By combining the scaffolds of UI-125 and Sorafenib, a series of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine moiety were designed and synthesized as novel DFG-out B-RafV600E inhibitors.  Several of these compds. displayed potent antiproliferative activities against melanoma A375 (B-RafV600E) cell lines with IC50 values of 3.190, 2.276, 1.856, 1.632 μM and 1.839 μM, resp., comparable with the pos. control Vemurafenib (IC50 = 3.32 μM).  Selected compds. were tested for the ERK inhibition in human melanoma A375 (B-RafV600E) and SK-MEL-2 (B-RafWT) cell lines by Western blot.  The results revealed that our compds. inhibited the proliferation of melanoma A375 cells (B-RafV600E) through ERK pathway, without paradoxical activation of ERK in melanoma SK-MEL-2 cells (B-RafWT).  Eventually, two compds. were selected to confirm their inhibitory effects on tumor growth in A375 xenograft models in mice.  Compd. I exhibited equiv. antitumor efficacy in vivo (T/C = 44.37%), compared to Sorafenib (T/C = 37.35%), by 23-day repetitive administration of a single dose of 50 mg/kg without significant body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq84bBDYugz1bVg90H21EOLACvtfcHk0lgDF4pUR-WiMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslOjtL7I&md5=6a65e09b0121c8f2f32facbfeae8f86b</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.10.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.10.039%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DQian%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DHan%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520bis-aryl%2520ureas%2520and%2520amides%2520based%2520on%25202-amino-3-purinylpyridine%2520scaffold%2520as%2520DFG-out%2520B-Raf%2520kinase%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D89%26spage%3D581%26epage%3D596%26doi%3D10.1016%2Fj.ejmech.2014.10.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Jorda, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Havlícek, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNae, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walkinshaw, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voller, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Šturc, A. n.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navrátilová, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuzma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mistrík, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bártek, J.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Pyrazolo [4, 3-d] pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2980</span><span class="NLM_x">–</span> <span class="NLM_lpage">2993</span><span class="refDoi"> DOI: 10.1021/jm200064p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200064p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2980-2993&author=R.+Jordaauthor=L.+Havl%C3%ADcekauthor=I.+W.+McNaeauthor=M.+D.+Walkinshawauthor=J.+Vollerauthor=A.+n.+%C5%A0turcauthor=J.+Navr%C3%A1tilov%C3%A1author=M.+Kuzmaauthor=M.+Mistr%C3%ADkauthor=J.+B%C3%A1rtek&title=Pyrazolo+%5B4%2C+3-d%5D+pyrimidine+bioisostere+of+roscovitine%3A+evaluation+of+a+novel+selective+inhibitor+of+cyclin-dependent+kinases+with+antiproliferative+activity&doi=10.1021%2Fjm200064p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm200064p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200064p%26sid%3Dliteratum%253Aachs%26aulast%3DJorda%26aufirst%3DR.%26aulast%3DHavl%25C3%25ADcek%26aufirst%3DL.%26aulast%3DMcNae%26aufirst%3DI.%2BW.%26aulast%3DWalkinshaw%26aufirst%3DM.%2BD.%26aulast%3DVoller%26aufirst%3DJ.%26aulast%3D%25C5%25A0turc%26aufirst%3DA.%2Bn.%26aulast%3DNavr%25C3%25A1tilov%25C3%25A1%26aufirst%3DJ.%26aulast%3DKuzma%26aufirst%3DM.%26aulast%3DMistr%25C3%25ADk%26aufirst%3DM.%26aulast%3DB%25C3%25A1rtek%26aufirst%3DJ.%26atitle%3DPyrazolo%2520%255B4%252C%25203-d%255D%2520pyrimidine%2520bioisostere%2520of%2520roscovitine%253A%2520evaluation%2520of%2520a%2520novel%2520selective%2520inhibitor%2520of%2520cyclin-dependent%2520kinases%2520with%2520antiproliferative%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2980%26epage%3D2993%26doi%3D10.1021%2Fjm200064p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Wyatt, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodhead, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdini, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulstridge, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devine, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Early, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltell, R. E.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4986</span><span class="NLM_x">–</span> <span class="NLM_lpage">4999</span><span class="refDoi"> DOI: 10.1021/jm800382h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800382h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4986-4999&author=P.+G.+Wyattauthor=A.+J.+Woodheadauthor=V.+Berdiniauthor=J.+A.+Boulstridgeauthor=M.+G.+Carrauthor=D.+M.+Crossauthor=D.+J.+Davisauthor=L.+A.+Devineauthor=T.+R.+Earlyauthor=R.+E.+Feltell&title=Identification+of+N-%284-piperidinyl%29-4-%282%2C6-dichlorobenzoylamino%29-1H-pyrazole-3-carboxamide+%28AT7519%29%2C+a+novel+cyclin+dependent+kinase+inhibitor+using+fragment-based+X-ray+crystallography+and+structure+based+drug+design&doi=10.1021%2Fjm800382h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm800382h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800382h%26sid%3Dliteratum%253Aachs%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DWoodhead%26aufirst%3DA.%2BJ.%26aulast%3DBerdini%26aufirst%3DV.%26aulast%3DBoulstridge%26aufirst%3DJ.%2BA.%26aulast%3DCarr%26aufirst%3DM.%2BG.%26aulast%3DCross%26aufirst%3DD.%2BM.%26aulast%3DDavis%26aufirst%3DD.%2BJ.%26aulast%3DDevine%26aufirst%3DL.%2BA.%26aulast%3DEarly%26aufirst%3DT.%2BR.%26aulast%3DFeltell%26aufirst%3DR.%2BE.%26atitle%3DIdentification%2520of%2520N-%25284-piperidinyl%2529-4-%25282%252C6-dichlorobenzoylamino%2529-1H-pyrazole-3-carboxamide%2520%2528AT7519%2529%252C%2520a%2520novel%2520cyclin%2520dependent%2520kinase%2520inhibitor%2520using%2520fragment-based%2520X-ray%2520crystallography%2520and%2520structure%2520based%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4986%26epage%3D4999%26doi%3D10.1021%2Fjm800382h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Hornak, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strockbine, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roitberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmerling, C.</span><span> </span><span class="NLM_article-title">Comparison of multiple Amber force fields and development of improved protein backbone parameters</span> <span class="citation_source-journal">Proteins: Struct., Funct., Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">712</span><span class="NLM_x">–</span> <span class="NLM_lpage">725</span><span class="refDoi"> DOI: 10.1002/prot.21123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.1002%2Fprot.21123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=16981200" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWqt7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2006&pages=712-725&author=V.+Hornakauthor=R.+Abelauthor=A.+Okurauthor=B.+Strockbineauthor=A.+Roitbergauthor=C.+Simmerling&title=Comparison+of+multiple+Amber+force+fields+and+development+of+improved+protein+backbone+parameters&doi=10.1002%2Fprot.21123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of multiple Amber force fields and development of improved protein backbone parameters</span></div><div class="casAuthors">Hornak, Viktor; Abel, Robert; Okur, Asim; Strockbine, Bentley; Roitberg, Adrian; Simmerling, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Bioinformatics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">712-725</span>CODEN:
                <span class="NLM_cas:coden">PSFBAF</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The ff94 force field that is commonly assocd. with the Amber simulation package is one of the most widely used parameter sets for biomol. simulation.  After a decade of extensive use and testing, limitations in this force field, such as over-stabilization of α-helixes, were reported by the authors and other researchers.  This led to a no. of attempts to improve these parameters, resulting in a variety of "Amber" force fields and significant difficulty in detg. which should be used for a particular application.  The authors show that several of these continue to suffer from inadequate balance between different secondary structure elements.  In addn., the approach used in most of these studies neglected to account for the existence in Amber of two sets of backbone .vphi./ψ dihedral terms.  This led to parameter sets that provide unreasonable conformational preferences for glycine.  The authors report here an effort to improve the .vphi./ψ dihedral terms in the ff99 energy function.  Dihedral term parameters are based on fitting the energies of multiple conformations of glycine and alanine tetrapeptides from high level ab initio quantum mech. calcns.  The new parameters for backbone dihedrals replace those in the existing ff99 force field.  This parameter set, which the authors denote ff99SB, achieves a better balance of secondary structure elements as judged by improved distribution of backbone dihedrals for glycine and alanine with respect to PDB survey data.  It also accomplishes improved agreement with published exptl. data for conformational preferences of short alanine peptides and better accord with exptl. NMR relaxation data of test protein systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmoASzza-Gd7Vg90H21EOLACvtfcHk0ljWzkQDO-e8Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWqt7fM&md5=de683a26eca9e83ae524726e97ac22fa</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1002%2Fprot.21123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.21123%26sid%3Dliteratum%253Aachs%26aulast%3DHornak%26aufirst%3DV.%26aulast%3DAbel%26aufirst%3DR.%26aulast%3DOkur%26aufirst%3DA.%26aulast%3DStrockbine%26aufirst%3DB.%26aulast%3DRoitberg%26aufirst%3DA.%26aulast%3DSimmerling%26aufirst%3DC.%26atitle%3DComparison%2520of%2520multiple%2520Amber%2520force%2520fields%2520and%2520development%2520of%2520improved%2520protein%2520backbone%2520parameters%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2006%26volume%3D65%26spage%3D712%26epage%3D725%26doi%3D10.1002%2Fprot.21123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Matthieu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thierry, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jonathan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafael, N.</span><span> </span><span class="NLM_article-title">Kinome Render: a stand-alone and web-accessible tool to annotate the human protein kinome tree</span> <span class="citation_source-journal">Peerj</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">e126</span><span class="refDoi"> DOI: 10.7717/peerj.126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;key=10.7717%2Fpeerj.126" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=e126&author=C.+Matthieuauthor=C.+Thierryauthor=B.+Jonathanauthor=N.+Rafael&title=Kinome+Render%3A+a+stand-alone+and+web-accessible+tool+to+annotate+the+human+protein+kinome+tree&doi=10.7717%2Fpeerj.126"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.7717%2Fpeerj.126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7717%252Fpeerj.126%26sid%3Dliteratum%253Aachs%26aulast%3DMatthieu%26aufirst%3DC.%26aulast%3DThierry%26aufirst%3DC.%26aulast%3DJonathan%26aufirst%3DB.%26aulast%3DRafael%26aufirst%3DN.%26atitle%3DKinome%2520Render%253A%2520a%2520stand-alone%2520and%2520web-accessible%2520tool%2520to%2520annotate%2520the%2520human%2520protein%2520kinome%2520tree%26jtitle%3DPeerj%26date%3D2013%26volume%3D1%26spage%3De126%26doi%3D10.7717%2Fpeerj.126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VU3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VU3','PDB','2VU3'); return false;">PDB: 2VU3</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1RJB','PDB','1RJB'); return false;">PDB: 1RJB</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i83"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01261">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_18638"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01261">10.1021/acs.jmedchem.7b01261</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">IC<sub>50</sub> of compound <b>48</b> against the selected kianses; growth inhibition by <b>35</b>, <b>48</b>, and <b>50</b> in the NCI60-cancer-cell-line panel; <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra for the target compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01261/suppl_file/jm7b01261_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular-modeling information CDK2-26 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01261/suppl_file/jm7b01261_si_002.pdb">PDB</a>)</p></li><li><p class="inline">Molecular-modeling information CDK2-42, 50, AT-7519 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01261/suppl_file/jm7b01261_si_003.pdb">PDB</a>)</p></li><li><p class="inline">Molecular-formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01261/suppl_file/jm7b01261_si_004.csv">CSV</a>)</p></li><li><p class="inline">Molecular-modeling information FLT3-26 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01261/suppl_file/jm7b01261_si_005.pdb">PDB</a>)</p></li><li><p class="inline">Molecular-modeling information FLT3-42, 50 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01261/suppl_file/jm7b01261_si_006.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01261/suppl_file/jm7b01261_si_001.pdf">jm7b01261_si_001.pdf (7.48 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01261/suppl_file/jm7b01261_si_002.pdb">jm7b01261_si_002.pdb (389.15 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01261/suppl_file/jm7b01261_si_003.pdb">jm7b01261_si_003.pdb (382.67 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01261/suppl_file/jm7b01261_si_004.csv">jm7b01261_si_004.csv (4.53 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01261/suppl_file/jm7b01261_si_005.pdb">jm7b01261_si_005.pdb (340.73 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01261/suppl_file/jm7b01261_si_006.pdb">jm7b01261_si_006.pdb (346.0 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01261&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-4%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01261%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01261" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"667989410e4a24ad","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
